var title_f38_46_39648="KS plaque like lesion";
var content_f38_46_39648=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F69203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F69203&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Kaposi's sarcoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 431px; height: 234px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    AIDS-related Kaposi's sarcoma appearing as plaque-like lesions with breakdown of overlying skin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     By permission from: van den Brink MR, Dezube BJ, J Clin Oncol 1997; 15:1283.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39648=[""].join("\n");
var outline_f38_46_39648=null;
var title_f38_46_39649="Paradigm of sexuality";
var content_f38_46_39649=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F50053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F50053&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 560px\">",
"   <div class=\"ttl\">",
"    Paradigm of sexuality",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 540px; height: 447px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted with permission from: Physicians for Reproductive Choice and Health Adolescent Reproductive Sexuality and Health Education Project. For more information, please visit",
"     <a href=\"file://www.prch.org/\" target=\"_blank\">",
"      file://www.prch.org/",
"     </a>",
"     .",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39649=[""].join("\n");
var outline_f38_46_39649=null;
var title_f38_46_39650="Cervical rib causing thoracic outlet syndrome";
var content_f38_46_39650=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F50430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F50430&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 518px\">",
"   <div class=\"ttl\">",
"    Cervical rib causing thoracic outlet syndrome",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 498px; height: 412px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Thoracic outlet syndromes are due to compression of any of the structures (brachial plexus, subclavian artery, subclavian vein) that traverse the confined space between the clavicle and first rib. Anatomic abnormaliaties such as a cervical rib (shown), musculotendinous abnormalities or scarring can contribute to the pathology.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39650=[""].join("\n");
var outline_f38_46_39650=null;
var title_f38_46_39651="Nephrology pattern 19";
var content_f38_46_39651=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F59983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F59983&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nephrology pattern 19",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 378px; height: 268px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39651=[""].join("\n");
var outline_f38_46_39651=null;
var title_f38_46_39652="Lichen planus";
var content_f38_46_39652=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F59807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F59807&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 387px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Lichen planus is characterized by flat-topped, violaceous papules.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Andrew Samel, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39652=[""].join("\n");
var outline_f38_46_39652=null;
var title_f38_46_39653="Cushings disease MRI II";
var content_f38_46_39653=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F50905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F50905&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 552px\">",
"   <div class=\"ttl\">",
"    Magnetic resonance imaging in Cushing's disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 532px; height: 284px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    MR images (coronal sections) of the sella turcica in the same patient with Cushing's disease. Left: Unenhanced image shows that most of the right side of the pituitary gland is occupied by an area of decreased signal intensity (arrows). Right: Gadolinium-enhanced image more clearly shows a 6 mm microadenoma as an area of decreased signal intensity (arrows).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reprinted with permission from Williams Textbook of Endocrinology, 8th ed, Foster, DW, Wilson, JD (Eds), WB Saunders, Philadelphia, 1996.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39653=[""].join("\n");
var outline_f38_46_39653=null;
var title_f38_46_39654="Rectal foreign bodies";
var content_f38_46_39654=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Rectal foreign bodies",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/46/39654/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/46/39654/contributors\">",
"     Scott R Steele, MD, FACS, FASCRS",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/46/39654/contributors\">",
"     Joel E Goldberg, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/46/39654/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/46/39654/contributors\">",
"     Martin Weiser, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/46/39654/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/46/39654/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/46/39654/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rectal foreign bodies can present a difficult diagnostic and management dilemma. They can be caused by a wide variety of objects, lead to variable degrees of local trauma to the surrounding tissues, and can be associated with perforation or delayed injury. Further complicating management is the variable degree to which patients are willing to disclose the underlying cause leading to their presentation and the frequently long delay before they seek medical attention. As a result, recognition and management require a systematic approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Published experience with rectal foreign bodies is based mainly on single-center case series (",
"    <a class=\"graphic graphic_table graphicRef56987 \" href=\"mobipreview.htm?15/12/15566\">",
"     table 1",
"    </a>",
"    ). Studies of adults have suggested that most patients are men (65 to 100 percent) who are in their 30s or 40s (range 16 to 94 years) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence is not known precisely but rectal foreign bodies are seen regularly in most large hospitals. As an example, in a report from the University of California of patients seen between 1993 and 2002, approximately one patient per month received care for a rectal foreign body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLASSIFICATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Placement has been categorized as voluntary versus involuntary (eg, rape, assault), and sexual versus nonsexual.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Involuntary nonsexual foreign bodies often involve children or patients who are mentally ill. They have also resulted from medical instruments such as thermometers or enema tips, and, uncommonly, from per-oral ingestion of objects that become lodged in the colon (eg, bones, toothpicks, and small objects such as erasers or broken plastic utensils).",
"     </li>",
"     <li>",
"      Voluntary nonsexual placement includes such practices as \"body-packing\" of latex condoms or plastic bags of cocaine and other illicit drug paraphernalia. Although impaction and bowel obstruction can result from this practice, more devastating outcomes occur with rupture of the containers leading to drug absorption resulting in overdose or even death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      More commonly, foreign bodies are introduced through the anal canal voluntarily during sexual practices.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The American Association for the Surgery of Trauma has proposed a Rectal Organ Injury Scale [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/6\">",
"     6",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Grade I &mdash; Hematoma: Contusion or hematoma without devascularization",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; Laceration: Partial-thickness",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Grade II &nbsp;&mdash; Laceration &le;50 percent circumference",
"     </li>",
"     <li>",
"      Grade III &mdash; Laceration &gt;50 percent circumference",
"     </li>",
"     <li>",
"      Grade IV &mdash; Full-thickness laceration with extension into the perineum",
"     </li>",
"     <li>",
"      Grade V &nbsp;&mdash; &nbsp;Devascularized segment",
"     </li>",
"    </ul>",
"    <br/>",
"    <br/>",
"    Most injuries due to rectal foreign bodies are Grade I.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     TYPES OF FOREIGN BODIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Foreign bodies consist of all types and sizes, with the most common items including phallic-shaped items. As will be discussed below, the shape and size of the object may influence subsequent management.",
"   </p>",
"   <p>",
"    A partial list documented in the literature along with the authors' experience includes balloons,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?12/17/12564?source=see_link\">",
"     barium",
"    </a>",
"    enema tips, batteries, a Billie club, bones, bottles, broomsticks, crab shell, a curtain rod, dentures, drugs (eg, marijuana, cocaine, amphetamines), fish hooks, flotation devices, garden tools, glue, a hosepipe, markers, match sticks, money, nails, ornaments, a paintbrush, a penknife, a pill bottle, a spray can, stones, a stove, stuffed animals, thermometers, a toothbrush, tumbler, toy cars, a trailer hitch, a turkey baster, a vacuum hose, wire, and a variety of fruits and vegetables. The wide variety of items underscores the need for an approach that considers the optimal methods and risks associated with removing the object.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition and diagnosis of rectal foreign bodies depends upon an appropriate history and physical examination and radiological evaluation as needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     History and physical examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients are often reluctant to fully disclose their situation and instead may complain of anorectal or abdominal pain, blood per rectum, or mucus discharge, while not volunteering the presence of a foreign body [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/1,4\">",
"     1,4",
"    </a>",
"    ]. In our experience, many patients will only admit to a rectal foreign body when directly asked about it.",
"   </p>",
"   <p>",
"    Many patients present hours or even days after placement following repeated failed attempts at removal. In some cases, patients present following successful removal of the object but with secondary manifestations from local trauma (eg, mucosal tears, sphincter disruption or perforation).",
"   </p>",
"   <p>",
"    In rare instances, presentation has been delayed for years. One report, for example, described a patient with a rectal perforation due to a thermometer who remained asymptomatic for seven years before the thermometer was discovered incidentally on a plain abdominal radiograph [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Findings on physical examination are variable. The abdominal examination can be normal, show tenderness or a palpable mass, or diffuse peritonitis if perforation has occurred. Rectal examination may be completely normal or demonstrate bright red blood or melena, depending upon the timing of presentation. Although the foreign body is typically found in the mid or distal rectum, the absence of a palpable foreign body on digital examination does not exclude its presence. The object may either be located proximally in the high rectum or colon.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Laboratory findings",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory examination is often unremarkable. The presence of leukocytosis",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    metabolic acidosis are concerning for extensive injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Radiological evaluation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A radiological evaluation is often helpful. We generally begin with a plain film radiograph (an abdominal flat plate to identify the object and an upright film to evaluate for pneumoperitoneum) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef58085 \" href=\"mobipreview.htm?41/4/42048\">",
"     image 1",
"    </a>",
"    ). In patients in whom there is concern related to a radiolucent object and in those who have concerning findings on initial evaluation, we suggest a CT scan.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients should initially be assessed for signs of perforation. Hypotension, abdominal pain, or increasing deep pelvic pain in the setting of rectal foreign body placement mandates an evaluation for full thickness injury; we usually obtain plain films to rule out free air (as quickly as possible) or a CT scan in more stable patients. Patients with peritoneal signs or obvious perforation require urgent surgical evaluation and treatment. Such patients should be kept nothing per os, resuscitated with intravenous fluid and appropriate laboratory evaluation should be obtained (ie, complete blood count, chemistries and a coagulation panel).",
"   </p>",
"   <p>",
"    If the foreign body is still in place, it should ideally be removed in an emergency room or an outpatient setting (see below). Clinically stable patients with foreign bodies that are located proximally can be observed to see if the object will progress to the distal rectum, which facilitates transanal removal. We suggest against using enemas or stimulant suppositories in this setting, although such an approach has been described. Use of these approaches theoretically risks forcing the foreign body into a more proximal location or causing more extensive injury (especially with sharp objects).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Transanal approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of rectal foreign bodies can be removed transanally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/4\">",
"     4",
"    </a>",
"    ]. One of the most important factors required for success is adequate patient relaxation, which can be accomplished with intravenous sedation and perianal nerve blocks:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Intravenous sedation allows patients to relax, decreases anal spasm, and permits improved exposure and visualization of the object.",
"     </li>",
"     <li>",
"      Perianal blocks with local anesthesia similar to that used for elective anorectal surgery can also facilitate patient comfort and should be used as needed. We use a mixture of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?34/34/35360?source=see_link\">",
"       lidocaine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?33/60/34758?source=see_link\">",
"       bupivacaine",
"      </a>",
"      to perform both a pudendal nerve and intersphincteric block. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40439?source=see_link\">",
"       \"Pudendal and paracervical block\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The patient can be placed in any position, depending upon the physician's preference. We prefer the lithotomy position, especially when an assistant is present, since it can facilitate abdominal pressure for stabilization and downward pressure on the object.",
"   </p>",
"   <p>",
"    We initially perform a digital rectal examination to confirm the object's presence, size, and location. Various retractors and clamps commonly used in routine anorectal surgery should be available. We frequently use a tenaculum or Kocher clamp to grasp and maintain control of the object throughout rectal removal.",
"   </p>",
"   <p>",
"    Standard implements for anorectal surgery may not always be sufficient depending upon the size, shape, and composition of the object. A variety of improvised methods have been described in such settings (see below).",
"   </p>",
"   <p>",
"    Following successful removal, we routinely perform rigid proctoscopy or flexible sigmoidoscopy to evaluate the mucosa for local damage, active bleeding, perforation, or additional retained objects. We generally repeat plain film to look for free air from perforations that may have occurred during the course of the object's removal and those that were not identified via direct visualization.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Blunt objects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many different methods have been described for removal of blunt objects. Probably the best approach is grasping the object; success depends upon the operator's hand size and the adequacy of anal relaxation. Patients often have a history of repetitive anal insertion leading to sphincter laxity, which facilitates manual removal of the object. Awake, albeit sedated, patients can help by performing a Valsalva to attempt to propel the smooth blunt object toward the rectum. When this does not provide the ability to grab the object, clamps such as those described above are needed.",
"   </p>",
"   <p>",
"    However, smooth objects like bottles cannot always be grasped, while objects such as fruits and candles can break with repetitive attempts at clamp removal. In such cases, we have used a technique of breaking full apples and vegetables into smaller pieces that can be grasped and more easily removed (",
"    <a class=\"graphic graphic_picture graphicRef60758 graphicRef72834 \" href=\"mobipreview.htm?38/5/39001\">",
"     picture 1A-B",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Several other approaches have been reported including [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/1-4,8-19\">",
"     1-4,8-19",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Placement of a Foley catheter above a smooth object to create a seal and pull the object down back towards the anus",
"     </li>",
"     <li>",
"      Injection of air above the object to break the vacuum seal that can be present in the colon proximal to the object",
"     </li>",
"     <li>",
"      Use of magnets to help extract metal objects",
"     </li>",
"     <li>",
"      Inflation of the balloon from a Sengstaken-Blakemore tube inside the object (such as a jar) to provide traction and extract the object transanally",
"     </li>",
"     <li>",
"      Use of an obstetrical vacuum device to provide suction to remove the foreign body",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Sharp objects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Extraction of sharp objects is often more difficult than removal of blunt objects and is associated with an increased risk for local mucosal trauma and perforation. We suggest avoiding blind attempts at grasping the object; the object should be manipulated only when it can be visualized transanally or through a proctoscope or sigmoidoscope. Extra attention during and after removal will aid in preventing and identifying mucosal injury.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Body packers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients who inserted objects to conceal illicit drugs (such as cocaine) are a particular challenge, since care must be made to avoid disrupting the outer barrier holding the drugs (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef59243 graphicRef78845 \" href=\"mobipreview.htm?40/50/41763\">",
"     image 2A-B",
"    </a>",
"    ). Most of these patients use condoms or other easily breakable material for the packets, which can be easily damaged with clamps and other sharp medical instruments; spillage of the contents into the colon can lead to systemic toxicity and death. As a result, these instruments should generally not be used.",
"   </p>",
"   <p>",
"    If manual extraction is not successful and there is neither obstruction nor signs of systemic toxicity, admission may be warranted for a period of observation to attempt to allow the packets to pass closer to the rectum. A more aggressive approach (which may include surgery and treatment for drug toxicity) is required if this is not successful and in patients with clinical features of obstruction, perforation, or systemic absorption. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12744?source=see_link\">",
"     \"Internal concealment of drugs of abuse (body packing)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Endoscopy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Objects that lie more proximally in the rectum or distal colon are more challenging than objects in the distal rectum since they are often not accessible via typical transanal approaches. In a review of 87 cases, significantly more patients with a foreign body in the sigmoid colon ultimately required surgery compared with those in the rectum (55 versus 24 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/4\">",
"     4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Endoscopy provides an opportunity to avoid abdominal exploration. We generally perform flexible sigmoidoscopy to identify the object. Endoscopic snares commonly used for polypectomy or ERCP wires provide excellent tools to \"lasso\" the foreign body and remove it alongside the scope (",
"    <a class=\"graphic graphic_picture graphicRef61271 \" href=\"mobipreview.htm?0/29/473\">",
"     picture 2",
"    </a>",
"    and",
"    <a class=\"graphic graphic_picture graphicRef76634 \" href=\"mobipreview.htm?34/36/35395\">",
"     picture 3",
"    </a>",
"    ). This approach also provides the ability to watch the complete removal of the object, and repeat the endoscopy following removal to evaluate for local mucosal injury, perforation, or retained objects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;The inability to remove objects in an outpatient setting does not always mandate a laparotomy. Improved relaxation and sedation can be accomplished in the operating room, often permitting successful transanal extraction. As noted above, perianal blocks in addition to intravenous sedation can facilitate removal. Palpation of the abdomen frequently permits caudal pressure and stabilization of the object, which may allow it to be removed transanally.",
"   </p>",
"   <p>",
"    Surgery is generally required if this is not successful and in all patients with evidence of peritonitis or perforation. Although initial transanal extraction can be attempted, surgeons should avoid any unnecessary, prolonged attempts. Leaving the object in place may help identify the site of perforation for appropriate treatment.",
"   </p>",
"   <p>",
"    Laparoscopy has been described to push the rectal foreign body from above to assist removal transanally [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. Removal in patients requiring exploration in the absence of perforation may still be successful via the transanal route by milking the object distally in the rectum (analogous to squeezing a tube of toothpaste). Care must be taken to avoid further injury during this maneuver when dealing with sharp or breakable objects.",
"   </p>",
"   <p>",
"    Colotomy with removal and primary closure is required if this is not successful. Proximal diversion is not necessary in the absence of perforation, gross spillage with excessive contamination during colotomy, or necrotic bowel.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h3\">",
"     Foreign body-induced perforation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Free perforation of the intraperitoneal rectum or colon mandates laparotomy with appropriate removal. Whether the patient should undergo primary repair or a diverting stoma depends upon the patient's condition, degree of injury, and extent of intraabdominal fecal soilage.",
"   </p>",
"   <p>",
"    Successful primary repair and avoidance of proximal diversion have been reported in trauma patients, but the approach needs to be individualized at the time of exploration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. Small extraperitoneal perforations in hemodynamically stable patients have been successfully treated with admission, complete bowel rest, and intravenous antibiotics alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/24\">",
"     24",
"    </a>",
"    ]. However, patients should be observed in the hospital for progression of disease, which mandates surgical exploration.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     POSTREMOVAL MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The length of period of observation following removal of the retained object is variable. It depends in part upon the clinical status of the patient, the size of the object removed and any resultant trauma associated with it, the status of the rectal wall (ie, degree of mucosal ischemia or injury), and the method used for removal (ie, spontaneous versus transanal versus laparotomy).",
"   </p>",
"   <p>",
"    Postextraction endoscopy with either a proctoscope or flexible sigmoidoscope should be performed to evaluate the anorectal mucosa for injury and assure that no other retained objects remain. In addition, an upright chest radiograph may be warranted to look for free air to assure that perforation did not occur from a foreign body or during extraction.",
"   </p>",
"   <p>",
"    Continuation of perioperative antibiotics is not necessary following simple extraction without any complications.",
"   </p>",
"   <p>",
"    All patients should remain for a period of observation and repeat examinations. Before discharge, all patients should be offered the opportunity for psychological support, while avoiding casting judgment or belittling them.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Serious complications related to rectal foreign bodies are infrequent.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The most common complication involves tearing of the rectal mucosa during insertion or erotic behavior. The associated bleeding is often self-limited, although more pronounced ongoing bleeding may require suture ligation.",
"     </li>",
"     <li>",
"      Traumatic disruption of the sphincteric complex often results in varying degrees of fecal incontinence, especially with repetitive damage [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/25\">",
"       25",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Perforation is associated with higher degrees of morbidity and may result in rare cases of mortality. Factors such as underlying comorbidities, time of presentation, and degree of peritoneal soilage (ie, established fecal peritonitis versus walled off abscess) all have a role in determining the degree of physiological insult. Case reports have documented the development of systemic inflammatory response syndrome (SIRS) and acute respiratory distress syndrome, leading to multisystem organ failure and death [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39654/abstract/26\">",
"       26",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=see_link\">",
"       \"Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29945?source=see_link\">",
"       \"Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients who require a laparotomy and colotomy with removal or proximal diversion, most complications are due to wound infections and incisional hernias (",
"      <a class=\"graphic graphic_table graphicRef56987 \" href=\"mobipreview.htm?15/12/15566\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rectal foreign bodies can present a difficult diagnostic and management dilemma. They can be caused by a wide variety of objects, lead to variable degrees of local trauma to the surrounding tissues, and can be associated with perforation or delayed injury. Further complicating management is the variable degrees to which patients are willing to disclose the underlying cause leading to their presentation, and the frequently long delay before they seek medical attention.",
"     </li>",
"     <li>",
"      Recognition and diagnosis of rectal foreign bodies depends upon an appropriate history and physical examination and radiological evaluation as needed. In our experience, many patients will only admit to a rectal foreign body when directly asked about it. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Clinical manifestations and diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients should be assessed for signs of perforation. Patients with peritoneal signs or obvious perforation and those with obstruction require urgent surgical evaluation and treatment.",
"     </li>",
"     <li>",
"      If the foreign body is still in place, it should ideally be removed in an emergency room or an outpatient setting. Clinically stable patients with foreign bodies that are located proximally can be observed to see if the object will progress to the distal rectum, which facilitates transanal removal. We suggest",
"      <strong>",
"       not",
"      </strong>",
"      using enemas or stimulant suppositories in this setting (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The majority of rectal foreign bodies can be removed transanally, depending upon the object's size, characteristics, and location. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Transanal approach'",
"      </a>",
"      above.) We suggest the approaches below, which are based mainly on clinical experience (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      In patients with blunt objects, we suggest attempts at manual removal after adequate sedation (intravenous and perineal nerve block). Other approaches can be attempted depending upon the object's characteristics and location. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Blunt objects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with sharp objects, we suggest avoiding blind attempts at grasping the object; the object should be manipulated only when it can be visualized transanally or through a proctoscope or sigmoidoscope. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Sharp objects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients who are body packers, we suggest not using sharp medical instruments. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Body packers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients with objects proximal to the rectum, we suggest flexible sigmoidoscopy to attempt to move the object more distally and remove it under direct visualization. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Endoscopy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In patients in whom transanal approaches are unsuccessful, we suggest assuring that adequate sedation has been achieved (which can often be accomplished in the operating room). Abdominal palpation and adequate sedation may permit the object to be removed transanally. If this is not successful, laparoscopy or laparotomy may be required. The object can be \"milked\" toward the rectum during surgery where it can be removed transanally. Colotomy and primary closure is required if this is not successful. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Surgery'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Regardless of the method used to remove the foreign body, we suggest that after the object is removed patients undergo flexible sigmoidoscopy or rigid proctoscopy to evaluate for mucosal injury",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      additional objects (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Repeat radiography may also be required if perforation is suspected. Before discharge, patients should be offered the opportunity for psychological support, while at the same time avoiding casting judgment or belittling them. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Postremoval management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While rectal foreign bodies are common, serious complications related to them or their extraction are infrequent. (See",
"      <a class=\"local\" href=\"#H18\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/1\">",
"      Ooi BS, Ho YH, Eu KW, et al. Management of anorectal foreign bodies: a cause of obscure anal pain. Aust N Z J Surg 1998; 68:852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/2\">",
"      Rodr&iacute;guez-Hermosa JI, Codina-Cazador A, Ruiz B, et al. Management of foreign bodies in the rectum. Colorectal Dis 2007; 9:543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/3\">",
"      Clarke DL, Buccimazza I, Anderson FA, Thomson SR. Colorectal foreign bodies. Colorectal Dis 2005; 7:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/4\">",
"      Lake JP, Essani R, Petrone P, et al. Management of retained colorectal foreign bodies: predictors of operative intervention. Dis Colon Rectum 2004; 47:1694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/5\">",
"      Traub SJ, Hoffman RS, Nelson LS. Body packing--the internal concealment of illicit drugs. N Engl J Med 2003; 349:2519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/6\">",
"      Moore EE, Cogbill TH, Malangoni MA, et al. Organ injury scaling, II: Pancreas, duodenum, small bowel, colon, and rectum. J Trauma 1990; 30:1427.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/7\">",
"      Chiu WK, Hsiao CW, Kang JC, et al. Intrapelvic migration with long-term retention of a rectal thermometer: a case report. Clin Pediatr (Phila) 2007; 46:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/8\">",
"      Johnson SO, Hartranft TH. Nonsurgical removal of a rectal foreign body using a vacuum extractor. Report of a case. Dis Colon Rectum 1996; 39:935.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/9\">",
"      Feigelson S, Maun D, Silverberg D, Menes T. Removal of a large spherical foreign object from the rectum using an obstetric vacuum device: a case report. Am Surg 2007; 73:304.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/10\">",
"      Ruiz del Castillo J, Sell&eacute;s Dechent R, Mill&aacute;n Scheiding M, et al. Colorectal trauma caused by foreign bodies introduced during sexual activity: diagnosis and management. Rev Esp Enferm Dig 2001; 93:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/11\">",
"      Biriukov IuV, Volkov OV, An VK, et al. [Treatment of patients with foreign bodies in rectum]. Khirurgiia (Mosk) 2000; :41.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/12\">",
"      Cohen JS, Sackier JM. Management of colorectal foreign bodies. J R Coll Surg Edinb 1996; 41:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/13\">",
"      Yaman M, Deitel M, Burul CJ, et al. Foreign bodies in the rectum. Can J Surg 1993; 36:173.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/14\">",
"      Marti MC, Morel P, Rohner A. Traumatic lesions of the rectum. Int J Colorectal Dis 1986; 1:152.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/15\">",
"      Nehme Kingsley A, Abcarian H. Colorectal foreign bodies. Management update. Dis Colon Rectum 1985; 28:941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/16\">",
"      Barone JE, Yee J, Nealon TF Jr. Management of foreign bodies and trauma of the rectum. Surg Gynecol Obstet 1983; 156:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/17\">",
"      Crass RA, Tranbaugh RF, Kudsk KA, Trunkey DD. Colorectal foreign bodies and perforation. Am J Surg 1981; 142:85.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/18\">",
"      Sohn N, Weinstein MA, Gonchar J. Social injuries of the rectum. Am J Surg 1977; 134:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/19\">",
"      Barone JE, Sohn N, Nealon TF Jr. Perforations and foreign bodies of the rectum: report of 28 cases. Ann Surg 1976; 184:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/20\">",
"      Berghoff KR, Franklin ME Jr. Laparoscopic-assisted rectal foreign body removal: report of a case. Dis Colon Rectum 2005; 48:1975.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/21\">",
"      Rispoli G, Esposito C, Monachese TD, Armellino M. Removal of a foreign body from the distal colon using a combined laparoscopic and endoanal approach: report of a case. Dis Colon Rectum 2000; 43:1632.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/22\">",
"      Demetriades D, Murray JA, Chan L, et al. Penetrating colon injuries requiring resection: diversion or primary anastomosis? An AAST prospective multicenter study. J Trauma 2001; 50:765.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/23\">",
"      Herr MW, Gagliano RA. Historical perspective and current management of colonic and intraperitoneal rectal trauma. Curr Surg 2005; 62:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/24\">",
"      Fry RD, Shemesh EI, Kodner IJ, et al. Perforation of the rectum and sigmoid colon during barium-enema examination. Management and prevention. Dis Colon Rectum 1989; 32:759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/25\">",
"      Madiba TE, Moodley MM. Anal sphincter reconstruction for incontinence due to non-obstetric sphincter damage. East Afr Med J 2003; 80:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39654/abstract/26\">",
"      Waraich NG, Hudson JS, Iftikhar SY. Vibrator-induced fatal rectal perforation. N Z Med J 2007; 120:U2685.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1377 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-961E418322-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39654=[""].join("\n");
var outline_f38_46_39654=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H19\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLASSIFICATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      TYPES OF FOREIGN BODIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      CLINICAL MANIFESTATIONS AND DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      History and physical examination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Laboratory findings",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Radiological evaluation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Transanal approach",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Blunt objects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Sharp objects",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Body packers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Endoscopy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      - Foreign body-induced perforation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      POSTREMOVAL MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/1377\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1377|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/4/42048\" title=\"diagnostic image 1\">",
"      Plain film billie club",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?38/15/39152\" title=\"diagnostic image 2A\">",
"      Drug packet radiograph",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"mobipreview.htm?41/2/42030\" title=\"diagnostic image 2B\">",
"      Drug packet ingestion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1377|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?14/2/14373\" title=\"picture 1A\">",
"      Tenaculum apple extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?41/10/42149\" title=\"picture 1B\">",
"      Dividing apple extraction",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?0/29/473\" title=\"picture 2\">",
"      Endoscopy snare billie club",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"mobipreview.htm?34/36/35395\" title=\"picture 3\">",
"      Snare extract billie club",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/1377|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?15/12/15566\" title=\"table 1\">",
"      Series rectal foreign bod",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/15/29945?source=related_link\">",
"      Acute respiratory distress syndrome: Epidemiology; pathophysiology; pathology; and etiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/28/12744?source=related_link\">",
"      Internal concealment of drugs of abuse (body packing)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?39/31/40439?source=related_link\">",
"      Pudendal and paracervical block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?24/10/24744?source=related_link\">",
"      Sepsis and the systemic inflammatory response syndrome: Definitions, epidemiology, and prognosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_46_39655="Gastric carcinoid CPC Light";
var content_f38_46_39655=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F65970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F65970&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric carcinoid",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 359px; height: 501px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAH1AWcDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKmhjnnYrAksjAZIQEn9Khr6H/YrOPHmvf9gs/+jo6APBPsV/8A8+11/wB+2o+xX/8Az7XX/ftq/TkyN6mkEr/3jWns2K5+Y/2K/wD+fa6/79tR9iv/APn2uv8Av21fpzvbuT+dLvb1pcg7o/MX7Ff/APPtdf8AftqPsV//AM+11/37av073t60odvejkC6PzD+xX//AD7XX/ftqPsV/wD8+11/37av0+3N6mjcfU0coXR+YP2K/wD+fa6/79tR9iv/APn2uv8Av21fp7uPqaNx9TRyhdH5gG2vFYK0FwGPYo2aGtrxQS0FwAO5Rq/RfxSNMs72LVdTjVTbxHbMRyx7IPcmvH2l1jx5ciK9vksdMVslY22+aSf4j6duK66ODVVc3NZGkad1c+RvIuskeVPkdRtNOFteN92G4P0U19p69oUss1tpumafqCrL8x1yOXEgkPBDocAoRjA7Yz2q/Z6Qug6pcXyzi4lkBjmvbiYIsEajgAZxy306mq+pRt8X4f8AB/4PkCp3PhxYLphlYp2HThSaX7Je9Ps9xx/sNX21DLo/hq6Gi24ZLi8mlvTFyIdwUEgN2GBnaOvrVLS/FF9q+jy2li7TXU0okF2x8gSsH7EZJQDgDgnFP+z3unoP2R8Zm0vhjNvcjPqjUjWt4pw0FwD7o1fYvirxXqNv4subf7SL9NLgV5Aqk75SMhVA9PTqa2I9nih9F126a7t71LfzWsiDgSHgM30x096ay9pJyloP2PmfELW92qF2hnCjqSpwKPs92Bu8mfHrtNfdeg2lzp+iXFvf3b3ck0xncSrxg9Bt7CoTugeK2tYyI7lnkuJ5GDrkDhiD3HQDpSeAV7KX4CdKx8Ni1vD0guP++GpTaXw629z/AN8NX27e619mVYYriJr9l3De2GcAHLY9ABWlY3k1xJp941zPcRXkYfJbEarj71J4C32vwD2fmfCH2S9xn7Pc4/3GpBa3jDIguCPZGr7qtFu7TUnuZb15IbucmVGfKJGBgKo6Dgn65pyLf2+rTXMD240SVSqwK3CgdCccLj1o+or+YPZnwmbW8GMwXAz6o1ILe7ZmVYZyV6gKeK+4LrxAlpp/2u4zeqrhA8C5VM9GAz0A71oaTfxW93cXJtYh54CyzIPmYH1pvANK9ylRb6nwj9kvv+fe5/74amSQXUYBkinQE4G5SMmvv63vZILlrVg7KcmNgcj3H9adrFoNQ0+ZBHbzTRqZIDNGHCSAfKwB7il9RV9ZDlQt1Pz/ABDckEiObA6nB4pVt7t87Ip2x6KTX1zbLZv4d8TW2o2F5Z2lptW4nVthldgGfaTxgYrotQmtLDSpxpk8ens8EMgmc4zHxjJ9SKt5elpzfh/wQdGOtnofEZgulYAxTgnoCpo8i6zjyp8+m019falNaT6yLi7cTyRxmaNkYgYBwB9fWq2l6hJql351tL9ncE/fGT6flT/s7S/N+H/BJVK/U+TVtL1s7be5P0RqX7Ff/wDPtdf9+2r7t8OatHYRtOjPJkFXI9e/6122l3y6hZLcR3I2Oxwc4P0I7GuaphXDroKdLl16H5tfZrzOPIuM/wC4aUWl6elvc5/3Gr9IbmwgkUDy0En8MgGMn61zGhG+tdd1BLpXVUjXOSSM5POe/WiOGUk2pBGmpJtM+BPst7/zwuP++GpRaXp6W9z/AN8NX3wkhS/i2yEjcVI/H/69adjvV96M23IOR27GreDS+0VKjy9T89fsV/8A8+11/wB+2qqxJOGJ49a/Ta2nyqKHyRx1r80dT/5CV3/12f8Ama5Jw5DAq0UUVABRRRQAV9D/ALFYz4913/sFn/0bHXzxX0R+xV/yPuvf9gs/+jY6ECPr1l5oCU8iitrktaibRS7falp1ITG4pcClopXATbShaUU+i4DNtBXFPrnfHWp3OmeGrqawx9sciKHJxgtxn8Bk04JzkorqNK7sY3iO1g8QeIYoluG8jTo2MylMxsze5+UkDg9xmsDWtUtLfS4l0+K1sYmlMcKnAeZVzkj6mvG9Yv8AWZjPoRvJptIgu9jBGCyNIPvO3IJAbt6fSuw8Ry3OsaLp7W1lJJqhgeEW6AuFCt8zqegOePWvbjhuTlTen9f15HXGFrJ7HZavoketaNJevq80lhP5ZijQf6mQ8n5s5IJxlelXoNOtp9NeylSKa3CDz/NQOjNnd79CM49azdA83RvDunaFct5uo2UZu7oIfljySUDk/wAWMcUlt/aemWdlZ6ZZx3UN/dvNctMoRLWDkkEk8kkk5qddk+unp3DRbHOx+Edbvnnt9J1WK5jF5vuZ7iTeIkwMoCOpxkn644qncaPDqPja3S1t10vQ9JiE0+pK7RowU52oucdOM4z1rqNbuhpN4klu0k+y48u2s4ZdkI3DLM2OuADwKu+Jp9Hg8JXEd1bJcrKBLKokIUc5C5HX6CtFUldab/1cbcnsczp/huK81DVddl1HduuGurREUiGMdA+3q74I5NdRdWmoSeHpbbTrh0uPJ2i4I+cE/wATeneoVeR9DtWsbdYfMKttbjC4GBjtT/tiXOmXUVrJFcbbny5BAdxDqOF464zSbbdxbGT4T0++ggmg1K5aV3t/s7tGxJQZ67j1Na8lpp2j6P5W6eRIlaQYzvYDnP1zVfW57rSNPWYJLPOfkW0hGWkY9Nx6Ko9aNFtdWuIbiWcCZpIPMkjToijkIuepyMZpS1957A7bmRotxo+p3v2t9Ga3vLqNoU88bnK4IGPw47dTXRasI5dMa2SSWBFiMX7kYaLjG5fp6VH4a+3Xl7bXEunwwbZPnDYBRBnqTyTVbxUdHvbloJtYijivOFlicEvg9FI9+DTbTnb/AIJcuV25SLwXZXH9gNDq8ksqPPkGVdh4H3seje/pWyNDhm0PVI0aSVZ1MfyvlWUnJ47VmeINVt9FW1spIZ3a4fblFLbT2J/PpWX4Vjez8Ty6xbSStpU9kwe3LHeSDtJCdOq+9Jptc23UjoW7GG8ifSbLwmtssFvOIrgTqRuj/ix61Qnnke91ZPD89w1wsoQw3sGyKPDfNsYdRjtW9qdqZdSjvknktbUgyshAGR2ye3NTatdQRXdrFLmWW6OGeNcqjYyoc9s+tUpa/wBfiUn1JLaLclnetuDoWhkGflYD5l/EetaE91YafA9xdTxxQxK25ic7RjJ4HfFZFpeXG6a0uoAI92YpogSreoI/hI/UVBqmm+fceba2FrNFMPMu1lLbpWRSFC44B6Zz1BqHFdS5bG2PsuqafG0flXmn3KBwcZSaNh6H1rnPFFvaTSWFpqME8lvdyeQ7RKMRLjILewxXQWU9ta6fD5cK2dpEg/dD5ViHXA/OqM12bGwuDr1wHH2nYkix8lHYBAwHQgnG76URumRJaWZz8+m2lto73mn+TLbPcFlZAdyROwBJB6YPUVltpc+nubmRw0rsFyRsATPIA9feuovNPuLe9sxYxF4nZYLmPPyLHk7n+o6/jXMePYb12S1sxjewO8HjHck1rBtu19xWaLtndfZpJmVVfexYMTxitTwJqBu7fUZHGVE4SOP0J4B9ulef2+u+S+pbFY2Fsirvfqx4H6nJA9BXUfD+6ikaW7WNmtZQCYuM8HjI9c0VKbjF3RfN7rR6Xb3zxAxjJjLYDNzXQWqQTQMUKSI42tjnj0rgrC7OpXE88q+XDAcBN3XFLFrFzE0s+nOfJlOCVHyn3+tcVSjzfDozN0uf4dzrotDgj3bAypk8d6r3v2bToVjkkMCH5m8vqwqzo97NJ4biuZW3zkNye3JxmsO9tJLqJTdZEhGcsOuCazgpSbUnsRFNu0nsdLYtbTQRvZsGhJ4I/rX5p6n/AMhK7/67P/M19/aRNPpd9buoLQzMElX88EV8Ban/AMhK7/66v/M1y4mDi0ROHK9CrRRRXMQFFFFABX0R+xT/AMj7rv8A2Cz/AOjY6+d6+iP2Kf8Akfde/wCwWf8A0bHQgR9gnrSUppK2F1HClpBS0hMKKKcBkVIgHpSigdKMc0AISc4FeVfEfxXpaStLcTB7SwLDCgnfL0IHqe1d54w1iHQvD17fXErRbEKoVXc28jjA7+v4V5LeN4ek8OW8t3KtxD5TyBSo3S4OCQPXJGa7sFSu+dryNqK6nlCO/ifU9Q1O3tY4o3JVIVIy8jYOPl54B5/KvUtFjudN1Pw3ZXU0S2cMy3Ds8bDBX5FClePvHofrXJ+F9Gjk1vUYxF/Zmk6bGTOkRyQSMhlPcHjGfWuq16+0yxu9BWeW9ln4SK334BVsYDgfzr2Ksub3F/Wh2uS5OVdTX1qO8g8U3zW2qWiWss0dxLGELs6qpHJxjJJHfooxVK5muPEfw/mlnufKiuZWlkklkURqsX3UY5wAXwSOOgBrY1DT1v8AWLB10uWaWPMQjE3lRqpHLe+BWLbR6brOlHw1oWlSroKXUstxMrlk8yNhgA9wTmuaNrLyt2MLWSRl+DrLULuRbzxUbS3t7RBFb3MknFyzc4Ts3bJHXFbN3eNa+IPsOvwfZtOF2tvb/Jl7pvVFHRBkc0zxbNo2nT2Ul7piTPZgGJI0LlCeiIB1Jxya0tO8S2HiLRU1S4twtzBM8AymGLAA8E9OuMj0q5OT962j/D0G+ZEGu69Ja6ppunw6e11bTTETSksoigB28Y6sew6/nVV9QTTrd7PwQtsyRymOWFGO1D1wXP3j67c807RtaM1nONWSCaTzDmFPmEGRhEBHfb1Y+tXGmhtntYraENbNHtbycRxQjsqgdWJ+lK1tGv8AJis73NC20iXW7FknV1MkREsqEgKSOSp/rVWxurSxvptH0iQC8t0SIpuOYxnjcenvW/q+u3sek3UOnWjPdW6iNbaJgGk46j6U2P8Asixn043iWkeq3QVrhNg86RsdTg8kcAmsVOVveXov8xczvqjkfGGq32i3Vla3ENpcxaiGh33FwF3KSA2F6nOaj8QaLYwaZpE1vp6wuqYg+zRgCEZzkDoB3qzqn2jXZ9UsNXsJ7i9gZ/s8kUQTYh/hVzW1pUAi0yztZwA1ugiWPJYKB1G443H6CtVLlS79RpvqSXk9uLjS7e9J+33MChcq2SwHOSP5msfTruw07VXvLeCe4up90QlClkiIHAPoO345q/pGn6jBf63qmtTtFDdyKltHDO0oQAHnaeFyMdPesGS5TRYrvWJr1JbUTiJ0tcvyRkbgQMH6VMY391ak3bN/bd6/4dS38QwW7iVZY54lbDMP4RwePwqKe6t9K01WTT7t4441gSOGIu5XopXPpTbe/wBM1e3ea1iS5ltHA2g/NbuRwR7/AFzUlrabdTOoPql6fM+Y2zzExqB1wvTFCVtH9w7FnTJYp4pVtJt0sQG9ARkH0OOhqS11TdYNeXUZhWGRN+B2J281iWHn+HrjU5NNsIU0+4PnA22TMz5HG08DAz3Na1ne3urTxGYOlo0b/aI5kX5geApUdGzg5pST+QJspXcdp4u07ULC3kkAhlaCVXBVvMUgrz/dJqzDIBFDBelPt00PMYwQ2MbsfiKsWUH2NJJk5d8kvnms+bQoL3V9P1kzES2e4hM43Z7H8RVeXQ0UbaszXvte+2XNqYUjEsc0cMyHIyFJRvbtWBYX2qanpdlfXilbC2hL3F3ty5dD86lP4sjpXYTC4jup7+JS0ceGSP0boV+neofD0t9faPO1xbyrHIzFo2XayMpweP7pFUpWWwkneyPPvFFtp7eH5pdPfzLd58kjgmTG4FvYqQRUHw71OOC/t7J2z9okIRe+7Hyn6Zrp/EZ0w2F7pgUJ5aIzSEA9DgBgOeOx9KyfBnhSS01t726Ku0SMUCnpkYH866FKLpNSFqk7k2h6xNceLGDFvs8COWPIBYA16Tp8sc3h+VLaIfuI1OB/hXLTWcWjaNf3BVHu78LGvpGm7nPvUHwtv9Tm1bX7bUDt02CEo5IwVfPyqD+ZrmqJSi5x2Vhc11fsdf4C1xb3zNIvNuW3GMLx05x/n0rqdV0+W5khEDeWick/0rzL4dtDfeOi9symGFpGGOvQgZ/OvZGHauDE/uqvumdb3Z3Ry9rpc6NbLIA4RyS2etfnZqf/ACErv/rq/wDM1+mxADKBwM1+ZOp/8hK7/wCuz/8AoRrlrzc7XMnJy3KtFFFc4BRRRQAV9D/sVf8AI+67/wBgs/8Ao2Ovnivob9is/wDFf64P+oWf/RsdA0fYZ60lKetJWwh1LTR0p2aQBTl9qaeh9aI85PpSJH0uaToOaQyJtLbhgDOaQ7Hknx33XVtpK20rny7lldN2F3FcDI7kgkfjXjniqzuYpLWZX/0OSJ2VYYydgyCyqB2yo57Zr3f4keH4Mz6x5jeROIxKhPAZT8rD0Jya5fUxmzj0e21Z9LSfZH5sA3uMDJUDsDg5PGa93B1FGnG3T+vwOyn8F1sjU8BTWWteFn1C3tkt7m4UC4OR8zKMDk9Rgd/WpdM8MaVd6izRac8l1K5uJZ2mJDuo4TPZeBwMCtzR9V0XTdOFvbxobaNDmWVhukKgBiQB9PzqRPGehrZabLpySytqZdLaOFCCdp+Yk9hn86wlOpd8kXrsZybd9CtrMl7pliDNp8+oa1dRsgFn8qRgdFXPAyawZg1j4Mj+1z23h+K3mU3cUTkrJJgkxhuMkkjOOOKl8LWN+PF2vmU6zJYW9wM/bJz5T55IjGOQO5+lWNattS1bxDHpVwtheabcTfPE5AMCgZDqMZLf5NXH3Xy3Xd/1tsJOz3OW8S64LeLTLPRFmgNwd0s6jfJs75btmtj4fS3lzpuraje6dbW1irCOyM/JZhncTj+HOK2PFPhWy/s2UXzTWmkRRhpHtDieX1XPYduPWqX2ma7XTYtEtTbaHBGq+XKDnZjoBzk8davnjUhaH3/11KcuYo63o8cT2MouLi1jL+Zdw6dEmGB6ByTxk9x61s22nXxgE6zRPZnP2SGJcrnPyscjrjjNYd2n9l6nd3r24nsZ4XF3JuJkOOgUfgK6mweWx0S1BzAJ18xYTjdGOoPtSm5aahqeY2fjXV9H8V20HiC0jsJi7fMZgx3k/KoI9QefrXYX9xomt6hbas8W/VrISqwgXJDhS2w88Ejoa5Txd4abxD4gs2TTftDMCHuxNsMJPcDHPTOa7Hwxpdh4Xu7uK2kSa9uVSVw77juUY3HjHIrWoo2Uo6St0/rYqWuq3MjTvEF3qWiakmrzrFp146xwBXNvPz/AGB68Vev4GudAuLKxuf7L+whTFOw8whV4KZbkkjnNO13RodQtrdYVNlNHKZw0bEB3HTIz90HnGRmrk4a106OTVGW4bBZpNgUn1OOlLTdaBbyMLR/FCRxRva3myJXEXlzqB5p6Z56/Wu78YaT5umobC1P2rZ5qrCvG7HJwOtecw6WLSxu9aubCLWL5udOt/KC+WuevPGfr6V1Wv61e/YPDkNxceQbxAJwmXcyADCAjjAzyazqx9+LgKT1TM/wVJNpunXMWtm0udVdyXECCPYMceZjq38u9TQW51AW808fkzKpLBGzzn7tMujLo9hO9tYLfXkRJ+yxnk5OCSe/XNOGpJZ6ULm4Q24jUSSRj5hGcdAe9Xa7cu/8AWwzMsZNXaSW1ubmGZoZcq1upBKf3XHTPuDWrfpcaTZS6hBFJNMwGVjOSB647itCERSWitDG4+0QrIs44U55xj1IrnXg1R01HyNX2rDcoySKoZYkxzF+PGafNfyKdTpE3dLLalHbM8qIsgz8pPJxx196W1kYpLC+GkR/LcjjJ61n2aXjWOGuYri7jYt8mMDncAcd8VcursNBJJs+zXU480qWDAOeAcj8KT3NeZNXZNf3sGlRRrduFiujtDdQsmeM/UVyl1c6/p8McpeE7NSO4k8fZSf0PPbmte6uV1fw+8mo2TGaBT58KD5hInRlHvUetE3GjsYJlt5YlUuGG54wQM5A70R03M7pO7KlxcaJJr8UN7ayW95qCNHFKyfKcfwt+lOeWHTbLUZJpo1lh2j5cAysThVAz1PSud1tmjt5L/Rp3uZIbmPzklXedg4YIOq5z1rrvA9tdX3ge+1DWo4nupLxhDKowXhQ/uyR7ZOKqfuxUvREOdlY47xFdXF7cw2EVytvdGMSxQTKSwGfmYgdSBnHvXa6wf7P8K37WiIGZBI3J+aQqM/l6Vy0Tf2ndyXWmtJFJayhWe7BRGUn5tn5d60bvWN8NxZPbXCtGMfaHA2t/uYPP1pyV7LsaOClaxc+BqxC4uA8eycq0g7HtkkfjXsDV4/8AAi1sobjU5YZ727u2GGluFIEa5+4D3JPP4V6+3WvNx/8AHZx1375Tvrj7OofY0hz91a/M/UjnULo+srfzNfoh4s8S2dhaTwh5TcEbVEQy2favzsvCTdzk5zvbr9a5a0HGKbRNmlqQ0UUVzgFFFFABX0P+xUP+K/1w+mln/wBGx188V9D/ALFX/I+67/2Cz/6OjoGj7BY0DpQwzQOlbCFFOpoNOpAFI7lRhBuk7Ln+dL2plrEY0O9t8jHJaloAiwtJhrltx/uLwo/xqR4kaMpjCng49KkopXYGZ4is473Q7m2lC+UVG7PTaDk/yryO9ttJ09rvWdUQ2S2JNs7g7zIhxgYHc7s89Ac16V451KSxsIIocF7hypGeSB6V5xrHhqwvZLG5u/MaNLmae4VmysjSKB830A49hXqYFNQ1ejOimpcvkOaCy0k3epyTT/2bLELaK3iUOIckbggPVmwOT2rG1HWdevr2S08MwW1vo9kBGiPDloMDJJ9yepFd9p50ZrRRc3HnQpJvEyjCbsY2oO+BxmsrxF4o0rw5Z3Oqy21zMEkxFEF2eaWOMk8ZH510wneWkbsd/It+EvFc+uaHNdXmn6hCkLljNgx+eePug87cd63Na161tdNaazs5hcXCEHam2VQehFc1pfiSa4todVWzlSadSB5z5GzORgDgccU6S0gSO91myPmahqJyshcsm8jaMeigDn6VlKjHmu1ZCcL6lGBGub9FmvpTLFDtFsxLCMHk7scBvqc9KbpOpxwtqU1tLfaw63CWxhRAqxk9AAo5x3NJp2oabo9u2lhrm61RbV751jix9o253AP69cD0HrT4te1O7u9D0/TNMk06G8gW9kCR7F5bkM3XIABOeua3d7NW/Qq/Q300uTU9RhjjmtbYIA0lu8gMynHAKj7tVvHtjqFzfpDaAu7IBE6r/q2AwCRnpz+VUdfez8BaxqGsIYnu7/52Wc4iyRgDd6Z9KsWeoeINW8Oy3F/eJpc8g2oYxvEaHkPx2+vY1jFTuqid4kq61JLGGbw/osKXkxutQVT504UKCevyr+lZq6orWhvlhWNc5nUkb1XPVh1596L+bULLRYxCtr4iW5kXzt05g2r3dc8j6ZqCe1a9uNYg8OWFnb2E9riLVba8Uu0oH3GyeDnrkVrHu+v9f1oO9kbWmW0Gp3Rngn8/5RIoPH6Vm2kmrTa1cNqOnxRWsanyZ5bjcrynoqr347VB4DtdWm1vTpL26sU8mDy7i1FykkyOGOHO3ruBrVgnuSblL3S5ba6t53W3W4ZT5vpIu3kA/nSbtJx0Y73Zh3llqjamILqzmDAmRJydqpnHGM/j0rpvCFjfafYX9xrg863BDWkkiK3lcEAhRz+JrBk0w3utWV5qdiYLqzbesyTNtLZ6DnkeuRXPrqXjHSr2QCB71tVuUQQSJuigAbgnHQEHpVyg6keVNf12HK7VjXtnubPVLjUQ0Oo3pRgjRRlMnODnnHv04qnodhtvdWhuLHUI0nTe01zJuhlYkHCg10XxLu9C0WaOK6iW1vpYhNKtvlQ2O4wM9aoXkmpXNrb32nol5LIieTDPujKqx5Lk98UU5OUVK1rgrNJl6C5Eq2DTyNa3UCFFtlYHKKSAce459qw9Vj0XQZbC7uLW8ltPOMiafaHKNM5wZZT3x0Aq5qmk22qM2o6dKllqsQEM07neyAdgvYn17isvX7i4kkt9P0RoLjUIlR545QUKxMfvr2Iz+VOCT0RKSZr6ZdSWrpFqGnLby30kuwQsWHlggKzehIz+VUtJZNZuP7F02SVJovMb+0HjUx2jA5Xep+9nPArahM7eTLcpEEO5UKHn6/iag0mxifX7e1sEjgcsZbhR1lXOd3HU0ujZ0UqSnBqTt5l3VtRXTtXtLV0kM02EWcDasjBcnI7ZwcCs97nTrfVprd2fz7qPzi0i4jC7sbd3TOT0NW/Gmo3mnTf2jY2a3SuSfLfpwpwPbJ44pNDbSvGOmTwSRyLEUR5rcPh48n+hGKhe7BSexnLRW7HLrotzo95LJBFPdrdTuT5QGLcbc7pM9QfTsK6bVhfr4Wt7DSk+0W15IxLQk/JHsAG0jp8wNVfiD4dt7q4sr+HUZLKXSyHUFiEnTGArfT+tRaJbN4d+GZs9OLkvdSTJJOpCR724Vc8/lRKXOoy63MnsrGFo9u9nZzafqV/LMt5ciO1jnk3keXGd249s4FRaslyJoXs0e3ixx3KnuD2NWfhhDeanoutnUYGe6tZGaCR8ZyThsen0qrEdQF6/mOoWJTvt+uDkYYfyNb3tNrsdeHi5QlZ7HsvgKFY/DNnJtUSSpufC4ycntTvFOtDS9PkkikCyH5Fbbuwx6cVyXwzvkGr38RWVXeIEqMlBgjoO3WqXxJ1uy0y4WzedYZpv3gJG75c8/nXnKhzV2nqcDhepZnM3mjar4m1OBL2JZRvG2aDKk5PU+gr4/v08u9uEznbIwz+Nffvw91S1u7Seey/eRQpk4yTn0/SvgTUTu1C6PrKx/U1lj5ybUHsh1Xry9itRRRXnGQUUUUAFfRH7FP8AyPuvf9gs/wDo2Ovnevoj9in/AJH3Xv8AsFn/ANGx0IEfYDd6RelK/ekXpWwDhTqaop1JgKvWn1HSg4qQH0UDpRjvSA4nx4Fe4sZJFTajsgJPKnAwR+PWvOtCuL/XdZ1iOG9smtxF9jWK2RriON8kiSU8DgZ4HrXpHjDUdLh1ey0e4027u7zUeQ0AwsY6ZZs8D6VR1HTI9O8N3FloMC6cC7rL9kwjHPG/J5/E16+Hny01G2r2N4v3VEyLOytdL0+C3vp2uymHM7AR+bnuqD7o6AD2rav7K01DSib+LzoD8g3NgDt+VcpJpl7oOm6fJqGsWz6FY2zm48z99dSyZLHB7gDGMGuw0rULKfQoZvsjnTTEtxAJBtZyefmGetaVG1aS11/r5jb0RzWvW8llr1pZWLxJpSRAuCPmLkDGCeg6VHcW8w8L6dpek3kH2iKYwP5q43KrfOMewYCmvqt5quvXENzYwmwKAxTqfnWQYwPp2rQ8ixbxFueaU6pJbKPLYsVCKeq9gfX1rXVJcxSTtqUbvTbPR7n7RZak9tFBam1S2lUui4H3s9c7uc1eFlfarpNjDeSrLI1sPM8uTAZzzgH3wBS6o1veC5kUDzo28tgV3K3PXFc7I9jrzXdndaVdxR2TIY5UZ4g8nqCOSMZ6URTkr/1+gK5p28et3L6Pp+s6HZz6asmbs3bLttlH3cMeWP8AOt7xX9l023a5mu4oLVwN0jSgIueik9DWB4kjvdY0qzt7W2eC3lYwXczz4aEBQcr74oNlp7+G9O0jSLeO702Fgsj3pLFyDktjruz+VTa7i9vJf8OTfXQseHreW4tD/ayWyJO+608mXcWX37YNUUsZbbX5LGyKQ6YEMj20NsqKpx1L555x0FahSx0++sSVLPCNkKxn5QpOa25gsbzgv3DBRwT9fpQ5tP1Hrucx4E0+NfEd9PNYW6FTlLhZNzygcEkdB24rM8TXhnlv9VW51L+zVQwfZ4IP3zux2hw3oCfwxWlPJf2/iHS/7LhsktXuVF3kkOUz2/Guj+JCJbxNHA08clxC0W6PPyk85J7dKHPlqq/VfkGvNbuRaLGBoEDXJnncRoPMkI3OQOScdD61TsLt31qF7kIzGVRHD+PX8Ko+DjNaeGjYzSvI8eT5kjbiSxOP/wBVT+H47VvEK3dyHe4toXKuMbS3b8aJR5ea+po1y3TJvF1xE/i2a0MT5iiEhkePKYY9Ax/PFLaz/uZlQMHb5ST1x7VU1a4mnEn25JB5r/cU8n3qLTtYgvoVTT4bjyS5hZJVKNkd/U04wagl2EtuUzLfRIxqBttF1KGEW7m4v7ZHy7M33S/fbyeKnbW4JfEd/FDaK9jptqIridoyGkZjwE9h1JNT2d5pej668CGO3u3JllUkB345Y568cVc1CzvHSM6XcW4WaVWYEqd0R6jBq5PXUT0Rn2uvfbvE62axyJFA4wWHDgr2/wAa6mFEsL2S6tog0ksZjPYgHsD2qjaW8Z1WSYzFjGAFt8jEQxjOB0J96s65NPFpym1hEzNIqnnG3nk5rKVm7IpOyOf8fx3aaU72KQzKAjIlwTsUhhzx6c/XNZVhp2sjWtSv/DrabaT3FpE7s6HcX43bz6bc4x/Oum8TRpeeHrkL50paNkMcPLk4zhfc1zul6/caOWsE09wVsEmiaRMNxgGNvU/NjHbafWri3yWX9bETXQ0J7+7ispodVs3u41t45DNnIlfoyKPbGTWl4ytFuXhtXcfYp7cMsO7DIMdh+NZRuRqsaxWE8a7SXuADjao6qP8A61V/jDPPFc6aLG5eKK6snitnEe4Bl2kOW6jj0pKP7yMVpuO3I0M0SwTRNAmtGilVY3zbrASMP2yfpk8+tZOmSJaz3rGBruZvklRCP3anGW564NdLHe3Nxod6v2WW6urBI0Bzhbl9pJIPXGRjnmsfT2ujFfD+xzYTpAjRk42yuy5Zc+zcVabd2zrpV9Jq9ubsdJ4UCaRbX95blZZyNoVOoXqTXlniu4l1/WzbXYRNZeQGzk2bo50J4QjsR7V3Hwya/wBW1W703W7RoxNZusrwt8i5wMA9jzxXoemeBtC06S2dbX7Q9uoEbXJ8xgR0bJ/i461lKvHDVHzbnJUnGnNkngnRX0Lw/aWlzHbpeY3TmD7pb2/Cvzn1P/kJXf8A12f+Zr9N2++v1r8yNT/5CV3/ANdn/wDQjXj1pOb5n1OS7k22VaKKKwAKKKKACvoj9ir/AJH3Xv8AsFn/ANGx18719EfsU/8AI+69/wBgs/8Ao2OhAj6/ahelK3NA6VsA4dKWm5ozSAdQKBQOtICSo7hnSCRok3yBSVXONxxwKdniuU8X+K7fQbmFnkDpFzcRRkFwD049e+KqnTlUlyxGk3ojC0x9SllN5qlncWk7wmeRpWDtBKTgRqR1A4/IVBFNLPpN00W6W+ZwokkbPy5xurXtpJL61uJWnDROxQAfK5Vugx27HmsW6sbfQHaCOeSa5uFR5GkIyFU8KFH3QT37160Wr26nRF9OpNPB9g0v7VPbpJDC3DyHLO7cfKOnPvWVdWeteIH1OznB03SYYlK3JkKkHg5rSm1ec6XeF7aO5nZ1MEWPlXJxn3xyaXUribUtEntL0tiT93LGjbcq3/6jirXPfYHcTwvbWEWnbPtzXLxriOTgtMQOo/pV+C7aaxj3Qtak8gSEsfTJ55NY2n+Grq1tWn0nytlrb7baBgPkfvKT378VStEvru1jtpr+RLtwS8qcM4HJC/pTaUpN3uVdsd4nl1EwSzaBbI8vmlpYshZGXHVRn7xPc1Xuf7TnjXTrS/gh1mRFnFpc/N5Kfx5IHI7e9EfyXcmrTSpp8aBuH53oowC7Ht16da6oz6ZPZNfyQwnU7iyDNNFEAZExnGfoapy5LK1/66k2aVzOmlltbSzhjQ3aTXOJWQ8KNvX8Tx+FU77RpneDUdHMcV5akw/vM+WFJJY7F6tggAmtHQLS3OixzaMd+I/OeEsfMTJPUVmDxDPa62kNtBBcWczGK+DuVljOPlKevNJPfl6ArNXZlLe28PizUri91zTWsLby0VVY71c4G136DnIxzW9f32of2zAUsFe0MRmluBIBuPJCqPXgDnjmjV/CGjASeTHG8F5KHnjlQDkchvryeaYmm2CL9ps7kyHc0cQL5wcYIOOOlVzxlZotanM+D7+fWPFty91NJbElAdNlIYRDP3sj+L2969K+I93cQGzht4LeWJmBuGuWKKqdPlPQn2rivCHgLULjxZaapfXAEUMplZY02b17K3rXV/GK0m1rQ1020eDDSKxMgLKMHPOOhrKtKEsTBRfr5ETd5pIp6Oka296pDGN1LIT2I6fzrnX1C4vIJ7SyZrS5aVVRzjdtB+YjjrWrpU4l0ueC3wZLYLBl/kEjdcD06d6pXDr56Tx20k14vy/uMNj1Ppgetapast+87o63ULuA3MSyEvdRwGXaF5OB/OuPc6reXlhcw6pc2UavvMQAHmgdmYjj3rrdXlll0WwvdPFu18dobzDtyueefw4rldXuNQs9Sie3sxcWLRvNcSbuEdRnH49PxrOitCYve5b1i3ttStvLvIkeUrtZzyWHuw5rU0yyWx02zjMQRgmFHUqmePxrnYoZtR1ZrubUxDZvDE4gEezYQc/Tkda6O4uZLq6+0Wk8Nzb8oyQDcdwGMFugANXLS0ehd1poVrRTDrd832FIIplVluFmBeUj+HZ1AGTzWJJN4qjsdQj1G3t7yKWfEaR/IDEc9D1yOK0dZ1OLRRFqWrPFa23EceIHdo2bgEsODz7VjaxHB4hWTShdmR7eb5mt5SNrqSCpPT6jrTiurWhLs9iHxYn9m6VYWNvdyWZkUxxxLmR5JSDgZ9Pfitrw/YzjQ4I74A6jb2wLpIwZkJ9ffkdKTR7bUJZr2PVrJfstqym1uJGDlhjBK+g6frWlf30VwLw6RPA9ysbRuQwPlSBTgP7ZxQ3pyjSueeWdnBZ60Lsk20tvG6/ZEyFJkJXJHfO3vXaa05n+G9rc2weWW3JdY4+pAbBAz0qtqmlmZUuAkYu5Ujkdl5B+XoPbLGpbkMumabaNGRaSI6TbeikNnr/nrRN8zi2a1bOCtv8A1YyPCWs3+p2M00NoRZmSNC+7JAwWIP8AtDp+NN0y01C48UR3OnMX0m5QxyWtwSxUsSCw9+n51TuSdG1GY2UpFrOuYYF4VS33nPqx/lWz8J0ll1yUvMGhB6FsneKKklBOSWn9fidKwko4eVeTtbbzO/8ABvhmHRmmuEiMUsyhWXeSPrg9K6cg46U6mkHHNeLUqOpLmkeJObm+ZkLf6xfrX5k6n/yErv8A67P/AOhGv02b74+tfmRqf/ISu/8Ars/8zWdToJFaiiisigooooAK+iP2Kf8Akfde/wCwWf8A0bHXzvX0P+xV/wAj7r3/AGCz/wCjY6ECPsI0gOaRzzTV61sLqPpRzSUooGOopKWpAP1rwue7tIfGX+lQG6uL28Il8rnDDrn8ABXreva5Dpk0FucmafOMdhXkWiWcmoXviJo9Rt/shR1d4wvnQO3Qj04z+telgYOMZSlszekmk2b9jfQNp7ajFBNZyy3JEsWMliD1UemKp+ObB7Xx5aahGbaJL6IRyea7GRlHQKvQVt+ZZeH/AApp8TWhv5oiwgTOT8o6k+5qpoWsHWBY6hr1hCmpcsN/WBDnBHpx610xck3OK01X9fcNPXQqeG72PWJZxFBdItrIY28+Mr8w7CovFuqT2DR3TPENIt0Zp8Lumdzwqr+Pc11sNvYXFy11HfS3N5sIhh5AB749T71gaLbX9vdXsWtS2kcc0n+jIrAsUx1PvnHFVGom27bFc3RlTwt4o+xXEOlxWtw8stus7mUf6tGAwG/2iOa1bKyibxVH9lV5PvxhyB8m4fMvWoJbuPUb+6trFcSW4IGMgkA9fQmmeANIvdM07xJeXDxf2heylbaVB93IPOD0PNKdlFyWjf6g9FctPpcMenTab4mOnaskkzBbeCM4jTOcMx755xUt/qamMxxWMFuLfHlLGpdti9Bj+grF0qzvbZ5TcTvcONieUwAAI6sDVvxFazzjdYTG2uiykS88AHJFNU1dXd/y+4LdS5pmnW8niTTNWt9QuoHkjYtCgKrMCOVZT/8ArqLX4LRXNzbGMrCzMyuoDA9vc4rV0/VlPiTTrW4s4jNcqximGcowGcke/pU0p8OardCPW4ILbUWk8tQzkB2GSCvbt0rF1HGd5J7dLPuK9ndo4xpHv4NIM96lvZYLTxzRkkhj0HGafNBaizj06a6g0mI58qaNh5ZLHA2n1x696sv8K7s6slxHrl7LCrmRRcSB4+eQB347Vgp4Svrn4iWui+KLaefRbgNLGQp8tXUEkbwc8+h9a6I1KTu4z2VyuaO6Z69drDomhW9tbpK6+WI9xOWYAd29a4yW6gl1FlknEcgXcIN/b1x+daHjbUtTtr+yttIhiW0tpFjmV2/5Z46/Ssw3Gl6hqJeOHF+VIlEaYcrjI59s9K5sNBxjzS66k03Zaoi8QpZz21vHcF08yTzFRBgnA9qxbyzmNhHcaZM0KxkmWAEFmYc7Se1dDJ4cuLnWrRmuZSLVmdQp2owIwCw6k47ZxWDZWVtZ+K4dK0Cw8vToJT9qnMh3CQrlyQRzkEc56cV0xkuj8y1a+hu299DP4M05p3ignOFZBJkK3PGe5x2pyKk9myEq0ZG0jsVxzWZqumpqrQRXUUAgs5vOhlUFcD3xwSfeqMl9crLb3NjcxWlgspabzFyZh6D0ojGyCOifMdFbC0JhguI1WKQhMEHdgcAVwHjDxZaeFYrMaJaQx2cTmJYs5xg5JI9Tnqcmk8RX19LqQ1K0ctNAqMsKOSuHbCn8+9cZ4u0/ZbSxTgySPcNLn07dfxroo0k5Lm+4E+aWho+KvGV9HdwRqz3NlcRrcKkqgja3OPqCCPwrr9E16y8T6I95p0fl3sEircbG2nd0Bcj7wPQMfpXO6dpX9u+D7GSQIZ40a2RCoAbDHqfxo8H+Em0/W3uCHhilAizFMU2cjrjqPrVTVNxstGipJpa9DsPD2sXCNKkt7bXeyZoYVhwmQMZQj1FX4LGw0NdUvYYn/wBK/eumCexJA/E5rNvdOszp3mwrDOY7zYwVgjiUYIY46tgfpT9Z1hotNkW/hjkDYVoVbDlCQpYd85Nc+790UXeNySz1X/hJdGs760b7NHbzbZEb/loqjoPbOevpT/Ca3h8D+IVu5ghttRlitpXPUlVPT6msRvDTyaRqmn2sghhuCssckRLFQuQMnuTzxXfaTolpceBo7SZ3Mf2hJHcnneoGD+YFRVlGKVu5Mn7qkc7p1u1zpcDatEvnNGA/H3XHBxUnhQ2Hh3WI7SGOQyXE/mP82SCRxgddvHNLo/iKC68V3eim2lIRMeYw+Uv0P860RHZwyXeo+WBfoDCZtvz4weAfQUTvZxa3OiUnKPL0PSLG6ju7VZomDAkjj1FSkk15X8Jp7+3vbi1aXfYyOzoN25fXKnqPpXqhOa8qvS9lPlPNq0/ZysRMPmX61+ZGp/8AISu/+uz/AMzX6bt99frX5kan/wAhK7/67P8AzNc9ToSitRRRWQwooooAK+h/2Kv+R913/sFn/wBGx188V9D/ALFX/I+67/2Cz/6NjoQI+v360LSSZB4GaF681t0F1H0UUUDFBp3Xj1poqnqlyLe1YbyskgKpt65x1H060JNuyGlc8I8Z61cav48u77w5dusdo4sbiGRC29kLAhQOzZIzx0qbS/DKSWd3pdxC9nq2ruk81sjguqg/xHsD6elZvhbSNa0vU9QvdVu4YYmly7xOOAoLMOP4sYJrtbG+i1GNtbtDGWlOI3UfOIgO5PPXNfQP3Eow2VtTqs9ojYLuSfxJNpKWLfYIbVQZz0UggA+54NX5rTzIJPLfzHbAHI+6D/8AqqjdagEtbOFkbfdrJJtiBclEGTz2/wAiszQry41SGKeC+vLZNu77GyoGVc9WUjPPrU2e6GvdZ0z2NxDCs5ilUR/KrAHK8ZJrlL3QrC9abU7aQ3F+xLQlpWKI4Axx9a37nULia6hslkd1Vd4+fJc+y+grK0y3nuLDU9OSJ9N+x3amKYHP2jj5h9BgYNEXJasUn3Eg1C/trSGLShbalrsJVLtfM2rHuyST/Kr3izU/s+mfYbLUfsFzNwkpxwc/dGT/ACqpZabNplrq0yXEEk9/c5V44gnloOxPUk81m6vZregy3lvBNBbAjceShxyR6GqtFu4RXMdfZXcv/COJcrE99cRKqsQuXY9M4Hr1qtql3JDbTTTqfNjTcyKu4g46D3qn8L9BtPten6haveqbWOQRxmYhGVicl179T+lWtb3RXVzbW++OZ1LRyKvCZ9Pf2rNWVRxQlu0UdLGozeI9CuoY1Ecc3mTmd9gjiC5ZsdzjtWBrFlZN4ibXS7XVvJe/aFXJZo2LbUKjsvLH8q1muriHT/tE7OwSIpICMkr3H4iub0LTW17XDdWxubSO58sWskHR4VzlWHQHJPHtW0FZubdlaxpbXmZuReKryTWLvQrqO4S0gYMsxfCgDo3pjv8AhXQ+EfGF3JFE9xfQywGbyx5Tbwee5PNU/Etlo0viOGa+jLrbIEJOcYxjnsaxZmttO06V9PtfOERDRxQjBP096hwp1Y/DuCSluer+LFtxLFeHYNq7fMb7vsD2rj3kW3naW3KpdnOSigZ45zWF4YEN1bRW+u/briwv5DMYLuUl4nPy7cf3enHsDWnFe2J8QT6FHHJ59mwK+apwUI4IY9fQ5rOlS9mvZ72/IiK5fdZr6Jr15/Z9xLrDxK0LACdcAOvXJHbFVptSsH06e8tLmPY5PTgSNjhRn1qO9sbdbIxSoZIxyBjge5Heuc0nR4nnutSuHjaEO22KFiY8DoQM8MD/ADqo046taFKNr62NI68os44ryKVZLiMvxGVVVBxhj6n2569Kw/7A1XUgLm7jjhtVkLRxIeqbcDHtisvXrjUNR1y0kty5sljOUHQnPT3NdpBDPJoNrIjytjdGkecYGa0fuWa6ktX1OT8IacLHxA0cZZ1nXYY2PYcjitbXdCcws15GojV9oA5Zh2NJ4btnudd+0r8saMygnj7vH616JDDaXCkXOCTgdev1qatVp8zKXuu5x+iQ2Gl2kVtMkkkpXzREoHyduah1GL7db3b2k0trPEFIkUBlBJ+U/h6VvNe2s9lffuYTc2khjX5fmdey1zFveTRaVdmZ1QkGVlKnKnnAPrUxu9RydxfF+ny6F8Orc3sQOp3c8c0ph5DkZGR6HByfc1k2FtBJo2kTNcXEtzdKYYLorluuQjH1A4/CrfgzWNM8X6jD4a1K+M7RkzWxG5cMAcjB+v5inanaPaXdzofnvDa4fKxrtYnrlT2Oate7+7l8W/yZNNO7j1L9/qo0rVbGwjj228riHyox/wAtGyxOe/cmui8NX8vky2MQQJHE80xJ4TB+X8PpXnk8pma11e3e4kditkba4l5DLwrD/abPJ9M+tdDplxq9pq0MF0BHFJA0V2IVG0sefvegwQPrU1afu2Na2q9mla36FHQ5Ps/jSWzimSeVVa5dj1MhPA/LFdPq1tNfW0sViyRXxJlV8ZGfQ+1czqd+1pGmqaPaC4vHj+VrZN+8A4OT1bArdurd/wC0dPvcSQGVB5nXByPmBolupf1oC1immbXwyS3W3kMsJt9TPzTRbtyZ6EofQ13dYHhq32pHKYtrBSu/jBrfrycS71GzgrO89CJ/vj61+ZOp/wDISu/+uz/zNfps33x9a/MnU/8AkJXf/XZ/5muap0M0VqKKKyKCiiigAr6H/Yq/5H3Xv+wWf/RsdfPFfQ/7FRx4913/ALBZ/wDRsdCBH1+/Wm0rdTSVv0F1Hgk0tMzTt350hi155451dZPGOiaLDFK1xJvYOnYhC35ZA/Outl12y3+XbyieXzPJIj52t7+1cvq2uWUg/cRpHqU9wtqkqL8zFhlsN7Ac9hXXhqclLma/ruXBNO9jD8CaDbG6vIbiMP58huLmOSTczs6srZHYVKmkyNe2un6Yix6eoeORUxg9l564AGawora18MX13qFhe3V3fatd/Y4x0AZVO4c9c469h0ru/h67w6Obm/VYrkndOobIjHpXfVlKCdRO+1jbma95HP6fBqGn+K7lkWM6bbxBYmPJkPpt7DFT/wBmW3h3XLjUzGr6jeruJ/uJnOMds8flVrXLgRSLLp+8o5aQRvySxz1/Ksiz+039i2qXkPlOV3TDdu2kHA/Pimrv3npfRl/FrI3rew0i1uJtVtrVvtzQbbi5LkmJD0UZ4GT1xWTrOoxWdrBJE8KyXDKsTu42y56/jWel9J4i8L3dncR3FnJcwNK8RPzjDY56c45xV8afpM3hbSdJuRDNFCGCJ/GzDkAH+/7ChR5X7z6/hYlqxb8ozDauAinJPoarx+H0tbI2tkESSV97PIRukdj1JPX0qS3kNvpwE6yQpszsc8gepP0rkGnuPEDxXvjR4rPQrYedF9m+YK6vlOnUEVok3s9P66dSnK2x3cGq2fg3RrYakyfbL+byIUh+cnnAAx+tc9daldy63OJbfbbIPkYsPmPcVqRfZL+2lW2nilNqi3dtIACWDckqvWsfTVXVIkmK/aGZyyu4KYzwcg9KinBK8uvX9PwCGjucla3rPFPZ2d75cckzNazs/mNJIxbIZccAHgCun0fS4LW6gvbvVbiTU7OBmgtUIRJGIwc49OtO+y6J4dulmI06O6mkbyI5mKsGPUr684ODxmqWmrdxXz6i1rd3F7dSG3aV5VZbWPHG1f7p9etbyfNe2n6/1/wxUuxU8RajqI0NJdUmsbO6kl2IxyVZSehx3qtczahpdkLISzPI+3/TEjBEWTwSPbv7VJf61DYQSnWLNpLSKURxyBQxkyeWK9gD3q9dK80pvEv1+xJAxEY4MhHPJ9KpO1tClJGXNC9/r1jdBjIltESs8ch2yPnOMA8+vNe06nNBqHhGPUlRWnjRWZwMMCPvA15toVvH/Z9rIY4UeWPzPLhwVI9c96t6f4g1LTbecyXtsltKwEUQUMQBxnJ6muevB1HFx3iRNXs10K17c6lq9pZ3WjOI7dpXju4bhCsmzHYfn+lV7bXNJk1KHQ7dmRSp5P3TLjJUnvjv9aybV54NSI1PWLiSAK7yPdTnzHkbjA7AAEYA7kVzFrfWmk6/Y/2fbR3enxNtNoW2uB/eDdyepz1rpjT5r2HJPc9UurC3sILP5GV1yUfoOc8H9ea6LS7drzw/bx2zI1yGboflYnnGf61ynjG7Opi1srIeTNM3ytJj5R3GD1PNdf4M2QXNtaySb2iQomR0fueK4611T5upKTULoj0fRm0+MfbY1VpGKqFIYcnJP4U+GEw3botxEZQ+94zksB6gfStLXZkt7uGaVGYbs5HRfSsbUoIXvBfPyHGQ8fJX2NZQbmrvqVF31fUpWNtLB4gnjVCsExJLkdQeMn8ax9c02SP7T5EM4hbdtlaXqfYelamveXf2PnQTMhdCsbIDtJ75PTGfWvPNV8V3enaTFDqrvG0XAnVgcnsCO3FdNOEpao0UW9TI8O+DUh8YWV7PdM8T3K71icqwBPPzDpXbfFu+uG8WWzaeoNzbyLFGjcghck5I7n3rK8Pa3DqPhyTVUf57KUSXDBQSUA6j3yBx71gW2sXHi3VrmaSeW3JnEqnIHygY2kd/X6mt+WU5+0n9nT7yOX37robFndTLPrEI82fVIWa+jSJeI4iVXap9ecj15q6+p6l/YoiSSO2vWgUkyjcVkPUH14OPxql4YMtnr2ru7OsU0mw56MCOAPbPJ96x9YiSPXHfUIX+03TNFBvkJiTIwrMB60KKcrFxjrJs9T8MafeaVbBxFBHFHAGjwR5ZY8sVB5HJPFVrLX7e+vLu0kleUxjLqinMZPp7d60/GsyWNxpeloxjRbTKovIJXHX8qz/AkNlH5kkMSvdXD4lDZ+Y+ma5Iy5oe0a3J5+aHNY0fBGu2k2si2gui+0mNlBwM9mx6H1r0c9K8q0Czih1ua409DZmWYmYSLjLDsPr/APXr1Q9K4sXFc6aOXE2umiJv9YPrX5lan/yErv8A67P/ADNfpq3+sH1r8ytT/wCQld/9dn/ma4qvQ50VqKKKxKCiiigAr6G/Ys/5HzXv+wWf/R0dfPNfQ37Ff/I+a7/2Cz/6OjprcaPr5+tIOlK/Wmg4rdbEdR1RXRUW0vmNtQqQxB6Cpa4/x/r8+lNp1jBp8901/II1eNCwQ56nHp15q6dNzmootK7PN9T0W78N69fW0Wu3ci6pbSi3JiwI3PQjn+EDH41Y8I/2lapHPq0lndJaRFNsDByZi/ztntheMVI1veQWlna+IrlTdi+muElV8JBbcZDnqemcU2HQ4LXVl1e0u3m07yWvVZTiFo8df5/nzXtXurSev5nQy74O1WHxDe3rXMTwW0BW4tzKoBOQwLL9Pb1FXLe6uWZ5dNuYZfD99GslqV/1hIPzZ9u1YtjqEXiCxS70CWLe85g2um07QOQPUEn8cVW8s2U/hNbq0lkntYJEE1udsS/KCQye5JxRye9+gHb2dtE2nqzqS3mbgD1wP65qxL/oWg3EULWxiMi74UX5o++GrH1rxDY6P4eXV7u2ubiyjKhoohzluAD+PeodEey1rV59c0S9nGkTwS21zaSIVVJlIbd7kc8+9ZOLer2/rQpvUjljIvE1DR2+0yLIsFzlsCJWGSSP0qh4YuNMGnXlvZW5067tp5pY2uSWZXwd77j6jFTAz6Lr4lsYFnt9RZYLwseNgHyOo7HnB+la94i6hMYJbYxpuMJUDGVHb61q9rdP66DcbjYb6DULmCyu54ppbxSASR8428nHcVHpwtLzQIobGHNjBK8LBoSoBB6YPaodK0i3+0/bxEplskKISfuKc5AqfUtUu7zQbhNJijk1e0Al8h1wJ0yMsPU4qXukv+GEynb3SQwanNptrBH4giiEMAmBCICeeR14FWdEuV1PS7S8VZIp7qPcIW4Y84BI98ZH1pLrSZr0TrIyQpc2ymSFTiTd3G7vVfWZoLSysprXAkaHakat8zlBjaPfj9apWfqxwXvCeKLCB7Jpp7GHUZ4FJEKbWYMOwz0Nc8bq8TUYoNEW4tJHgikEd2n7pFP3l4/iBqzp02o36W0tvbG3WePfJGxG9B3B98+tPTR7rTZlfzLu8htXefYOWbPPlgk889K0jpoyy14phj2XCTWsL30Y2QeeQqySMoyoPv0rJTSTDNpEs8BtZ7chfKEg8pc9VOeorpvGDHVPDGjX6aLLcvcHzn89MPbhcjJTru6YrOS+W7kvLCeyuFaNVmQyxDDg9g3rgn8qmEm46f10EndB4lu7OPUYV0m2a4urWQRHadkcKnqfp6VwPxAit4jHY6ewjufM7vgAHsP8969BubNJ9WivpLqaJBEF+xpjae2T+VefTWVtrnjq6zHJN9jIYxr0PoCfbrW9BqLv2RUVoTa/o89v4MjvJVE08YVnk3FnLjp97sBz37elc/4Wia+FtqN1BtkQExzg5ViD3A6V7PZwNd2X2RVxtUyBCAVXIwcmvNr1ryyuxH5dvGirgRxDaGAOM4p0qjknHqXToyqSsjau7x1b7QDvCxDbsw2192ckdR+FS6N42u7HUFmkCNumXaFyCQe5FZZ1ezWDbbxGF1QKCMYz6fSr+qSGbTorzT2t4wqAklfmJ74qOVbSjudkaHLHlmtz3W5EGqWUcrxZVh8y4zzWMulyQSC3uipglYtFsHIH90/41F8NvEMd3YR6feusd2ijAf5S+R1FdwI4+CFBx+leJOpLDycOh5E3KlJxMePRtOtNBe2vIo2tlDO+8dM18ieOLLRp/FNxHY3d/bJLIwIuwTG+f7p7fjX1F8QNcgi09rSOcBJOJHXnHtxXl1v4Msdc1CFRetE24Pv2Z3Dqc57V34BuEXOo3qbUYvlcps5L4UveaM/iDw/cqsc08AWMS4wee3rxU1pp0eneIYZvs0r3bS4lgX7oUcb3z6E8D6V0PiGOU+KoktLOOUqRHDMq5K89z+HStDxPLBEsUMpWKa4KZlI/5aE5HPoSMV18+u3xGtkvmZmkXUKeKrm1u7aZbu6lCo23KBEXg+3fn6Vh+INZstN8bO9zbi+toSqKkcnWUHO0+mBitSTV00fV2luHj852YRxjkmPOefxzXNWGjz+Idbv5riJktRKsjOp8tcEc8+vQ1cIrWctFYtRkrvoeteKNTtfEUS3Ng7I8kWxC3VR3JrivANvr0niBLQ3UloyXC4kUBhKuc5x/WrMFvYx6nNc2ayLcROLaRc/KMDrj0r0/w34Xhh1K21mK8IV0G6DI27yMcelccqkaFNx/MwlNU4W6DvGOm3Kara3dpIotHJ86EjAMn8J3fTPFdZYOz2MDP97YM81Hq1iNRsnty5QnkMOx7UthDJbQmKT5guMN615cp89NJ7o4nLmgl1RM3+sFfmVqf/ISu/8Ars/8zX6at/rB9a/MrU/+Qld/9dn/AJmuer0M0VqKKKxKCiiigAr6H/Yr/wCR917/ALBZ/wDR0dfPFfQ/7Ff/ACPuu/8AYLP/AKOjprcD69frTaV/vUg61utiHuOrmtf8TCwvzp8EMjTnb847Z54HeulrhPHmqXlg8Fxp+mRXtwblbYK524XqzEjnFb4eCnOzVzWkk3qcx8QJXuZohploRezWT3Kh/lQOCQVJP48VB4buvsnhifRls7i8tJrJLu0mm+5JE74MJ91Oc+orc1PVL7xLp0sOkXENrqNpdf8ALQfeC8lFJz97gc/Wl8R6YNaltRHJJBLp7rIsUTmIBe/bHfmvRi/dUJf12/r1Nt9H0ONvvEclv4esdW0exhW0s7poZZoV27YEXJAHAyGBH5Vutqlxa3eqTqi3UWoQrPpkUwAiT92GBOOQTvx17Vn+K9Pnn8GWseqJDpMUt9PFcRxbUjuIyfk5z1Oc561r+JYdO1CP/hFplNnN9lSe3n3YVtu1dh98DNaXi7ad/uv/AFsN6rU1/CjjUtH+x61BElw6ESRDlPmxkc9QCKytJutKjj1axspGgmtbl1kSRAuH2kDGOoNLok0Ulw1vFPHJPar5MoQ52NgEZz147jiruvR6VL5TXloqtI6SCSIbX8wHh2Pf0I+lQ1aT8xmfobs3hyGDV7rzdUtAxZlT5XQsdoyB1AIrRtdcsLy7uk+ySyTWcgSR3Jw3HDD6YqV7GBruOMzqmxMsVGC6jtzUVuptYp7i1XLSllYEZ2gE5GKbtK7LsuglxCLh9RdpB9muIuY4uqMD94ViWt6+nararp0Mt6yTLaXHkkfuQf42HUe/4Vet9QGrHT7jS1SCESPbzjkbnxyceh4rP0myuLe51CSdY4tTvI2imlhBGewJ7ZwKuK3TEtb2Ohv9GuZdW1C9t752t3QpHCWVVj7lh6k/pWZYaCbCxggub22l8ly1sSu4x5OWLH1JP4VLZR6jamaF1RtNhgRre6zl2JPII9Ov5VWGoPqC3kMKy2j2koDvcqAsqHup9DkUlzWtfQSehPd6G2neHEis5RZXssheVurKpOQPoaytZk8+NTYXZ/tTyhsySUJHqo7nsK07qA+IPD81vfeZbLE5to7oS4cgc8H+lZkkEuiRtcR2kt7JZxrnywPNlwBzn9c06fm9blR1Tua2g6zeX/gmV9Zsp7W5hk8kSkbBKSOWA7DmsmaLVYvDkKWDJc33neWZJxtzD2OR1x0rpdJ0q4uNH2atqktzbSuJ42nwjxow3BDgdRVOzlL6lJaIu+1UMqOABxjI+tKMo3bXe4oO6OYezPiWwd47i6so9PujbzK0e03DYBVt3XaCD061zWhXaaXr2qbYyomlO45znuT+hr0Se7EN9/Y8UkIkkhadAW2sz87ePfB5rxjxRqF1perW19PYNbSMhM0IP8bcnP0yPzrqpe9eLL5kmeg+OdYutL0WB7GV1huEDfhj1+tea+B9Ul1LxZaQIWYhdoLc5J7V0/jK8bVPhRpGpROWmeRo3Tvkd/yrivhRBPJ4ltRYFvtKyCU7ewHOM+9EVaFvW500ajtZH0N4o8IWUVlFNFDGt02A0a4OSe/NeY67p2q6IzyCMpGDwQBwMcEgV6T4n1qe5mhLyQ28q8EKcbj+NaVsn9u+EJ2JhnntsxyYOTjHY+tc1KtKklz6jjVnSinLU8v8H2Op+J7g3WnysrQYLlWxz7e1egTaprlncjbqXmuVGV2gfXI/rXn+gQ3ngXx9Y3tkHOl3b+VIN3ykk8hvQ9x613Hxg099Ikj1+yu5Wtp2AfoRGcjBUjqp9Dn2qq1pVYw0s1p/kTWxPtJpSSsU7qaW9vjH+9wcMvygZPermnNe2LSWcgiEjkqrdOe2T2rP+HOu2XiHxVZQlV3KHV0JySwGQR7V1Nre2reKNQ02+RQqO0auTgYPY+gz3rOo+RuLWqVyXUXw26F7w2NOW88u9V0vYwQwdflUkdm6H2ryz4tW0UGsxC2M72qgAg8bWzkEV6Zp2hNpl3cJcsDabMp5jbsHPY+lcL4xvrXVlvrSzmUzxKrOhzlV+tGHdqvOndfgKk4xq86ZxTWMGvLDqEaP51smxmBLbk961tF1G3WVNIlRTG/3gz481F56d+nSuX1e9uvC2kYt2Edxc7UeJeSqYznFWvAGnyTapFrE8q+f5ZjtzKeSOjEfgetdlRrlfboddWceSSijs/E14+oWumXWggW1vLLunZ4wrN25Fb1ndXM9jb2sVyQEAkLLxzk/nWH4pt7nTvDgjsYlkEMyrubn5WPJH09a634UWlpJBJbSlZXjO9CWyRzyPpXJUajT5uiONpKm5PoenQZ8iLectsGT74p5oNJXiHksjb/WD61+ZWp/8hK7/wCuz/zNfpox+de/NfmXqf8AyErv/rs/8zUVeg0VqKKKxKCiiigAr6H/AGKv+R917/sFn/0dHXzxX0P+xV/yPuvf9gs/+jo6EB9ev1popz9aaK6FsQ9xs8qQQSSyttjRSzH0Ary3WfEMupXYtLC9aCQyKZX8oSMijJ24PAJB69h9RXXfEq4uIPB96bPHmttU5Gflz83H0ry3wxc2ItY5JrlFn1GaSXcfl3NnAGexAAH4V6ODpLlc2deHpqSuzrI71ba7aZYGkNy6qyquVUqCdxIHH+Nc/qMSaHqVxqFrd/Z7bW4pLVmfcVhuHJ2tgfdUnIPpnNW4b9Utbt73ZbxW7bXfzFOVOcMADkfzrnPE2vJeNZ2URkkEyG2aPOE2vljMr9DhSMEdDmuyMdbI3modCfWdCuPEmgafoF6JJra3t0lttQiY7JmCDcee+QfwrptRMOzRluoJLqV7mKwe6Qg+WpXBLD0+UA1R8Nfb9K0u00c3yXLRea7D+KOM8Rr68AH61kaT5erWdt/YGorZ3X2qWa5guiSHhWbLyIAOTkgYptN+i/XqY7K7NPQTpkOoXsOkZkvbTZFN8p+ZADs5Pp61r69piatbTretKu/Zt2LyuCCCD9av2v8AZdvq8sulxRMbza7zgAKEOcAHucYrOv71LuGxntLlrkSiVTIDtD+W+MYHfsfpUc7ck0NO7siHxPFD9un1e3ge41K1tJIoU3bQwwCRgd+DzWloFy88cV5EXjiuYfOCvwRvUZU/57VkaRos17repX8GoZtXKkxu2DCB/EB07Gnz6tbXGtadb6dIslrdTEAoc4UHmm0muXeyKir6DbPULxZ9Zs7bStkls4a33OFSdsgE9sH8aveIr6LS9MlvLvMIVlR2AyRu7nHucZqpfa/odzHFcWtw4m1BZYooChO8IcM+ew44q7b6jb6z4RlnurNxJbtsmiA370PA3A+wFDdmm1oTe3vGZFPaTeIdNkQ3Wz7O+xo2/dOrDDBh37EVSuZ472WTRcNqmnESw3jtw1swIaMHvjOa3LSGBYXhtVO0JhYz1Ue36VE+m7Wu7uwjihvbyLDO67gXAwCwq01cq2pmWmjXVx4RjikSFruyuGuIYLdyA+FAQEnucc+1T6fK9lfWuoamGttSWPYEjYtECP4T61pC6utPs9Lt/Ptf7UuYmacJ8qtg4yoPSs7xFqNzLrNlpmmyvBcgiWZ2hDxsvfn1wPpSTcrrpqK52unXVjqOnzXJYiNG2ywlc7WI4I/2TXC6daalp2qXt6twkmkTRkRKG+aBschvQdee9avhjTZ9K1HXby6vEms7uFFitScGOQ84z39cCuc8I6Iy32s21zB9m04HzVmadn39cggnjr7VFOKjzWd1oG1zbiYXzQX8CQXJjTakyAE7c5wD6da5Lxx4fbVLK5ljdTHuAj77l9D7g5/Ouu8KWlilsqaNcI9lEJEARyw35zgk855z6YrQa0i8mWLZtMqGQr05x1/StVU5JXXQte98jxbxe40rwdbaVDvaUZO1f4c8ZrW+APh+aPXFvD8ipnIxnc2Olcv4rv5D4thEXOC0e3H3sjGK9o8JPD4a0eyuLy3MVw8ZLhhtZR7fWtK9407Ld/qdDSULLfYpeNdNeWYtFEXO5jwucV0Pwlt57cTI+GtblCjpjow7/lkVLHfC6eaZID87ZQRnIx9a2dAZ4psxphs5IxiuKs26TiyK1R+y5GYOu+HbW6vLm0x/pEJ3gZIGD0OOh+vasL42al5fhix0KwiBgUrE2W3YKrlQT74Ird8UfbRqzX8FyyMCEAPGPQH1B6e3Wq3iHQItT0u2a13vd3EkZGWzvYZOTnuOaunJKUJze35nO9bXPOfgHYzf8Jvc3FlInltZSNHJIufLfoDj68H6mug0vVZtR8ValPP5DyzODsVsuh6YI9M9PrW34Wih8MeHdYkRAt5cy+XkdiRyR7E1g/D3Tr668Y6eVt1dbaZpZ7hTgqvcN2PIHvW85qcp1X0Vvu1LS1c10PStbDFdO00Pt8iAGQdckY4/nXJ6rpFvZxahfKVQ3CZlJHTA4xWVr2pXY+Id0LG7IjZyT8wbcmccL6ZzzVW31lNa1u50++kie3c+TDIr7kkZzjaPUjvWVKm4RXpdlRVkmzyLxDdLe+IZLsxN9onG2BDyoAGBkV31nDfWt5pVvc2kGZFEZMeMiPHOR9T2qhqfhOPQtQuLC4YTzDcIDnBQEjpjqPeo9IW/vtc0mbUZI42WTyGIJyYx7dueCa6qjjJXW3/AOx2kk3pE9N02WHURcxXLJ+7TbEpbGR3yPbj866L4caUtjfTvDGViMXBxjqelQ6Bo2mx6o2qSpE8sSkD1UsAD+eK7jSnt3hc2owC2WHvXlYiraLiluefVqcsXGPUumkpTSV55wELn5l+tfmZqf/ISu/8Ars/8zX6ZN94fWvzN1P8A5CV3/wBdn/mairshorUUUViUFFFFABX0P+xV/wAj7r3/AGCz/wCjo6+eK+h/2Kv+R913/sFn/wBHR0ID69frTKWTqaagrpRD3Ir23iu7SWCcZjkUg18vR2wbT763t5GlvdJvy8KZwQpboM9R396+ifG13dWmgzGzB3vlWcHlEwSSPwFeH6A16LuK81m2tobWZsmcYEjbWwqe4I9fXNepgU1CUjroPlTZb8EWSadb2bS28ouZLhy+zhZM9WdT6e3PetGfwfoV/c+bJG+m2sZMskpX5cBvlU5PCk9u9V9c8UWunXM7XVlcwi1IaORVyG3cBPr39BipviDfW2t+G4103UY7hrDbe6haxgu4jx7dTzjNdfvuSe1zSc3Lcb4mkuvDesXeqwNFL/aRt4oY+RsAGSc98DJFTpLFrt9YX2nbbf7E8qSTOgWO4ilUbuRxg89O9INYtdTutLtBax3ehajCyXKvIN0aqvCrg5DDHX2pqi51FZ7Gys4IdItrUNYyWsg/d9RtAzyRndn60uivv/SJsa9wdO8PWekx3jBYS6xIUyxXHrjoMAnJqSbTFj0VLfw/ewrY3Re4t7hvnCu7klvc5zWd4LuI5li0rWrnzL+dDav5oG+Ylfv4PY46960bbGgebAIo18N6fC8q3sZ3Qxsr4KYHORzx1zUN2lbr+YN2Y92n0Pw3B9jQ6jdy4aTC7RNzjp+FZ8+nWml2ki6LAlpKzM7BDvwGADbSeQcenpVqHzdX8RaP/YGqRXGmRRBriEHbIUYZVsHt/KoNQvLEahf2dmt2stpOYpHmQBG7gL6/WiPb5v8A4I1Zsg1e0s/7K0q5iiT7RFbYEpGPlPQ8dN2Mms/4N6jq0HjODT9VSKK3uopXYZJ3/wB3Htx3rodOW31Xwub6EeYizSW5BHV06Hntg1q+AZbXVJ21G2hLG2P2cSMAqjbwdv40VJ2pSTXdfMG/caMrS2SXx1dWssTWuspv22/Jjli6blb3A5B71NJFex3939rkVoGbEUeOY/UU+/1m9ivL+W9t7e0mSVo4GTAkKZ5JPXmr/ltdWdtdFwwmTBY8e9JN6Ngk92Zt1PAbVneya6u7RWeIlOx7Buoqa1uvtNpZXEsL23nJkq3BQ5x1qprsmpQWLQaLdpZSynOZQGDgdQQf8KsTzvHp9jJeBHjEao5iG5WPfAqrFRTk7Iow6Xpt19vs728FzdWzfaVCTYkRh7D6j8qdYi8RfID/AGiIrtmDIN7ccNmt/S7TThNJcNawJdtHseQp8208dax5WtdP8QTW1ncK9+0QkMQbOU7EeoqVK7cSVvZi6Jp8ltPDFZWsUNiGd5VOFIOOCAPXmtWZmns32jbIEdAW65U5BHtyKyL3VGtpIDcTQW11NlFsnYDzCvUKfXocHrUmr6lNo9hZ3t2VFqrlLjK7mUyEBMY7ZJptOTTNGkle54b4vhnHjPSkEW2Z7lJCMYAAYZ/DNeu+Nib7xZexwzyTxKUijGBsQ7QSAa5/XdFnW4e7vQry2+4SE/edFYkY9zgZqv4H1FtYZ4bw5uUmaSWTOCM84/DOK6JrmSmuit/X3Di3zcx6BotnJYR29plWlA+ZVx857YrotPvYo2YFZE4O47T6d65pJ4oDFPA3nyow3gNznP6YrYtPNe3l2vsaRt2CcjGc1yVFzLUU3zbmZPqjz6xFaxqJyzoARxkZGc59K4bSfFF7dfFzT7SGdv7Ptr1wIex38bs/nx2rs9emjsLyzmmiCyI+/cOfl7/WuK+Dnhm7vviBNrt4Y1s4k+0ud2TvPI/DOT9K1jyRpzlLaxnp1NzxTYXem63eWeno0ixSNIiE4XYxBP5BjXU+FrKDSvCtxe6YjCad2Xlicsx+ZvfH9Kyb7V01bUp73y0ijmk2Jk5O0HClsdzjOK0vDGsWS6QtnZhxBb3fkxZ6H5S2cnsTmsZ8zppPyuE9IRMnxhoNrpfh06lGYDqcZEMVxIBuG7rk+nPSsL4VeC2tI08QaukQTT5HKKi4EjcFWAHGOc/lT/G9wus3aRNe262aXRb7NEdyzE8fMf72c8DpXpOi6INA8KXMF5dAG4xtRuEiGMKij2706lWVOkot6yf4dhSbjC76nkGuO+r+KP7XtbK5aSW0eOFDyFfJ+/joP8ap+DdVn1PxFb6dNp8KpkmVxhihHXnsOK9EhsLvTmnRVEccS4Co+Q6//X6mvEvDMlzF8S5BYYjhM7IqkkBlJyVI/UVSkpJ2N4SuuVbHvviHTorXS59RsJZBdxAkxxn/AFigdCKyvAviWJ7eC4juGnD/AMA689j713lvYKNILSxAySJhvcV4xrMl3pHiCKz0a2tolkf5iRg59sCs6PLVjKBnTamnFnvyyefDHJA42vhgfUVNWV4ZEg0eFZeoHBz1rVry5LlbRwSVnYgb74+tfmbqf/ISu/8Ars/8zX6Yv/rBX5nan/yErv8A67P/ADNZVdkCK1FFFYlBRRX0N+z/AKD4fsvDA1HxemkFPEl6dMtl1HAfyFQiSSAlT8/mSRrnj7p6UAfPNfQ37Fn/ACPmu/8AYLP/AKNjrw/xXolz4b8S6not8P8ASLG4eBjjhtpwGHsRgj2Ne4/sVjPj3Xf+wWf/AEbHTW4H10/Q01TUrp+VMCe1dF0S0cV8Xb25s/CBW1RG+03MVtIWzhUY4J4rwSHxHcLLfsJIDc2irbWysPMRAG+aTHcnj8q+lvGv2VfC2pvqK5tVgYtlc8gcH88V8+eD9JtdVig1QwyvfWs5LGMABkYAKSOjAGvXwDXsndbM6KTfLYXVdTg1MQQpf2CXokjBgmDAyluNoP8ACT2zVrwpcz2usnUdF8NSCVYmtLthKXZ2OAAV4A4B9+K1/EOmxWKPbzNGbt0M8V09sNgcDcVLfe46gZxUHhKTRp7OafzUA1OZ4Jnt7ho0knK8kA8g85HvXXdcm39fgbXvHUtaxpWmaTommsq2+h3P2p3tYp1MqCfkjYe3XkHjnFU9I0/xHpGg2EtrY2SwS3zC4it1JTyWx+8VSflGc9DgZrXk1S0tNXg8JXcUmu216/lKl0QDCwXKEYGeo+971c0fXbeOz0f7Np9zFaXUj20yzA/6OcE7X56HnBrO87bX6/n8/vJWujIrbTNIj8c+GbvUkb7ZOp+zTKDhHTcVDfUE4NN0k2aa94g8Nxo0Uskz34ctuikLMAVA7dP51ZsdCstG8SQPaT3s0dzKz5kbeEGCCvsBk1HLfWFlcXk2pTPstkPmMiZYHcDu9+nIqd3o29P1H1ubOhBNL1VJUtlVm22zyqoH4D270njHSru/UDm1SVSDcMwXYfXnviqfhSG5tD5H9pTXkc027dMoG9H5UAew71D4+vrm3uTBfWsr6ObYu12kg3wsMgfKeoNTyv2um4K/Mbeguv8AwiFxaaVNBc3NvPw5U4OQBnpjPtWfJZahdaXFp1hdRaOwvBPKZYiguQeqqexzijwZZQ6J4J08RSO6XgkmV36uM/LTfEOlr4gtrKS6uLtWh2ODGcH5f4cdqUYrmdnpff8A4Arb2MT4k2MVp4jtdUeG+urkqIJY4X3LG3Tey9cGuyuNOttb8CwWlwpMUhPCOQVIIIwR7iuX17VftfiqWKC2ecFQJpt/3DjpjtXZeVIulJaJtjVsGMpwV45/WnPmUYX3QNvlRz11alzaoUhlSFhvEy5YDp1/CpYL3S7aGe1thFJced+9iTkqOxxWNozz6iZrW71MSXtndnLQgqcdlYd/rWl/Y1vbak17bhYpXBMzbcmT0HtVuNtGCutUad9pFxL4ltbgXksUEaFZoAuVlBHQ+nauRv8AQb6yv7ODT7f7RCqzQvcM48+3RzkFW7gc16bZo0sNo0jESOMZx1xWdqMP2O5UDBMsh+RRnpjn+lZU6zT5RRWtjgYLmz0+PS7C7tbq8uI7sJDcXCh2+b+MHHt+QrpLu0+0adeWtrKbVW/eCVjuVXDAn8zms7Xl1tJklhlMxlmVmjlICxIOpXpj0rr7SwjktX3kKGff5fUkdvwrSclFKTLS7nnnimcahoouGdpfs0qr9qtyHWVSMOWA68jnHQ1hyaJdeGfD0l3DB5r3bMWKn+DsR74r0O+szYX0NjZ2EEGm3AZzNGoGyX/aHfd0q94Zu59Xa70W+ghSBEL2cinIkXuMEcH2p+15IXXw7/IesUmeK/D/AMVyTarHakqFEjEMTjd35969I1XxDDpxN7CylQnzRodwGOvHvXL2PgSGx1q7udRtJIHilO13XasmTwcDjrVqw8Ex28rXN3eyO7KfMdMRIw6j5RwMetb1PZzlzItrmIxq7+MPGWhwkyR6fuVy0eAQQemD2OCK9HOl/wBgWWr2mnoyNcMY1IbO2MjqD+J4rzp7az8N+I0urRftGryqBBFnG4E5A9Bya9I8WXTT3zGM+WkMSpIW4G4jLY9ccDNc1ZNzjFfDYzkveSOS8MR20bajpdlbyG4gRWM7IfLLEYXJ7nvxWbq1zBo7XqTzOLe3hd5fLU580jrgcE4AH0rUHinTdKt52Vnll8nzEjRfml54x+nJrnfDWr32u+JpF1XbHI2mTypaBQS2OQ7Dt0A9615ZayewS1ZY8OeF7bWNU8O3VvuSytmW/nUJnAYb8NzxyK1PE3xGTWdXNnplpNPCsxhBK4AP97+dWdW1ez8H+CfMNzB/wkV9bCOOHqqDHTA6Adee9eY6D4qthbpdFTJeTgq2yPALd+KwcXVfM1e2i/U0pUnWd+i2PWLzUSbH7PbNFKzRBXmVcEt3Az2rj7DwzMmsabrMUEpu3uVSGKMKHIU5ZhnjBGfwrpvDXk29nbXVzytwT5cZXOcdSfQVp3GtCPVbR1aOHyVKoGTPB7D0/GskpJNRHNOK5IHpwAC7QoC+npWc2jWb3KzPBGzjuV5rkX8ZyxzJDNLbKd2CQetaXhrxVb3zBPNaUSMdrYyPwPpXL7CrBNo4nSnHU61QFACgADsKRjx707bnmmleOK5TGxCx+cfWvzO1P/kJXf8A11f+Zr9MmT5hx3r8ztT/AOQld/8AXV/5moq9Boq0UUViMKKKKACvSfgb8SYfhl4hv9Sn0yTUVurX7MI0mERX51bOSD/drzauh8DeEdU8ba+mjaEkL3rxtKBLIEXCjJ5oA+kP+GsbA/8AMoXP/gev/wAbo/4axsP+hQuf/A9f/jdeP6z8DvGGjIGv006Niu7YLoM2PoKwk+G+vu8qqlqTFgyfvx8vOOa3jQqyV4xbQ7M93u/2qtNubaWGXwdM6OpUq98pB+o8uuW0X4+6Tpdu5j8ID7UygF47lUTI/wBkJ0rjYPgf4wmhSVV0wI7bFLXijcfaph8BvHDO6pbWTbG2ErcgjpnP096uHt6acYplJyR1uofHvQ9W+fV/Bz3M+HQSC7VCFb2CdccZrh7P4h6dbrhtKuiQcK8VyIiqbgwAwuM5HXvV0/AHx6HVTYWnzEKrfalw2fSpbn9n3xzbSKksWmBj2F6prWGKxUPdiwvJ6FfxH8VE1jxJZ6olne26W7pKIUuV++pBJDbeM45rqR8frP7bezf8I1Oq3kQWYLfZDuOjYKYHbpXNn4A+NVSR5F0qOOMZd3vkVVHuTUVz8CfGcFvHOU0ySKT7rR3qMP0oeJxMrL9CnKdzqn+P1pJFCP7BuopoGDRSxXagg5BOQU5qxqv7QWk6iHWbwgdrxlGY3Q3H2PyYI68V5Zonw413WdVl06z+xC6jDErJcBAcdcE0w/DrXf7RaxQWklwpKsqTg4x71beN5tU7ryE5z3PRNN/aAuYLqJrvSfNgSIL5aTBSrjjKnacDbgY9qS4+ONnd3c897od3OJ9oaN7sEKo4wPk6Vydn8G/Fl3kRR2IIOMNdKDTvEXwY8V+HtKGoamNNSA4AC3aljn2pe3xfNa2r8l/kPmmjutb/AGiY9QlSKDw39m0+CFYreBbgZT1529OnasbQvjcdI1N5ksLyWykfe1s1yp574bbnFcJZ/DzXrzTHv7eO2aBASf3o3cHHSp/D3wx8Sa99o+xQW6rAMu00wQH2GepqlLGwg4qLsvISlOyR3y/G3R11S5vk8M3KSXLbpNt6Of8Axyr2ufH/AE7V9NSzm8OXcajHzpejPBzx8lcdb/A3xlcqWhi09gDt/wCPpetSr8BPG7MwEFh8pwT9rXFRKvi7pu+nkN+0WjOqtPj5plpO8kPheUO2CX+1ruYjuTs5NOT9oKzjuLqRPDlxichzm9Bwf++OnNcm/wABPGyLuaHTse12tNX4EeNGIAj07nj/AI+1pe3xT1/QOaZ2U/7Rm6/0+aDRruKC3GJIPtalZOev3OP1qe+/aL0+7im8zw1dmSTgH7cuAP8AvjNcFB8DfGc08kSwWIKDJZrpQCPY0w/BLxeN2Y9P4/6e1pc+Kvon9wlKZ2t1+0Lb3RDT+HZt4Ty963YBYYxk/L196dp/7RjWmobm0WeWyWERpHJdAyZ9S+zn8q8+t/hF4jup3gtptJmmQFmRL1SQB1NS6D8GPFmuyXSacmnyNbNtkBugMGqlUxSjqtPQOeaPTbj9pWymiEbeF58Bt3/H6P8A4iud0746xWmsfbf7LviocuEF4M9c4yUrnYPgX4zmneJYLAMhwS10oH51OnwC8au6oiaYdx2g/bFxmpVXEwTX6GsMRWimo9fJHceIf2k7bUmjNr4ZlgO7MrPdhywxjj5BiuVvPjFYXNott/Y18sBl8yRftoO8ddv3OBWWPgV4yMmzy9OB55N4uPzqa3+AnjS4k8uJdLL4zj7avSnCtiqStHS3kZ80zU0v4z6ZaajLqFz4euLq8dlKs92Nse3oFGyrF78evtok+06LK5kYl/8ASuqnt92sJ/gH43W4EAg09pD/AHbtSPzqnL8FfFkcjoBpj7G2sUvFYA1Sr4uTuvyBSn0Oit/jmkep/aJPD0TQrGERBKAQR0ydvOKrXfxxuxqEl/pOj2tlqEgKNdDDyGP+7kjiub1n4SeKdIjR7uG02OpYFLgMKl0/4PeKb+ziurdbDyZACpa5A4PSq9rjLXtp6f8AAH7So9Ctr/j9td1I3+oW0rXDR+WSsoAz0Bxj0osvHVvaSQvHp0paMjkz/wBMVqSfA3xlHy0Wn49rtTUh+BHjQQpL5WnGN+hF2vH1pfWcYv8Ahl/kb08TiKa938kaEPxqkWOBJbO8KxTGQ7bhQXU/wE7OnpRJ8Z0aQkaRKV3blVrgH8ztrLg+BvjOa4MKQ2AkHY3SjNWf+FA+N9obytNweP8Aj8XipeIxUd/yX+Rlz1dxbP4t20JmEuh7lcllKzjcCevVTXUeFPjvoXh6OER+Fr2UxA4U36hefbZXND9nvxzkjytMH1vVrnfE/wAKfFHhuKOTUra32OxVTFMH5H0o9ti6/uK7v2REqlRrU90/4awsP+hRuf8AwPX/AON0n/DV9h/0KNz/AOB6/wDxuvHL34KeMLLS11C7hsYoDF5xDXS7lXGeR2PtVXQPhJ4n17S21DTVsJLZTtJa5CkH0xXMqFa3NyuxFpHtn/DV1huB/wCERuf/AAPX/wCN18r3UonuppQNokcvj0yc13b/AAl8Sx6eb2X+z47cNt3PdKOa4jUrOTT76a0maNpIm2sY23Kfoe9TUpVIK800hNMq0UUVkIKKKKACvZ/2Ssj4w2xHUWVwf/Ha8Yr1j9ma/Om/E+O4SJpn+xXCqi9SSvaqjFzkorqNH0DfXUuu+Kr7+0Y5GhBKKsf8OPX2rovD3gCwhjku7lVWOYcqW+Zh/tGtfwxbW11aPfxwyQ+ep3rKOd2Tk1l6nfz6prlpptiwktl/1jAFQADz+Ne9Kcm3TholuauakJrq6bpkUEMdtudovlwf9V9B3z3qPVvEk+i6VDqoVf7PjVUkVBls9jn0NZniq60ubV1hguYPtiqFG1jxj1xWv4OvdOv9LlsbyOOV0YRurgMrYPHFNr3E5Jspp2ON8R65rGtaONV8L3l0hkDEtM5AgUdSgx9a1/Bs93qkFveG8muIvs6x/MMEsP4j355rtPES22mRW4WJVjzsVFQbQD1GPSqFkqWFpO9nbwEkkCLdw3HTnn8qcasXT92Nuw4tpKTRm+KNGt/Efhi60eW7ltxcsuZVXJUqc9O+a8y8S+Jbnw9HbadY2jrolmyWVqJQQ87qcvJ9Ofzr2uygj+zpcTKF3Lu257muc8TWOlLPb393dWeUP7lpQHkVv9le1XSqR5uWWq/UNG7o888R6vp2j6lBevaRLqcgCtIi7WK+p7Z962NL8HoLe5v7a7hSe9G/zJW4C4zgDvWnL8KYPE93Bqd7e3Eak5ZQoyyZ9+mam+IdwujaTdWnhW1Ml6iLAsv3vLHQhB6471p7WMrU6bvLr2DmTfKjzRJ9d03X4EeeKWIS7UWKTcHP4dK6f41XUaWGkvrDkyklhbR8BwAAAT2Hv1pPgr4Geylu9d8SSBEA+QSHPzdSxrb8QL4e8X6xbXsCvdi1Jij3ZCMc9SO5rSU4+1Wnw7tIlttnG+HYNY1u7sb+a3bRvD9qoIVAUVgOoUfxE+teleGdQTVbu4CQpHaxggYUAfp3ramtrK70eQ3e+SO3URiJPlUY9aq6OIZbcfZbdYIP4VAxk+vvWE6iqX0tb+vmEddxdY1ey0LSJ7sqzRQrkYGC2fT3rgtH8f32qf2lJqHkwWW0CGNPvbs8ZP0r0G+0U6jZNbS2/m2j8nf90kc5zXD23gmz06/kuJi0rk5SMcIo/qaql7Jxd9WU3d6HWeGbuW48K3UjI000bEAKckgDNc74W/ta813z5hKIRu3hiQo4OFHvmum0a2miizZARgn5iDj8K3TPBdSA+VLhUAkA4ye9YylyN6XuQ04mDeWVykLBYyx/i54I/rWbrehale6NOluwtZbhdkef7vfHp9a3b3Vo1WWSNQ5ijIMA4AAHTPfNeXab4y8Q6rr4aCAlY8gQfwovT5ia2pRqSXMraFK5v+CfAR0Vr26mvFe8MDRDaMqoPU+9dN4H0WDQdPuWjLvJJJvllJ5c9hj0qjo+sqb57cOJJJE2fIPlz6CtyGcWsaROmzeDnvgipqynO/M97F1KMofGrFHVrudbK8ubOF5biNHfy8bScDOB+FeeaP4+a7uo7hw0bxyAtD1H1r0i8mlt9k6ceX8/19sVw1pYrd+LlbSNMgt4JZN82U4Bzy30q6fLZqSM7tHea3ayX1msllHtS4Xcy9CueaxWjvINVSC0RjsiDFlP4V1WVjvlKnMLfKrY9KLiGG5nUwuFkK7WKnk4/lXPGfLo9hpuJmai2pf8IfqCy/JPMrJGwG1iMf41wnw08LXFnPeTagx8gqPlJ4Df3j7169rEMlxokcSK0skS/MfauLvNVhsPK09YWeV2y5HGO3NVQqtwlFdWOLvqMl1/RLPULfTNVeEicgCOZdwbJx+HPrVPxlMPD7SPbQPJAWGUA+5x0A9Koan8OY/EniS2vlvHht/lEq/eb5TnC+lbXj3xkPDt+LFtGS6+0LhvNGflHTNa2TnFU/edtUJuzutytZ+IbT+wI7u6Ywws+xRL1z6VvaHKt9E9pDIv75PMicc4NcdqunQeLtHt/LtxpaKcqqAn68Gt/wAOWi6TJYwwZ8uEKiknk0TiuTTfsaq8kx+gTXfnPb3wC3dtJhX6bl9DXQGIpdSHd8j/ADfQ1DqUIh1Zy6jfngn9KuQyq8aOxAJ+XB7kVjOV0pLqDulcLRJS9wZZMQsmFXrgg5zVeeCKdl+0Ij4IIDDIBHSpJr63sji7cIMEgH0A5FZfh3xLpXivTp7zRTMrW0gjnhkHIz0I9RULm1lbQi+tmWtZg/tOzls7vlJ1IPtkYrK0HRrPwxpUWi2ZaSFTmSRhy5Pet1oOd5bkHA55qGRD50rupyFHJ/iOOCKuMtOVbFJI8+8RabJdaZeabGvAkJDdB+J9K+VPGlo9j4p1K1lxvilKnHTpX1b4h1nV7Px5p8FqN2nyQqZo2X93IOdxb3r5s+M8izfFPxK8ahEN22FAxgYFc2ZSkqcYvZ6nNPc4qiiivGICiiigAr0f4BarbaN8R7W9vG2xJBKMk8AleP1rziuh8DWv23XPs4OC8TAZOOeK3wsVOtCL6tAtz6I+IHxP1DXbdrTwvcSWMUI3TzRjazNn7o9v516F8OJ5Z/D8F5JKs999mJZgclnA6/U14ZNo11p11bSWzRTJFhZY8cPzzn/GvRfAMV7p2suYnWG2uclLbORj2PYV9NVo01T5YWOlx6GVeWmy3n1O8cJdFiVCrtyfpV74NXUl54nuIC5GctjHX3zVbxUkviPULq30S0upHikdGPO0kcFvzrsfhp4dh8M6aPEWsl4ZEhMe08LgH734mqqTUaMubd7IqVS1PlW52XiiU3WqWlts3xRMN4/Dr+FcH4iuo9O8bWV7eXQFoy+RBagHAc9Tx+Fbmi6ldeImvb2KMRWgbEbE8EdST/jT9CtoL7UYpb63jlSJiySMucY/u+nTrXJTiqUbPoiX8Njp9SuLGzhsbae9S1muiEi3kZZsZPFcnf6ZZ6XdW2oTIt3NvPlpMuE+oHt71zWs+HPEPir4k29/dxiDTrd8W67s5UcjgdOe9d74ksEXTrWGeQbofvksKmMVS5Y8129xR3szN0fxPrmr+IZkEccOmxHbgJjeAOTnsKnn0pJ9QCxb3W4AeRwMZ74UdhXL+PtT1C4/svSNHZbSymUvI6DDOBxk+1dn4NnW10rz9RvGmnQBViA+bA6fgaJx9nHnirX6ImzWqI/HPhnUrrwhJYaUyRtJIN5ZtuI8dBXN+E/C7aHYraxyJcXjPl2Gdq/Stbxnr1xcabLJLcGJAN2xeOPesPwHqM2p2LyFHEbS7Rz1UdauiqsaTUu41Bx3Oo1+4isvLtpXUIy5II4z6+9RGRFgRRKiqwCow/hzUGv6fJfXG+WUFzg9f0AqveXWm6Mti2o30McjsBGhbOSDjOBRFaJdQ12Oj8SXUyafaW1nKIoo1+Zjyx+noKw7MxyqN+HYZw0h6j2Aqx4hDW0i75ElaXnao+Yg9Kdo+lSy26STKIEJ53HG1ainywhuELLcgg1OMyLZJC4CjLSL0zVbU/EKWMDQhl3TZ4zyAT09qy/HupS6RCLLw7ZzXF3cnLXYXIj9lHr7mqHg7w7N5RudbJnvi29GY528fdJ7mtlBOPO/+CU5XR1NnJDceHXaeJormSQMdx+8B0/xpqWNqlmxuWEAlB2omAzf7R9av6B4fuLiG4u5jv2KWRH6Mw6D6Vw1taajda/Jc6l5gfnAbpxUQabai9hQqcr0Oo0LStPh1GzZHMjuwZXPGK6HxUNqssUY84AqpUYI9zWZo+gX02owXUhVIo8NEuevqSK6bX3thHLHFJG92g3lc/NjvmsKlRe1jZ3HVqOpO8nc8w8S3t5p2jzfYw73CgAnbu256tWr4POoXWj6fNPIz5iPmhhjd8xwTUsOt6Ha6jtnm2zDhoywPPrW4sqNGl9C5EUasNoOM/hXROenLb5hO99Bt+xxb4dXWPluO9efeJLjU9L05r/TpHlkjlKjb2Hqar6141ms/E0lqtu3kbgrEE7ue47VqW9//b9xe6E0JgYwmTKDjA7fWrjTdOzktN/kTZG98I/E2oeIdD1FdVZHnjYquMBiuOprS8Q6XHG8VwtuVJTBkxkt71zngvR08LaXd3lpulMjbXY8nj2rpLe+ufENuj3USqIjuBBxtA9qwqRUarnT+EnaRx+k+Ij/AGh9ltfNWZMkE/1rsNTW31W3jkmjje+UYYgcn/69UraCFJp7mRY0HQER/Nn8K1rL7Ilt9pupgoJKq+cZ9/8A61Oo4p8yRo2t2ZEluEVI0ba+c4KnGKltfLjlQCRZZCckqMjPpWIPEUsfi2bTbqEG1ZB5FxtOCfRvrTfEugR30afZ5JLa+X5o5YHKgN79jWvK9FLS5akdfqZMyebx5iAI307Vh+ItFu9d8Ny21hefZbpJhMjZwCQMYNR6bqM7oIL6GZbuJAk3y/K/+0K2bWQEyQlgonG3J6AnoayScFp0Ha8LHNappZ1SO0s49Ti/tK0iC3MbH5jjvV3wT4Nh8JzXk1jeiVL5SXiYdB1AB9uapW3g61k1641p2kTWVheAqG/d5Ixux644q74bmu7e08u+RjLFISn0PUVUr8vLF6dTNRctzpVfhccgDBHXv2rH1DxDYxa5baJeAw3Fwu+GYn5dwPCmrry7D5nSPYTn8cjP05rK1zS7fWWsr/YnmRyZjlqIxV/e/plSTvoXtTsoppzFPGPlbgnjPpz9a+LPiyrp8SPEKyffF0wP6V9geN/E9voen2t5d2sk/mzCAtGw+TPO4+vSvkL4wSLN8TfEUqfde6LD8QK4scpKlFtGM2mjjqKKK8oyCiiigArqfh1HHJr0nmkhVtpGyPUAYrlq3/BjSLq7eSwVzEwyTj0rqwV/rFO3dfmOLs1c9T0kz3ryR2U2JEBLSztxEgHJPau38BaktuS4uHu5hhRM+TGq9PlGOayY9ANpotzZSiOW9mCtOsXUcZCA+pzk13fhLQhbWFpaNAieamZFI5Ue9fWVpxcWz1aMIcvNUNNryOTxvotpo94lvbWzhrzHWUt2OP8APNbXxlENz4amgvpTb6fb5nlCcNIB92NfqcV534Sj0O28Ry6zcx3kLJd+QIscZLADOex616z8RLDSNW0Vk1SdkgVsko3cHvXmVUqdenvp5dTz5JKRxq+LdNOl+HrExfZPtdujrBGp24zjn8q2ptdgsVFvp9urlTh3fooxwPesDT9F0CW9t76ISXHkhYEdidqgeg+lZWgSTar8QZbaNkGniYyPE2AzKOmPy6Vq4Qadtlq7jVoxXMdL8XtTvdO8N6TpOjsbbU9Y+a4uUJHkwqAXOew5H5VxvhDxLpl0g0w3EnlwHbHJMxZ7hsc/nXpGq251bUb+51OSOKzjQxgyD5EGMDPtXh+reDb+Dzp9KuLbUbln8uNNN+ZYlPenhoxcOSTs/wBX/kEVZeZ2GjWl3qms3N/eTI1wfkjjjbckMQ6AV2cSW1kwQM0kzgEgAkhff0pfAfhm28KeHITrFyItQMe1lkYYUHkj3rL+KNnqbaPph8KRNLHeOxnmTgj+6SfT3qXUVSpyJ6bX6DU0P1eG21eeOxVSfMwcDp1710GlWUGiW32dYwJWfYMj7iZxn8a4a11fT/AU+m2115moasQqskZysQJ5Ynuc9BXoGtXYutSgRcCMRgyOf73pSqKV1H7PcfNd2HX1tL9rCqkfU7HYgYH4964a8+H2oN4mbWNfurea3VwYIkbgKOR+np3rjbmTVfEPj5tVvZZbPSNPmJVmJGFU9AO5Neqa54r0nTrCHUvERkt2uEH2WwX5pWTs5H8K1VqlFxjF3bWtlqZ31saX9uaZZhIyim87NIMkfgKbcXzXg3IwfbwArcVwXiDT7jWLpJdJuora3nQM+ARIAfWtnwlp8ei2ZhjdppODuY5JyaSoxiubqVZF68t7hbW4uUU+cikrCvVzWX4MttX+yXd7qczIzqVRG7c8kDtXe6XpbTFpJ1IUc5UEsTWX4ou7fSrDfdMkNopwCepI9u9Qqyk/Zrcb1drmjpd7c6dpA8whQXAJbliuOuKpz6tHeXSlLdSUyNo6H3NYFhqttrkGdKkklR32b2QoWx/T3roz4dZ4hYafcCMuQ1w6dSvoKiUIU25S3G1GOrI9Pum8i72StHczAqD1Ce9cf4R8Df2RqN3q9xqs+oXskbo244A3de5JNcN4ittRh8TXFnqfiiCCGK4+W3jdjgZ4BCjr9TXsXgu18wzFRv8ALjyeODnp/jW9ROjByT0l/W4OzXMeU3fhL+zr6a8uJmliVt+FHzNz0r17w7cxa14YWOaIQlPlTC8px3rkfEV1dW2o/Z4LYyqx5OMiur8Fxvb6Hd+bGx+0HO4cBcDgVOKm5wUnv0FPRXRQOgxSTGcwQyzx48t2UFs1i+ILO6hS5/seBE1C6URGReNo/iOfWtbT/E+m3etxabCZ3lcmMSA4AI68de3Wpb3Ube01EWbu0kikH5RnihSkpWkJyVyb4e6M9hZzfbGd4WiCtvOQTkkgVv6ZqOjT30un2gRJgCGQnJOK4m08V30OuS2k2nsunfdMmduT61U8L6Dc2ni2K+uJNsKyZVt3L56CsalFy5pSduxDdzovFljJqFrq1hpN0kN55IKuW+4/p7Vj+BfDmqWPhyTS9emS6ufNMse2TfsGO5rql0trG5vFiG5pQ2D3Pfn1rKF3Ij4t/lReoIx9auEm4ckXfYta6XLNlZxy2sjSq4li42lADn61UtIySZAroRn7zZrM8U+JbvSdPS706yNxLI2CiDIz71Y0vVp5bGO51KyS1u5/n8h5ANv19M1XLJLmezC7TsbkcuFBKdR0IqykVtNBkhY5F5Az1FNRY7yEFdqzL8wweo965WOe4GqyBw4YN0NZpc22jDmd9DrZWEeoW7tGWWYBWYdQegNNkjxcyZVfKz8z+4/rVTWbxtN0mwviuQrlGyffv+Fc74l8cro2u6Rai1Z471t0shztRM4JHr60oQlL4fP8Cm9EyP4hLd3Phe5ttKDvIJFWVRwdhPNWPBj7PCunWpYP9mDRSrnO05JrpYLa1mZ5kUslwo+YH7wrF0XQf7MvruNJUdZHDIpznnqTWntE4cvbUafvXH32mWd/o1zZ6hCs9vJIHCv/AEI718a/FmNIfiP4giiBEaXRVR6AAV9lw6lb6k81vbhldAVUMeHx1xXxx8YM/wDCzfEW7732ps/kK4ce3yJeZnUStdHHUUUV5JiFFFFABXXfDCCGfxQBcDMawu2PUjGK5Guj8CXD22ts6KGzCykHuDjNdWCu8RC3dfmNWurnvegXUl5d3P2KIrGgUIS4LMcksT7nFeieDL+5eFnvoi8spIRRztAHPPftWb8NvD1noemDVJyfsasWVnP33IyMewroND1mXU7M6ld2yRIchNgC8An046V9FiJKTaitEd1WXPypHHQPq934iks7uwZkMwaJVHzAAjDk9Pzr0oaV9ms5YJplknk5dGO76/jXlniTxxLDrDQRhikjiPI4O3PSvRbOa9tbCOeMEEIQH6lh2FRWhOydrGUldnK+H9H8QX3iO8j+zNHYRArGgwAOf5/41BpXw68QweOYdWuZ1ht/N3IoPzbfQit+ez17Ur60js7h7aPr5cZ2lj6k1D4u8T3fhzxJo2lRXC3NySgmBOc89/el7SpzctO12tvIUr7MufG/zr7Q4bDSyseZQ1ztOAeO9VvAPhpvDuixytdmKScbo4lHzS+/stZPgq11bUdd1a+1d2axlkZljl5wxJxgHoMV2xBtbWW5uXyAp2lhzx6ewqdaVNUE/wDghFKxw+teENS1PxOl/qGsT3BZwEgB+VB6fSvU9JjVdLh0lZlSWJMAtzj3ryHXfFyaV5t9cM+5x+6THJ+lYOg+Pbr+2LOW8ilE8swwik/6s+tXUw9WvBdlsE43R6Nd+DtObxANVkTzrkEFTuyhI6Nj8Km1PVbXS1xqYIuLkjyhkZIPt71sa5qcdlcEBVQyJgDp+VebfY5U8TSa5rlwlyLc/wCjxhvkX+7kn+VTTvUV5voKOx6Be6Ba3ot57ny7YJHvNnt+8/8ACTj1rBk8J6XFqt1q2sNPqWpSNvU3BDCMdgF9ugpy6q9nF9pnYyXlyd7Shtx5/hWtfSJ7Ro5ZrorNL97ynJGT7mpjz003f7ghBJXIbJHkikeO3CSNgJIV+UEfpXZeFbGFbM3FyYjO3BYY+X/A15na3GsSaq+oajOYLKMERWqfKpP0rqbi6vLfSLaa3kIe4Ibpntxms8RTlOPKna4p6o7O81SCzjZbeMMBwCDgZrhNb0Ky+IViLO4vHsp7Z9yqhDB196Xxqb6fQPN0WZPtkiCNwwyA3ernwugvtN0F5/EGwz9N5QA4rCFP2FL2sH71/mS1ZDNG8L2+mLHZwX0QMeI1igOTj3P861dT8QaboV9bWpYpcSH5yRj8CaivNZ0611RHsjFNKoO5UI6n1964z4qW5TV01KS2lmV1XEKrnbx6+lXGEq80ql7NfiN3luYnizwDZWd1e6rZW91c3DMZFSVw4DHnOB1/Guh+E0+pw2upT6qZBayoEVpRglh2FJpOsanqmkyiO3EFwnCeZ0x/jU+hWbWTGfWr+S7uJcKIYySic54Hc/lXVUcp0+Spr+YcjNQwLM7yEnYchSfWqHjzV9S8PeGLSHw/bwXEwb98JTwvfkZGa32bztrCIQ28LAqmM8nufWuT8T+AJvFmpW01zqEkUX3GCKCvXOQCetZwlByTquyQ5vQ0PC6SNpdvrOraDb6fqVyhLvAmcp2I5OCe4rG8S7ZbhLu3SVLg53bl5474rubZLbwvpNnpUUckkVvF5SbmDMMnJY9smuW1mz0DULgz3WqXtqqHbgY+U1NKfNJytp066fiQlpsN0DVYr0wR3dqUn5BDrw/ocdq3DFFHEskiOYs7voBXLeN9Vh8INbkQyyG4QGKQEfOuByTTNM8fWi2dtcXlybdZzhY3G44HGcAdPetfZylFTitGXFX1N6fRNUfUH1KDVnS0i/efZmJLt3xVXxZ4h1TSNPiuNJ0xJzL/AAum7ae+QK07+S5WCG5s5d8Mo3B16EEcUywdmxHOVcdyTyD3qI66yV0hJGN4Z8Q6xfukuraRa2xIzugByee6nj0rE+IXhO6uvEG9dUQxSYYRFDlFI/LNehQrbCcOiMoX+L7wB9eaw/ENkuv2Xl/2jNZTKSyXECZPPVSPSqhPlqc0Vb+vmKUWtjo7ea1sNFiQJuhijSJ0LAyYA4J9+KfPd6RMxkWwlkuMDYmApk/w9zXn2maZdeGtGu0tZW1C6d/M3yryxx0xnp396m8P6hq2ozsNUs1hZVyssRK7ufukdvwrP6stWn+NhKDOoN/pmtLf+G7iGSCYgyRBjkfga5vVdKi1EW+n3VsXESAxs7EAEHGMj6VueGrCdLy4v9YRDdGQiIrwFTHH171cSJZLpixJAPABpwahJ8v9M1hG5LpvmW9ri4K5TgIv8P0qpfzu8/2iIjehB4/iHr/n1qwyNCpKEtjP3uaqWUiOWilGUyGU9x9KIxWsjWEbanlXh+HVbf4hXlv5khUziTLfd2k5BH4GvC/jYVPxX8TlTlftjY/IV9pvY2cMsd2h3SMhQH+6K+JvjCGHxO8Rhjlvtbc/gK5MzqKqlJKxzzXunHUUUV5BiFFFFABXf/BHQ18ReOE015DGsttKdw7YANcBXqX7N141h8ULaZFDN9mmUAj1FbYdyVWLhvdDjuj6xfTobDw5b2MkbS2MaFGYd27nI71xXiXRNd1PSLfTfBtsY4MfvvNn2MuT1weo+hr1XaZLbclz5alWyX6Bj6D2rnfPms5HDXQuJlXhlY/MfpXuUaru2t73Ojd+6cJd/DmWwvLRLexmvNUJUefJIfKTplgvr1616ZJLZ6ZYrZRyLd6lGixnnO0470nhVb+e9la4nfJjKKOuw+tXNB8HwaRqEt287TXMrFmdhn/JzWdfEa8tWW34/wDAM2+WWoWFhd6XYyXcvz3TjLu3SMe1cLYeDYdZ8XN4juJCWgHmbZWGwsOnvWn4j1/xFc6rNBp8XlwcpGjJuVj0BNYXhjw7q+gNNfeLNQkm1C/YItqjZRADxwOBWlFTjGUpSSk/vDfR9Tp/G3i6TRzpel6bHCb+8xuZowVUepH0qnpkGpa4ZhkeQxIUsuBjua1fFUGi6bY22q69JFDeLF5cRPU8dcVhaJ4l+22hWwnC2jKVV0H86KKXsr01r3ZtBqMHZalXxTd6B4dZGmt01GdRlWmXPPqF6AVj/Z7Cd11q7t183G4bUxyeQMdgK5PWtTuNV8UI0NosqwPtBcZAAPJPajX7bXNd1WOw0ssYJGCsiNgkds12xouNk3r1bYl1Z7jp/h+21JEu5bgztOgfcemO/wBAK5jX/Cel6hOGgunnjhbCqHwm76V12j6JH4b8F2ul3E5yISsjg85JyfwqroWkWKl5HdHtQAysx6nsSK86nWcXKak7LYxi3ueW6r4wtNKvxpKWM1zco6qdi8/Qf/WrtdKgttO+znUuJbn5kgb72D60/V768tNfjuP7HsDbOxRJvJUuvod3Wr8Vha+KL61vJpXhvoVy0aD5eK6Z1Fyp2survctzb9ChHc2HiC2E0VqbeCFyvynhyDxmrGq6vG0kKLFvhhQIFHHbk1tS6TBpcUlnbR/efzGHJGT2/KvFvGvgzxNp2uX2uLco9qrfuA8m3GegK9sClQ9nVe9u1yotaHqPhrUoLW/E0UnnQyEAqw5T6iu01e0j1aExQSrC4jypB/pXyz4N1s6Frlydevh51yVULycnOMn0Few6b4nttLv4ZNXuADcHZCd3A9qnFYR86nF6r8QqK+q3OO8OeEdS0jxlLc3Uxky7JhGyJMnq3tXpGreINPs4449Zmj3MwRFPIHbNT22srNrtxZS2UTymJ5baYj5mcLkD3ryGSe58UXLW+sWaq4LM0iZUq3r/APWrZXxMr1NLW/pCT5tEe1+Ibu4tPDJfwbaW13fbAwAxyPbPf2rmPBn/AAk406e68ZeVHNdOI7WDaqvGO5OOg6e9NT7JoWkWcbXSwSyIBEpmwzn3p17cT+XaPO7sSCeue/BrCnS5YuK1u9+v3hCN+ozx/rll4UvYp5nuHaThUt15IHqx4AzxTPDWvyalZx6l5kyw8Miv356EVsXFhZa14Xz4ijjkeLmLdwf8+1ef3HieGG5WytbIC0jwibTjv6VpSipw5bardgtXZnptp4gsdRuSt8hVyOOKuXPg7SL1BdxQtI6kNtJ4J+lcFe3dskkUkYUTPgnLgbfbHWvXfDyN/Zi8gkrxXFib0IqdN2FUiopNHnHjPTZby8Q39vFeacQP3cxwYiO6Y5FcHJP4P13VrezL3NrPH+4TaP3bc9Aa9e8R2c96kqW0TO6AjgV5jY+A9L02+XVddhe1jjk3orycyNnPyrXbhqkPZ+87Ppb/ACKXLynqmk6URpywRIRDHEFRc9ABgVkSQPFKy7RgfJlDyKkGtPePCYnkjtAwKoOw9/WsDQoLm01e6ubuXe8m4Ku7OQTwTWMIzjdyEnKLK8Yura9aJiSGfDJng+4q1Z6/p0F+bG5vLWO5XAMbNg89q1dMgMduwuHSWYuW3Y6Z7VyXjLwrpF3eJdajvguyMh4D8x9M+tbx5ZPlkOClKySN++1ZYbxLdkBEgyrH0NR3rSSwI0UbEHkhfas+ytWkggVfMumjGFkkGD+OK6bTtPIhLTFHXPQE8e1KVoLU2kko2e5DpVzNa2jrdJ+6YgnvtqwsyOPPh4TdheQc1h+NYtSs7VG0xnEecS8A59M+1UvCDC6Vnd2iulH72Ifcf0YDtUqKa50Km4ao6Ka4ee5EEIyW96itp4p5WEW5ZFHzIRg/Ue1aWjwwpfwnA808fTNZevRppl358fL79gx6E9KSknLkRd3KajAuzk/ZmK8EEZHb3I+tfFnxiG34n+Iwf+ftv5Cvs6YN5m0ZAdcjI6eor4x+MQx8TvEY/wCnpv5CuDH/AAL1Oet8JxtFFFeUcwUUUUAFet/su2YvvixbwsQB9knbJ7YWvJK9Y/ZjmaD4qW5RwjNaTqD9Vq6d+dcu41qz7dm0iBlUHLYGMDvVWLw7bpdGVCAMYCEZrDg1lYbS7N1eTSfZwC0cahS3OOvpUHhfx3DqXiQ6HGEk2jAcdcYzzXpujiIxlyu6W5o1JI7W0t/IiIgKM5Yl3PevLPih4w8XaFe2/wDZ2mF4nbgKm8cepHer2sfERpfEU2g6Lb/LCCJJvfPQf41ifF651ew8PaW+nQy/aLhjvkRSxXpgD3Nb4XDSjUi6yT5ujCKtub3hHxBrmsW8L6hZR2E78t04966PxDfWGlQRjUSLm7HzpkYKL9frWH4M0PUofC1nd6m7Q38sIMikfMhz3HritTxTp0GqwrcTXMaRbAjnGGYj0pVPZutZaLXYE02uxyXi2DSPHthE2Hj1CA5Te5ZWHp9Kf4a8Im2svs5Zo4tvzueMiqOleDobrxva3MGsulshylnGhxx6npXrV1pn2q2uLQ5Rdu1GHYdq0rYhUFGnF6b+g3JJ2R4n42jl02Bo/DunSajeOwQBY8hT/ewOTXT/AAs8LatoemTar4rwb+U70hOB5Sjtx3rqngi8JaZJdeX50pOGbOCeM4/SuQtvGWp+JIbmAWcShQXQFdxGMce3BpurOtDlpr3er6sJSctFsaeq69FeX7WUrKWnxtDsBtPp9Kx/FUV5NYC2sCYFjkwzscF+2cenpUVj4WU3iX90zPKx37cfdrobpo5QhO5CwKEOOT71pFRg0oj2MvwnCJdEutIa/SW6GX3dcPxgCpvDsE2mX7SBn818Rsij73Nc7pelTeGby61aWd7jyFaVUQY3cdDXT/Dg6jr6DUb7aIDM527cYGOMfie9Kr7kZSesf1Fzcqs0dfcahE9mjAkyCTMgI+Y47VxvjBv7Zt1R42BD5UA/xVuX0sYvJEtRmFONxPU9zWFfOyi4kA+cLhSOduaxw9JQ95IpLk1PBNQ8Cag2uXF3ctvjyXyOScfw+3pWre6VrPiHw/at9nk+0Wz42MNuRXSaZ4H1iTxGlwdWuHidvMK85I9GycYr1q30+0stNeS4uNkMY+YDrmvSq4pU2tU36FSa3H+FdMK6JplxeBUniQBsn5hxiqGq+GoLzWpJ9LmjWKTlo+OG71Jp+oWd7DJFp80pKcMsq8EH6U2GNluD5Kg5z8wrzoqam5XsTBPdHm/xGs9Yh8QWtnYaXa3Qt1EjXUwDqD1xknAAFdppWu6VrEkaWoDLEu0sq/KD3x6jNX7m2S4E0MiGQMuyTfwGB7epp2laTaQ7o7W3EaquMW64UfVq6JVE4JS6D5Gne4y+sVlcvNK0sYOEA4A/CuA8Sz6Zod4QsDfamGT5a9PT8a72/uPsm5klwIxvbI6AVz1jYWfinWPtF1AqspJkdTwFHf69KdOSirz2B2iYPhv4ZW99ZR6xqupSi1m+ZEK/vX+v+Ne0eF9RhFiLe1jbZAoRQTngetcH43k1C50NLPw5CVkgUpEHOwN+NXvg5a6lpOiyp4iuUnvZ5iQsZ3eWuOhP1rHF81ai51HfXREy1WpqeKPFSWmpJpdhcA3h5l8sZIPXaTXNXdudV1cXt+RM4XHzn5RWS9xp+h+Lry3SG4uZmnPmSufmView7iutk06O2kinu2d1cFhEuATVU4QopWX+bHC1tiWxsElnQOyiMAjaOB09arrax2txuZvNR2wh9fQVieO4tUvdHX+wEZSp2lIzyBnk1F4GXUdN05zqlwZpSeI3Odn41pytx57/ACGnds6xnzcR54U88VUurOPUZ2ufK3OowCTnp7VT1PUY7Sza8cHKDaq5xuNWvBupDVdGuLyGMJIhMRj3ZG7sazd4LmRSqOGqL728unaajIiBGJB5zg4zXK+IPFf/AAjcUJaHz5J2zsLYAUdTXT2Ml29lJHqa/vyeFPRh/QisLxVpthc2kbXKI0qHEas2CxPb3+lOla9pq5ldtXZB4p8XQaCbSZ45biK9jEoQcbEIzzmlsNc0p9UEMEHl3DIHUlcbx6fWrupaZb3NnZT6ja73UAbmQFVPYA9qp2umafDdJfyzxmTJVGJx+FUuTlXccHZly9uPKTzM7WVsjHGK1NftV1Sws2hBYEKzMP1qtLapdlxxtZMjB461U0S31O0k33c6mGPeiKDkOjdj7ilLpJbo7HU5eVrdGhqUm53kHCphhgdsV8WfFqdLn4keIJo8bHumIx9BX2Hc3++CRiUWIHb659RXxz8VI1h+Imvohyoumx9OK4MerU0vM5az91I5SiiivIOYKKKKACvQPghf/wBmeOVvBG0jxW0rKoGecV5/Xq37NEMVx8T4oZwCr2VwoHvsrbDtRqxb7oqO6PorwrL9u0LVNa1GAq+oMoSJmOCVJwQOwwav+FtG0/wjHdeJ9QVYZJRiFWONxPf6UzXdYHhXTLeWW3W4k5S2t34Veep9q5Lxp4iuPEGi28WvRIplwYxbkqE+g6H8a+jcJ1W1HSMnr6dkbJXVjZ1HxP4W86bUrWSC2vZTlmUb8nPpXe6B4hh12105bK5jkPVnYDdx7ds14ZpfgGR2E4ElzbbeMjbjPrVe11y+0rxLDp+h2LTzRyKjBAcj2GP51dTC06q5YO7XfoNxXLc+kdTu7lLqRbCIO5TBLA4DZ/rU02kR6lawPcYDooBVOme+KwILrVdP0gmQMGPLTYB2/hU/hvxJe3YZDbGYR8vKvA/w/KvJlRqRjzU7adTGzaujasdKstDt5Joow04Utknk+wrjIPFd9HNdXF0HSMBn8tTyTjgfjSeMNevI3a4tN4Vj5YbGcDvisWxa4msZLrWGFtbjpJNwz/7o6mt6NDRyq6tlRiloxNL1zVNWe7OqloreYbirDgemKr3+u2eixLbpZXj3U2WAtkzn6noK2NLubG9Eq2sTsq9XlXj8KzvE/iiy0OOKJ4w7H7sYH612QScuVR+RqkraHTaFcXV7p8Ms9pLCx/hdgWI7ZI71PPZviXYxluOox0iHfPrXMeKdZ1KDTtLk012Sa72g+X1Cn2rd0eHVLnSnbV5xp9qyhUaYbGf1JH+Nc004+9dK5DaWhjXdylxeJbrJ5kg+9joAf512tnLaaf4SmZVCZUrgcc+gqHw/4Z0dbuW4hvBeTcDIxtXjtW5qNjEumPaoiiIAFi3f/wCvXPXxEJuMFfdeRLkm7HlutXNzE0c6ShET70Xr7msrwz4ltfEGsfYLHzmlw2W2krgda07vSLr+0plghRkY7VVjnP1rovDPhmx8LI02n20UFxOMSyKvI/8Are1ehOpCEPPoaSlpoalon2JXkuV3uThEUcgdqzNWiTUciYsmOPLQ9frRqtzK0xdppSjcDnGcVymk6hfXeqFLqP7PaMeCVwPwPesadN/G3qC03OhtYbezXyEi8tj+ZpNQujFbxxRLKX/hCjJNZurpLar9vmmzCDtjIYYNW9M1+11GzkxgTKdr8ZPT1rW2zWpV9bIjt7a6uJA8i7RnDAtzWzf38tjtishGRtG/n+daGk2CXVuzwgGMDPP3jXCeN/D+s3Mskmk3xiLYBhUkH8/6VEZwqz5ZPYmUrvU2bG1fUbx5riWEWyg+ertwVPaql1qNnpVzCmlhVi34y38ZJ5xUPgfw5f6BoV2mv3kTXFxIJI42fcyrjk8/yqTU/Dt69o9zawGWSLDwk/xE9DVtw5n72m3kF09WZ1y9+uqyzzXrTRox2xnGAPTFJbeKV06YCRcPK3A61DpGka43y6uqrluXIrcTwk97cAW6gxx9XYdauThFWk1YtuKgdPY+F9N1a8j1yWMJcMoLH1x3xXH+M/EGl3julnfTWgh+TzWiJXjjqOce9eh+YdB0mPzwXAG3joPeuAvrLQrq9kmSzxLIpwqvwzfQ8VxYZuU3N3aWxhBSeqF+H6TxLNNfalHNbMN0ZRtwf6f4VzPjm58STeIR/YaBLYPzswS/19q0ytwuk3EOlwLHdMQvTHlDucCsfVIvENho8f8AY58+5X/WsU/eN7qPau+nH3+bTXuauOtzdW3vNR8Lzx61AYiWABXhuvWt/wAC2cGkaJew2wLunzqZOpOOtY3g99Xm8NEeIA8M7t8nmrh2Ud8VY0wXEPiI3U8zRaYsR3JjO8/41lUjeMo36ktaMdYapdNqca3qGQnO0qMc1ka/4SvdQ8WW2rXl8I9MgKyeTkl8rzgD39a6db6GYSKkYXB3KNwyD6Gksw1wlz9pYKrLuAzgjntQpOGq0FyPqcbpOoeJfHHixjaCaz0a3YhhjCbemD6sa2dY0DZd29nHPH5isdscjY357j1xWF45+IWp+HZrWx8PWiQWH3jPJHvMrZ6Z6CltvD2peIvFuleILiZ0t4cPcEtgrgZGPr0q3B/FK0Y20+Xf1Itp5Hd2ETRWYj3DzE+XPrxXL2Ty23iJo5Wk8qQFGBORnsabYa7dv4gvbZ8GMTZjA5AQ5FM17XbbTNXhWe3VlIA809jUqErtI66dOVX4R3iOIWNuLyZXTTrYb5XAyBzzgdya+TPiPfW+peOdZvLHeLaa4Lx+YMNjA6ivrP4eya74h1nUF1+JR4eKMgt5F4bnjb39818u/Ge0tbD4p+JbXT4khtIrtljjXoowK87MmklB7+W3/DnJUvc4qiiivIMwooooAK9V/ZnDH4q2gT7xt5gPrtryqvWP2Zb0WHxSguDH5rLaThF/2tvFaUb86sOO59V+JNBa/wBQilukHllNixhd546n2qLVfD9lutVutPdGChI9vQgDv71vRa6lnHHLfSYaRd20DnHYVk6z4k+1XUYhhdQpwW6jFe3TdZtRtoja8r2LOjWd0LkxwrCbLYQVcfdz/WpJ/JsJGtdJhh+0sgMs6oAzZ7A+lcF8TPH0+ieG7caXDDFPeyPHJMeSAuOg9TmsLwB4h17WmiuHlAMfySPjBYVssPOadWWi7f5hbXU9e0UzafaXM+tABicRxMwOffH+NYPxPOpT6NBp3haVYmLBpfKOCV9M1Qu5J5JZHLOAw2spPU+tamgTxPujEivOvLKeWX3qfZckvavV9uhXJrdlfQrG60+18/Up/Ml8pfMyf4h3rlhMfFniHySZJrG2PDK20fjXb+JJGjs1soYy97eAqB2Re5JrM0yC38MQTwx28dx5amWVm65AJNXCd05degcq2RqR28FtBHa2cZbPH7teM56D1pJfBmlX2oRXviEB5ohlYA3p3YVz/g74hp4xtdVtrLT1sdVs4TNbtncjpnBBP8LVk/DPUNc1FfEU14jNJDE4iUjHz7SQo9eQKTp1YqV3yuP36kt8yO61Txbp9lci20iEM4AUzlQAoHZa5/4xQalqejWJs5XlxJ+8UttHI4rhvh8mqeIb4W88cjSwsHdyMfLnoa+gptJgi06R54vP2qDs+lZ1VTwVSPVr5g+VWscj8I4Vs7GC3u5s3EcTHcTgNk84z6V0154l02zMsE8q3CKcblbdlvSvL/GniNI4y9zMLWNjsQRjG0e3eua8I+FLu8vBeWN9FNYfeLiQnPPOR6+1XPBxqydaq7f13G6aT1PXNT8Vwabpt/dR2HlvCqupUAmQE+9ctZ+PzrcTS2BhbGPMiZcOvtXT6rb6cqRfaI5ZrVYxE5UYAHrVPTrLwp50i6dB9nkXAaQfeI9qzpqlGN+Rt/18xaLoaGoaY2uaPFJYMLa+YKdsp27RjpXNX/gO/nsJJL69S2Ctt+Rsk1zvxF8JX2s38M+ka1HHChIKyF4z7Hjg10mo20uteDoNAh8QRRazEgjWSST75HqffpWqUqai4z0b7PQLySt0F1mEeGvBd06JFqUdsm942AfaM8nFcv4L1y01LSb27m00afHboZESEY+0YBJx+QroPh14O1zRNNvLPWdQgWWVZYxIsokyrDg4PXB5rnvDvgbUtD1131rxHZPpcgZJQ0uS4I4wO1axlTtOPNd99dQTsdH8N9di1a5hns2ljcybZY2fIINdPf3JGtP8zodxBC/1rJ8AeCrDQbo3Gl6kl9G8m5G4OPbj0qp8RtN8bp4stZvDAgOlvgyvIw4b+LeDzj6VzylSqYhqLsrddAclc1bjTYrzUEurti7IcqXYgH2qbU7u8mbYLxFj2kJGoOB+lQ3dwzqYTITIBhiOnviuej8N3+mLLLptw8s8p3fvTwv681SinZyfoVa2pgaTpfim38VRTR6r9rsnkzJGWyCvptNafjnx4vh5Ta6WCztJtkGDtXHXBrZ0SCa2EVxqDA3gIL+WuASK5nVvCEt/4luLy6Vf7NL7gh5L556dq6eaFSonU2X4g4/idvb+N7HWPCWm3Mt0tu83yvnt2/nVvUPBFjqunJcadeP9oxuEgPyn8BXgmt6RrVz4ngsRYTw6eJRGiICI1TPX096+mNFsn0DwwiKxZo48+vauPFQWGjF0ZWbexnLS1jzvU7LUrKExWsh85CPMkbnNalnrb29giXUlvaThTjYvLe9cf4h+IVpLe3TPczOYOqxjgt6Z9a0PB2q2viyxu5L3Sypt1Xy5N5GcnpuHfvXTOlJQUqkTWWxdsbmS8kee4mMhPAYnj8Kvavpl1qeg3UGmuI7wgmNyeD6j2rm/GPhiTWrOzsdKm+ziOTefMJwfcn1HOK3NENx4fNtpLzSPDHEAtzJ/Ex5Jz26nilPSKcXr2E3pZnDWFpP4LaS71iV5rqVCogjYMPdm7V2Hh+/iv1FzAxPmRFjuHTPGK1dZ0PSr+YS38bShQBhX6is+fU7HQNMurhrP/RbdQ21Oo5wBTc/aq6WrEm7a7GBrU1nZII724tYg5+VZGBJP0rqdJvIVsopvPWMvFsKk8NjtXmmq+HYPG7Rav4cmKxA+XPFOfnibOevcV2+m6EWmsrXz1/0dSWAPB4GOfXinUjFRWuvXyHL3omja2u28lkURvvXBZV5XHasLW/Cia9qcZlkcIvzbB/EfSt2K3NnckIWAJwQTwTSXdxJbETofuGlFuLvF6nVQvFaFHRNRe3cWiuBnjYO3bBr5U+NYx8VfEwP/AD9t/IV9aeH7OHV9Sa8jxvDAyAdc18ofHMY+LnikDoL1h+gry8za91InHuLa5dzhKKKK8k84KKKKACvUv2bfN/4WhatCpLLbTMQBngLXlterfs0CU/E5BDKYm+xT5Yem3pWtHSpH1Kjuj6i1HTLi4ujuXc7DJ749a2bHbZIyLEXlYY3bQVH1NZ1xfiBUfz2jjt8ZVTyxq/pl3JcsDDlDKpYgLxXvVOZx12NpXe5geJfB66zDHut1mjJLD5c7G9vSqnhrwxPoOll4wgYTkMM5yMdTXbai8lrEqRyMNvOWPc0alLDb+FZ0jcs7LtbYckZqFiKnKo9Gwcm0rnCvren6hqcttaSGSeMYOOmRxxTPAu//AITzXVkUqWtomQH9ayvD+iW2k300octkkKX425Ndfb3VnpmsWrSKBd3J2KyjgqOcZ/GuupZRcYa3Q+lmQ+NtctNJ8trwyYkAGUGfz9qxdJstR0+11TWp5DdWGA0EY6y7geB7GtLxxoen+IbkW/2kpJbHeQvXaecfpXSqsOmWFvYRxBrdY1HlycjGO/8AOseZRpxUd3v6Cluef/DW8j8i9intBYSOSV8pQCe5DDvXaeGNct7xb2KzRQyAFmGMA+v1qC+vdFt7hpBYIHZTuePKY47561R8BaPZwR63c6dO3l3YGEkGNvfAoquM4ylJW2FfoO1O7uCl/JpK/Z2mIXCcHHr9at+ENavNJBt9WuRK74bBfPy9MkVdsNIeR1cgKhHTuD6Vy3/CHapp/iK81C8kafzf9Xx27AelH7madNtFNRbsW/FnhXw94suoILe8ktpVbOEXIJPXg9K6G28OR+HdFisLCLZbxkDzd3zOfWuF0f4f67N42Guajf8A2Kxjfdu34ZgOigV7OFtyk080hkj2YReu0Ecke5rHE1vZKMIT5l28yHKzONurq4igeCMBos9OpP4nrXOxPBYXCNEnlyPwd561uaxLb6cgkup4re0JwjzNsGfTB71x6+GYfFeofa7TVhJbo2MxHIX2rppcqjd6It2tc6+80+68uGWJfMhfgnIIFcjrHhTSdMvJdZ1O+dEVxK2T8obPT1rvdOFtpy/YEaSYbAmXbke+KpeJkgTTZvtMMd1DwBFJ8wb3PtUU60lK3T80Tzdzn9O8X6d4gna10Z5pJo1yQFKjHTvWR4h0aTWybZHCbDljnC/i3StjwdbSSy3EltawWtqikHykCDJ7GqHjTRpdZkt47fUfsyRKzGHaf3uO/Hf0zW8JRjO0Xa3zHzaWR0PgLw0+kBYjcs+4hv3ZyB+NdB4v1CW0s3eXfDFCpJKk5P1qp4BtEsdFiVJZGigXAMhySf8A9dZXi/xC8mq3GlrZrOoISbfyWzg4Hp1rjd6mIu9bEp2ZzOheKV1Y3EOnWsgmjRnQseGPbP1rX+H/AIkvPEmkTtqFg1vc203lMwJw34YrN8TamPBGipc6FpyGe5m2ZKFgvGcmtvwBdX+qaajT2traXNwzSFI12Bif4iPU111UuRzUdOmv3l3bZ0t3asIrdlGZJRnaBzUWoXMdpEsTALJ0bua1bu5uI7VI1fZIBsbA9PQ1x99C1xcb5H/d9OTxxXJQTqfFsikubcu6VGuoXsRLERhwSSeK7PxA00VqFBDW7AhwRz/9auDtplU28NrgPv5Cn7xrrfHF5JYeHLm6jha4khhOYl78dR9KzxMW6sERU3R5kvh3RU+0W6WcSRO/muXG7efUE1vWECW9stvaQiO2UEgKMfmKwfCeotqulrezW5hbcRtI4IrbmuHQx7QPKJzkdhnmvQmpXtLoa3sjdRxbaYWcLJOAQqHqPp9K8z8TaBqut+Io2Nw/2PCBV3YCHv8Ajmu+aTzmEij5ieGzz9DVe6urDS7Y3uqXMUEGQN7NgZPp6msqTdNtrdmfmzkJfGqy64mh2dok1tAoge4JJc4GCeOMV19pp8F5ot3HdxpJDJGQy+o/GqWk+GNK8mbUtJktDZTkyG4hO7cOvPpWf8QvFEfhrw55OloTdTDy1kbnbx196p2m1Citf63FdKJb8H6HptlYX9jp4WIkiUgtluPX8K2kEWnRDciGR1wWI+8K4HwDbf2X4WfW3DT6hqBw7se3XmpPFviW6TRLae3jOZMqSRnZim4OdRxTvqD3sdQLpJNdWJgoRsgLjoeuav6tYHkR8xyAAfXFcX4K1A3cumXFwfNmcEM0fTIzy1ekqytHtfkgVnUbpyNabcdSl8PdOtNLjuW63LZO7PBHYV8YfGt5Jfiv4oeYYka8YkenSvsqZJfLJgYISPzr4w+MO/8A4Wd4j8w5f7Ucn8BXm5hH7be5liG5Scn1ONoooryznCiiigAr1v8AZgdE+KSNMypELG53ueijZya8kr1f9mewttV+Jq2F8XFvcWNxGxQ4IyvrV07c6v3Gtz6Ai1zQNY1K5stMuHkMZLYJzkD3+tdl4YsHW7+0SyeVCnyru4Dewz1rnLfwh4b+HcF5fRXU11KELESBS+Bzj0HapfB/jCXxxp1w4tBCYZNgQHOR2/Gvpar9pBulfl7s3c21bud5rWny6nsW3lCxjAYYBzVDVY7fT7AWGUKD532kAr6sc1JbXlzY6ZIZVVrhiec8Aetec+LjcatYXEEdxtuZWySCRwO2a5MPSlJ8rfuolJvQ2L3ToLyy+0adOk8QcbmUgkH3q3eC4fQJ5bGzgudUt482qynjd0z9cc4rkvh/p15o8d1BcMzpcbTgNwpFdzbMttbOzyPsTLFyMnA7muuouXS97FpN7nM+ELC9+xSXWrjZqFyTuUjkH3rs7yEX+niVOZFiw46EY9KxtB1/TNecjT2lMi4Yb1xuB43D2/Wrer30ljJa/Z5Nk3LcjPHTp9TWdTmlPazDS10Yl5aJPA4ueYwAcgdB7+9W9F0iNbGU2lx5MKjOD1J7c+tW9WuYruwjkeIIZP8AWbB8uR3AHauC8a67c6VaQ/2bFM5Z8DGSufU1rBTqaLRk3e5p+LrDxdc3Frd+H5pDHANsiBwoVs/ez0PpXbeGpNdk0aJdSuI5NRUje2MLz0H1965Tw9f6kPCkSXqyQNK3mMvJI9D61o6dd6ha3jBGDWjsoTce+etKrGUo8lloDWlyDx1eXVvazQKRNfRAiONpMBz6DPWsL4NR+KdQ1LUJtTBg05QMhgeX9B/WrniXwTf3njp7y9vD9iLrIpByxHZQO31rqLfxNHGW0nToxHGo2Ftv3j35pOf7lRp2ba37Ck7qxlfEzQbPxNZJaanctC6y74JM8k9DweoxTfBugx+GWaO0ZXgCYVFOST6mk1rRRqd5Hc6jcS7FUDy0Hp+tdCY7UWayxFlaLCuGPI44HvS5nGmqd9B2u7GBoFhepqzz34bc0vLHvznI9q6rV413NDKyIjHliuRjr0rnZtZladYkIA7HFdNKxudOiuHAL54PrWdVSUoyY+W25X/dtb+XbWv+jJgnoAT9KytR0oXMrXRnCME2MOm33rZlkQWZKsqzf3gRisfUUWcMZHdpQMhjRSvfQaSexV0/W7Gy1GDRo7tJLmVwCm4An3rubnSYrhPty20LT7f9Zj5yB614yfB0P/CZ2urLeMZBIshjxj5ulfQMG1dPXA2qExxWOYNUnCVN6vczn7rPNNWmkt9F1JfIWdk2sB3HNcL8PvEmpXnilI57WJbVSfMB4K+mDXXeItUk+3SWscTRRyAqXHWue06wFteefGxJznkda76aXJJSWrOmlBSi22en3jI8SsG4RWJNchdTpdRPGilZBnB9TW1HKTYQuzfLIDxWJOFtWLQY+rHvWFGHLdEJNIj+HmkXU2sSyzFisZyQ3auv8Raj57COM/KvY98VS8GajMttqLXwWN1ARCB161jX9tcXNx5okkMeQWUDmpa9pWcpdNhXvK43Vybm2KxqiSYyNqgD9Kk0q2m+xhro7YiQu7HWqeo3EkMwS3XHfHUk9uax5fHNzDr0ek/YDLlwjDkEeremO+a6FGTVoITdtDtvM86Ax2cOxou+ASw9cVxXinw5J4mks47qcx2tuxd0jXlhjt6VrB5ZL0eWzK+cYU8Yq7qtzJbQiW4kMaL1OO3vShem/dLaS0Y/wvHb6Rbi1sYglqQFEQ5z7n3qLxFp1tJdvDcQRyxE7lSQBgKz9G8QQXF2fs13bSAfwcBh710kEKaxEkjuqsuQWH+fWol7k+didk7nN6nrOnaRaQ6bfRuUmG7MagCMdBUt7a2GmeH2cWpulLr5cZ+7jrn1p/iDwuuq3FtJBcKPKXa6YzkZ6n0Na08L/LC7IsMOB82McD3o5o6cvzM1q2YnhmBLy4W6+zJbKeRFGNqj8MV10Y/eEAfw9+1VbcxbC8IGzdjdjGfpVpGIJwSzHuTk1lUbkzboUtXVIrdZVfY6cZr4p+L7mT4meImbGTdNnH0FfXPje2u5kt47Viq5yxB618g/FaOSL4ia8kxJkW4IYnucCuTHL91H1Mar92xydFFFeSYBRRRQAV6r+zSD/wALStiDgC2mJPttryqvVf2aopZvifDHAMu1pOP/AB2tKP8AEj6lQ+JH1Nquhx3d7Pcak6m3lQL5JPzMD14p+lQ2Hhu1IsbaK1tUBPlqMZPqSf5mneIbV9DtFup5xLcyHjfjPHTHpXE+KINW1XQIVgJE8j7nUcB17c+1fRU17WKXNp+Bq9TV8YeIboaRLd2UUcpUBQEbOBXP+DtWu9aWX7TbhChGHAwD7V2HgnwXJa6E8urztmQbjGrZAGO5qZ202ymaDSY0LZwztyw9hWkKtNXpwV2upUGWra0RNu7KouGJQE7q1rW2ubpZPOSKC2xhUkI3P9R71oWl/ZRr9ngOZUiyFI7/AP664y0n1i81eX7XGrKCfvDPArkUp1L9LdxOVzb+yWGmyO9nZ29lGRlzEoBY+px2qnrNlBf28F3NP5SR5iHlgF5QTnA/xq3I6tzMSImx8ncgD9BVDU7uSSWOO1tY1WNcID05/r71UIu6B6KyM/U9XttPjjS5ljhyu1EJ6DsPpVRdbiiWK4uoB5bHG1EBP1rO8feEJtTvZNQtLld3lLst85+YD7uemPepvBmm6rZaLMfEjxNKz7lU4IjXHdh/KupKDgpJ/Im7bL+ra/Z2tsl3LIbeF+Pm65qTT9Qi1KC3uLV1uIv9YjDvt9qzp7DQPHSJp9ndTMLPO94hxnvjPWt/TdGsNK0+Oz09dqW65BZvmY5ySTSbjFcrvf8AQrmNfWbgS3lq+GyyKuO4OOtc9Dolq2qYfzTOQ0y4O1dwyQBVTxeNQ/4TiK5txM1sI0MTJ9zBAyD75zW6J/IuUMjffyig9s1jBNU1y9iYrmOH8OX2q2Wq3V54pma2sdhUJIeWbttHt610HiPXIbXSZbxzHFbzMGWZWyGHqKueLPClnq8doNRMvmQpyITgEe/51leM7Lw2fCNnY6xqH9nIj4gjQbnZR7f1raM4VJRlbfTRdCo3jqZ/hq/t9W2y2sv2kF8A4PBr0S6dJ7MWqSqHhXJHTI71wnhq58MeHPD6T2si2do8uz7bcnczkj+ED/IrpESe8sLqbS54JZ2hJgcv8rN25qayTlfZLa5V76voJHKhO0spHQgHrWR471UaPZS3RiJxjamOTWT4S8P6tZ6y11rd7yOdm7cC3ocdBXHa7c+J5NWmn8SXTx2qSHMaEbGXPRQK3hSi6mjTS/H0CLbex2vgfWl8Q2yzPA9rJG+Oudx9q9tsix00Z9O9eO+B3sr6OGWyVYlBBKr0/wD117MjLHp24LuAXp615eZtcySVtdjOrpY4zxVDBLN5XnxRynBAbHze1crdQtZziF1Ln7uQMYqp4r0H/hIPEAvmvLi2jjYL5ZGMfStZnZmjjXJ2gJk8k46Gu2lHkile5pSk3oby2m/RrWVUIMYPLHAx61gzxRSFvMhZxnO5m4/Kt+wlkt9Kuo5RlVXAz/tGvP8AxHe3K6k8Cs8aRgbccD6+9RSveSfcl3R0Gsatb6JpcUyLud2OIwDjFdTol3bap4ejuGTY8qA49DXn1039sW2nxyuCYhiUDvnocV3mmPFp2mjzFwiLtx24qK8VyK29xS2uURp8TajC0sfyh8ZLYrN1B7OKd2uNJAlQ7d/mt09DWnp+pxX4v9qNuQb0H0//AF1ykMtxqF9cLcM5C8g5x+BFXC7b5uhUJJuxlSfEqxstfisLPSBdMZAjCMYx6getegXZh1qO6tbu2VVC7gB3ArmYdPs5bguIIkmHys6gKfzrYCtZzmRLhHQZXOegxWlSMG04qzHyrqcheeErPTBO+jRx25lGDKzFmB9Par3w/wBNvLBbi0vbgSCQb12sTj0ralnilCiZDs/vBc/pVjw7pzSXrzZ/dRIWLEcH2p1Kj5HzMrlVixb2giiZ5ywVDwA2CfaqPjDT59T01QJACxwIxx9MVrTyq8pJDFVPyj1PqazfEkGoX2myw6XcrbXZH7uZuNmepHv71lBvmTegOOmhNo9rLpWjWNlcuzSoDuzzznP6VW1vxRpGkTQRX9wI5ZTlRjn8aTwra6npulPba1qK6jIr71fBLKPTJ5Ncz4y8Dr4g1GLUo3l87btaM8BsdMGqhGDk/aPTuibtI7LUr611Ky8m3lV7gL5iZGMgj19a+J/ieJh8QNdF1/rxctu5zzX05ruhao+kaeLXYtzCSskQlw2B905H1r5f+I8dxF441mO83faFnIfccnOB1rgx8FGjGz6mU22jm6KKK8cyCiiigAr1n9mK5S0+KtvJISAbOdRj1K8V5NXpn7PCB/iPECAcWsx5P+zWtGKlUin3RUd0fZWv6WNYitJriUCJIsyOx4Wm6XNYCCytUZJYm+XIb8q5rxdeXN14etbK03uWf98F44HQGq2kwSWsMTFREF+Zu23Hf2r3YUG4Wk/Q1UG7nQeKtVu5NBu7WwQRSFmjjPdiATXmng/SL+wS8vtWmdU2FDGzcs2fvYr0TWGkdYyjqYyN67edxPUn3qOC1a9jEJhRVlA8wtwOvr61rSfsqbS0TFFdTF8LXEeotNexXDR21uTuDjqB2q3beLLfUNUaLT1KuAcMe4xzit678J7tJls9L8qCEZ3ZH3zjkZrhtN0mDSZnZUd5Rldzfw+wohKnVbaGlzPQ19S1oaXbMGthNNJyqljnGeuaZP8AbtS8MieRTay3AJRUP8OcDk9zVu1s4L+UrdRLLLFGflPvzz7VjavaXmpa1BbsXW1ixgKflRQMnj1qtnYHdOwnhvVDa3T6aJZZJVG45OQgH94+9d3c2dl4i0CezjvGSTBV2TjAI6Vz0K2QWceVHGkgLySbAHAHc1d8HXto1rf3NsrGBXCjLZJ4/KsqyuuaOjVh8tkHhXwhZ+ErKeOF5GV1Lec+PmboMgVzdnY6q2r+czMYiW3HdkMK7462l7p06iJN8Q3EdlA6cVzPgfXkvtW1C21cKjoh2HoM55yR/OpjOpaU6iuyG+5pxBVMe5S49GNQauwlhGxT5g5Hr+da02mxz6YbvTLprhSM7GIJ9+a5bUdUGmrELkMWLA7R+dXTkpu63RrCaWp1+nyQ3tlc24mVtQ2KroxGRjvXmnxG8IPrFzDPKl2kiKUXYu4MM/kKx9M8PyaZ4xk1ux1FjG+5xESdzbuxPcV7VpuqR3djAl0g2xhdx/wok5YWXPSd0/wJTcTx7WvCUWpeHtK0xmNrNYhtq4zvB5OfetDRrG90bRbbT4DIsZflmOCwH9Mmu51iyt5dZJtwnk4DIf55onvVlkW3uBEoB2pwAfwrX6xKcUum5Wj2Oa0r+0kvp2vJHNp5bI3TGSOMVx/je6sGY2940gZvuqB3r1PUvs0U0lnHwOM+gOK5abwnbardGa4hLyRnaCehqqNSKfPLQqNkcN8PLi+j8TW2nwHdaludox+NfUdomy1QNzgVxXg7wnDYTi5MSb/UDpXbXTIsWGkMZ7EHmvKzPExr1Eo9DCrLmeh4t8fHSeyt0s5vKkacFk3bd4Ax+lV/h2W/saEy3P2toyV3ls7f9n3xWp460Sy1+dEvYmdImLKVYg/nWP58Phy0Sy0eFIkB3EsM5PrmvUpWWHjTW5olyK52bkx6dKFbmSVVYH0xnism8tBeW7khBMPlJI5X8a0pIxdaHZg/urqePzTjgKT3rGitZNNjEM1wGckt8xyT6Ee1Z07NP1KXLKN76lDTrF7K9ee4UMOF+X69a9E0tINS07Yy7uDuBNed3+oXxASwtxK7YBPbFdp4FnI82O5O2QAEgdqjFRfs+ZbomcdCsttbaLdOIjtLHqxwWyenNUtUyJkezHl4J6Lg+9TfELRLfXmtvLvWtvLcOGCFs4PcCo4bXydPELyAz/NlycgnsfalTacVN7smL8ilFNFeXCgMiTnCswGCT64p+u31hpOiXd0Zd8sJCNGVxgk9a4fQ9B1e08R6gl8ZVs3iZwwzjdngg+1bmj3MGq6LcnV4fPdFCuzdZFzjn3966JRSas7rTYb12Klr4le7022ukiUebKV+UE8L2r0qORLbQIVDLGXAkkduMA9Frl/C2kaRZWQjs7VUDSFwHbd83rzXQyPZTW7RNdiTzn2ooO0AjqQe9YV2pOyWiZUpOyKqXkUt00CyxNJt3EIck+9WBGWWSWRxGgXCs+ME/WsuO0stNu86TavPNIpWV5STgei00aXJeQNb60jSorbo0Vtgjz296NLdg5nYdp1tGNQe5FyZYFPzBDubPoccYqy1+VvZTEVjX+Erwfpj1rmdd1/QPBbRyPZ6giyfKUiUfOPck4qzJfaTJY2N3aXCeXqMRltYZZMSSeq4PftV8rfvNbiUo3ML4pa1rdilncWbLsl+VikQYk+hNfLPjyae48X6rNd/695iX+uBX1pp00epWx/s92C7tskEw+ZD3+tfLHxXi8n4ja/HkHbcsOPoK48yaVKMLbMzqLS5ydFFFeIZBRRRQAV6j+zgSPiZD8m8G0mBH/Aa8urvfgpqTaV46huVjMp8iRNo9xitsNFyrRS7oadndn1wUZ3HJ5OAAa0Whtpj5N6pFtsywGfmPpVbR1MsCyzRsjldwDDGDUly4NuYi4VwSQT39q+hm7uyOq6MiXVbG51J9Pt7lWuIcfulPKjp/hmq2l6ncm+vC4byklRFDemfT6Vy93Y2XgaK41txLdXs7GOBZG4UnkmneH/ElxN4av8AXb+0Cx20gSNQSFkc+vsO9dDpaXjqtvmQ/M900u4WO0KyyAjOBj0NcJr8Ztb4YBCtITz6DmuR8EeINU1xrqW7GERxtdFKr9Pwr0HU9QzpMUE8MMryH5TJ/D6EGuNUJYap3vuSly6mF4Js5rfxDqM93IsnnowjIP5U86pp2mayTfyqFkBjIDd+1XPDENw+oqpVQN2GUjkH2rZ1rwV4YOqxahqaj7QSCqFuGI9qKlWEKnLO+q6DlJRujn/FXg3/AISLRri20rVRbiQBpG2HOBzt461p/D3wJH4X8Ktp1zckvK/mvI+BgngDHan32rb7wLp6eUI12q69eP6Vna1599NC1xPKVAz97rStXnFQcrJ6+YNSkaGrWMGnOoMj7n4dkIzisnXLC1wH02FIxtx5gGCfUUSuJbaZIwWMY+6DnBq34U1Rb2KVGtJIpE4bzMfyNaWlCPM9bFpqOpifDbxVqdn4km0S/sh9nP8AqXVeg966XxJo0d3qEf2yArHKcqw6J9avaJdWz6hLDFEivncAwCt/u1Z1HVYlufLuY8JjDAntWFSb9tzQjbTX/Mzt7zsefDTbU6szRtIBA2CjHj8BW/ot7i98lXWWI/Iyt1XFN1iJFR7uNoRt52hvmrD8NXXl3t3LsIXpu+tdTXPA0toGoeIra81uS2jedATsRyuBntTdI8MiLV0uru7eSTPmIjP+tSwWeg2uqrfXUE7srblAfIz9K076CC8nu9R0a5KXDx7ViZMFR6inzcvurTQVnHco+ILuRLiW6RGCo2Se5rovhtFqGp2jz6jEYoCcxg9cVh2WuaVBHGmus0cjNtLOBtJ9cV6ropi/s+I2zI8BUFHQ5BFceNqunT5Ut+pNWWisLNiyttsYJduF+tcnq0txHE8s7F5FB2xg5J9qt+Jrydbgw4YcAjGcH8a5q7lZY8zEhF5b3rPCUHZTfUdOD3CC6lvJUa5i2BMBgpyB9PX0p0+mWlxb28lzErTLJjb65P8AKo7LUrW4iPkzIWXqoPWr1tN9offsBjQ8duldkrrbSxpKN9Ucz40GoyX8C2O0YBDD0I6fpVRrG9eUyzl3YKvI69K2NU1qIanJC0edigs49T2qOxmuEu5kunRY3GFTOD7VpHSKM7L5mM/idNPuxa23MkhxJleQK6rwUz3BnlVlDFvWsvV9EQSl44ohIy8tj5qp/D2ZbC+nN1dbtx+VW4AHpU1LSpvlHN2idb4j/dTRvB9xRtFZ9m2Vct0JyPrV/wATXsDSwRy3EUL87YycFz7VmW8sEm0JIGUnp6exqaP8NXCnZou3DE2727y+UJ0K/jisjRNKNnps9vMEaSV+QvICj/GtpvnCuACFXGSKqRt5tyqklLVeXbux9Ka2LUbDptKDwLFE6o/C7QeQPb3Nc7pXgu8h8UXOuavdn7PbAi2tomyFXoBz3NdFa38FrqKGRQ25vu561U8Ta85vmtuIYQ+HAO3cfWlzVE+VbNEz31GR6vJHPi/uY7WHdgQocsM9Mt60zUPFUWlXSQMmI5OkkhzlRXifj/Uns9VkWKQuvUDNb2l6vJrfgy5cAST2sYkLn720dga6pYZJKT2YNpHQeJdd0jxLFJZ3Zl8vqCzZUEeh7Grtt4V0jxD4csLOczQy6eCltcwNyiE5wQevNeGzXt1PKDnaA3HHauo8NeOrjRLxIrphJbk4Mf8AEB61tPDuKtSew7xkrM9X1CK90l1WG0EqKoQ3JXmTA+8SO5r5U+Kcpn+IWuyMpVmuSSCckcCvq7WpkvdJtrgs39nzgGO5Rtyqx5AbHTPrXyZ8So/J8ea1Hu3bbgjPrwK8HMf4UX5mVTY5miiivHMQoor0r4efCXUvG/h0atZ6pYWkb6g2mxR3CTMWmEQl5KIwVdp+82Bx7jIB5rXp/wCzpL5HxJjlESyslpOVVl3c7eDivNbqFre5lgdkZo3KFkbcpIOMg9x7161+yvcQ23xat5Ln/V/Y5x0z/DV0naadr6jW59RaCmrTyNealKfJVDtVhjn2rm9b1e0sbgtev5e9z8pPXmvSbzUIL+ye204iSU44xgYrzbxN8PpvEF/FcNdeQY/9apXjGe1fQ4erFybq+6jSLtubj21hqFiVmt4LnKhlDruXHrzVr+yrX+yvIuo4RbsMJGy/Kx+gpdO+zInkRERrDGIlBIzx61leMNZjgmt45GICqFVU55p+9KXKiou71GyI1naLsWKGJTtSOMda4D4ga4Z9TtreK8MU0QGUXnaOxr0DTVXU7GeRNzt8rKD655/Sud1bwXaatqsL3SAXCkD5TgkA9DXTSlGM7y6GujVj1DwtZxaVoP8AaV1KZpBD5m4joMZ/OvMrzxc119p1DyJZJvM2gPzgen0Fer6hJ5WlpZIE2NHsI9umK89n0dNKLReSJImb5wecemK4cK7ylOW7/Iwj3H6Nd/2jpqztGImBxgnj61u3kRlto9u0gDBI7e9ZdxamW1hjtQqbe3TFayBlt1SQAgIB9TXRN6pmutjkNb1GTw7axyw7WlklwMngAAZJ/Ou60a8ttY0i2v8AckBlTDkL/EO3/wBeuY1TT4L+BYLqJmQEOM9j6GtC2tcQGKHEUCIDtJwOlKrBTiuj7k8jex02j6LbC6+2x3azIOSCmCK0dW0u11iF/IdROO/+Nec+AtTuV8bz2e9jbvlSh6DjIIrpNae40fX5ri0mKpwTF2I71xTpVPbWUtbXX+RNpc3mUr/wBcuWc3Ibucda878VT+ItE1E2un2Ans8clV+bd7+1ez2PjXS57qKzmmEV267tjEdKu6jp1vqMbyW5RnYdR0NXSxlWlK2IjoHO7+8fM1jqWs32qLHqNrd2pjOdsaEKfqa6nXfEB0W1W+dT5aqEVIupJ7k17DZeFodxa8II6BB3/Gua8beA/Ps7r+zVVhIvCOMgn0IrrWPoVKijsvwNPaR2uePvYzfEC5hm0a4CsxCNbyKcxnv07V9FeAtAfwt4Vt9Nmm84wqSzdsnk49q8h+CGnXuj+K7q2u7M2rAYHynDfTNeyeL5biPTx5EhQNkMaxzKpKdSOGi1y7mVR8zsjmNZ8WWUeqpZGWLbJ1V37+gqfWdKs9XsntopJE81CMoa8+8SeE/t2tW9/b3CLAVQuP4lI64rfbXRYCWbayxiQIqA8v7Z9Kv2Ciouk9RxUojNG8OQaUrQWMJXaOWc5Zj6VYF40UUkLPjPUHirFprS6ldTzackkEqoNytyA3bFa15Yre2tpdzQx/a0yGwOGNU6rTXtOpop2R5zYy6veeN2lk01bbR4hh5JOs2OhFMv/AV9rXiiXWL++lGlwHzNi5DcdEX2PrXoel6Sl5Obi5R/LHRGJxms74la3/ZegNbTrI8E8ghYxfKybhwR7DFV7eTqKFJa7f15iau7GXBNKNbV3YEynYFPIX0xWslppdnqPn3yBJ+qkdD7kVxPgTwxdWviWNhdXc6gniZshPeu08SW1rf3xlVGbZhSpY/Nj1oqJOfJF6WCcXe1jhfiD4e1C68SRXttfwPakLtG/wCZR9O9dYtqV8oxOY0xk4PPH+J61LY2MQYTzx5Xog7Csq+v3udRa1tRtTpn19Me1XztpRfQqHuEsnjTTLPVoNPlEkkshEZkTGwHsP8A69bOt3cdtYlkALAEgbvvVysujaZbX/8AaN7GhvCRtjVs7vf270k7rePPdpOzpGp3ccR+1JxjdNE87W5zuna5ftq7fa2xhsrgYCjtVfx/qcmo6ylxCRslUbfr0J/Ol1q226E+pQOxSVCoZe/OKfJo/k2OlicFpIYhuGedxOcV0RcVJVLeRK956nG+PbEvcQyAZYoNxHrXQfCg2ogvrWRirhCSpGcjFZfieUz3U3lK2wHaCaZ4IzH4hjjBwsilWIHatpxvRs+x0ci5SzfaRDullQMkfISRFzg+tclqWgNbQGUSCQs33lr3fVrKF7ZYIQEZxsUf/WrlZvDRSQQSTtJHnoFwKzp4hNe8Kye6Mf4cXfiK10O6t7NI7myVxmKU8jP90V4r8SGkbx1rJmjEchnO5B/CcDivpXQNGl02dyhCwu4yR/WvnT4uf8lK8Q8k/wClHk/QV4+bSjJLl7/oc9VJaI5CiiivCMQr1b4Z/FpPBXhSLRm0m8unh1gaxHPbambUMwjVBFIojbfH8uSuRngdufKaKAL2uai+r61qGpSQxQPeXElw0UK7UQuxYqo7AZwBXov7Nxx8TYecZtJx/wCO15ZW14S8Sah4U1hdT0lolulRowZUDjDDB4q6cuWal2Ki7O7Ptyyae0uJLqIsW3bUB6Y71g+ObvXJbYPpyu3mviQRkll9Pwr56f46+M2CAy6fhRgAWi8Uxvjh4xLqxmsMqcj/AEVa9lZjR5uZo0c4vVnr1lofiCJzc6hcGCDIcru5UD1/wrqtLvrTX7yYw/OYByCOuO9fOV98afF17bS288lgYpBtYC1UcVV0D4teJtC806e1ipk+8XtgxrWWa0ZRu079NA54p6H1xpBGnBjLsSIn5tx6j1/+tV2CJlvTNEEZG5Vj+lfGuvfFXxRrhT7dcwbV6LHCEH5Ctaw+OfjKysoLWKXT2jhUIpe1Vjgep71hPH0Wrq93vp/wR+0Vz6m8XeJYvD1k8ksZmmyACOxxnFVvB2vDxTp7XQg8o79jAnOa+W9U+NHivVImjvv7MlQ9vsijH0o0z40eK9LiWOx/s2FFHRbRefc0LHYdU7JPm7k86vc+w57CONSQWVWOTzgAVHdTRjKxjD8Dntivkq5+PPja4j2SXFgBnPFqoqGH43+MohgXFk3u1spNZxxtO15XK9qnufVM3lqXkeQhV4bnjOMVUN2ApERJTgV8xn45eMdjJ5mnAMcnFovWoP8Ahc/i7cT5tjn/AK9VreOY0eqY41Ypn0n4ZlYeMbdt6xln2hmIG72HrVv47Samj2raQGLEYlCda+TLr4leIbrW7XVJ5LZ7m2YNEvkjYCDn7tdDqXx58a6jcCa5m04uBji0UA0nj6KrQqxV7LXT/gk88XK56RZ6RPqHi6xuzdN9qtUUz5PQnov5Zr1vTtcn0m48sk7PfoK+R4Pi14mt55ZoTYJJK292FqvJo1b4ueK9UiVLi4tlA7xQBT+YrSpmWHq2jNO3oUqkLao+xtZ1y+1KGEWzeXtOcRNgtTdJ8WToVjvJN+zOeeT7Gvjux+LviyyVFhurc7Tkb4AaZN8V/E016Lp3s/NBzxbgD8qx+tYS3JbT0/4InOG1j7psvENlcSRObfZIzBS3Hf3rfvbWO7tXicZVgcHrj3r4Lt/jp4ztwBFLp4AOf+PRa1x+0p8QguBc6bjp/wAea159apT5k6VyJOP2T6a/s7yLkJdlXiXI3DP8uxrP1fTLK+VY2ZxsbcNq8GvmiX9oLxzKxLzabk9f9DWqx+OnjPJPm6eM/wDTotd0cxjvK5r7WPU+pNEaPSLl/LQ4cchv51rab4m0u6uFsJTsnD4Unjca+RJvjp40mjVJJ7AqvT/RF4rNuPiz4nnlMjSWQc85W2UUSxeHqayTT8iZTg9j7njmWKEdQSTwO/NYHiKyjvzLKVLOzL+7Pt7V8pr+0F46WONBPp3yDaCbRc/nTf8Ahf8A44D7xNpu7Of+PNawp4uEJcyCFRQ1R9Wyu1ojwqyp8o3Mg9R0FUYZrTzNkkuyQDiN1+Y+5r5eb4+eNmLM0unFj3+xrx9Kz4vjL4siYMJLEsDnLWqnmuiGPpW1uP2qPrm5by7Rcr5s7fJGqjlj/hXGaoLbRA7CffeSnLspJ2+w/wAa8Gb48eNmiMYnsFUjB22igkfWsK9+J/iS8m82aa23eggAFXSzCiviuKVRdD3bUbmS61uELIPL2HI9DjisC+jvrCedIJpVYjcVHTnqD6/SvLIfip4ihZWT7B8vQG2Uipbv4teJrokytYZOASLVQSB2reOa0IvZ/cRzRPoD4eK93oJ0u5RdjNlVcc4zmta8tVE7qR8nv6181WXxc8U2c6ywSWSuvQ/Zl4qa6+Mviy5KmSWx+X0tlGfrWcsyoyk3Z6lqcUz2LWNIWWQRw4JZ/mo8N6IbTUS7LuYJlT6c14w3xd8UF1bdYBl6YtlqW1+Mviu2lEkb2BYf3rVSKr+1afLy6mscRFKzPqaHTGnmSUryo+9tovNOSPCopebruHf8K+bk/aD8doMLcafjGMfY1xVV/jt42eYSm5sd46EWq1zLMIX1RPtonvd9cmzs7h3DFY23OMdAK+VfiPeR6h441m7gBEUs5ZQewwK6uf43eL7iBoZX01kY5b/Q1y31rzrU72XUtQnvLgRrLM29hGu1QfYdqxxeKp1qajFa3Mqk1LYq0UUV5pkFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQB//2Q==);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Medium power view (upper panel) of a biopsy specimen from a gastric nodule showing replacement of the glandular compartment by an infiltrate of uniformed tumor cells. At high power (upper panel) the tumor cells have uniformed small nuclei without mitotic activity, and basophilic cytoplasm. The features are characteristic of a gastric endocrine tumor (carcinoid tumor). Immunohistochemical stains may be helpful to categorize these tumors, which are positive on staining with antibodies to chromogranin and synaptophysin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Donald Antonioli, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39655=[""].join("\n");
var outline_f38_46_39655=null;
var title_f38_46_39656="Membranous EM";
var content_f38_46_39656=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F55226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F55226&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic2\" style=\"width: 1040px;\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Electron micrograph showing membranous nephropathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 391px; height: 252px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph shows stage II membranous nephropathy. Electron dense deposits (D) are present in the subepithelial space across the glomerular basement membrane (GBM) and under the epithelial cells (Ep). New basement membrane is growing between the deposits, leading to a spike appearance on silver stain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
"  <div class=\"figure\" style=\"width: 450px\">",
"   <div class=\"ttl\">",
"    Electron micrograph of a normal glomerulus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 266px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAEKAXkDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6J0yyhitoAiAlBhTjtmrV1bRzJtlQMOwNPsRmFDnn+XJo1XUrHSrGS81W8trGzjxvuLmVYo0yQBlmIAySB9SKAMPxHoQ1KxSGKNNyfdLVwll8NJW1GX7VKFtx1EbZJPWu3f4ieCNhH/CY+HeeONUg/wDiqji+IHgcAg+MPDfPP/ITg/8AiqAOF1/4dSWsiyaU0hQn5lUc1Utvh/fS20cwBQfd8p+vWvR/+FheCA2f+Ew8Nk/9hSD/AOKqJviD4JwB/wAJf4c7c/2nD/8AFUAc3a/DmM2WJCqy46L68Vn+Ivh7cpZrPZ5eWPkKO3HpXbr8QvBKxqP+Ew8N++NTg/8AiqfZ+O/CF7eRW1r4p0Ga4ncRRRR6jC7SMTgKFDZJJOABQB4pql1qkFzGbgN50Q4bHf6etQ22qTecn2oEsrbgxGBnHI/WvbfEPhW21OEyFFEw53CuW07wDHdRyG+RlwCEx/OgDgpNYhktprSW1Xk580DJX8fSjTbB57g2+lvHNd3GArD/AJZg5z+HNep6P8PbGHzDcpuByFUcDGPT1rpNL8P2OmRbrK0SOQj73c/WgDx7xf4ZvPD2mQ30N/LLMTsmD9OR1GOlYugXkNgwLnzn3FnYnGT9Pwr0j4gadqN1IXwTapghQMgn3FcFp3hW91CYC0jfaG3Oc4U0Ad/ZeIrCOdBCFQypkuvIU/StvVFGvWS2dq4bPzO+OBXN2fgqeC5tvMcOWPzYBwPWvStMsYLCIRxRhRgdKAPJ7v4a30twMyJ5THLMOprsLP4f6Ytkkcyu7j7z7utdwyq6ZAGPX2pcALg4zQBxD/D7RpZt5gZV6BQcD6/Ws3xB8PbSeA/Yo/KZSBtHINeksnOf/rUoUDdgdaAOI8G+EP7DuQsjrKMZ+hrtwgzwMYpxXA46+uKdigBAoHGKdRRQAVynjPxOulwm3smDXrHHHO33pPGviQaZEbS1ZBdMAWYn7ik//rrzew19Flv5bhmeJI+XLfePsT+HNAGmGN1Ksl1L9peQHzJGOVXK+nt6VUtvEGk2d+kV9OhjVDGw25UgcDjsamW/+09YzCxiaRo8Ejjo7NjuPT1NeQybr5nkZ8M+5+nIyeRjqetAHtYW2vFgm0iTbaFdhMhJ9cFfy/KuPnvj/bKxyXqW8aKGkkJAXGeOO/bitHwPc3Q8GB4zH9nihl8wkfNuGdv1rzYzNcuVnBkcjg4zjj9KAPXdVjW9+zarFf4tYQdxBG3pwT6dcVhXV5aGaTUpUxCIN0WBgFugOO+P61zPh7UtRitbjS7aYGORQymTGV5GQevGPX0rqNQsvtmmwadMkaTbcEqcLn2H4UAc5YeOBHLJJPafbZlyiowOME9a7KDxLpFzZ2YiKW0i42RM+1k5z8p6fhXlt9pN3oV4UukKZYqG9/X0NU3mRQqXEhXjIKjkH1AoA931aeSRpLqLYqyw71GMlxjoAOCcisuw02O4sYYJklE6rvDc/KB2P06VhfD/AFyyk0VoNdllmETYjKs2T7HFdno+oaHdxMbIuREQEDNuZM9efQ4/SgDsvAuoT3ukeVejF1bnYw9Rjg/lXR15teTyad5Oo2rvD822QAYEvPII/P8AOvQ7O5jvLWK4gbdHIoZTQBNRRRQAUUUUAFFFFABRRRQAUUUUAZtiP9Gj55Ocfma574ig/wBgWRbr/bOk/wDpwt62LJi1uuD05H61i/EOTdoNiO/9s6T1/wCwhb0AakWt3L/EK60IpD9ji0uK+V8HzN7yyIQTnGMIO2c55rmfBvxFk1zS9IhudNvJdXvNPjv5jYRoIYY3kePfmR+NuwkjkkdA3IHReIfCUerasmqWurappGo/ZjZvPYNEGlhyWCsJEccEkggBhk80aF4L0rQ7qKbTvtEYi0yLSkjLhlEUbMwPIyXJc5JPPpQBy9v8VNOtNGtp/sHiLUreLSLfV7q9MNuGit5d2HlCuo3DYxKxqfYHBxtan8RdJ0zxjaeHbyKVLm7ljhgmFzbMHZ1yv7oS+cBnjJjAz3xg1Fb/AA00eDQr7SUudQNvd6LDoUjGRN4giEgVgdmN/wC9bJxjgcDuP8N9POs/bo9T1WKE6jHqjWSND5L3CAAMxMfmEfKPl349AKAJdM+INjfxabcDTNWt7DULpbKC8njjEZlO8AEBywGU27tuCXUAnnFHxTrlt4i8CWmo2UUy2j67p0cTSgDzVTU4F8xcE/K20kE4JGDgZqz4j8Def8M5/CWjSgB9qxz3UhDRZmEhkBRfvryV4HIXJHJp3jyxt9L8D6XYWMYhtLXU9HhiRf4EW/tgB+QoA6lYxg7e/NMUHcRjaB0HtQrDYPpikDfMSCfT60APCbsk5z7U/HC9QRTMkMDjnvTlckYyQT0oAJIFdTvG5DweKgt7GC3AEMSoo7dKthsHocU7cCSMZ9aAIli+bpikWIbm29SMVPlcZ7ds03eMnkjPpQBGqMDgHjFPQZYE/rTgd5Pt3zTTjsOh/KgCbAwR2NL9BVdWyMZ5705JBk7iRz3/AAoAmBz6jmlpOM9aM4Gc8UAI7qgyxArndf8AFlnpbJHH+/lbkheQB7muc+JVxd/akigbYuw4AONxrgNMeeWVPtErJvThVAxnp/SgDotY0m81m4urq5V1aYBlAOPlx0JPaqq2EZ0gaTFZt5QkdGY43ZUZ+XJ7V0EGq319pTWktmFuowCsrNyewOMY9O9TagpbT1eOULclQqs33gQfmIoA4nULCS7061S1eaW3gDKxkIRymAQAfQ9eK80vYHsZWj8t1cevJIOelex+IvD18JGubW/W8bygiiQAMDtG7BHHP4VzsyWU08Kag7CWKMqyumZF454wMgYPPvQBN8O9w0mSCdAEVizDnOxgR0+tcZdQ/wBl39xHfQeYhJZSWIwDwCMfSu2mtRbW0sdhcsLi4KB5BlQUHIJxwB83OetR6hp9pem0t5Fae9iUQqIx80gABJ9vX8aAOY8D2M9/qq3KsEiGecdcZ4x9K7i60173xGbiQpHJNHiNX5w3QYA6HApLXSp9B068u7y4giVhtjCLxGOME+4q1Z+IJ4dN+1/JLNDlnZTvZwAdp9j0oAz9c03UorVLX7Ja3UTM+91lO4H2yOP/AK9ZkPhBLmx86dYo7kHIt3YKxA75HrWbqnxHv9Suh9oiWBUIIbpyO4zXo3hqdb2C2u7qEyrOmJJ5AMAkdR9PSgDm7E6NFr8NokIgupQPNizuC/8A6+KydQ0VtCv9UUySQwTwkwzoTtDb+mPx/rXfXfhi0jv59QeYyxyoAnADKRgcH8O9Za3cWpeF7211NEkPJgMmMvhv1oA0LDUVu9F+z6nIJpAcxtGAduB29+P1qfwp4mk0N207UYpfswb905HO31rKuRZNLDJbWktmbeEuIlOQ/J5A9eTVu4t4r29iivIJFJABlRSAo7g+tAHqVhfW9/brNbSq6N6HkVZrxbUIL7RNWt59OeaeONhlASN2Of5CvUPD+v2urx7UYJcKPmiY/MKANmiiigAooooAKKKKACiiigDFsUxbRsTgHP49awPiGCNF0/r/AMhrSv8A04W9dBZvi1UAbu3H1NZnizSptb0kWtndR2c6XVtdRzSwmZFeGdJlDIGUkHywDhh1oA5D4jvrS+OrV9OHiG4hVLdI7W0W6hh3ead7rNFmEnBG5bhcYT5T8xxg6BfazcXxu9GbxPqWqwaxqovIp5rkWL2iPcLHEjP+63bhCq7PmU5zgDFd8ZfGucLr3hpj/wBgOf8A+TKg0+DxfaxvFZap4Vt4i7ylYtAmVSzMWZsC76liST3JJoA8+0d/Ga2GvmxbxCYpdPtZfLa3vleF/tH+kJC15I7tKISwBTaCQpC55q9r6apLJZx6DdeMbTwwZbnzpb201O5uBNsh8vaqSx3Xlf6zBJI37sjG0jvN3jjP/Ic8NfX+w5//AJMoDeN84Ou+GwfQ6HP/APJlAG/4KF4vhLSF1Oe6uLwWyCWa6g8iV2x1dNzbW9Rk81mfFEZ8L246f8TjSv8A04W9V9vjfjOveG+eeNCn/wDkyq2p6L4q1mG2ttV13RGs47y2u5EttHljkfyJ0mChmumAyYwM7TwTQB1QQKMcjPJoxhfl4OO9OIDAbgKawPIYnjigAAO7DZ+tSxttPJJH1qM5B9ietKpG/dyDxQBMoLLjPH86VR82S3B61EXOGABxj/Cmh8YDZHIJoAtbAY+CcZpNozjOff0pNxyBnn+KnA7u1AChTgleKUINhBOaa7MoJUFhnoPyo3ZwD9ODQAhU5HX8KGjO7Oc/WnqdzEgnqaXggYODmgBAjY5PIp/XaMds0AYOSR6UpOCATQBw/wATbBZLa3uYh+/Viq9e4rFggtPsJaO0LzJFvkkAA2Aeh/oK9D1ixj1CxeB+Mjg+lee+HdW01Hm0q+icyBvKY4+XAOOtAGdoes2l3a3UVwLkEKG3d3UkgHjvk/yq/FqFvcaUFiSQQQRnJc9eDuJ/GrNnp+k2lldeRAVt5XADM2SwB6CqDWk+nXrXqAtpgjG2JjgnPtQBix67NpssttPZNc2StuLq3zL04/lzWy+oeHNXtljuohbShto8wbSmRz836dax9Tjkkn863wsUkZcxFsAhe5z+HNbNtoThUgmhikik+ZiQDhTjv/SgBv8AYelQW8t01ss1qwbexY9PQ5PPQVTtLOOxkjv0EVtHDJuEIXLFCcNk+wI/Kq5hefWZLK1gkt7RLgboi24MAB0GeF5z361b1q6t1028S0nhLIxSORELYyMFSM88g80AXfGdil/oU0iMiwB1dnd+AgYZ/MZrHs71tQ0HUYJ/JaRx5cBjG3Khew9hk9afpVtqNxoLveLDJE0QTyHQjPHI47/XpWb4WstOillW8vr23BBiQTNwi9MDPBHsKAPM30yeSRrdYWeZmIUMDz2yfzNewWLzad4Q0/Tpy83mKCrgYwB6Gm2NzJNczwac1pdLGylbg4U47K3Hfrx61t6xdyyACVUZI4gQiNnkn+WM0AWUSS6sbbyZC6uobGcHHTDA1LqdjZaZbNPqEELKsoSKJIgeT0H61kWF9ayTWfJMy/K2FOOf0rpruzt9ajWXzZIcLt257qeD9fSgDjr66F0bSewuUaZrlWkYE/uUA+6QemQefeqDwyXF5LOjHmVkKowUyNjsp6nGamvoAL29XUoHgcMigRjiRlyN2PfIOcVoalpmn6rplpMBiWB95MTDdvB6ZPbGc/SgCveavf27mG1tRIquJNsgO8DueevSk8j7TP8AbA8sV0oHKuVYZ6AmmCPUxfNEiSBC4MgK5ABP8J4yMDGfert3NI94jQyeU8ymIW7c5bP3gPoevtQBDFrviG1dZRNOd7DAZgyqPcHt+VdRo3j0yyJFqVtswdryxg4Hv7VxOoyM0kkcDuZ2bYxI64Hv+X410Oj6Iuq3SMDskiBMkJG057H86APS7O8t72LzLWZJU9VOanrzqe0uNMkik06K5hnJKlhwjHtntXSaZ4mt3XydUItLtAN+8YRj6g/40AdDRTIZY5o1kidXRhkMpyDT6ACiiigDCtf+PdMn3/WnyfdJGcLzUdmpa0jyTk5/nU5UOpwcgDn3oAog5Ylcgfzp6J/tEZp7WxUA7jx7USLn5Sw6Yz6UASkDbwSR296jYnOepHY0yA/MFYscdOKmKgA5zkGgAjY4LZJNWUkDEjPI/SqzBY0y2B75rLOs6fDfyQG4QSnggnGKAN/Khc5GcfnTX5JwxOeazbfVrO5kKR3CO4ONoOTUer6xaaXGHu5Qgc4HegDWAzjnBNPKhc5PPYVyP/CZ2Jy33VyArEdarp8QNMkneJC7FP4gOKAOzl+QgFuM81Umu4oyxLAAdTmvIte8Y30utM0MkiwquQg4AGcc1j6jrmqancvF9qJhwd4ztzx9KAPU9Y8a2Vlas9s3nTE48sdas+G/Gljq6+U0ht71ThoZOD+HqK8L1OSa2vYFy0kTAF229fb612ng7w7Lq14L9le3t1JIZ85k+ntQB7OsvmAc9RgY6CkUdfmOByPeqlmpSELljxtz+lWoUyR12dM0Act8TNc8QeHtHh1Tw5pkWqx203mX9qSRM1uAdxix1YcHnPAPBrX8IeJ9J8WaFa6zodyLmznH0ZG7ow7MD1H9MVqOMnAIxXkHirwrqvgPxFP4v+H9s1zZ3B8zWtBj4W4UcmWEdpB6Dr+JBAPYzKEyXOABk57YrjL3xvLb3PmC0ElkxIXDHeV/vYPGKu+HvE2keNfCP9q6FdebbzRsmD8rxPjlHXswz0/EZBBrgbK3tNZuLORb1fP03EV5bq3QkAgH04YGgD2Oyuor60hniYNHIoZT6g15drGlCz8VajMgf5mV1BOFIYAEfp+ldT4BkZbe+hZ/9GhnZIh6Dr/M1F47tZC9rqls+Fg+WYYzlCeuPagDi9P1KXU7crOjwm1m3j5eGXOCPWr1lrUttaTx3Nx5sdqSke1N+Fz8ocdc1UvPMumk1Cxu4gBFseFBw5z6fSqtnYW+k6l+5ecXW1DKeCM+jDGSetAGxb3eFkvb62EaOGWNpGIVh34PXI6fSrVnc28V6fKOX2sNrOQijoMUmrXFrJ5LXqb4pcRxpHzg4+8PTpWfBNZ3l/Nc3EMapG5ieNmAGB/F1544/CgDmLtzPexXLNHA0kjbpGJZmA9D9a7Dw7bxXdh5t7EyzsTD5gG3fjOCR175rEsLGF761RJhAkbttWUAgA8j/wDUa1JB9iURuGcs/wC6Jb7rjJOMcgnOc0AZ8D6xFHtVRa2gnEbSKu0Ec9jyM8H8als78jUXg1G1eNCx8oCMr93HzEng5yDx6VoanIzW0lrbqH3qCqE7jIQOM5+nWtC81S08qETzGK6AB8koSd/Hy8cUActY32m28PlQqzySSNjZGQV25AJHp6VHe65PbiKQxlJnJR4JBtBPO3BIHHfPsK6B9ckWaSW1soQFX94042k8Af48VR1bWl1MeXeWsCocZIY88jleOcCgDQ061sZ0ZprgwyTKrlcgKGAxtz+fPfNSwG41G5gls5sW6u0YXIO5QME4+tY0egxQgz6beQ3NsBkp5m7AB5H862vBl/axrO726WzRSmKJ8YDnnjH9aAFcQR6lPczkSTeW0e5SWWIDkBs/T0rDsPl1aODygLPzCs0bqCGGPXPU56+9dRNPaaxNNJArW98qhNgPX3I7iua8YWUd/YW1pqtpE/8AxONNSWCVAyOjXtupUg8MpGevrigDqND8U2uo6lcWUNqY1hU+W4GFZQcdKyLyxlsdVub0ytLDjzGmLDAAB+UKD1ArH8VHwPoni670P/hDfhtbfZ7aC48/WriCw83zDIMRr9nfdt8vk5/iFbkVt8Jn1YaYfDXh77YLlbNmXQcwLOygrH5/k+XkgjHzDOeKAMrTvsFzdQXouWVXAdkOBnnp+nattryK4t9SOmrMlwwVWMTfvCCew7CsGx/4V82u2OkN4M0DUGu7W4uEvrPw0wiDJcmEIyeW+0A5DSM4UbcnaHWl8BzfDHXvDFheap4Y8MWmonS11G7V9CEEIUAeY0bSR4dFY4JVmxkAmgDvtNF1JoZh1LJVPlkWYdV9c+tKbW0e2U3Fu7QluJS28bfTPauIv7f4eTS6dFong7w608mpW1pdQ3vh/wCzyRxTb8OEkjRudhw2COD1qzHZfDKx0G11DVfDWg3FvKjyNfWfhRxbqquQWciNxEBjkuw6E9KAOlm0uW3EkmlXDQSsfkEZ+XA9ccHgelb+kaqZ3FpfIIL9VBZf4X91P9K8j8WeHvC0/hz4pwweEfDNv/Y1hJ9juLbTYkkBayEu/cB1DNwRjGB35rvfEYl2pdxYR12uSOD8pBHHWgDtaKjt5VngjlT7rqGH41JQBjWS/wCioN34n61KVwreh6U3TyfsyEnOc/nzUz/NgAjPp70ARP8AIuTzis29vra3Dfa5kjBGQWOK02G5CCTwOv515r8WFVNOWcMN8Zx0ySKAOqTXtMRJWW6jLL0yep68Vz8vj+zjld7j5YQCMjkZ/rXk9pbvqFq7WszBhk8eucY+vNSNYhVVJHkiupWAML88j/69AHVa78R5bphBZrIkRBA2/eP+Fcwl1Jd3UrzNLG+3n5TkAdSaYLB7K8jntYt/2olTHtGVOMEfyqzcWkkE1zbQyNllG4HoCByxJ7daAGWt1eQTiWO48mTI2ueD9eK2bGK+12e6N/ctcXEYAQO+NvPJwOO1ZV/aGH7NG5JWYDziFOV56D14NXNImRRqJmhCm3COEPHmAjGCc9eelAGnZadbG7nklbaqJgIW4J7kevQ1kyMkN99itrYszHc8qcqn+POKlne5srczNFm0dlVUibBQdgfzNR6RoN59pjVHJguHDJ8u1tucl24469KALlxaw3eryxyQpGqKcsD8pI6huw9easahHaW80VrJLELxiAhAyEz15FaV1p9vDqKeZB5jjCrHn5CcfeJ6etY9/DEdaa7cKskTERqXID8en1NAEOoR7Zoo4gsrO4DOoGevSvYtNhW20y3RAAEUYHpxXkei2sl34mtUswCm/wA2Rc52HofpXsE0bpGATyRzQBYtLk4RQOTxzV6M4XGcVlQIWkB3AYPFagjIG0NnNAEN5cNEVSNcySHCjsPc+1Z8trqG/eL/AP4D5YwBU2oO9rPHcyITCAyNhckZ6Gq0OuWVwrMJMOpxszyaAPnn4o3a/D7U/wDhJvD2oW1peajIV1PRjIFF2MnEyoDlW9SPX3Ibh/gP4pXU/i7cxazK8Vvr8rnarfKsvLIv0xlR9RXtXiz9nzwz4oWW9ha40jUp2LmWBt6MxP8AFG3/ALKVrxHxR8BvHfg2+j1LRYl1eK1kWeG4sD+9QqQVJiPzZyM/LuoA+0rSGG2jEVvGsca9FUYqd4kmQxsFZSORjrXKeG/FlnqPhPStZvJUs3vIx5kMp2tFKPldCDzkMCPwrq14hEiOCG6EUAedXemt4W1t7mCLfps2QAoJ2exHpnvUtxZya7IkelygySKCZ058sd8n17V3bnkKQD681Zt444VJgjSMEc4HWgDiLP4etbzLJDqckb5+YbQ3XqRnpWivw60IjM0csk55MpkbOfWtfxDrkOiWyzSgyOxwsafeb1xTdH8S2GrRFrebEoO1oWOGU+hFAHMaz4AmMqT6deO7A5K3HJJHTBH/ANesO68Ma/CsWLeNiWJJSTk8euPavWkkbPOM+lDMSw6c+9AHl8WieIomikS2BOwod0ikjPvV+LwjqGpSx/bJI7URAfMBvZvTnp/OvQ9p2jJ4POBUZfaW/WgDM0rwtp2nsX8rzpj/AMtJOT+Hp+FacunWdxCsc9vFLGBgB1B4/GvNPEPjq6XV5E0+6SOKMlFUrkOR94k+3SvRtEvTe6VbXEmA7xqzAHgEjpQBh3PgDQZWkeG2a2dxgmByv6dK57U/C11oFotxbyrc28R3PwVcc/eJ6Hj2r0eK6glYiOaN8f3WzS3UCXNtLBKAY5FKsPUGgDyKJka+VWkRp3ONyMRjOOcjt/hWx46+zzaZpEqFTMuraVyOcj7fbd6x/F2j3tgbiKEZmABSVMKXjJOcehHTisK3ivE0yzknjkW2k1nSQm5uhF/B2+lAHp974b1yLxdqWuaDrOm2v2+2t7eWC9017nHkmUqVZZ48Z805BB6Cubg8J6mt74gufEmp2On+Gxrq6yyNCA8ohSFlczebtjj3xAlSm75D82DVjXvEk0Pj6606/wDFI8PxwG0+wWf2eJ/7SEjfOcOpd+cpiMrtxuORXml94w8Sa94L8SjWdZ0rM+iagbvRluA9xaSLGcDyltkaLaQQfMlfdngnuAenaB4LbT9Ssn0bxFZS3Onpc2t9G9r5paK5uBc7cLKDE4BGGO4EHO3tSXPwqgu/Duj6Rd6o7Q2Ggy6IzpAAZN/k4lwWIGDAPlOc7uvHN/wD/wAjp46/6+bL/wBIoq7ugDzbRfhl9geB2n0K3aK9tbvGk6Glir+Tv4fa7Fmbf1JwMcKMnONrnwXbU9KjsTrNlJGunSWAN7pf2kQl5JH86BTKBHJ+8wW+Y4UYK17FRQB5p4z8Of2J4A+Jd59q8/8AtHSJW2eXt8vyrHyuuTnOzPbGcc9a0tftp7W0WZWhNs7AIQSWwegz+NX/AIsf8ks8Zf8AYFvf/RD1gypJdafbmNY0kjkWVoZZCE3j+EDsO9AHe6QrLpturjDBeRVuvPLTWNRF35r3g3t83kqp8tecbefXHWtH/hMZ/wDoHN+Z/wAKAN6zB+zR7T68fiae6kHI5qCzYm3jx0wf5mpw7BT2oAhmJEbYwP61wnxGs1fw/PPguIQXIPXFbt74r05NXj00v+9Z/LJxhVPoT0zVjWtO+2abdwYwJYmT8xQB4X4bMlpZ3r28IkaeQKjg/wCrGeT+tdLPpUCXcV5czeZKikgg5Lt2FZOjSDTU23EbrbiUKxYDg55/UGur0vU4Db3k9ysckSueFwNoUfzoA5+9FrbXMdwzLLKgLGM8EFs8H9BS3l5p+r6pE00YN1ImYkPCnhuDg9eo/CodUtJJfJlSLzWilZ0bPBUk8dc55/SiCS30kSPLOEvH3Skom4KxH8Pc4HUe9AFOXU7rzLaG4t90gSRmC5Xb6cev48U/SJodctCks3lCL5CXxjI7ZH+eaIt80d2zFFldgEMkgVmXHJx/XNMt5Db2V3FayCW5U4IYfKRgZPGc4P8AKgDbdsaVsaCFlhBCbTu8w46j047mrH/CQW1vDDEIHeQ5RlU7TuxnH9a5Uw3d3f6X5UkmJVEjwh9oXb1yR2Pr2rp4o7HRb5b7U5IlmbDCFHL+WDwNooAoyQarqULFvMQbcqvJABHOfWqUFnfzajavqNusH2dCjOAfmOMk46e2a37vxQjt/wASOB3jjwryN8gYk4xzyT+FP0k3/iDWYS+2PzVHmRr1ijHUZ9Txz/hQBu/DHSFjt7vUChXz3/dEjH7sdP613EiFlwwzmprWEQW6QwqixoAoA7CnsD0455oAgiRVIYAAjH0qrFr+nSagtil5Abg8bA3NZfja8ksdAv5VYg7SqYOCCeBivENGv549WW7XlYpY2TGMhd369aAPavGGpSrqVnYQziIEh5ucZXPSn2Gm2tlq9s9mFzNuV06/KBnd9c9/erd1o1prMsM1whDKu3K8Vd0zQ7PT5TJArGYgjczE8e3pQBZ1G8TT7CW5m4jhUsTXJeFvGk2ra1LZ3VusS4LR7Tzgdj71L8Up5YPDwKKxRpFU7e3Ofyrj/hYftWvtI/30jkbPHOSP8KALnxEnh/4SJ/tJEkaW4IUjgEk5FdN8NtUa+8PCNiGMDmLrnjqP0NcN8WoZv7TlaR8I8auhHtnj3q38HJp0ee3x/o7RiQgf3hx/LFAHra7CSCQdpyeeKa17aiQRmeINnpu5rz7xz4jeA3Gm2TiJlXdLIjDdtPb2NeXQ61MmsuYyDLGwkjbq2R1BPfIFAHqvxcMix2rwoSpR8MOobHT+deaaVcywXdjcQeZFMC3zMepzjP8A9avT/G9/a6r4GS6EkTK7RtEc5+YkccfiK8hQXdvOkkUqiFAH8v8AhJz0H4fyoA+kdJllewha4I8wqCear+JdTbS9KnuQu50X92MfebsK81n+KnlWkUUGmylwhDtkYBFZ2vfESDW/DSQNHLHcLKmcHocgg0Aafh3xRq2o+KLOCW5YSs/zxADYBg5wOor0vVtVtNNtJJr6eNAAeCeWPoB3NeE6X4jm07xDc39rbKzxWrHL9SeOSfrWRc6te6kEubzdNdOcsSSduemO35CgDZ1Kx/02Byxb7RuHljJKsenP1r1rxtPNpPg8CDMWSkRZOw7/ANa8h0ecG5sx5itmQBuc4bcB+derfEmbdoVrauI2aWVeM7chQSf5UAeWaVrEtrq6vDA0HIeNgx2tjkg/WvojTL1b+wgukGElQOM+9fPsNvPqus2lpYQs5liXJbomSd232Feu61rKeHNPtLK1jNxdlQkUQx2GMn2oAk8f4jisLmJC91HLhUGMsCCCMflXll5aanqU+3ULu80+FJ47lJY9pKSRyLKhVXUrwyL1BFL4o8R6o94t1dPtmiPyonQfTvn61pQ6i3ieKKBoSH2glxzkn1H1xQBnHXvFU15DHY+MNbuI3kKHFnY7h6H/AI9+nqa2za+Ppr0wWvizVnXYHL/ZrEhc44JFv1xWNJaX3hPXRGqr/pIyJNuQM9RivRNJuJoysAKtJkksGCl8/wAX4YxzQBzOkp4qvrme2PjbW1nhbB3WliiuMkfKTbn0qac67b3Hkz+N/ECysnEf2WwyrZxyfs2CK7pLOSe2lbykUqC0LkA84OO/rXBXLtPdJcFZZpElCCVhtYY9R2BI6d6ANUaX4iFva+Z4515LiaULsNtYdOp/5deuBnNY+kDxTqer3sUfjTXIrK3l8oM1rYFnIxnn7MB39K7PVLlLq0tbvT7qIYYEEnGW7r7d6zbPT1j1+6u2vXWWTAeHcCFBxk88H2IFAGbqfh3Uta0690y/8aeIpLG9gkt5YjBYDdG6lWBZbYEZBPTBq1rqRabL5MtqGa4b/VrIQHZlPJPVeh6VoeJrm1WFXa4Z1ibKpbuAcjucdutUm1S32ve6lvDWylpGyQTnG0qpGDnBoAzVe2SK2kISAzMIo975EZ5J5PLD0rS/se8/vj81rzfU9Xkn1G6kk2+RcEgW5G4KOo5z1z3GKj/tqH+/qH/f1v8AGgD3OzJ+zJjpyenvTrxWlhYoSr9iKhs3xboc46/jzUF9q9rZBzdzJCg7yMBnNAHlug6NqV/rH75JFWG48yaRxjJDk4Br10vnGMgYxzWPB4l0m4kEcF7bs2egcda1BKJAcEH6HrQB5Lq1mtt4ouVuT5lqC0uPYn0PcGs2+vE0/wC1tHbZikjBQEZJ45wOldH8T4ZY9StLtFKxqNsjAdq5AhtRvU+xWM92wCndnIP17YxigB+n3TyWT2sO13lAdWQHC8E4wPxrOu5p5rm3ItopCwO5nibGc4B9sA9a3fDvhrXJb54ktRp8J4Z3AJAxztAPWugl8FarJEto2oxta5yW8vDf/XoA5HX0sxMk8zGWSQKsuDyGwV/yKNHgtFtbq3C30wkwBLGhJJPX1/8A1mvR9K8B6NZbTPE91IG3FpmJz746V1sEEUKosMSqqcAKMYoA+ftblfSrC1TT3nsmttybpUILKxycjH+FR6PDbnT7e7vZZvtqMX3IRmRSf4sgnH+NfQk9jbTsv2i3jfr1XNZlp4R0WC/+1QWMQm6g7eF57elAHnuk6VrN+xbT7RYLWZiTLcDB68EKOemPyr0fw1oy6LbMrN5k7nMkpGCc9vpWvHFtyAPu9hUgYAYDKRQB5/8AELxJcaSYrGwkaKV23PJgMcE8AD3OfwFY+geNtQsLhV1B2uLQ7S5KgPGG6H3HWtj4i6YYZ49c2JJBEAs8bDPAzhvwzXB/2FBa2N1eLcDbcZcRseT6c9e/60Aep+PNuoeCbm4tTvChZBtPUAg/yrxzwnZTS+IIotu7zp0I5P3c7v5CvdfDcKy+GbVOGWS2UHA9hzXnvg+0XT/EturYZfOePeSPvDcB/KgDu/EOrf2Dpgl8vfK7BI06ZOP/AKxNZXhzxdd3epx2d7HGROjNE8TEjjsc1Q+LVxn7FboWyoZyAOvGP61wHh3U5vDl9BdPGGWMlXjdueeSR6dBQB6r8T1ebwvK4z+6ZX/WuW+Gix2mvBAwxNbnaoOehzz6Hml8f+Jft8Gjrp5ZrO5JlkkAyCR0HvzXJabDq134hs306C5t4vNDNLtKgpjnr0oA6z4lT/2lrC2lqFkaOEo+4cZJB/PFVfhfqtppqX8Hm77oxAxxjknAPT8ayJfD+oNq1xPc6kI7SSVn3PkS/hVyw0zSNMvvtiXs8kmzCljjaP0oA5m71abULy5JVxNO5EiIDvODnAFR3NncSCN7fTrs3DKQw2YJJ78mu0udVs7d91jaxyytg+YRhs+uRT4dbvxC6m3TK/MH9c//AK6AOb0nw/rNxoE6MHtjFcmaOGRie3T2FXLfwtqN1byDUb1LQEDaka5yPc1alv7+KSXDsCxCkbvlPHrRN9rDxzyTNLGwwyhvujuSe1AGfc+EZo1ympoAByFUZOO5qxpPhvRxDOl7c+ZuG0fw7fep9PtZdRk/0WeJm3bSqybmGc9R/nrVTVNNj06Z1urxI7hTyn3sg4ycen1oAP8AhHdLsElMN48yyoY5Mt0HXgk9aoaj4Qu4oUm0i8MyqM4bGQPTPp7VY1S0SxWI291HIko3DuD6nj6mpLGW7hZY4Lj/AFWCyAg5wM5/WgDGuZL3RLdRf2RhJUlWU8SE/wAjnH5Vraxrep6sdBluG3KbNmZehD8A5q//AGtaavai01tMIejDnH+FXZtG0vXbWzhsrjymszhWz/Dx/WgC58Ikhi8R3TXUhMpiVod7dAScgflUHji98vX9SlyQ0K7Y9px6/wD665vxdaah4d1K2ms5WkijIkin2jg91bHGDUGvalM93DfIGAvYMlGGP3nQjPp3oAgtXOo3SQTuVkwXZ9ueew/T9a9b+FOiJDbyX0qjLjC/Ljj1rzK1litgss2YWkYGXBB256jJ6V3ngHxVb6R9qsNZuFjAUSQHPEin09T2oA2PiKtrdyWuwAzW7bshgDkdv51haBqscrz3ctrApDFQeCR79Ko+JrqfyxfGPbLeM3lRk/Mg7HHrzU3w/wBAu7zVAJQyWsQ/fdwc9vqe9AHW2vi6CKzYoqr1wjZIJ+o4pbuwjv8AbPK8ElrK25tny7e4Oc9M11z6faPYNZGBBbMhQoBgYrhZdI1DwwTLFEt/abs5wSyLnuOc9uRQAlhaQacqs8/+iKpEkagDMmewz2yavgxXLnyIVubReQFIYxngYKnr61mf2xG6wi0TMsbea4KfLzmkguLyO+mvZYYwly4LfL90evvQB0N7DBNpBihJWXePur93HcL2HHSvP/GNhqMu9TKJmjAKMvQr7jvz713uq3tpJJGdzCRQAuD8uSO1TW0SXcwF/FG6Y6Z+WgDweUZmX7QWiZ2HJGR1/WrO3T/+f27/AO/det6t4TslnQR2SyxEnORllHqP1p//AAr7TP8Aniv/AH0aAPM9W8faibFJ7eRbSMS+WsTLksMnqT0rK027vtfa5uipmuI32ebI3y7evHpj2rY8N6TZa34df7daGKRWIG5iRIRnn9as6DpZj82FLaOzABjOWJUjHXGfpQBjXei3pSSaaOFYEG5ZouNwHQAjrn3qY3+s6HDHNZXNzJAzbSJDlVPXvzXRhni0/wAuUMI958sxjGB24qvBbjVBPYxTKIomEh3dCc5J+mfSgDW8M+K7XxJBHbXsJjuhw0TfxV1VvBHBlLeFUXsFFeS+IoX0PU7e4sA2UUl5iOGz6Gpr/wCIeoxW8Jto4oSn8cpJ3n2xQB67JkKAOoGDTHlCIZMfKOcg9K5e08RPq/gya+tF/wBMWJt6L1VwOlZvw4uL7VdNvoNQdpbcHash75HI/DNABqHxLsobySCK2uJgjbSyAY/CmJ8R5jM0S6axKnp5gB9en0prfC61mjcT3sxZc+SUG3ZznJ9TXM634Z1jQ7tpAhukblZo85Bx3FAHaR/Eq2Mh8+znhj+6HOCN2OnBrf0bxfpupE+XNtcclJBtNeC3M97JBLbyR7SDkBl5z35pmnTSGR0Zd7HoU+Xbx+tAHuXjfxDLp2kobGVEuJnCqSMnn2rzKTWb2zvnuG1C6a7QLk+Z8rZ/2TWVPe3qCCS6a5uDFlYtzFgD7DtWRK80t1M8plwSM/X3oA+htJ1RPEHhZ5JI1BeFlkVhkA4ryuS4ig0lYRPGqNuD9DkZIAP51R0TxNq+n3cOm6aoktbjAdQcnpz9K0oPCoTVEe8ulNluZ1hP3gx7E0Abnh3xsNK8E3cJkM17ZAIoCngMfl/nj8K5a5vpRBM1q80t2SGXaCxRuoPHvXQW1ho1hDe2cURuFn5cMcgAHgDFWbWT7LHJZ6ZYJAhG4DGST60AZOo2et6vLp1+9yBcG2CTJN8qoeucUy78O2KlHu9Sled1AcIAUY98DHTFXmtZlt5Jb6QQRFNxWVtu0euPrWRdXnkW0C6dZT3crBgGKkA+/rQB0On3FjZ2Nta2qySyWxIR3Pr14qVtV1CZWa3AWFSdzADKY9aydP0rV7145LiRdPj2lvkjAY8c81kWsOoX2p3dn4a0a91y5tY0muJDNAkaiRpAvEkiZz5b9AelAGo8yT3EplneaYcny1L+/UVWlLT37RabYtKNoJMp2lD9M1rWGneLkvIpbzwPqrQqCrwxXliA4xwP9f074q0LTXLOK7nbwPrEYbc5dr2wVY15OSftHYdzQBlNZX8l0Ujt4oE4BY/OSD7DipzpEjXzO9xPPayfI7byoDdDjHvWjGviC/0mKOLwjrhtpYd8c9tfWBDlsEMCLnBBHfPQ1S0KZ9ctp1ayuka2uJrZ7eeVMxPFIyMCysRncnYkdOaAKdx4cm+zPvEhjGf3VzLgexHas6z8NQsZTKuy2jwJATkEcnj8qsXtpIZp7a8iubuVYtkB3blGc5JYcZzzn2rcs5o0FvaW8jzuyhbhl6DAAyCf6UAQeF9G8uGbWrO8jtLdTtQBQSyg88HuelQattvvtNwto8l1Jw7BS6oOwOPw9qz7e5g0nW2tNVQ+UN7RqHO0Fvukjua9H8K6IUjS9upj5EzF/IYALjGAPyAoA8+u9DiS2sZ541aUqV2xpjp34+mazZfDE4to9TtHSRmYMzKxGATjn0616F4v0C605vtmimSS0lRlaJPnMZJzuWuH0Wa90qGS0iaU2t0MEXKEKGxyAevfHtmgDattGt9Y0O4vkMdvNH8jJwckcHgfjWfaaZeRW5ltpCJRknaMcCpYrLz455QbeC5t1MbNCx/ekdSentTD9ptmhms5yZYG3SbzuBU9F56jmgCy+qyyxpa6gqtbnA+cd8dP/r1evdPsNc8MC3t9kbQuSuOv09fWq7XltrcaxyR+VdjOQAEHB6j8e1U9GuW0/VJCzKYsgF3PGKAMLQ4y1/JZPvkVV2MJx33dR6cVuWl1cWxiM9uk0ELlxKwVii56Anpg0vj61urmWyu9KgZyAWaWFfmP4CneCrG71W/U6xI1par2kO1pB/umgDovCtjqHiMlnHl2mf8AXMAzYzwF44PFen6XZ2unW62tqAoHJ5ySfU+prk9c8Zabo1mbXSfKnuVACqn3V92Irzlda1O9vmuJZ57bUFPmRybvv/7ITpjHagD3+ivNtA0zxHf3IvLm7u0JGd0reWpPsg7Y712uiW9/bI6X86yqOExkn60AO1vSodSs3QoqzgZikAwVbt+FcDeLfW9/DZ3Ya3l6RhvmR/p2Pb6V6hVLV9Pi1KykglABIyj45RuxFAHKQ6W+6MzShtuZEiJ+8SeMEV0unFLqxLz24t2HLxFslCPU1z+k3tvaxR2ssKrPGxRwe7d/1roYWt5Q8QcguQ5GdvH4fjQBVlubma53RQl4cBHB+Uqp6svqK1PMt/74/M0jylERRhWPAAOR/jTfKb1b8jQB4fpN3LYafYWVyjl5Cw3A7QWzxn9Kti1v54Yo5roBclcsTuJPbpio57ZJ9KtmuJSsoZpVIBZiAeRiqFp4iuYGuGldpYxL+7QxjK/L3HrQB0KabcDTRbNeGFmwhKNuKAZ6n6VFZWB+0W4lLDeWMhUHnHv09Tinu6xW1vd3H+j70BckZLOf7vvV6e7jsrNgu6FSN5kkORk8Yx3NAGF4ulspohZW0m+Qr0ZsgAdRjt0rzHU75o76C1kiLrC3ygDt649eK6C7uYrzUbhbaTG9hkyjBceox+FcTqc8kesFW/1auGJYbs9sUAe0fB+Pba3smB5crcBhg5rsr/WtN0W233DLCOvlqOT+Ark/hBdQyaPPAoIcPnb0I4rm/iMVi8UEXLugIDAZ4AoA7aL4laZ55ikgnVsnAKZ/Hiun0zVrHV7cNbSrIo4weo+tfPFy9sbxpmutrsdoYDIAx1Pv7VYsdWudBnkmsrwvAvLSu4Cggc5J4oA9a8aeGoZopb22QJLtycDqO/415dct5EzIkLLIowjHgLjHr+PrXT2Gt+NvFWhXdxoOjJJp6QmRbi6LRfasDJS3XGXJ6BjhMnqa5u00G11i2i1CTUJWt5lWVCpwcH1z0I5yPUc0AMt9VgjkhiOZ0dioP8ROOuB37Zq/p3h+4nBudWla1tFwQin58entS6fb2eiyONHhkmnckCWUBiPp6CttrbUE02S7v2eOCNNxyMlvTHagCCxa1sJFXTrcCNSSXxlmx6mpppLZI2m1W4jhJywDNncAOMc1jwvreoTvb6VaqZJY2ZRjlVyMgk8dD07Zra0vwXqkoSKZMeYcySuvzR4OeM9aAIHvY5Imlsbd2jVFJYkKcn0HXPerFnNr+l67azzQv5UhC5kjyrjk547gV2+leBrCx+zzSzTXTREPg4AYg5B4rrNQRZLTiKN5VBZA3QHFAHnGraONW8QRwapcKYbjMkJiDAjGOOeBjrk1RvtHk0zxDDYxT7rXbuUEgEfj+taWh65Hb+JFt7qNnPKGQg4Vj0xn6VZ8dWYtNRt9RYJ5G4B2OMkntnHcUAUdQ0fbpF5IuXmgBkjYSbhzwx/KvPNVksrmDXy/2C2tGm8OiZ76IPbgfbbjc0qllDJjO4bgCAeR1r0WzuLbUNTC6ck6B4zHhpCY+fb6VjW/h3V7PVb7UPCnih9MSWJLe5VYoHA8ouVyZI36GR+mOo60AXNKlWG58O6T4N8R+Gbe11PUZ0u7jwpptvEgCWzSBSrPMu/5R83oRwe+Xe+NNRvPDlvB4h8Uf2NA+mX3+lLDAjalPFcSQiP50Zc7UVikYDEvxgDFaVtd+KFmgS+8caygmJCFbOxXIxncc25wD2NR6heeKrSV4z471EuWARfs9jnb6n/R6AKFh4w1bT9Os7aHW/sd5aWmkx6VonkRN/aqSQxGRvmUyN8zOmY2UJ5eWzmqvh+yvNR8Q6zBYNJHt1jUzLIjcKPtk3J/Pp9a6dJPEZtYrr/hPNWeA8SFbawBU/8AgPVbSLS90LSNS0+2me5n1G6mnOoSlAXeVy7E7AoByzcAAc0AUEFzbWVxa2VyzFHeJ7qJATjHQ56jJ69eKZoRvYtPuo9JtywhTE0hyxzjoM/0Nauj6RPf2cunWaKsbgefc9gehC+p9+1eh6Jp8OlWAtbeFVjQY9dx9TQB5/4I8JS3CHVNYgd7rO5Vl9sY+leluUMRRl5AxjFOWZChjjdPMJ6ZzT8MGUMFLKMKM9qAESRAoRipPTFcJ8SliSSyhKxqjksQAAVAwSc13UEbK0s0vQnjPavPfiDdpeXcUtvaTTC3JjlO0gANjBH5HmgDhtZv2twn2a3MhblmKkHOeQOPTHXFdNpUkEscGn4T7UYmYpkBiucgjPX+VZ97JbStF9mWeRUwzRurMp479zzjj2qnPOscK3f2WeCeOLYlw1uw2jpz36/lk0ASeJjKiRyrFulZyM42sp7ZPTk5qaVPt1oZwAsrAfKCMZHXio9Ju7vUIo4JpLcnfuV1yf8AaA57DpVfW7SS1le+sdxm3ZlQnIHHOM9qAOg8K6xJEzwTDMmAqEj7p/z/ADrmvFOjjR9ckub5nu/tD7kcnJUk8LUyMkhtLy2d1ZkBJP8AeAGV/lXVaxBYa9paG7bymVfMMgGcf5wDQBy2m2v9t3VvaRqxuXGFRQAB6k+n/wBavVNC0zRfCcLPe3MAu3+/LIQCfYDsB6V5n4P1qz0Ge8GkWss11KuBd3JUHAHYZ6CsXUbnU7rVLlxM7XTxkuSeZDkdD2A9qAPc7jxroNspzfCUDvGC49eoqo/j/T9scsNteS27HBkEeMfga898FeH7rxDdWf8AaNtI1hED57OcLI3QY/8ArV30HgnSLO68sXM6W24OLUyDZn09ce2aAOxtpkuLeKaP7kihl+hFSVCk9uoCLJGABgAMOBUqMrjKMGHqDmgCpeaXY3jbrq0hkf8AvFRu/PrWNeeGmhd59IuZIZccROdynHoTyK6WigDlba+nivlOtwzRSAbYQoyGxjJyD1rpPtMfrVfV7P7VbZTieL54z7+lcl/bl5/ct/8Avo0AcKLSUrB/pWHAaT5SWzz0+lZ6WMja3OJJ1CiMSldoxv6bT6Hr+daWnxT2+mkpHiRhuDEY5B+vPesrUYBBFFc6ihlJl3TbHxu9MjvxQBoaldSW4iDSRSLEpfbwcZHoffvVS0stW8U27LbMqwxHyxLIevrtAqXw1pS+ILsSshj0iFiC5yGm5yB9B0zXc2GsaPb6mbKyz5n3WCElQR+goA4jVfh/fQ2SyWsoluUQgk8E+4rzzVdMviAJYh9ojfays2GB+n5fpX0aup2bTiITxlm7buRXB/FbRY/Ii1e3jDSqwV8d/T9aAON8Bak+ka3bi5kdCPkkVieP0ru/ijYWlxpI1N1+cLgsvUivMdVuree6V7i58sKceXkEA46gjn9abbTXk97ZPrl5qLeDVlCXpjkMRWM/KGDfeCA4LFcHbnB4oAr6XbXHiXUI7Dwpp02pXUPD7vlhg/66ueFHX5fvHsDXX+GfD2g214q3sra7rVzJJb2NwbNzosF6qOyxjkeaQUbL8gbT9w8V1djpNqdf8RaXaacC+hyWzaRo8N61la+S6I32pimN58wyZYhiNmAMnniruzgu9MvNe1LRNPl0bWI5WP8AaF4Vs9Hvw5jnljB4dZD86NGpckEAjOQAXbfU/GHiPVdJ8Uro7x6x4es7lLhbZv3VzJHLGstoyEkxyFDJgHIJVGUkZxb1zSLWDxxHFphY2eu2x1aCy+7LbScGRWj6oGLBwTgBt49BUel6tqV9DeReAPtFpLcwQxXeqXan7TfPDGE81IWO2JmGMu+WP90YBrpPhf4XvdCnvJ75JFuLpg88ksvmSysB953JJJ/GgDldT029ttaighYQT70McRjy7ggdx26/lXpviLSZrzwtHbiMvOpRgE4G4HPPt61sXWn2NzcxGaJGnTLKcDIzx/WtGC3SOFoi7Ffc9KAOZ8MaDLpUkt/fCP7XKNoVM7VHU4z3J6n2rqvPTy9zADPUkYpYQsEJVm8wnoCentTFnjmhI8s8EjGOetADrQloxypUjI2+lNHlp+7LZAO3HYU8yl4m8lQjAYGexqGKAhouhcH5z60Aea+KtPFhrU4eAtDdfPDzgbhyVz+tURqVy6f2ZrDG4s2bKvjcyccDPevTvEGl22s2rWE5OSNyv3Q9iPeuIXwbqcOsKNwkgJ5k4UEdsj1oAz4YtW0S4SdbM3FiG3LMp+6D2x3Aqa5vdKvLSWeaREQ5zBAfmZxz9316fjXpsVskcUUbAfuxtH1ryjxTfTnxNiBILaSN/lkeNRjv94jvQA9L83DS2V5ZSLcyIARdsCXj5xjHA9Me9O8IwpJrnkXtsqtGWLB8bWHXgevIrKgl1nWPE0cFvLaz3kURcSEYUrkcEjvnoa0dXaeDZLqq2dvOW3fNKXkJ6cKo7+1AD7+Wwit9R8mRI7OGcKq78D35HvWnZX1tqVoJLlzaaVCoChsKZiPQ+n061w4jlkvVACJG5DI7hSqk9lQdOh5OaZc2cjbvPmupkkUhWd84Geo/EUAehxeI4Z7uG0sY0ggDbFZSBwD0wK6uVJpNq7sQhCSRwSa8P8Hw3Fh4ptY7tD5LNwxOckdjXuWJDKsm4mMkYHpxQBat0RFBjQYxyfWoo22XW4ZZydgJ5A71JC0eWCljjg96QkR3AIGF65PTPSgCZpxvRGjbJ7gcUzUbUT4VMLyN57sPSob5iJIwrMpzuJHOR6VOtyXDSrGWXHAHBNACqkcER/dKuOeF70xbWLy282NZVfqHGRSebI86l1VIscknnNYPxC1Oa0sIbWwfbcy5fcByqDGSPzAoAx/G/hOG3hbUtGik8zdmaCM/K6nuB61xF1eyxuha1lgyNqh48hXwP4uuOn51654K1OTVdAgmuAvm8odv3TtJGRWZ8QtNe8sYZIGQPHJkR8AvwcgetAHDaZrlu1omnXNqFK/KZJO7YHb05FN8Psyau9oQhhkG3yychV9MfXFYur27ppsUN1byW7/aAUlZT83vu6fhV8wyQa5GUmWRuAxHYHvQBh66i2OuX9na20smT+7ReMZxnp0Ar0rwzoOkWunDUPEksHnEDMZk+RB2B9T9a4bx3fv/AG9Ha+ZJaQ+XukkjUB5W7Dd6VV0OxmvSYLOx+0zyH5dx3BB6se30oA9K17x15Vs0OhxCGJRtWZl/9BX8+TXBy3OqX7RvcZkkGd3nSF2Iz1A7fgK9C0fwna2cSSeJb+N3YcwbtqDvj3rt9OtLCC3A0+GBISMDylGMfhQB4PaP9mjmkby5JYsABOp55NLaeIJ7a5/0W8mtWBGIxIcbiehH0r23WPD2n6pbCOWFUkUfu5UGGQ+ua8h8XeHJLW/aNF2XEaqXdUz5wJPzZ7GgD0vwj4pj1QfZrr93drx8zD5q6qvnPQ5nmuEA8yORAWTA5OO/14NfQmnTfaLC2mzkvGrE++KAJ2UMpU9CMVxP/CGP/wA9j/31XbMQoJJwByTWd/bNt6S/980AfOaeI55tHhS+WRLgsPKyCpADcgfWsjU9Wmu3cSRSJFjYNzDrzz+teoeLNHt9U0Ty0ASaPLRsONpB615PBLIY7q3nkVxCPlJAJOeOvrQB6/q95DoXgiL7IijMarEBxzjr/WvHJNSu4bp7i3nPnxncShwSTx361q6x4juNc8P2Vikey909gJEQ8MgGNwHXpXNQ+fcO8Nokk5248wJjb9aALi6jdJcob/ehZsq3mEEN25robPUdT8TaDd2D3zr9nmV4ZGGQ/wDs571Wi0exskhnvJHur0cmJuQG9a1hd3EojSCAW0eM7kAUcA5zQBQ0XTNO0XzGvcXt6w3AlSQDzwP0qzq+oSyWv+kokdoV2mPHytnjB/A9Kgsln1G8EdpZMzhuZZGAQH9MjjNamqaVLbPcyahtup4ApRXHyH6AdKAF8PahBr2m2Phm78MWmuanp58vT9S1WMCCO0xlRIfvuy8rsAwwVSSM5rQXwBrWq+JEm8Tambh7cEWxWPbFCg4AhiHyRjHHdvUmrPw7tZdR1yO8myGg3ltowM5wAPYV6vI7CRAI8g5Bb0FAGZomkWumBRDCitEm0SY5I/yKWfUwdUt7aNSxbnK9K24oY4lIAOCR15plvp9vHctOiKJMcN7elADFtbYagt1LgXABAYnt6YqeSLfOkivhOjDGc027iJVniQNKuNvGeO4qrq+pW+iafNd3WR5akgA8sewx60ASX17Y6eDLcyxpGoJbJ6DvXK3PxC0/LtZW1zcDPBVdoJH1xxXGXV/ca9cS6hfjyY1yyQqRhfw7n1q1pWnfa7FprcxEzcgBixAzwMqOCSDQBvRePw8jy2+lzNM55BkXgD15qOHx7erczsNKba5GN8wHbtx0rDurSWyhaWxtnmIBM0vO0N02+pxUOEvHEFq5zKwURkY4HUj6YNAGve/EHU3LfZ9PtoplUAs7s23J9AP1ph8Q69JFHK98iw5J4i4Len061halZx6Q8NzaXUslsxEUiSjJPPPJq9FJarqbOdghHLBjxuHPGTz/APXoA1LXx3rEc0YuLKOdcjJjYqW9xWf4j8QLrMhEmgxeafuu8hDH16f41VTXZbvVLaKOCJ0zlvlx1PUemBVi0McTOoAluJgSPMIymRwO9AGdodlqMEZawuIoWkXa4iOD16bjk4qays2mly5VLh8F3dtzDknknn8qkmU28lxNbSD5ASE3bj1zgc9PrXMPqGoXOv8A2kZESA5jVsEDgZGfr9eKAN25T7K7SOC0wwE2HgdT07VLFMkNoORlgCG8vdlsnOfas+9uGvzDIkZ37sBwCuMDk+laEKrZaej+SGDdN+GA45z/ADxQBBeASec5EPmqA0bsdpU9sevX9K39I8a3tioTVo5LhYiF823AZWB4yR1zWXYRWd3aSJ58ClpAw3SD5Qc++cVJfQQ2amCa7xF5WXlUcHrzn1NAHf6J4k0bUI3e1u42mBOULYYfgfwrbglR35lV1X9K8Rm09LyyW6URgIQ28fKzZ47VTZLzToz5Gq3FuWPIM2RjoO5oA+g0lin4UBlHU0142JUR/dyVOe3vXh2keKfEGgSlryb7VZp1Dpg/UV6L4a8ZWetjbbMUkYBiG7+uKAOslt4hAIpGbkgAk81z3j/QGv7OK5tWZbi3UrtDYDqeoP5V1BlDEEEBc85FSpMGKqRkEde1AHL+BdNbT/D8UcgaJ1JwGOeM5/nUfxGtJZ9HhMBYzLMpUKcYzxXUExRT7SclsnB7VxXjO7TUtSazs7ySDyITLK8I3E4OQo9+M0AYPiK1lt/CNvb3pV5DMrgLHgkfeJwewrDu5bWe2gazR0hwBMvTJ9j6cVoW95PJaQS31w7XNym1Hl+YY5HP5elUNOsWjvdWMBZ0jKovoWxkjHrQBa1bSYPENlBKkgge35chQcLjqc9TWf4Y8THSbOe10SCO3hY5N3cHdJJgfex/KtDQL2Ay3NhKRiSPZnpknrXIXNvHZXtzZyAiWEkRqBjjHHXt0oA2bl7jULIyy3Ez3bOV3Scke+O34V0fg/WtS0e7tbe5lElvLII3wcqpPA9xXJ6TevFMFfGCu2TK5O7HGOa3PDGiX2u3EaWoEdvC6tLOXzkg5AA9elAHuY6cVla7okOrIjGR4LmMYSZOSB6EHgiodd1uLRraOM/vrxwFjjH8R9T6Cufi8a3FtcKL6K1lhIJb7NJmRcHBO3vQBDJ4CujKI0vrb7ITlh5G12+pBru7K3W0tIoEJZY1CgnvTraeO5t454GDRSKGVh3BqSgDG8V+e2mCO2yZJJFXaDjcPSs37JqX/PB/zFaXiWQJFbnGWVzIOfRT/Uisb+1tU/uxf99N/jQB4FpnxB1C7VbG6jjVpgYjIgPy5/GsSLRtSlvXtJsJDG5zcHGCD0wO5rY0b7FBZf6HZpGQGG4ryTk9TVC+vZCGV28xIyMjOcUASpJY6IX+wmSe4YgNIT81WbO6uJmnkjVIIDy5X5SPx/GqOm4uIpZYogrom7bIMNj2+tRCxa+kS5v5SijCsvQAdO3XmgDbmutPClLOZbm4cjkHA6cnJ7dav3RjaPT2uUBjUAtFE+CehJOOv0qCzsbS3nG8FY3+WOUdufrVvUreedWvoI1gMU3G4g+ahGMn0H+NAHR2usrdQGOK0iRZNz+UOCiAdWPqf6VTn1eK+vLnR7dwWIErTZyw7cD0rOSKGGIPaiOW8mY7toBQMcAe2AMmp9J0l9PjlEEsk+oag+1pMDcD359PpQB2/wALdL+wWE0+S6ynKse49fxrvYQEAyc8569K8g+F3hXw1et4as7zwz4fuIZPCVhfSebpcDO878NIzlNxJA5yffrWz9g8D/8ARPfDf/If/sP/AI8YP+/v+r/8d/WgD0WW7SSJvJJyCV3AZwajtrhntdz8yZwcZ9eteQ6aNJ1OXSEs/hF4NI1dbhrNpJIVGIGAcyYtjtznjbuz3x1qpLrfgue1sX0X4T6VqE8unQ6jcW8ekGRoxIXAjQw20gL5jfG8xqeOeuAD221Ty5l2E7FHVjkmvNfi3fN/aVpDIMooLqN2BnsT+QqhGvhZ9XkRvhb4YTR49Yh0Zrp4IROJZVQq3k+RjAMigguCO2elZd5pP2bwjKbK0hSztNX1NIYIUCLHGt/ONoA6KAMYHAFAG54Mi08QTXOu2iSqyjD3CjO49kXHT3rt9New0DT47ZXVgCScKAQGJIyB9cV5FZXMMTJP5kjIwBwuCOOg55H+c1Pc6he2t9EV3yp/eYbtozwQAeef5UAdR4xvDPA9vGlxb28j7YmQbQFH9TVC3s20yGOdJElDbtz8kxAkc5/Aio9Q8R32o/Z4ri2jiiX58ry3A547Z/xFbGl3JjdrZ1S5DnhpCMYzwCegNAGJrhivrIRxyZjik+SXgKW64I7gf4VV1i3sVtBHbxqLqOMEMVwWYkZOfX+lX9TQ286Okm/ySwZUAYBCMYz35pdQt31S1TU4Ag2psjUkRsezHn8ulAHA61qt612sFtII7NOSIefM9ct3Fc9fzzLMrQlkIyAY3wT+VaeqSpE4RGVCGLf/AFqxLubc4KexP19qALem6pexyBY7uQBRn5/n59813GjalBcWuUeL7U6lZF2kAdv515/pzpvnJTjAAPXvzXS+FpYoJZ2MMbQltuXPHTn8f8KAO0Z7I3jrJJF5KgIivkhRxk8d8nua4DxbqDzXjwROwt1JG3AHzeox24rs5ms7iGR7YRrIOo6fJx+ea4i+05ZgTGsqqHIJYYyM+/0oA5uctE6+VMy4PZuhFdV4T8SXLNJp8zlnIGyVskYHY5OMc1y+pW4tp2hcE5GVAHOMZ5xW34W0+aKZbm+zGhBCqy54wfWgDv7B11WaTyIhcrEdjopCqpAPqfXBqtfX9zuWFdGhaJOPmiz+OR171WYmK4ebTiAj4w79CM4x6dv0rQF26p808rO4Yjc3CnPUY7UARzBp4NjW7KiAkKFCqTxkY7nkVl+ERNZ6yEEjP8+3C9ucDn8q0L7VWmtJm+YSKvPHXH8VbPwo02S9vzcuhIQgkuvfqDx9aAPXYot9sw81t+AQPTH884qxY7ChWNTjdzk9DUd4/wBmCyFS2044Hapo+YDsQozHOOmKAMPxdrFtaxi1t5U+2SOFADcqCDz7VwF5Yi3hna4mmiSOTEsgfb5+R1HfjpXQ6h9mv/F17OSmy0VY2XHJ4ycD6989q5zxTfJ9hczM2RJ+7XBXPAOKAM+xEkerpGt415FDnyxEpbamQfz6dKsTXv8AY+rS6lA0kkN6NkkQXGCRw3PQ5GKo2l7BYNZ6rsMclvJxuPEyMACB6nPOfarOq58SSXL6NavHDgSK4O1MgnJI7k5xQA5UFrrEF0Y1EUhDLznGfcU/4gT2X+jCWwV7qQbFkkGCvI7jk/8A16zba6E1l5G3F1bsI2Un6nit7xNpkup+HrW7tn/f2/zbByX6cD3oA8+t7R4Y5JGs0uW3FTiV1bj3Br3b4Xtp48MILOBrV0f9/G7klX9yfwrwiR7iXUTBExSWIgOGJX8SpxXTWk12LaSSJZXeRdswidwpA7ttoAv+J9ba51y8upd+1mdLdwQY9qlev1HT3NYnhu6efVHEhWC4WUMqkkZVyAVHqOc1vaduTS5o5DbXdpMUcxMuwhs8BT2HAFZ96tu2rx6jJBDb3SYQ7WLgrjg88fpQB6p8Mrx5tFntZcbrSdoxj+6eR/M119cr8PYidOubwIyRXMu6PcMZUDGcfnXURyJJu8t1badp2nOD6UAYOuSrBrVlJdkLaOvl72OFDE5x+OBVj+04v+mX/fP/ANetSeGK4iaOeNJI24KsMg1i/wDCKaX/AM85P++zQB8veG11V2SeKEQxqu4+dyW554Hc9a67w/oDeJ2u455DDHEwBZYwoLdensPWpbK1W6tXu4ri3H7tkjjK9WPfHsB1rY+Hut2kOh3Md1NGJYJCrHoXPYgUAQeJNB0nQPDzRWys9zI4QOeWyfftWObWL+xlUwx/aZlyrZLDB4y3+FaviTXoNQljt4LlRGj+cpHUnoPyzQkUV8yQRjMhXLr90njrQBh2NuHhffI7yxDb5EaDnGeVHc1a1e5trULAsk8tzchQ0co2rGBzx7mma3H9nE6snkyDakajLEDGcnHf6etRWnhXVNWtob8XahJW2kDjaM9cUAWrCdYdNSSHyzKzbdqLknIxtA9zXdeDLC6iikv9ThVb52CqGH3Yxjjiq2ieCIrBraZSHvI23b35H5V1l2jvb7Gby2Pyk+1AHA6X4e1qPSdDgudD06W90zTINM+2WXiy/sjLHGoAysMA4JycHOM9alTTdQfWzqA8E6abqC4W8DHxVeGLzwoXzfL8jaXwoy23J75rtbJmhbywMjGAcYwakYLE0iPPsDqWJ6EH2NAHO6PFrNu2nGx8IeHoTpgmS13eIrk+WJTmTranOSB97OO2KzLzw3cJHZWjeD9EgSG2FlGbfxXfQl4ck+U7JbgyLkk7XyOTXc219ZSF44ruIyqeTuBP41aXUrIK7q8bsv3uRng0Ackmnatuktk8JeGvmvk1RlHiK6/4+I9m1/8Aj07eWny9OOnJrd8K6M0PhS4tNeSzNzNd3t3LHBIZI4/OuZZgodlUtgSAElRyOlaa3EMcrmEq0rDdgjoPT86sQOn2eQSRp5h5YDkZPrQB5Zqng6/sA0umFbm2wWEefmBPYfnWDHerEssV7b+XOHyokQoQccjP15r3aNrW1QKxjjQcnsPeuT8X6l4auMw3SJczkHiBdz49OOn40AedRtCUZoxGHK4KqxYjtx6jHarYS7hhEJiAQt8wHfvjdRZ2fh2SZ2tdRuNL8z7q3Chgccde3T1rYvfC0lzCsdtr1qRGwO1UGGPv83WgDIBlgYGSNzbysQwU8k98gVdjltpiwi/dsE4PAVSCeTnj0q3a+D764G3+3Yh5fACLn6d6bF4MniilaTX4TjJZygIz6k55oAwPEng+C8vftBaRJHABdSCpOB/niucTwHvceVfxSSOPubSO9dvDZJ9mMcfiS08zAOGTB+oyaH0SS3gBg8Qae7OSAWAXn0yDQB5tD4J1ETB5XgiRiFC85IPf0rp5NEkS1SOyC+UqjdvIBfB6579a6r+zrox7ku9PmDHjZIVAOD6VCNB128j2xWMaq3JXzAFP/wBbPNAGJpyT2tpIhijchMtlc4Pp9O9EdobuSz+1PkrGW+UAhVxmugsvAuuzQu8l5DbBiFVFJf5e/tWhJ8Or+WcN/bCxx91jgAJHTA54oA4Py9PRMpbL9oBCxuV3HOOpB7fnS3QjuFdo23EYDEEKCDjtXf8A/CtbJpl331w0m0K4yF5HXpRD8LdMgYgXV0FfKnD59/8AJoA85TdbRwsyDyYyTzj73X6dKmvtWtpyJooVVEUDC8e9d3efC62nRhBeXCMOQXbdyOn86z1+D7vdK7avOAozkKAOnpQB5/NdzpYH7S6yy4bZIFxgnHygfj+tex/C/T3sfD9u8mA037wjkHB6VkaX8MrS01iL7fdTXSJ88asMKTjrXoAhMMccahDHtwdp2kfSgCzcJ5ziHp0LZ9PSriBV+XP41XtJDI4IVQg4JPB/KrEq+ZAfK25I4OKAPKPEfm2XiK5Ol4lnlJjcHphgf5fnWXDYyXUEK3doWVm3oWO7gDkVZtWKa/ex3z/Z542ZV3fxA/8A6qv3WrwoTapIAMcyqn+r6cKT0oAqQ6dYMqWDSStB5LFAxBHqQO+Pf6UzTXj0OPeZJIoYgMRsTh1J5K568Z5+lQQ3umfagFmlSQEIrnKenPJ//XTv7TMryMUhuVEmIc5J2993+eKAKN1Kl7quryxReWFAfdkdDT9SkmuvB92YHlLRMGDjkjntjnFPf7UdYiIliksbxtuzPKttwP0BrW0GGOCbULJykq4O1NuM+v8AOgDH8Ia9Yw+XJ4jsI9QfaFS5WIFxjsQev1FexaJqmmanapJp0kRVhjYBtYexHUV8437yQalNb3AFuwO8DByCf5DiugsPtcF9DPbk72KNvjXpyMgmgDr/ABR4dfTNW8+FQtjOzbWU48tm9R6A5xUnhXwudXf7RfsDYo5Cp1aXB7nsK6fxwxfwkXcKXJjbnpnvXLeEdak07U0s0nSaG4nAaEqd0e7nIPTHT86APTvLCw+XEAihdq4HArK8OabcafFP9peMtIwICdsdz7mqHibVp4NRs9Ot5Rbz3Djy26mQAfMPauljJKAMQWAwxAwM96AHUUU3cf7jfp/jQB8/31lb6dZzT2VsrMFxtzgAHuP8eKxpdNQ2gvILXyJnUhmVhsAwcAe9W7JLY+H7d57ndNIzFt78Z5+X/wCvU1pbyW+kKl7IzRB95QEHHoFwKAOe8MaTc3MrojlNoIJbBDfj24NdPZRvZ60jTbIxBHhpOTv+lVtKWbT9QlltITJaSEk+acbB3yabf6/P9ldp4I28x9oB5DA/lQBe1hv7Y1GySCEMZmALg9MZzn2rqLrxBo+gWMNrbMksyceTGckfX0/GuA1CTVkhtLryWtVm/co4BDY5PHpwP1qtaeVZzPHFEGnkHKhd5LA9Qc49f0oA7WTxlq0kUi2dtbRyE4BZyefyHH41iXXjTxPK6+VbWzR5y7hTnrinwX1rPrC/6DJCAgJhlGfMz6c/jTNQvLKeVY5ne30/exn2ZBxxgZ6j/wCtQBNJ4p16W2UiW2hY4KhIy2fYnPWqOdX1i/eO9vbtYimGVhhOnTjHH1qSJEsbUS2+TD5xktvMPzsgzz6+nWsWzvbi7v7q5FxIzEkqcYHtQBo2dkwtpGSON+Sqtt6HPU4Pt3qrFbwIoRpZhKcFk3nA9Mc06zs5LGJh55lMp3AAE4Geev4/lSpPB5V08yLGUIy38SjI6Hrn9aANS2v5Y7lfK1O7CqdmT82MfXtzitG38Ta/ATC91CYnOBIYSXIAPocZ/CsK3iS7jdgXjKspZJYyrDPQ89vetKxQNCI1eYyqTuHQAA9T6560AXTbvrNor3Wp3EzsCAu/jvjgD171BbmK0Edus8YaIkssYB3HJ79OM/pVRozDqMMUskcKmQKXycKM5xx3x/hXomkQ6VHaBtI8mS6hcErkASNjB/TNAHCj7NPK0Rih3HG/sA3v9QKuz6fBeplbWF5sAFVGMZ/yK6X4kWyRw2l7FFDHcHAdyO3oR3rkNI1b+z5lugXkiwzSFUAOOx9hz0oAkS0CasiySFVYbTNGSmO2SB+XSoo7GGy1SNz5nlqSxkYkqRnqB0z0xUGqeLIbS4Rls4WWVmd07njg59c80n/CRQ3+nwpbgyCP93sk6s2PlB9zQBc18JdwFnghdvmZSF+Y/wCHes3SbS3ubaWQRsnzqGyoDY49OKq+HdOtr3StEL6XPqer6m2r3Es1x4mvNPhijtrvywoEe5R8rqBgKAF960vCOl+DtYOoXUmk67DpUdjp97DHbahqdxcZuBISGSKViwGxcFV6ZOcUAMn0nTLeT54cooJZkOQcd8Cr+nw6npl19o0nUrj7G0YbY7eYCPoecd+KdNb+AG1vQ7G0s/E93BqQuUaWO/1cvbyQsimN4gxZTljndt24BPBFS6xZ+BIdG1iXRZtck1C00+6u7TztT1VILjyUJPlyGVVlUHGfLY8H8aAN/wAPeP2V1s9bi8hwQPOCnY3YH/Z/Gu/s7m2vEWeGQOrdCrZBrylND+HYks4tSk1oX0ywLM6anqjwxSyqpVJJhIUjJ3LgOwJ3L6isK2k0Z/h8de8JW/iPSb611S0iEVzqOpCBgdQSEj96wjkDKG3KAdu7BwaAPc5oh56yDDDYRnvzTUJZCsgC46EVwGn+PDFGBqlrNAvJZ0AcAg4PTnrWvb+ONGvZo4re8jyc/LJ8mT260AdREWkMqeZwwAQ459+atIFEajO4jgnNZpvEubbfCcc4U/1HrVxZ0VVTduJ44/nQBLO20ZWPc2MLUYy5RZEyQetORBHKW3kgnIyelSkxrgAAlvQUAU2RFvFCH5nUqQO3vV4YiQDHyikykSFiAqjOTTgynByKAMPxF4ctNb2NIAsnQuo5IqJvCunfYJ7eOMCWRCpmYbiue/NdEGB+6c/Sm7VTcxJPrk0AZNrpentClobOKSGJApLRgg44rD8X6NoVhot5KIorOaRNiNGp4c9MAepror/ULPTtrzThQQSI15Z/oOprjNbsh4+tiYfNthaTYJ35DjAPQfhQByF0gm8Nm9t5hb3cARwm7pg9f/rU5b2SeKLUIACFPzmNsBieT+Ociupm8EWWl6Dq13qhW8k8ourBdpXA9AcZrnfC+l3V/wCGZ5Il2QLIRkgr0ABOOc9P1oAp+Obbdb6ZrtrGBLuWKcE/dB9c1X0BTDqUMbsrrJMh2YPyjdjFa5zqOjXmnGJFmaE4O44J+lcloWqra6rYW14v71riNXDAjBDDn6cUAe0fEqdIfDqxZI8yRQMegrgdFlhl1mzuWYq8bDG3ILc4A57cfzrc+KGrW032eJP3kUQ3ybT0yQBXM+EwlzrdjHlXMzh1AP3Rk/0xQB7Jq/2O3WPULm3SWeDIhbGWBPYGofDupi/jmR12Txtlk9M/5NVPGU620OnsXVAJ8gMeDhT/AC4qLwSkhfUJpGRtzIoKnIOFz/7NQB1FFFFAHy1omnab/ZthdXMrSHADK8h3Jzz8uMH8q2dQ1WCKRlswZIuyEH5cds/yrqNN8CBLSFWnLqGy20Y49R71tW3hqCO4tJ7W3jijXPnGQbmb0wf1oA4ZNJ1LXJFWGJraFgC7OPlHpgV0+h+CLSwmiubtluJoznc44P0HauxSONA6RlRgZwe1Zs0U8qLG06bw+4h+MjPHFAHNfFGCRfCxuUkA+zzLJjHGOn9a820SQw6mzYnPnx58xAPXJ6c/jXu2o6el/YyW06qyOpUgcivLrqzbR7pdJu1l8lSTHKX2l047/TqKAGR3Y1DWbSaxUF4gd8u7KqAuME9Oc/pVFddgtJ3S+jWSRFKgAfK684Bzx3rQnWOG5Ftpv7m13h1xn94M9WPevPvF1vdLeSM7BlUnCr8vT2/GgDvZ7iKbSBcykbfuxxwgq6nsD7DPvRb+F7vTI/7QtzKp27iz5578j6VyPgtp5NMnVpGjkZs46lsHI4969y8Pa1a+INMKIyxzqm145R8ynvx3oA86h1EXrzzhwAAGOAMqRkY9qy9lvPBLFOCGGSGjwdrdvw4HWrvibTotFkuY7fdIsrE5BHU54+hpEFiNCyd/nbtxAYemMe2BQBZiZpbxry9uRcz+XsDlVRUx0GPxNSbJIHjkSRXkaPaevUHH44ridTuS8jNv+b7uVOM4A6+/atnwlfLC7SxEP5ZyyFckn6/ofpQB0VtBa3TywarOil8skh6B8cAjqPWstNB1HS7X7UFEdwD56zK5VgOf4f8A69Ymt6hLBBIUYgyuRtTjj0x6VB4d8VTWWxZMSpjaYZcldvqPQ0Ad1Drd9rmlvDrSLmPhQ/DN3Gew9s+9TeIooYYYZLCcNHIhVk3gHcB047DPT1rMn1SK6j8iKOcQzRiVJFXCjkenerT6O95pS+XM6RbcYC4yW/pzQBwOsXG26m8xyzR8KGOQKteBUae8lmllKWm9QRjO48857devvS3vgvUkkSKeWBYnyBLuLZre0nRINKEYtGMjIdgV03bmIznr6/yoAuaBL4OaPRY/FlvPN/ZFxrCDT5/D9zeRP9ovd8ciuI2ThUGCM539Rjm54n1TwhrU2rXtvrV9BbXL2StBL4ZvpbYC380eVKoVd6N5n3MrjaOvSucY3CWSF1eO6Y/LJu6fN82efcflW9dSxvZwpp7QySN5pk3YUcsBk+3WgBug3vhzw/8A2VdaXr00M1jdXk+B4QvltjFclC8aRqF2Y2DadxA9DWdolr4J03TLzTrHUYktpLK5sIbmHwTdLehZUZQZZwmZNoPYIWxyTULyu63CtkiZ8jyT8oAHT3wKq6XMLDUUdFyhJBHVSO/4/wCe9AG0T4Ih8QyahFfRSGWS3mna/wDBV1c3MbRIiHyZWj/dhhGDgq20kkYJqDX/ABXott4C1Dw5pesz6iZNTt7mwtzod3ayRg363EgklcbGwCcHCYC9yatvG07lhFtEvJcnkADpz+NYwstOtbof2pdBI3OApGWOTxyPrQB1Wn6TNqk9pbi4QP5RuJZMbgi54AXuf8KmvvDWhTaIl+q3UkYOyX7yEvyCcdsH2rC8V+I7fRdC1m30C9MjtbRRK6nLINx349wprH+GXis6NPqVtJeyazp0kKyxq/3hI38Jz046npQB02iW1y9ibe21KSC7DeWI4Zdy455weBnj9altotYsJoDcazdGUMcKT8pHr6EetVJ762tr4GSQl2Un90wwN2cjrz0FXLYLqVuJGyEfckfJOCCMY78jPFAF+51zW4ZVW11TzZTljHIoYEA4yOnFadp491aBsXVpBOCob9yxVsewPX86xzaQ25t/P8qRXwU2k5Hs3pUc05svPdSGlR0A3DKlMgH6dMZ9KAO30Tx9pN3GXvUms1lbpOmFB926V11le29/b+bZTRSxZ+8CCCPavGioOlxi6aJ1nbP7kcBCBgYHJ5p+kwXemySXOkyG2lDAGMhikwGBnb2570Ae0bUhLSrkZxlR0zSu3mHCgFT97P8APFYHg7XodcsXU4S8jbE8THlT7e1dEYgo3RKA4HGaAOU1XwY2oav/AGh/alxA/TbFjgegJrb0jTo9JtRawBihbcXJyzk9Sa1McAH9KjjVy+9+OMYz0NAFe4sxdW09vKf3UilOeoyOa858SeIbnQYZtCsbAKU+bzHb7yE8nHevUwcjIOa85+KUKHUNNlZljVo5Edj+BH5c/nQBxLagEMN7Y7vvAPxwB6fSprvSrW4nTxGZY1SAb5kx98rzVe1tdt1e2F1GzSbd8AUn5wPb+dT2yR32m3mlyMUEi7EUdm9KAORvr9tWLPyDM5faTjOO38q9I+EGibJJNYmCpaxKVRierY5/IV5MySW2qNDfxsk0bYZCcDH/ANfFet+LtT/4R7wjpujwY8xoRJOATk57HHqc/lQBX8Z66mt6qlurfuQQEQN0XIO4/X+VdloM8Ph3QBdX7Msl24KR9+BgAenAz+Ncf8NrOPVNTha9jUGNDODnmTnAB9uOntWh8Vr9TqENohO9FCKN2BluTx9AKAOhtPGAu76GOOHER+9hhnBrsK8e8IWTt4isUmISRnLmIHO1VBODXsNAHHWc5ayjuIyzDBOM4BGamkWSRQWZkIyyr2NVtIE32bFwvyHgADsTVme089QnmuoXkMDzQAlrMkyu0nylPlLdz/8AWpsEcSBvMk8+Y/KWwM47ClMEcIGYw4XHXv70ycKlzuYqq5BQDjn3oAt223c6qHGDg7qz/Eeh22t28cF4uACfnA5HHY1OkEkkak3Bwp3Ag5/CkDyTRMRKPlOQp7Y9aAPJdT0fUdEuC+oRNJp8bFY7heqehYdR9arXGn/amM0IVrZ/mclgeOMH3Ne2XYt5rR1uNjRlTuVuRXlXi7S38PSIbRN9g/zJkEiNs5A+np/+qgDmQTNcRQxRR265OGGfUYPT0qXz57a7juLe5SOQfxqSMg9c/l0rQuLJ3tIJhcGO0lU+bJkBizetcyJIYryOB12o2QWYEnHYmgDcmuvtzAXKwgs25nDcHP49eKovZ208rkRyeSGyRwM/j3rX0wWyafHNcQGRmBKIuCCM8FgfQ5qO9837MuxyDnqnbPU4/wA9KAMO+0Nry5L2uI0CgnLfdOcY+vNXrDw+9lbgW03mTupOyPGDyDgk9CMEYq1qFzZ6fYxzQyl75lwI2Y4PGe3SuWtvFNzbXaeYI1iyA4UZIGc/h60AUNQadLiaS6XbMMjBHU5IxVCxiuLrUIo7VS+CcdsCvTn+zywfMqv5q7wWXJXOOh/LmuH1jWT9puIrPbFDgJuVRnj09PzoA7yxEVpbW9pcBCVACsh3DtknHSujsUvZrYRaeFj+fcg4O4D8ePX8K8Y0e8l81NshAjySeSW79Pwr0C1S9vtZ0rWvtpt7UKCYxnG4dflHqaAJvEMA0+FWuHEgnbaGOVKbVxxx0z/nvXFPPcRSlxcqrF8qTnkA9f8A61eg+Mbd77SM2v8ApDLufGSeTySFPQV5ZbWlzc3fkGFn9c8Ac9aAPQtJFrrelGS2z50SsCSONx43Z7c81c06xhtdNI1S5gN67/vdqcFR0GQBnil07SBo+mJBP80UqFmVcAcYyc/j2rGn161iuICykBHB2Agg9iKAC6nkvNQls7FJ7e1tE2jzOgGOx569ayNOsLg3kZ84fZypy2ehHJx7+9dK00OrwSLDO6MMrlucHH+AHFMW0KpHskWWQM0LL0Q56dfagDPk8RWZSSG2W6Z0Vg4ml+V8sMH2rk764M88rTuSmSwHXJI4P0roNO07TZL2e3eRIpQ5VllYc5/u44NZOr+FtWspG2W0k0G3KyJ8yMvY/rjFAEOgSxy6pEJxGsD/AOsVhu3dh+tdOq6ZDa3r28CxyYBVNoy4JwM49snHtWJo+jSWkm69+RjGPLXZkgZ9Pzz6V1OkWcFpE9xdg7wqgxfdD88D2GKAMq5gWBTFKd+4DYQDwOv+NaehvK9wYA5SYQM0A6Jk4GT78DmrdnaW9zqUsUu4ypyhTABHoTnGMUmj21yNdS5t7iNGhX50wPmUH+HPc4oAw/DL3ketXFpMsnnvnYTJtTcDkkn047V0rxXl/abmwiHKg7CBMccc+nGatXektqcjzNdC22FpUbOTk5yPpj+dbGkeIYH0+ztDHFJJDiDzVICg8KSD7ZoA5aGaW2vntmgay3AERyENtIHBX2OM1u3Za5Szuo5Ps8mwjDJ/rAD2rQ8T+TDqNrdBY2ufK2h3fjbXMJc6xqE63MVmsUFnkhYnyXHBPX/P5UAXdFW50bxNZXdrcuYZZFt5lB4KE4H45PSvc1PAOK8LtxJNr2kRAMsrSKzZJYKRyeD7D869o8y4RFRPLkY/xDsPU0AXCQMZIGeBS1XigLKvnjcVbcvPenRFi7ls9cAZ4xQA4N5e1TlsnGa5n4iW0c+hGSSNZPKywz2/ziuk4W5wON4JIxxniuP+IepwxLY6TgtJcPvZQ235AD+YoA8/1W/8iexuFaUMCsiyhNyqOVZcjqMZJpfJZCmoRNmMM0mYhgDJ9+amis1a0EUrgTDLrjkhehwM+veq/hud4rebTpgFCEuis/MinuB/SgB3iqx07bH4iuTMHJTbAAAJG7bj2ANZsl1c6pHuvis2oXDY3LzwOgAPbHqPWukgjttQ01rG8IaNjgBum7np+tcjqNld6BqP2eNnkV9scUir8yqT/TNAHpPwz0q4Fy19LtWGIeUuBgMfb8657xnfW9xqd9f7mMscxSJWHysFGAefXHauz8Q6jLpfhGG30YMsvlKiuoztGOteZz2y6kts10yWkto21oyOZB6j3yOlAHRfD23vY9TsDfr/AKa07u3z5/d7T2r2CuP8DaXJ/wAhW7UrLIm2NSO3978a7CgDjtNeQ2wLoypjOW+tWixkiLQspBGRiq6gGyiBAI//AF1JbALbxBQAM44oAfAftMBDjY6nBB9RVTVniiEQIZiW6qOnvVi44lGO9VsAsARxt6fnQBILVzblElCKcdBjHvVmKEopYYKnACgd+9Y2tMw34Yj923et22/48If9z+lADIkRldWj4YnPHU1DPb/aYZLa9gEkcq7COxB602zdi7ZZj/pGOvbArbXmPJ64oA8Z8X+FLjSmElmJZdMXsOXj/wAR/KuejENxdrMluLpkXZ+84BB7kjjvxXvGsgHT5QQD2rx7xfDHb67aCCNIhIGL7FC7ue+OtAEFmEhZ5ZD8yMu6LjBXOPw9ail/0qVZiFKhcCNRnf8AjV63AMCggYIGfzNZYULfxKoAVVBAHQUAcz4i3rc3KzRyJKGbjoMEDbxj0xXIeWxkcRseeprtfFrE2yOSS56t3PLVzmAJYgAANy/zoA7nQIWHhwQztL5ywkBlO7BxwuAa4C9h2YZAMtgMMYwec5r03SQBokbAANuznvniuI8bKBrXAA+QHp3x1oAzdGlZLrbFGHZ12jC55r0zT47S1ghtbmYoEyWEmMgkHPHbHFc94ZjRWR1RQ/2hRuA5xgcV33gOGOa3v5Jo0kf7QRuZQTj0zQBHFftEIbWyRLq4Ix5pPyr659McVn3BktbkNMIzI3yiREG3bnBFcz4gdoPGdysLGNSAMIcDoPSrlnLJNqV6JXaQK4C7jnHzKOKAI/HF9eQWcIt7gtHgCQKcBR0Arz+VHCqGJzksTnIOa9f8ZxRnTWQxptwnGBjpXgt+SJnAJAyeBQB6Zot75rbLWdFkZS7qCPzFP8Wymws42nDqjuMlSSMY46+/aub+F4D6heBhuG1Rzzxmut8bASeF42kAdvLY5bk55oA4aebzG86Jg8YwQQQBmvTPD2u3l3YQWokL3dwvlxxINoQ9M59sZNeNaezeRIu47RzjPFeq/DUD/hItIOBk+Zk+vSgDd1Ky1DTNVis9Re1mEyhxNEhBQA8jHpSatYwT2ygFJFt2yoOT3wuQPrXQeIju8WWatyptyCD3BBzTJYo4bG6MMaRkRuRsGO1AGNZ2t5/Ztw9qYlfB3KRtdQGP4ngg/jUNpYB7GdnnfEPIUHBZiR+PHX8axdDuJmuRulkO4jOWPOWOaL+WQaXbASPhpTn5jz8xoA6XSJbe8t5Uhi8ma3jfkOcSrnoQfUUzRbTydbnsLYxygYXYz847k/h/KldEj02Bo1VG+zSHKjBz61b8Lop1eeQqDJ9mU7sc5LnPNAFDxzpVtqV8Hs55YzbqC8WeXkY84/AEn6VsSXUB0VbWNEheJk3iP+MEHjHr0qk43avAW5JIyT3rV8CRRzeMrnzo0k2AFdwB2n1HpQB0XgPwqbXdqWoLh2UpBEx5RD2PucDiu3hhdQpTy1HYAcYpLz5Yfl4ww6VZj/1aUAOYEjg4NVYFlCqjqqjOSVz61bHShegoARgcgjtXnXxRhtIb7SrtsC6EvY87e/4dBXoh/wBav0P9K+eviHNK/jS3V5HZVEu0FiQP3nagDtr2OB7ZLqxSPET7JmY/dXPPI6HP4CuK1fSnswuo3AV4xKH3RHk/N0P4V1Gmon9jTptXY5YsuOGOR1qnq6L5VuNq43BcY7ccUAVpZblYonSECEqJFYjk98cVpXphvtGe/MIFxGo3E8kDIqro4H/CO2vA+8f51Y8OknQ9XyTxCcUAXvh/qc2tbrG5SPfEMLwclR3ru4vD2mQy/aZoI2lXku/QVwfwjAN8XIBYxNz3611/jaR0tQquyqV5AOAaALd74htoW8q1VpnOQpUfLkDpms/+2tR/55zf9+Kybcky2iZ+XbnHbORVrzZP+ej/AJmgD//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Electron micrograph of a normal glomerular capillary loop showing the fenestrated endothelial cell (Endo), the glomerular basement membrane (GBM), and the epithelial cells with its interdigitating foot processes (arrow). The GBM is thin, and no electron dense deposits are present. Two normal platelets are seen in the capillary lumen.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Helmut Rennke, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39656=[""].join("\n");
var outline_f38_46_39656=null;
var title_f38_46_39657="Techniques of breast and chest wall irradiation for early stage breast cancer";
var content_f38_46_39657=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Techniques of breast and chest wall irradiation for early stage breast cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/46/39657/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/46/39657/contributors\">",
"     Lori J Pierce, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/46/39657/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/46/39657/contributors\">",
"     Daniel F Hayes, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/46/39657/contributors\">",
"     David E Wazer, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/46/39657/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/46/39657/contributors\">",
"     Don S Dizon, MD, FACP",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/46/39657/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 13, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) has been a component of breast cancer treatment for almost 100 years. Although initially used for the treatment of postmastectomy chest wall recurrences and for advanced inoperable disease, RT has evolved into a critical component of therapy for women with an intact breast following breast conserving surgery and for women who have undergone mastectomy who are at moderate to high risk for local failure. The importance of technical excellence in irradiating the intact breast or the chest wall cannot be overemphasized, since many women enjoy long-term survival following treatment for early stage breast cancer.",
"   </p>",
"   <p>",
"    Optimal local management of invasive breast cancer requires a collaborative effort between breast and reconstructive surgeons, and radiation and medical oncologists. This multimodality approach permits the coordination of surgery and RT, and the optimal integration of both local and systemic therapies.",
"   </p>",
"   <p>",
"    Techniques for irradiating women with early stage invasive breast cancer will be reviewed here. Complications of breast and chest wall irradiation, the role of RT in breast conservation therapy (BCT), indications for postmastectomy chest wall RT, and RT for locally advanced breast cancer are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30359?source=see_link\">",
"     \"Complications of breast and chest wall irradiation for early stage breast cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link\">",
"     \"Role of radiation therapy in breast conservation therapy\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link\">",
"     \"Postmastectomy chest wall irradiation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/55/42873?source=see_link\">",
"     \"Radiation techniques for locally advanced breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H612454\">",
"    <span class=\"h1\">",
"     TYPE OF RT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The type of RT varies with the surgical procedure that has been performed:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Breast irradiation for women undergoing breast-conserving therapy (BCT)",
"     </li>",
"     <li>",
"      Chest wall irradiation for women who have undergone mastectomy",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h2\">",
"     Breast conservation therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;BCT consists of the surgical removal of a clinically evident tumor followed by moderate dose RT to the whole breast to eradicate any foci of residual microscopic disease. The rationale for whole breast treatment is to improve both local control and overall survival (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link&amp;anchor=H8489445#H8489445\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Benefits'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      One of the first studies to document the ability of RT to eradicate subclinical deposits of breast cancer and achieve locoregional tumor control was designed to examine the incidence of supraclavicular node relapse in women with positive axillary nodes who underwent radical mastectomy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/1\">",
"       1",
"      </a>",
"      ]. Compared to prior historical reports (20 to 25 percent incidence of supraclavicular failure in the absence of adjuvant RT), the rate of supraclavicular relapse was 3 and 1.3 percent with doses of 30 to 35 Gy and 50 to 55 Gy, respectively.",
"     </li>",
"     <li>",
"      Multiple randomized trials comparing breast-conserving surgery only versus BCS and RT have consistently demonstrated a significant reduction in in-breast tumor recurrence with the addition of radiotherapy.",
"     </li>",
"     <li>",
"      Results from the most recent Early Breast Cancer Trialists Collaborative Group (EBCTCG) overview analysis indicate that not only does whole breast irradiation after conservative surgery reduce the risk of in-breast tumor failure, it also can result in an improvement in survival [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    With the significant benefit in local control and overall survival by the addition of radiotherapy following conservative surgery, radiotherapy following breast conserving surgery is the standard of care in early stage breast cancer patients desirous of breast preservation. There are no subsets of women with a good enough prognosis following breast conserving surgery alone to warrant the elimination of whole breast RT, with the possible exception of women over 70 years of age who have T1, ER-positive cancers and who will be receiving",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"     tamoxifen",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link&amp;anchor=H611293#H611293\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Breast conserving therapy (BCT) without radiation therapy (RT)'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link&amp;anchor=H729991#H729991\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Can RT be omitted in patients receiving adjuvant systemic therapy?'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Thus, whole breast irradiation is recommended to all women undergoing breast conservation surgery for early stage breast cancer with the possible exception of women 70 years and older who will be receiving adjuvant endocrine therapy. With the development of megavoltage modern RT techniques, adequate local control of subclinical (microscopic) disease can be accomplished with the preservation of a cosmetically satisfactory breast. The benefits of whole breast RT and the contribution of adjuvant systemic therapy to local control are discussed in detail elsewhere.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Postmastectomy",
"    </span>",
"    &nbsp;&mdash;&nbsp;While postmastectomy RT has consistently been associated with a two-thirds reduction in the risk of locoregional recurrence, its impact on survival has been controversial in the past. However, contemporary trials and the EBCTCG overview analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/2\">",
"     2",
"    </a>",
"    ] demonstrate a survival benefit for both premenopausal and postmenopausal women with node-positive breast cancer. This topic is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link\">",
"     \"Postmastectomy chest wall irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     THE PLANNING TARGET VOLUME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Three anatomic regions must be considered in defining the target volume (",
"    <a class=\"graphic graphic_figure graphicRef57770 \" href=\"mobipreview.htm?39/39/40563\">",
"     figure 1",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The breast or chest wall",
"     </li>",
"     <li>",
"      The internal mammary (IM) lymph node region",
"     </li>",
"     <li>",
"      The supraclavicular fossa and axilla",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Depending upon the clinical situation, one, two, or all three areas will require treatment in an individual patient.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     The intact breast or chest wall",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breast or chest wall is typically defined clinically. The target volume for whole breast RT extends medially to the middle of the sternum and laterally to the mid-axillary line. In a woman with an intact breast, the field usually extends 1 cm beyond the palpable border of breast tissue. In contrast, for RT of the chest wall in women who have undergone mastectomy, the lateral field edge will need to extend beyond the mastectomy scar. The inferior edge of the field is approximately 1 cm below the inframammary fold in the intact breast or the contralateral inframammary fold when treating the chest wall. Superiorly, the field typically ends at the base of the head of the clavicle.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     The IM nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;The IM lymph nodes follow the course of the IM artery and vein, which are located superior to the pleura and lateral to the sternum (",
"    <a class=\"graphic graphic_figure graphicRef57770 \" href=\"mobipreview.htm?39/39/40563\">",
"     figure 1",
"    </a>",
"    ). On contrast-enhanced CT scan, these vessels can easily be seen. Within the IM chain, nodes in the first three interspaces are more likely to be pathologically involved than those in the lower interspaces and are typically included in the field when the IM nodes are to be treated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/3\">",
"     3",
"    </a>",
"    ]. This allows the RT field to end above the level of the majority of the cardiac silhouette, minimizing the risk of long-term cardiac morbidity [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/4\">",
"     4",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients treated with surgery only, pathologic involvement of the IM nodal chain has been reported in up to 37 percent of axillary node-positive breast cancers that are located in the inner or central breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/5\">",
"     5",
"    </a>",
"    ]. The IM nodes will be found to contain regional metastases in about 8 to 10 percent of patients with axillary node-negative disease; this is most likely with medial tumors over 2 cm in size. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link&amp;anchor=H7#H7\">",
"     \"Management of the regional lymph nodes in breast cancer\", section on 'Internal mammary lymph nodes'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, whether the IM nodes should be included in the RT field, particularly among patients with axillary node-negative disease and or patients receiving contemporary systemic therapy, is controversial for the following reasons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/6\">",
"     6",
"    </a>",
"    ]: &nbsp;",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      On the one hand, several series report a less favorable outcome for inner as compared to outer quadrant lesions, suggesting a need for treatment of the IM nodes in these women [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/7-9\">",
"       7-9",
"      </a>",
"      ], and benefit for including the IM nodes in the RT field has been suggested in at least one nonrandomized phase II study of 100 women with high-risk stage II or III breast cancer who were treated similarly with doxorubicin-based adjuvant chemotherapy, followed by high dose chemotherapy, stem cell support, and locoregional radiotherapy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      On the other hand, clinical evidence of recurrence at this site is uncommon [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/11-13\">",
"       11-13",
"      </a>",
"      ], although detection of an IM recurrence is difficult and as a result, recurrences at this site may be underreported. More importantly, a survival benefit for routine resection of the IM nodes has not been shown in at least four randomized trials, supporting the view that radiating these nodes may not influence survival. In addition, at least two retrospective series were unable to identify a significant cause-specific or overall survival benefit for irradiation of IM nodes in conservatively treated breast cancer patients, even in node-positive or medially located tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/14,15\">",
"       14,15",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link&amp;anchor=H7#H7\">",
"       \"Management of the regional lymph nodes in breast cancer\", section on 'Internal mammary lymph nodes'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    However, the question of whether the IM nodes should be treated has again been brought to the forefront with the publication of data from randomized trials testing the value of postmastectomy RT, which suggest that enhanced local-regional tumor control (perhaps as a result, in part, of including the IM nodes in the radiation treatment volume) is associated with long-term survival benefits among patients receiving adjuvant systemic therapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link&amp;anchor=H14#H14\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Modern clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    It remains unclear whether it is the treatment of the IM nodes that is responsible for these findings. Nevertheless, despite the lack of data from randomized trials to support this practice, we include the IM nodes within the first three interspaces in the treated field in women with positive axillary nodes undergoing postmastectomy RT, if treatment can be delivered without irradiating the heart and without significant risk of incremental pulmonary morbidity. We do not include the IM nodes in the radiation field in women with axillary node-negative disease.",
"   </p>",
"   <p>",
"    Women undergoing BCT differ from those undergoing mastectomy only by the presence of intact breast tissue. Thus, in theory, the survival benefit realized in the postmastectomy trials for women with node-positive breast cancer should be applicable to those undergoing locoregional RT to an intact breast. In fact, the similarity in the survival benefits of RT in women undergoing mastectomy or BCT was shown by the Early Breast Cancer Trialists Collaborative Group analysis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Benefit for the addition of regional irradiation to whole breast RT was directly shown in the NCIC CTG MA.20 trial, in which women with node-positive (90 percent) or high-risk node-negative (tumor size &ge;5 cm, or &ge;2 cm and fewer than 10 axillary nodes in the specimen, ER-negative, grade 3, or lymphovascular invasion) breast cancer undergoing BCT were randomly assigned to whole breast irradiation using conventional fractionation (50 Gy in 25 daily 2 Gy fractions) with or without regional nodal irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/16\">",
"     16",
"    </a>",
"    ]. The group receiving regional nodal irradiation received concurrent treatment (45 Gy in 25 daily 1.8-Gy fractions) to a field that included the high axillary, supraclavicular, and upper IM nodal chain (the first three upper intercostal spaces). In a preliminary report, the addition of regional nodal irradiation to whole breast RT reduced both locoregional (all benefit was due to improved regional control) and distant recurrences, and there was a trend toward better overall survival, but these improvements come at a cost of modestly higher rates of radiation dermatitis, radiation pneumonitis, and lymphedema, and a poorer cosmetic outcome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link&amp;anchor=H730200#H730200\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Benefits of regional nodal irradiation'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Based upon these data, the risks and benefits of regional nodal irradiation should be discussed with all patients with node-positive breast cancer who are undergoing BCT. For women who are willing to sacrifice a modestly higher rate of radiation-related side effects for improved oncologic outcomes, the addition of regional nodal irradiation to whole breast RT should be strongly considered. . &nbsp;",
"   </p>",
"   <p>",
"    Whether the IM nodes should be included in the radiation treatment volume in patients with otherwise node-negative disease remains uncertain and at this time is not routinely recommended. The MA.20 trial included patients with high-risk node-negative disease, but they only constituted 10 percent of the patients enrolled on the trial, and results were not reported according to nodal status. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=see_link\">",
"     \"Sentinel lymph node dissection for breast cancer: Indications and outcomes\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=see_link\">",
"     \"Management of the regional lymph nodes in breast cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A second trial examining the benefit of regional nodal irradiation in women with stage I, II and III breast cancer that has been surgically removed is underway (EORTC protocol 22922 [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/17\">",
"     17",
"    </a>",
"    ]). Pending further data from this and the MA.20 trial, we do not routinely include the IM nodes in the radiation treatment volume in patients with axillary-node-negative disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Axilla and supraclavicular fossa",
"    </span>",
"    &nbsp;&mdash;&nbsp;The supraclavicular target volume lies superior to the breast or chest wall field; the junction of these two target areas must be carefully matched (see below). Superiorly, the field extends to cover the top of the first rib and may or may not extend beyond the skin of the supraclavicular fossa, depending upon clinician preference. Medially, the field extends to the pedicles of the cervical spine. Laterally, the field is narrow if only the supraclavicular nodes and apex of the axilla (infraclavicular region) are treated, and wider if the entire axilla is treated.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     SIMULATION TECHNIQUES",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of simulation and set-up techniques are available for treating both the intact breast and the chest wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     The intact breast",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simulation can be accomplished in one of two ways: either as a clinical simulation or a virtual simulation using a CT scan-based data set. With either technique, it is critically important to provide good immobilization of the patient.",
"   </p>",
"   <p>",
"    Using modern CT technology, many institutions are using virtual simulation for their breast treatment set-up [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/18\">",
"     18",
"    </a>",
"    ]. The use of virtual simulation minimizes time expenditure for patients and permits better visualization of the chest wall, outer breast contour, central lung distance, and the cardiac border, thus improving target coverage while sparing normal tissues. This treatment planning approach is particularly recommended for left-sided breast cancers so that the heart can be fully visualized and spared in the planning process.",
"   </p>",
"   <p>",
"    An immobilization device is used and the borders of the field, scars, and any match line junctions are marked with radiopaque catheters. The patient is then imaged on the CT scanner through the desired treatment volume with 3 mm slice spacing, which produces high-resolution digitally reconstructed radiographs. With a modern helical scanner, the entire procedure generally takes less than fifteen minutes.",
"   </p>",
"   <p>",
"    The scanned information is then brought up on the treatment-planning console and one can treat the data set much as one would treat the actual patient in the simulator room. After the patient has been simulated, daily treatment progresses in a fashion identical to those cases that have had a clinical simulation.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Large breast size",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with large breast size represent an important challenge. The dosimetry of tangential breast treatment can be quite inhomogeneous as breast size increases; elevating the breast off the anterior abdominal wall is critically important in order to avoid an undesirable skin reaction and late long-term telangiectasia and fibrosis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/19\">",
"     19",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Others recommend treating women with large breast volumes in a prone position [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/20\">",
"     20",
"    </a>",
"    ]. Homogeneity can be improved using this technique, and some have suggested that scatter dose to other tissues is reduced [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/21\">",
"     21",
"    </a>",
"    ]. However, if the prone position is used, the target volumes must be carefully defined to avoid missing critical tissue, especially if the tumor bed is close to the chest wall.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Chest wall",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simulation techniques for the chest wall are similar to those for the intact breast, utilizing either actual or virtual simulation. If tangential photon fields are utilized, the simulation techniques do not vary at all from those of the intact breast. Electron fields, if needed, can be set clinically or planned as part of the CT-based plan (see below).",
"   </p>",
"   <p>",
"    When the IM lymph nodes are to be added to the volume, CT-based simulation techniques are extremely valuable because of the variation in body size and shape, and the thickness of the chest wall. Thus, we perform CT simulation in every case in which IM node coverage is desired, typically treating the IM node chain in intercostal spaces one through three.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     TREATMENT TECHNIQUES",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     The intact breast",
"    </span>",
"    &nbsp;&mdash;&nbsp;The breast is treated with a pair of tangential fields. Several important factors should be noted. First, the fields are angled a few degrees beyond 180 degrees opposed, so that deep divergent edges of the field become coplanar; this allows all divergence to be directed into the air above the breast, not deeper into the lung. Another technique used with modern linear accelerators and asymmetric collimator jaws is to set the isocenter at the deep edge and to half-beam block the field using the asymmetric collimator. Half-beam blocking with a so-called \"beam splitter\" is discouraged, since these external blocks still transmit 3 to 5 percent of the incident radiation, contributing unnecessary dose to the contralateral breast [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minimizing toxicity to the underlying heart and lung must be carefully considered in the treatment plan. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30359?source=see_link\">",
"     \"Complications of breast and chest wall irradiation for early stage breast cancer\"",
"    </a>",
"    .) The amount of lung projected on the tangential field at the central axis correlates reasonably well with the volume of ipsilateral lung that is irradiated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. If this width is kept &le;2 cm, the risk of radiation pneumonitis is less than 1 percent. Using CT-based planning, calculation of dose volume parameters such as the V20 (the volume of the lung that receives more than 20 Gy), can help to predict risk of radiation pneumonitis and thus guide radiation planning. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Compared to older techniques, the volume of myocardium that is included in modern RT fields is quite small to none. When optimal treatment planning techniques result in an undesirable volume of myocardium within the field, one can shape the fields using custom blocks [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/26\">",
"     26",
"    </a>",
"    ]. However, this must be done carefully to ensure that relevant breast tissue is not also shielded. Newer methods of radiation planning and delivery (ie, conformal or intensity modulated therapy) may permit maximal sparing of normal tissues. (See",
"    <a class=\"local\" href=\"#H21\">",
"     'Newer RT planning and delivery techniques'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h3\">",
"     Dose and fractionation",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single optimal dose and fractionation schedule for breast RT has not been uniformly accepted. A standard approach based upon data from randomized trials is to administer 45 to 50 Gy whole breast RT over five to 5.5 weeks in standard 1.8 to 2.0 Gy daily fractions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H759493\">",
"    <span class=\"h4\">",
"     Shorter fractionation schedules",
"    </span>",
"    &nbsp;&mdash;&nbsp;Shorter fractionation schedules (eg, 42.5 Gy in 16 fractions, the Canadian protocol [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/27\">",
"     27",
"    </a>",
"    ]) have become popular, particularly in countries where RT equipment is in short supply or where patients must travel long distances to receive RT. Data from four large randomized trials comparing hypofractionated versus conventional fractionated RT support the view that hypofractionated RT appears to be a reasonable alternative to five weeks of therapy using standard fractionation for patients with node-negative favorable disease, although the following caveats apply (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link&amp;anchor=H600305411#H600305411\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Shorter fractionation schedules'",
"    </a>",
"    ):",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients in three of the four trials (both European START trials and the Canadian trial) were treated primarily with adjuvant",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?32/27/33208?source=see_link\">",
"       tamoxifen",
"      </a>",
"      and only a minority received chemotherapy. The potential for complications when chemotherapy is added to RT is well described. Caution should be used when applying shorter course therapy to women who have received adjuvant chemotherapy, since the results from these trials may not adequately represent the potential long-term complications of RT in the presence of chemotherapy.",
"     </li>",
"     <li>",
"      It is not known whether shorter course RT is equivalent to standard longer course therapy in patients with more aggressive disease or in patients for whom a boost has been shown to be of greatest benefit. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'RT boost'",
"      </a>",
"      below.) Further study is needed.",
"     </li>",
"     <li>",
"      Treatment-related toxicity may be a concern with shorter course RT if applied to regional lymph node regions [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/28\">",
"       28",
"      </a>",
"      ]. The START trials both used short-course RT to deliver regional nodal irradiation. However, this is not an accepted approach in the US because of concerns about brachial plexopathy. In one retrospective study from the United Kingdom, the incidence of treatment-related brachial plexopathy in women receiving 1.8 versus 3.7 Gy daily fractions to the breast and lymph nodes was 1 and 6 percent, respectively [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/29\">",
"       29",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38437?source=see_link\">",
"       \"Complications of peripheral nerve irradiation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30359?source=see_link&amp;anchor=H949706089#H949706089\">",
"       \"Complications of breast and chest wall irradiation for early stage breast cancer\", section on 'Rib fracture and brachial plexopathy'",
"      </a>",
"      .),",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H759835\">",
"    <span class=\"h3\">",
"     Accelerated partial breast irradiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accelerated partial breast irradiation (APBI) refers to the use of focused RT to a limited portion of the breast as an alternative to conventional whole breast irradiation for selected patients with early breast cancer following breast conserving surgery. There are several techniques for APBI delivery, including external beam RT, interstitial or intracavitary brachytherapy, and intraoperative RT. &nbsp;",
"   </p>",
"   <p>",
"    Since APBI delivers radiation to a limited volume of tissue (partial breast irradiation), a higher dose of radiation can be delivered in a shorter period of time (hypofractionated accelerated RT) than with whole breast irradiation. The rationale for APBI is based upon the observation that most local recurrences after breast conserving therapy with surgery with or without postoperative radiation are within 1 to 2 cm of the original surgical site.",
"   </p>",
"   <p>",
"    Although early data are promising, whole breast radiation is the preferred choice for most women following breast conserving surgery for breast cancer until more data from randomized trials comparing partial breast RT to standard whole breast RT are available. It is unclear which patients are at sufficiently low risk for local recurrence so that the advantages of APBI (short treatment duration, decreased cost, reduced toxicity) outweigh the possibility of an increased risk of local recurrence. Longer follow-up and confirmation of local control, survival, and toxicity will be needed before concluding that APBI is an acceptable substitute for conventional whole breast irradiation in women undergoing BCT for early breast cancer.",
"   </p>",
"   <p>",
"    The rationale, efficacy, and techniques of APBI are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/27/12728?source=see_link\">",
"     \"Accelerated partial breast irradiation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h3\">",
"     RT boost",
"    </span>",
"    &nbsp;&mdash;&nbsp;The influence of a radiation boost to the primary tumor bed on outcome from BCT is controversial. Many have argued against its routine use, based in part upon National Surgical Adjuvant Breast and Bowel Project (NSABP) trial B-06, in which the local recurrence rates in women with negative margins who did not receive a boost were comparable to those in other series in which a boost was routinely used [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/30\">",
"     30",
"    </a>",
"    ]. Others argue that only a very large study could demonstrate the small improvement in local control that might be expected from boosting the dose to the primary tumor bed and that the boost does not increase the complication rate or compromise the cosmetic outcome.",
"   </p>",
"   <p>",
"    Two trials directly assess the impact of a radiation boost in women undergoing BCT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. In a French trial, 1024 women with invasive cancers &le;3 cm who underwent excision (98 percent with negative margins) and 50 Gy whole-breast RT were randomly assigned to a 10 Gy boost or no further treatment [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/31\">",
"     31",
"    </a>",
"    ]. At a short median follow-up (3.3 years), the five-year actuarial rate of local recurrence was 3.6 versus 4.5 percent, with and without the boost, respectively (p = 0.044).",
"   </p>",
"   <p>",
"    In a much larger trial performed by the European Organization for Research and Treatment of Cancer (EORTC), 5569 women with stage I or II breast cancer undergoing BCT followed by 50 Gy to the whole breast were randomly assigned to one of the following groups based upon the status of the resection margins [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/32-34\">",
"     32-34",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Women with negative resection margins were randomly assigned to no boost, a boost of 15 Gy by interstitial techniques, or a boost of 16 Gy by external beam.",
"     </li>",
"     <li>",
"      Women with positive resection margins were randomly assigned to low-dose boost (10 Gy) or high-dose boost (either 25 Gy by interstitial irradiation or 26 Gy by external beam techniques).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the latest report of the 5318 women who had negative resection margins, the 10-year cumulative incidence of local recurrence was significantly lower in women receiving a boost (6.2 versus 10.2 percent), with the greatest magnitude of benefit seen in patients under the age of 40 (13.5 versus 23.9 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/34\">",
"     34",
"    </a>",
"    ]. As a result of the gain in local control, the number of salvage mastectomies was 41 percent lower in the boost group. However, overall survival at 10 years was similar in both groups, and there also were no differences with respect to breast cancer mortality, overall incidence of breast cancer-related events, or disease-free survival.",
"   </p>",
"   <p>",
"    At three years, cosmetic results were excellent or good in 71 and 86 percent of women treated with or without a boost, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/33\">",
"     33",
"    </a>",
"    ]. However, with long-term follow-up, there was a higher rate of moderate or severe fibrosis in the group receiving a boost (28 versus 13 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/34\">",
"     34",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    As a result of these findings, most treatment centers deliver a boost to the tumor bed in the intact breast after delivering whole breast RT particularly in young women [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/35,36\">",
"     35,36",
"    </a>",
"    ]. Consensus guidelines from the National Comprehensive Cancer Network indicate that a boost is recommended for patients at higher risk for local failure (younger than 50, positive axillary nodes, lymphovascular space invasion",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    <span class=\"nowrap\">",
"     close/positive",
"    </span>",
"    resection margins) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/37\">",
"     37",
"    </a>",
"    ]. A boost in other groups is considered optional. &nbsp;",
"   </p>",
"   <p>",
"    The boost dose may be supplied with electrons, photons, or an interstitial implant, with equivalent outcomes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/38\">",
"     38",
"    </a>",
"    ]. Historically, interstitial implants (usually 192-iridium) were placed either following the completion of whole breast RT or at the time of the lumpectomy to permit direct visualization of the tumor bed. Subsequently, electrons have generally become the method of choice at most institutions [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/35\">",
"     35",
"    </a>",
"    ]. Our typical electron boost dose is 14 Gy, which, when added to the 46 Gy delivered to the whole breast, gives a final tumor bed dose of 60 Gy. In women with a focally positive margin (in the absence of an extensive intraductal component), we typically give a higher boost dose (20 Gy) for a total 66 Gy to the tumor bed. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link\">",
"     \"Role of radiation therapy in breast conservation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Since the surgical scar does not always correspond to the area of tumor removal, the tumor bed should ideally be identified with surgical clips at the time of lumpectomy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Others have used ultrasound or CT to help define the tumor bed [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. CT-based planning assists in defining the shape of the field and the depth of the tumor bed for proper electron dosimetry.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h2\">",
"     The chest wall",
"    </span>",
"    &nbsp;&mdash;&nbsp;The anterior chest wall can be treated with tangential photon fields, similar to the intact breast. The supraclavicular fossa and axillary apex should be treated with a direct photon field. The field borders are the same, as are the considerations regarding the underlying volume of heart and lung.",
"   </p>",
"   <p>",
"    Delivery of an adequate dose to the chest wall skin is important, and the skin-sparing effect of photons must be taken into consideration. When the photon beam strikes the absorbing surface, there is an initial build-up of dose that reaches a maximum, the depth of which increases with increasing energy and then attenuates. This skin-sparing effect is desirable when treating a deep lesion but not superficial tissues such as the chest wall skin. In these cases, a bolus (a material with similar density to tissue that is placed directly on the skin surface) must be used to ensure that the skin receives a therapeutic radiation dose. The beam strikes the absorbing surface at the bolus, whose thickness is calculated so that the maximum dose to the target volume occurs closer to the skin surface.",
"   </p>",
"   <p>",
"    Use of a bolus is typically associated with brisk skin erythema that develops over the treated area; patients must be forewarned that this is expected. The reaction peaks toward the end of therapy and then quickly heals. Over years of follow-up, superficial telangiectasias can develop on the chest wall secondary to long-term thinning of the skin; this is rarely of consequence to the patient.",
"   </p>",
"   <p>",
"    Satisfactory treatment of the chest wall can also be accomplished with electrons [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/43-45\">",
"     43-45",
"    </a>",
"    ]. A particular problem is that electrons deposit a high dose to the superficial skin, which cannot be modified from day to day, unlike the placement of a bolus during photon beam therapy. Patients with sensitive skin can develop a brisk skin reaction before the treatment is concluded, making the last few days of treatment uncomfortable.",
"   </p>",
"   <p>",
"    Given the low rate of axillary failure following adequate axillary lymph node dissection (ie, 1 to 2 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/46\">",
"     46",
"    </a>",
"    ]), there is little reason to offer axillary RT, and combined treatment increases the risk of arm morbidity (see",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30359?source=see_link&amp;anchor=H949706075#H949706075\">",
"     \"Complications of breast and chest wall irradiation for early stage breast cancer\", section on 'Arm edema'",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Microscopic extracapsular extension beyond the involved lymph nodes is not generally associated with an increased risk of axillary failure and should not prompt full axillary irradiation [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link&amp;anchor=H4#H4\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Risk factors for locoregional recurrence'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h3\">",
"     RT boost",
"    </span>",
"    &nbsp;&mdash;&nbsp;The decision whether to incorporate a boost to the mastectomy scar for stage II disease should be left to the treating radiation oncologist. When a boost to the scar is given, generally 10 Gy in 2-Gy fractions is delivered. For women who have positive chest wall margins, stage III disease, or a resected chest wall recurrence with negative margins, we use a 10 Gy boost to the area of recurrent disease or to the mastectomy scar. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link\">",
"     \"Postmastectomy chest wall irradiation\"",
"    </a>",
"    .) Women with gross residual disease on the chest wall may require doses as high as 70 Gy or more for optimal tumor control.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     The IM nodes",
"    </span>",
"    &nbsp;&mdash;&nbsp;If the IM nodes are to be treated, we plan cases using CT-based planning to determine if the optimal dose is best delivered with photons as part of the tangent field, with electrons, or with a mixture of photons and electrons.",
"   </p>",
"   <p>",
"    If electrons are used, the angled electrons may have to traverse a significant distance through tissue to reach the deep aspect of the IM volume. The distance traveled will determine the appropriate electron energy. This is another reason to individually plan these patients using CT-based planning. &nbsp;",
"   </p>",
"   <p>",
"    Another approach to treat the IM nodes post-mastectomy is the \"reverse hockey stick\" technique, in which anterior or anterior-posterior opposed photon beams are used to treat the lateral chest wall, axilla, and supraclavicular area. An anterior electron beam is then used to treat the majority of the chest wall, with a depth chosen to match the depth of the IM nodes [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/49\">",
"     49",
"    </a>",
"    ]. A similar technique was used by the Danish Cooperative Breast Group in a randomized trial that showed a survival advantage for postmastectomy chest wall RT [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/50\">",
"     50",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link&amp;anchor=H14#H14\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Modern clinical trials'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Another approach is the use of partially wide tangent fields. With this technique, the tangents are brought slightly across the midline to include the internal mammary nodes and then blocked back to treatment of the chest wall only just below the level of the third internal mammary node. By blocking the field back to standard tangents at this level, the amount of lung in the treatment field can be decreased compared to deep tangents discussed below.",
"   </p>",
"   <p>",
"    Two particular methods should be discouraged. The use of \"deep tangents\", which are tangents that are brought across the midline to include the IM nodes inside the high dose volume, has been abandoned because it includes a prohibitive volume of lung in the field [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/51\">",
"     51",
"    </a>",
"    ]. The second method is an en face photon IM field that is matched to shallow tangents whose medial entrance point is the lateral border of the IM field [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/51\">",
"     51",
"    </a>",
"    ]. At the junction of the medial tangent and the anterior IM field, a \"cold triangle\" of tissue cannot be avoided; this is especially significant with an intact breast. These photon fields also deliver a substantial dose to the heart, predisposing the patient to later cardiac events [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/52\">",
"     52",
"    </a>",
"    ]. These techniques are of historical importance only and should not be used in the delivery of modern radiotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=see_link\">",
"     \"Cardiotoxicity of radiation therapy for malignancy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Axilla and supraclavicular fossa",
"    </span>",
"    &nbsp;&mdash;&nbsp;With virtually every treatment technique, the axilla and supraclavicular fossa are treated with an anterior photon field. When treatment is limited to the supraclavicular fossa and axillary apex, the field is typically 7 to 8 cm wide. We angle this field 10&ordm; laterally so that divergence does not enter the cervical spine in case this region requires later palliative treatment for metastatic disease. When the full axilla requires treatment, the field is extended laterally to include a part of the humeral head, and a posterior axillary boost is added to compensate for the underdosing of the deeper tissues in the axilla by the anterior fields.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Newer RT planning and delivery techniques",
"    </span>",
"    &nbsp;&mdash;&nbsp;Conformal and intensity modulated radiation therapy (IMRT) techniques are evolving as a means of improving the planning and delivery of RT. In contrast to standard RT delivery, which uses fixed fields that are shaped using individualized lead alloy blocks, conformal and intensity modulated therapy permits the delivery of a high-dose volume that conforms in three dimensions to the shape of the defined target, while minimizing the dose to normal tissue [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    IMRT uses a computer-defined variable intensity pattern to modulate the intensity of the delivered beam over the treated field so that a uniform and standardized dose is delivered over the entire breast. The technical aspects of intensity-modulated radiation therapy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32630?source=see_link\">",
"     \"Intensity-modulated radiation therapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Early data using IMRT delivery to the breast",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    chest wall in patients with breast cancer suggest that dose distribution is more homogeneous [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. This has translated into clinical benefit, as evidenced by the following results:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The short-term benefits of IMRT were addressed in another trial in which 358 patients with early breast cancer and three or fewer involved axillary nodes who were referred for breast-only RT were randomly assigned to 50 Gy in 25 fractions using either &ldquo;standard&rdquo; 2D RT with wedge compensation or IMRT [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/56\">",
"       56",
"      </a>",
"      ]. All patients underwent CT simulation for RT treatment planning and could receive an additional 16 Gy boost to the tumor bed at the discretion of the individual radiation oncologist.",
"      <br/>",
"      <br/>",
"      The better dose distribution achieved by IMRT translated into a significantly lower proportion of patients experiencing acute skin toxicity (moist desquamation) during or up to six weeks after RT (31 versus 48 percent). However, the rates of moist desquamation seen with conventional RT in this trial were higher than those reported by others. The use of IMRT was not associated with significant differences in pain or quality of life (QOL) endpoints in all patients, but there was a significant correlation between the presence of moist desquamation and pain as well as reduced QOL.",
"     </li>",
"     <li>",
"      A second randomized trial conducted in Europe demonstrated a significant improvement in cosmesis in patients undergoing IMRT as compared to two-dimensional standard treatment planning for breast cancer [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/57\">",
"       57",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    While these results seem encouraging, and utilization of IMRT is increasing, at least in the United States [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39657/abstract/58\">",
"     58",
"    </a>",
"    ], the impact of computer-controlled treatment delivery on oncologic outcomes, long-term toxicity, and cost must be addressed before IMRT can be routinely recommended over more contemporary non-IMRT techniques.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6921914\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radiation therapy (RT) has evolved into a critical component of treatment for women with breast cancer who have an intact breast following breast conserving surgery, and for women who have undergone mastectomy and who are at moderate to high risk for local failure. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=see_link&amp;anchor=H11#H11\">",
"     \"Postmastectomy chest wall irradiation\", section on 'Postmastectomy irradiation'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link&amp;anchor=H8489445#H8489445\">",
"     \"Role of radiation therapy in breast conservation therapy\", section on 'Benefits'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Three anatomic regions must be considered in defining the target volume; the breast or chest wall, the internal mammary (IM) lymph node region, and the supraclavicular fossa and axilla. Depending upon the clinical situation, one, two, or all three areas will require treatment in an individual patient. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'The planning target volume'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      A variety of simulation and set-up techniques are available for treating both the intact breast and the chest wall. Many institutions are using virtual simulation using modern CT technology for their breast treatment set-up. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Treatment techniques'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For women with an intact breast, modern treatment generally consists of 45 to 50 Gy in 4.5 to five weeks using daily 1.8 to 2.0 Gy fractions. However, hypofractionated radiotherapy (42.5 Gy in 16 fractions, the Canadian protocol) is an acceptable alternative in selected patients with node-negative disease. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Dose and fractionation'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H759493\">",
"       'Shorter fractionation schedules'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Most treatment centers deliver a boost to the tumor bed in the intact breast after delivering whole breast RT. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'RT boost'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Whole breast radiation is the preferred choice for most women. It is unclear which patients are at sufficiently low risk for local recurrence so that the advantages of accelerated partial breast irradiation (APBI, short treatment duration, decreased cost, reduced toxicity) outweigh the possibility of an increased risk of local recurrence. (See",
"      <a class=\"local\" href=\"#H759835\">",
"       'Accelerated partial breast irradiation'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      The risks and benefits of regional nodal irradiation should be discussed with all patients with node-positive breast cancer who are undergoing BCT. For women who are willing to sacrifice a modestly higher rate of radiation-related side effects for improved oncologic outcomes, we suggest the addition of regional nodal irradiation to whole breast RT. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'The IM nodes'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=see_link&amp;anchor=H730200#H730200\">",
"       \"Role of radiation therapy in breast conservation therapy\", section on 'Benefits of regional nodal irradiation'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Following mastectomy, the anterior chest wall can be treated with tangential photon fields, similar to the intact breast. The supraclavicular fossa and axillary apex should be treated with a direct photon field. &nbsp;",
"     </li>",
"     <li>",
"      Despite the lack of data from randomized trials to support this practice, we include the IM nodes within the first three interspaces in the treated field in women with positive axillary nodes undergoing postmastectomy RT, or RT after breast conserving therapy if treatment can be delivered without irradiating the heart and without significantly increased incremental pulmonary morbidity. If the IM nodes are to be treated, the amount of lung dose must be carefully calculated to avoid radiation pneumonitis. We do not include nodal volumes (including the IM nodes) in the radiation treatment volume in patients with axillary-node-negative disease. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'The chest wall'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/1\">",
"      Fletcher GH. Local results of irradiation in the primary management of localized breast cancer. Cancer 1972; 29:545.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/2\">",
"      Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005; 366:2087.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/3\">",
"      Fletcher GH, Montague ED. Does adequate irradiation of the internal mammary chain and supraclavicular nodes improve survival rates? Int J Radiat Oncol Biol Phys 1978; 4:481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/4\">",
"      Marks LB, Hebert ME, Bentel G, et al. To treat or not to treat the internal mammary nodes: a possible compromise. Int J Radiat Oncol Biol Phys 1994; 29:903.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/5\">",
"      Lacour J, Le M, Caceres E, et al. Radical mastectomy versus radical mastectomy plus internal mammary dissection. Ten year results of an international cooperative trial in breast cancer. Cancer 1983; 51:1941.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/6\">",
"      Pierce LJ, Lichter AS. Defining the role of post-mastectomy radiotherapy: the new evidence. Oncology (Williston Park) 1996; 10:991.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/7\">",
"      Lohrisch C, Jackson J, Jones A, et al. Relationship between tumor location and relapse in 6,781 women with early invasive breast cancer. J Clin Oncol 2000; 18:2828.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/8\">",
"      Gaffney DK, Tsodikov A, Wiggins CL. Diminished survival in patients with inner versus outer quadrant breast cancers. J Clin Oncol 2003; 21:467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/9\">",
"      Zucali R, Mariani L, Marubini E, et al. Early breast cancer: evaluation of the prognostic role of the site of the primary tumor. J Clin Oncol 1998; 16:1363.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/10\">",
"      Stemmer SM, Rizel S, Hardan I, et al. The role of irradiation of the internal mammary lymph nodes in high-risk stage II to IIIA breast cancer patients after high-dose chemotherapy: a prospective sequential nonrandomized study. J Clin Oncol 2003; 21:2713.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/11\">",
"      Katz A, Strom EA, Buchholz TA, et al. Locoregional recurrence patterns after mastectomy and doxorubicin-based chemotherapy: implications for postoperative irradiation. J Clin Oncol 2000; 18:2817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/12\">",
"      Halverson KJ, Perez CA, Kuske RR, et al. Isolated local-regional recurrence of breast cancer following mastectomy: radiotherapeutic management. Int J Radiat Oncol Biol Phys 1990; 19:851.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/13\">",
"      Schwaibold F, Fowble BL, Solin LJ, et al. The results of radiation therapy for isolated local regional recurrence after mastectomy. Int J Radiat Oncol Biol Phys 1991; 21:299.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/14\">",
"      Obedian E, Haffty BG. Internal mammary nodal irradiation in conservatively-managed breast cancer patients: is there a benefit? Int J Radiat Oncol Biol Phys 1999; 44:997.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/15\">",
"      Fowble B, Hanlon A, Freedman G, et al. Internal mammary node irradiation neither decreases distant metastases nor improves survival in stage I and II breast cancer. Int J Radiat Oncol Biol Phys 2000; 47:883.",
"     </a>",
"    </li>",
"    <li>",
"     Whelan TJ, Olivotto I, Ackerman I, et al. NCIC-CTG MA.20: An intergroup trial of regional nodal irradiation in early breast cancer (abstract LBA1003). J Clin Oncol 2011; 29:779s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=102&amp;abstractID=79126 (Accessed on June 21, 2011).",
"    </li>",
"    <li>",
"     Information on EORTC 22922 (NCT00002851) available online at file://clinicaltrials.gov/ct2/show/NCT00002851?term=EORTC+22922&amp;rank=1 (Accessed on June 23, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/18\">",
"      Butker EK, Helton DJ, Keller JW, et al. A totally integrated simulation technique for three-field breast treatment using a CT simulator. Med Phys 1996; 23:1809.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/19\">",
"      Bentel GC, Marks LB. A simple device to position large/flaccid breasts during tangential breast irradiation. Int J Radiat Oncol Biol Phys 1994; 29:879.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/20\">",
"      Formenti SC, Truong MT, Goldberg JD, et al. Prone accelerated partial breast irradiation after breast-conserving surgery: preliminary clinical results and dose-volume histogram analysis. Int J Radiat Oncol Biol Phys 2004; 60:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/21\">",
"      Bieri S, Russo M, Rouzaud M, Kurtz JM. Influence of modifications in breast irradiation technique on dose outside the treatment volume. Int J Radiat Oncol Biol Phys 1997; 38:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/22\">",
"      Fraass BA, Roberson PL, Lichter AS. Dose to the contralateral breast due to primary breast irradiation. Int J Radiat Oncol Biol Phys 1985; 11:485.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/23\">",
"      Kelly CA, Wang XY, Chu JC, Hartsell WF. Dose to contralateral breast: a comparison of four primary breast irradiation techniques. Int J Radiat Oncol Biol Phys 1996; 34:727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/24\">",
"      Bornstein BA, Cheng CW, Rhodes LM, et al. Can simulation measurements be used to predict the irradiated lung volume in the tangential fields in patients treated for breast cancer? Int J Radiat Oncol Biol Phys 1990; 18:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/25\">",
"      Neal AJ, Yarnold JR. Estimating the volume of lung irradiated during tangential breast irradiation using the central lung distance. Br J Radiol 1995; 68:1004.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/26\">",
"      Hartsell WF, Murthy AK, Kiel KD, et al. Technique for breast irradiation using custom blocks conforming to the chest wall contour. Int J Radiat Oncol Biol Phys 1990; 19:189.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/27\">",
"      Whelan TJ, Pignol JP, Levine MN, et al. Long-term results of hypofractionated radiation therapy for breast cancer. N Engl J Med 2010; 362:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/28\">",
"      Harris JR. Notes on the Ontario trial in the context of breast-conserving therapy for early-stage breast cancer. J Clin Oncol 2000; 18:43S.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/29\">",
"      Powell S, Cooke J, Parsons C. Radiation-induced brachial plexus injury: follow-up of two different fractionation schedules. Radiother Oncol 1990; 18:213.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/30\">",
"      Fisher B, Anderson S, Redmond CK, et al. Reanalysis and results after 12 years of follow-up in a randomized clinical trial comparing total mastectomy with lumpectomy with or without irradiation in the treatment of breast cancer. N Engl J Med 1995; 333:1456.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/31\">",
"      Romestaing P, Lehingue Y, Carrie C, et al. Role of a 10-Gy boost in the conservative treatment of early breast cancer: results of a randomized clinical trial in Lyon, France. J Clin Oncol 1997; 15:963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/32\">",
"      Bartelink H, Horiot JC, Poortmans P, et al. Recurrence rates after treatment of breast cancer with standard radiotherapy with or without additional radiation. N Engl J Med 2001; 345:1378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/33\">",
"      Vrieling C, Collette L, Fourquet A, et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC 'boost vs. no boost' trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol 2000; 55:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/34\">",
"      Bartelink H, Horiot JC, Poortmans PM, et al. Impact of a higher radiation dose on local control and survival in breast-conserving therapy of early breast cancer: 10-year results of the randomized boost versus no boost EORTC 22881-10882 trial. J Clin Oncol 2007; 25:3259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/35\">",
"      Pierce LJ, Moughan J, White J, et al. 1998-1999 patterns of care study process survey of national practice patterns using breast-conserving surgery and radiotherapy in the management of stage I-II breast cancer. Int J Radiat Oncol Biol Phys 2005; 62:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/36\">",
"      Ceilley E, Jagsi R, Goldberg S, et al. Radiotherapy for invasive breast cancer in North America and Europe: results of a survey. Int J Radiat Oncol Biol Phys 2005; 61:365.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network guidelines available online at www.nccn.org (Accessed on September 01, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/38\">",
"      Frazier RC, Kestin LL, Kini V, et al. Impact of boost technique on outcome in early-stage breast cancer patients treated with breast-conserving therapy. Am J Clin Oncol 2001; 24:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/39\">",
"      Hunter MA, McFall TA, Hehr KA. Breast-conserving surgery for primary breast cancer: necessity for surgical clips to define the tumor bed for radiation planning. Radiology 1996; 200:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/40\">",
"      Harrington KJ, Harrison M, Bayle P, et al. Surgical clips in planning the electron boost in breast cancer: a qualitative and quantitative evaluation. Int J Radiat Oncol Biol Phys 1996; 34:579.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/41\">",
"      DeBiose DA, Horwitz EM, Martinez AA, et al. The use of ultrasonography in the localization of the lumpectomy cavity for interstitial brachytherapy of the breast. Int J Radiat Oncol Biol Phys 1997; 38:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/42\">",
"      Messer PM, Kirikuta IC, Bratengeier K, Flentje M. CT planning of boost irradiation in radiotherapy of breast cancer after conservative surgery. Radiother Oncol 1997; 42:239.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/43\">",
"      Gaffney DK, Leavitt DD, Tsodikov A, et al. Electron arc irradiation of the postmastectomy chest wall with CT treatment planning: 20-year experience. Int J Radiat Oncol Biol Phys 2001; 51:994.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/44\">",
"      Feigenberg SJ, Price Mendenhall N, Benda RK, Morris CG. Postmastectomy radiotherapy: patterns of recurrence and long-term disease control using electrons. Int J Radiat Oncol Biol Phys 2003; 56:716.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/45\">",
"      Spierer MM, Hong LX, Wagman RT, et al. Postmastectomy CT-based electron beam radiotherapy: dosimetry, efficacy, and toxicity in 118 patients. Int J Radiat Oncol Biol Phys 2004; 60:1182.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/46\">",
"      Recht A, Houlihan MJ. Axillary lymph nodes and breast cancer: a review. Cancer 1995; 76:1491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/47\">",
"      Pierce LJ, Oberman HA, Strawderman MH, Lichter AS. Microscopic extracapsular extension in the axilla: is this an indication for axillary radiotherapy? Int J Radiat Oncol Biol Phys 1995; 33:253.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/48\">",
"      Leonard C, Corkill M, Tompkin J, et al. Are axillary recurrence and overall survival affected by axillary extranodal tumor extension in breast cancer? Implications for radiation therapy. J Clin Oncol 1995; 13:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/49\">",
"      Steeves RA, Thomadsen BR, Hansen H, et al. A practical alternative to conventional five-field irradiation postmastectomy for locally advanced breast cancer. Med Dosim 1994; 19:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/50\">",
"      Overgaard M, Christensen JJ, Johansen H, et al. Postmastectomy irradiation in high-risk breast cancer patients. Present status of the Danish Breast Cancer Cooperative Group trials. Acta Oncol 1988; 27:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/51\">",
"      Lichter AS, Fraass BA, Yanke B. Treatment Techniques in the Conservative Management of Breast Cancer. Semin Radiat Oncol 1992; 2:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/52\">",
"      Cuzick J, Stewart H, Rutqvist L, et al. Cause-specific mortality in long-term survivors of breast cancer who participated in trials of radiotherapy. J Clin Oncol 1994; 12:447.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/53\">",
"      Pierce LJ, Butler JB, Martel MK, et al. Postmastectomy radiotherapy of the chest wall: dosimetric comparison of common techniques. Int J Radiat Oncol Biol Phys 2002; 52:1220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/54\">",
"      Vicini FA, Sharpe M, Kestin L, et al. Optimizing breast cancer treatment efficacy with intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2002; 54:1336.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/55\">",
"      Hong L, Hunt M, Chui C, et al. Intensity-modulated tangential beam irradiation of the intact breast. Int J Radiat Oncol Biol Phys 1999; 44:1155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/56\">",
"      Pignol JP, Olivotto I, Rakovitch E, et al. A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis. J Clin Oncol 2008; 26:2085.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/57\">",
"      Donovan E, Bleakley N, Denholm E, et al. Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy. Radiother Oncol 2007; 82:254.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39657/abstract/58\">",
"      Smith BD, Pan IW, Shih YC, et al. Adoption of intensity-modulated radiation therapy for breast cancer in the United States. J Natl Cancer Inst 2011; 103:798.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 789 Version 18.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-3384FBAA07-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39657=[""].join("\n");
var outline_f38_46_39657=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H6921914\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H612454\">",
"      TYPE OF RT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      Breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Postmastectomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      THE PLANNING TARGET VOLUME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      The intact breast or chest wall",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      The IM nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Axilla and supraclavicular fossa",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      SIMULATION TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      The intact breast",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Large breast size",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Chest wall",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      TREATMENT TECHNIQUES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      The intact breast",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      - Dose and fractionation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H759493\">",
"      Shorter fractionation schedules",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H759835\">",
"      - Accelerated partial breast irradiation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      - RT boost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      The chest wall",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      - RT boost",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      The IM nodes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Axilla and supraclavicular fossa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Newer RT planning and delivery techniques",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6921914\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/789\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/789|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?39/39/40563\" title=\"figure 1\">",
"      Schematic of the breast and regional lymph nodes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/27/12728?source=related_link\">",
"      Accelerated partial breast irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?33/21/34137?source=related_link\">",
"      Cardiotoxicity of radiation therapy for malignancy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?29/41/30359?source=related_link\">",
"      Complications of breast and chest wall irradiation for early stage breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?37/34/38437?source=related_link\">",
"      Complications of peripheral nerve irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?31/55/32630?source=related_link\">",
"      Intensity-modulated radiation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/52/42825?source=related_link\">",
"      Management of the regional lymph nodes in breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/3/41017?source=related_link\">",
"      Postmastectomy chest wall irradiation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?41/55/42873?source=related_link\">",
"      Radiation techniques for locally advanced breast cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/7/11385?source=related_link\">",
"      Role of radiation therapy in breast conservation therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/47/36602?source=related_link\">",
"      Sentinel lymph node dissection for breast cancer: Indications and outcomes",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_46_39658="Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion";
var content_f38_46_39658=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Metastatic gastroenteropancreatic neuroendocrine tumors: Systemic therapy options to control tumor growth and symptoms of hormone hypersecretion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/46/39658/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/46/39658/contributors\">",
"     Jennifer Ang Chan, MD, MPH",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/46/39658/contributors\">",
"     Matthew Kulke, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/46/39658/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/46/39658/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"mobipreview.htm?38/46/39658/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"mobipreview.htm?38/46/39658/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"mobipreview.htm?38/46/39658/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 5, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H190948900\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroendocrine cells are distributed widely throughout the body, and neoplasms of these dispersed cells, which are termed neuroendocrine tumors (NETs), can arise at many sites.",
"   </p>",
"   <p>",
"    Systemic treatment options to control tumor growth and symptoms related to hormone hypersecretion for patients with advanced or metastatic NETs arising in the gastrointestinal tract and pancreas (gastroenteropancreatic NETs) are discussed in this topic review. Local management options for well-differentiated metastatic gastroenteropancreatic NETs are discussed elsewhere, as are the clinical presentation, imaging, and biochemical monitoring; pathology and classification of gastroenteropancreatic NETs; clinical features of primary carcinoid tumors; diagnosis of carcinoid syndrome and tumor localization; the treatment of early stage carcinoids; bronchial carcinoids; localization and treatment of pancreatic islet cell tumors; evaluation and management of neuroendocrine tumors of unknown primary site; and management of symptoms of the carcinoid syndrome; carcinoid heart disease; and functioning pancreatic islet cell tumors.",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=see_link\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=see_link\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=see_link\">",
"       \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=see_link\">",
"       \"Clinical characteristics of carcinoid tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=see_link\">",
"       \"Diagnosis of the carcinoid syndrome and tumor localization\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4153?source=see_link\">",
"       \"Bronchial carcinoid tumors: Treatment and prognosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39897?source=see_link\">",
"       \"Treatment and surveillance of non-metastatic carcinoid tumors\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16888?source=see_link\">",
"       \"Treatment of the carcinoid syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12472?source=see_link\">",
"       \"Carcinoid heart disease\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18330?source=see_link\">",
"       \"Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41174?source=see_link\">",
"       \"Neuroendocrine cancer of unknown primary site\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=see_link\">",
"       \"Insulinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31640?source=see_link\">",
"       \"Glucagonoma and the glucagonoma syndrome\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3623?source=see_link\">",
"       \"Somatostatinoma\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16311?source=see_link\">",
"       \"The VIPoma syndrome\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1973644\">",
"    <span class=\"h1\">",
"     CLASSIFICATION, BIOLOGIC BEHAVIOR, AND IMPLICATIONS FOR TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neuroendocrine tumors (NETs) arising at different sites within the body are classified according to their histologic features. While there are differences in terminology and grading for tumors arising at different sites, all commonly used classification systems reflect a basic separation between more indolent, well-differentiated tumors (which in the digestive system have been traditionally referred to as carcinoids and pancreatic neuroendocrine [islet cell] tumors) and far more aggressive poorly-differentiated types that behave clinically more like small cell carcinoma of the lung. The World Health Organization (WHO) classifies well-differentiated gastroenteropancreatic NETs into low-grade (G1) and intermediate grade (G2) categories based upon proliferative rate (",
"    <a class=\"graphic graphic_table graphicRef60365 \" href=\"mobipreview.htm?17/14/17644\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/1\">",
"     1",
"    </a>",
"    ]. All poorly-differentiated neuroendocrine tumors are high-grade (G3) neuroendocrine carcinomas. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=see_link&amp;anchor=H2474956#H2474956\">",
"     \"Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system\", section on '2010 WHO classification'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Poorly differentiated NETs are associated with a rapid clinical course and are treated with platinum-based chemotherapy regimens according to small cell lung carcinoma guidelines. (See",
"    <a class=\"local\" href=\"#H190949019\">",
"     'Poorly differentiated tumors'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=see_link\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    As a group, well-differentiated gastroenteropancreatic NETs are generally indolent malignancies, with a prolonged natural history. However, clinical behavior is heterogeneous, as evidenced by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Among patients with low-or intermediate-grade histology and distant disease, survival is highly variable. As an example, among patients with advanced carcinoid, survival varies according to primary site, and is worst for patients with lung and colon primaries (median survival 17 and 7 months, respectively) and most favorable for tumors arising in the jejunum, ileum, and cecum (median survival 55 to 65 months). This heterogeneity in clinical behavior complicates the comparative assessment of benefit from individual therapies.",
"     </li>",
"     <li>",
"      Carcinoid tumors arising in the tubular gastrointestinal (GI) tract and pancreatic NETs may have similar characteristics on routine histologic evaluation, but they have a different pathogenesis and biology [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/2\">",
"       2",
"      </a>",
"      ]. Pancreatic NETs have a worse prognosis than do GI tract carcinoid tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/3\">",
"       3",
"      </a>",
"      ] and respond differently to anticancer agents, with most agents demonstrating higher response rates among patients with pancreatic NET tumors than in those with carcinoid. (See",
"      <a class=\"local\" href=\"#H190948956\">",
"       'Cytotoxic chemotherapy'",
"      </a>",
"      below.)",
"      <br/>",
"      <br/>",
"      Intermediate-grade gastroenteropancreatic NETs have a slightly worse prognosis than do low-grade tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/4\">",
"       4",
"      </a>",
"      ]. Although they are treated similarly at present, as new treatment modalities become available, it is likely that the histologic grade of a well-differentiated NET will affect the selection of appropriate treatment.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1974073\">",
"    <span class=\"h2\">",
"     Overview of treatment options",
"    </span>",
"    &nbsp;&mdash;&nbsp;The majority of patients with advanced gastroenteropancreatic NETs have liver metastases. For patients who have potentially resectable disease, resection may provide prolonged control of symptoms and tumor growth. However, the majority of patients recur, even if resection is complete. For patients with unresectable disease, options to control symptoms include somatostatin analogs, nonsurgical liver-directed therapy, and systemic antitumor therapy.",
"   </p>",
"   <p>",
"    The following sections will discuss systemic treatment options to control symptoms and tumor growth. Local treatment options are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=see_link\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190948921\">",
"    <span class=\"h1\">",
"     SOMATOSTATIN ANALOGS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with metastases from a gastroenteropancreatic NET often become symptomatic from hormone hypersecretion rather than from tumor bulk. This is especially true with functioning pancreatic NETs (which account for 10 to 30 percent of tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/5\">",
"     5",
"    </a>",
"    ]) and for patients with midgut (small bowel or appendiceal) carcinoids in whom symptoms are typically absent until hepatic metastases supervene. In such cases, vasoactive substances such as serotonin enter the systemic circulation, causing the carcinoid syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=see_link\">",
"     \"Clinical features of the carcinoid syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    For patients who have",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    -avid disease, symptoms of hormonal excess resulting from hypersecretion by functioning pancreatic NETs and carcinoids can often be well controlled with somatostatin analogs. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=see_link&amp;anchor=H5#H5\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Somatostatin receptor scintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190948928\">",
"    <span class=\"h2\">",
"     Octreotide and other somatostatin analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Somatostatin is a 14-amino acid peptide that inhibits the secretion of a broad range of hormones. It acts by binding to somatostatin receptors, which are expressed on the majority of NETs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/6\">",
"     6",
"    </a>",
"    ]. The presence of somatostatin receptors can be determined using a radiolabeled form of the somatostatin analog",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    &nbsp;(indium-111 [111-In] pentetreotide, OctreoScan). We do a scan in most patients, but in some cases (ie, miliary disease), we give a trial of somatostatin analog therapy even in the presence of a negative scan. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=see_link&amp;anchor=H5#H5\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Somatostatin receptor scintigraphy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Somatostatin analogs such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    are highly effective in controlling the symptoms associated with carcinoid tumors, VIPomas and glucagonomas (",
"    <a class=\"graphic graphic_table graphicRef78817 \" href=\"mobipreview.htm?34/9/34973\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16888?source=see_link&amp;anchor=H624742796#H624742796\">",
"     \"Treatment of the carcinoid syndrome\", section on 'Somatostatin-analog therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16311?source=see_link\">",
"     \"The VIPoma syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31640?source=see_link\">",
"     \"Glucagonoma and the glucagonoma syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Efficacy is less predictable for symptomatic insulinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/7-11\">",
"     7-11",
"    </a>",
"    ]. Initial therapy for insulinomas often consists of carbohydrates and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?13/38/13924?source=see_link\">",
"     diazoxide",
"    </a>",
"    , which directly inhibits the release of insulin from insulinoma cells. Among patients with insulinoma, somatostatin analogs should be initiated with caution, as they may result in transient worsening of hypoglycemia. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=see_link&amp;anchor=H25#H25\">",
"     \"Insulinoma\", section on 'Medical therapy to control symptomatic hypoglycemia'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Symptomatic patients are generally initiated on short-acting",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    with rapid transition to a long acting formulation and subsequent titration of dose to optimize symptom control. A depot preparation (Sandostatin LAR&reg;) has largely eliminated the need for daily octreotide injections and is now considered a standard approach for symptomatic treatment of advanced NETs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/12,13\">",
"     12,13",
"    </a>",
"    ]. Sandostatin LAR is typically initiated at a dose of 20 mg IM monthly after a brief trial of the short-acting formulation, with gradual dose escalation as needed for optimal symptom control [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/14\">",
"     14",
"    </a>",
"    ]. Patients may use additional short-acting octreotide for breakthrough symptoms; therapeutic levels of octreotide are not reached until 10 to 14 days after the initiation of the LAR injection.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/34/7717?source=see_link\">",
"     Lanreotide",
"    </a>",
"    , another long-acting somatostatin analog, can be self-administered once monthly using a deep subcutaneous injection. Lanreotide is available internationally for the treatment of carcinoid syndrome and in the US for the treatment of acromegaly. It appears to have similar clinical efficacy as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    in the treatment of carcinoid syndrome. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16888?source=see_link&amp;anchor=H624742796#H624742796\">",
"     \"Treatment of the carcinoid syndrome\", section on 'Somatostatin-analog therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    is usually well tolerated, and side effects are generally mild [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. About one-third of patients may have mild nausea, abdominal discomfort, bloating, loose stools, and fat malabsorption during the first weeks of therapy, after which time, symptoms tend to subside. Use of pancreatic enzyme supplements can ameliorate symptoms associated with pancreatic insufficiency. Mild glucose intolerance may occur due to transient inhibition of insulin secretion. Octreotide reduces postprandial gallbladder contractility and delays gallbladder emptying; up to 25 percent of patients develop asymptomatic gallstones or sludge within the first 18 months of therapy [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190948935\">",
"    <span class=\"h3\">",
"     Use in asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;Past studies have indicated that few patients with advanced carcinoid (&lt;10 percent) have objective tumor shrinkage with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/7,8,13,17-19\">",
"     7,8,13,17-19",
"    </a>",
"    ]. However, more recent reports suggest that, in addition to an improvement in symptoms, treatment with octreotide may be associated with disease stabilization in patients with small bowel carcinoid tumors. In the PROMID trial, 85 patients with locally inoperable or metastatic small bowel carcinoid tumors were randomly assigned to receive treatment with either octreotide or placebo [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/18\">",
"     18",
"    </a>",
"    ]. The median time to tumor progression was significantly longer with octreotide compared to placebo (14.3 versus 6 months), confirming an antitumor effect in this population.",
"   </p>",
"   <p>",
"    Given the variable and sometimes indolent disease course of some carcinoid patients, the optimal time to initiate treatment with a somatostatin analog in asymptomatic patients remains uncertain. Additionally, an antitumor effect in other carcinoid tumor subtypes or in pancreatic NETs has not been clearly established. Ongoing randomized trials are evaluating whether somatostatin analogs improve progression-free survival duration in patients with non-functioning carcinoid tumors or pancreatic NETs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190948942\">",
"    <span class=\"h2\">",
"     Prevention and management of carcinoid crisis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carcinoid crisis is a life-threatening form of carcinoid syndrome that may be triggered by tumor manipulation (biopsy, palpation at the bedside or during surgery) or by anesthesia. It is less commonly reported after chemotherapy, hepatic arterial embolization, or radionuclide therapy, mostly in patients with extensive tumor bulk.",
"   </p>",
"   <p>",
"    Carcinoid crisis results from the release of an overwhelming amount of biologically active compounds from the tumor (",
"    <a class=\"graphic graphic_table graphicRef79329 \" href=\"mobipreview.htm?34/59/35771\">",
"     table 3",
"    </a>",
"    ). In addition to hemodynamic instability, symptoms include flushing, diarrhea, tachycardia, arrhythmias, bronchospasm, and altered mental status.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     Octreotide",
"    </a>",
"    should be readily available during any surgical procedure. Preoperative administration of octreotide (300 micrograms subcutaneously) can reduce the incidence of carcinoid crisis, and is recommended for patients with a history of carcinoid syndrome who require surgical procedures. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=see_link&amp;anchor=H691406#H691406\">",
"     \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Resection'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Treatment for carcinoid crisis differs from that for other causes of acute intraoperative hypotension. Symptoms are generally refractory to fluid resuscitation alone. Calcium and catecholamines may provoke release of mediators from the tumor and worsen, rather than ameliorate, the syndrome. During a carcinoid crisis, the blood pressure should be supported by infusion of plasma and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (300 micrograms IV) given immediately. A continuous IV drip of octreotide may be needed. In patients with high risk of carcinoid crisis, an IV octreotide drip may be initiated preoperatively. The symptoms, prevention and management of carcinoid crisis are discussed in more detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16888?source=see_link&amp;anchor=H624742810#H624742810\">",
"     \"Treatment of the carcinoid syndrome\", section on 'Prevention and management of carcinoid crisis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190948949\">",
"    <span class=\"h1\">",
"     INTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;Interferon alpha (IFNa) has been used as a treatment for advanced carcinoid for several decades. The ability of IFNa to stimulate T-cell function and to control the secretion of tumor products led to its initial use in patients with the carcinoid syndrome [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/20\">",
"     20",
"    </a>",
"    ]. Interferons can exert antitumor effects via stimulation of T cells, induction of cell cycle arrest, and inhibition of angiogenesis [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In large retrospective series, low-dose IFNa alone reduces symptoms of hormonal hypersecretion in 40 to 50 percent of patients with carcinoid or pancreatic NETs, and induces tumor stabilization in 20 to 40 percent. Tumor regression is less common, though has been reported in up to 15 percent of patients in some studies (",
"    <a class=\"graphic graphic_table graphicRef78817 \" href=\"mobipreview.htm?34/9/34973\">",
"     table 2",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/20,22-30\">",
"     20,22-30",
"    </a>",
"    ]. In clinical trials, IFNa doses range from 3 to 9 mu (million units) subcutaneously, administered from three to seven times per week. IFNa is somewhat myelosuppressive, and the dose is often titrated in individual patients to achieve a total leukocyte count of",
"    <span class=\"nowrap\">",
"     3000/microL.",
"    </span>",
"   </p>",
"   <p>",
"    Relatively few studies have evaluated interferon prospectively, either alone or in combination with somatostatin analogs, and the results are conflicting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one prospective trial of 68 patients with liver metastases who were randomized to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      (100 micrograms twice daily, increased to 200 micrograms three times daily for persistent carcinoid symptoms) with or without IFNa, both treatments were equally effective at reducing urinary 5-HIAA levels [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/31\">",
"       31",
"      </a>",
"      ]. Patients receiving combined therapy had a significantly reduced risk of tumor progression when compared to patients receiving octreotide alone, suggesting that the addition of IFN had a significant antitumor effect.",
"     </li>",
"     <li>",
"      Other studies, however, have failed to demonstrate significant effects of interferon on tumor progression. The comparable efficacy of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?7/34/7717?source=see_link\">",
"       lanreotide",
"      </a>",
"      , IFNa, or combined therapy was evaluated in a prospective randomized trial involving 80 therapy-naive patients with documented progressive metastatic NETs [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/22\">",
"       22",
"      </a>",
"      ]. Objective partial response rates were comparably low in all three groups (4, 4, and 7 percent for lanreotide, IFN, and combined therapy, respectively), and the number of patients who achieved disease stabilization was not substantially higher with combined therapy (28, 26, and 18 percent for lanreotide, IFN, and the combination, respectively). Similar findings were noted in a trial in which 109 patients with progressive metastatic gastrointestinal NETs were randomly assigned to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      with or without IFNa [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/32\">",
"       32",
"      </a>",
"      ]. At 3, 6, and 12 months, rates of objective partial response were low (3, 2, and 6 percent respectively) and similar with octreotide alone or plus IFNa. There were also no significant differences between the two groups in the rates of stable disease at the three time points, time to treatment failure, or long-term survival.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These studies, however, were likely underpowered to detect significant differences between the arms. The combination of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    plus either IFNa or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    is under study in a large randomized study performed by SWOG and the North American Intergroup (NCT00569127) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The more widespread acceptance of IFNa for the treatment of metastatic NETs has been limited by the potential for side effects, which may include fatigue, depression, myelosuppression, and alteration of thyroid function [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/34\">",
"     34",
"    </a>",
"    ]. Currently IFNa is considered primarily in patients with advanced carcinoid who have worsening symptoms or evidence of disease progression while on treatment with somatostatin analogs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190948956\">",
"    <span class=\"h1\">",
"     CYTOTOXIC CHEMOTHERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190948963\">",
"    <span class=\"h2\">",
"     Pancreatic NETs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pancreatic NETs are clearly responsive to cytotoxic chemotherapy (",
"    <a class=\"graphic graphic_table graphicRef63537 \" href=\"mobipreview.htm?6/42/6829\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190948970\">",
"    <span class=\"h3\">",
"     Streptozocin combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"     Streptozocin",
"    </a>",
"    -based combination therapy has been an historical treatment standard for patients with advanced pancreatic NET. In an early randomized trial, streptozocin plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    had a combined biochemical and radiologic response rate of 69 percent and a median survival of 2.2 years [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/35\">",
"     35",
"    </a>",
"    ]. A more recent retrospective analysis of 84 patients with either locally advanced or metastatic pancreatic NETs treated with streptozocin, 5-FU, and doxorubicin and using current standard response criteria reported a 39 percent objective radiographic response rate and a median survival duration of 37 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"     streptozocin",
"    </a>",
"    -based regimens are clearly active in patients with advanced pancreatic NET, the widespread adoption of streptozocin-based regimens has been limited by a relatively cumbersome administration schedule and by concerns about toxicity, which can include nausea, hair loss, and renal dysfunction.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190948977\">",
"    <span class=\"h3\">",
"     Dacarbazine (DTIC) and temozolomide-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     Dacarbazine",
"    </a>",
"    is an alkylating agent (like",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"     streptozocin",
"    </a>",
"    ), with activity against pancreatic NET. In an ECOG phase II trial of dacarbazine in 42 patients with advanced pancreatic islet cell carcinomas, the objective response rate was 33 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/37\">",
"     37",
"    </a>",
"    ]. As with streptozocin, the toxicity of dacarbazine based regimens has limited their widespread use.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    is a less toxic orally active analog of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    that has activity in patients with pancreatic NETs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/38\">",
"     38",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In prospective studies,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      has been combined with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?28/62/29673?source=see_link\">",
"       thalidomide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"       bevacizumab",
"      </a>",
"      , or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      , with overall response rates of 24 to 45 percent (",
"      <a class=\"graphic graphic_table graphicRef63537 \" href=\"mobipreview.htm?6/42/6829\">",
"       table 4",
"      </a>",
"      ) [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/39,40\">",
"       39,40",
"      </a>",
"      ]. In these studies, temozolomide was generally been administered using a dose-intense regimen of 150",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily for seven days on an every other week schedule. Prophylaxis for Pneumocystis carinii pneumonia is recommended in light of lymphopenia associated with long-term use of temozolomide according to this schedule. The relative contribution of temozolomide and the agent used in combination with it to the observed antitumor activity is unclear.",
"     </li>",
"     <li>",
"      Retrospective series have also reported promising activity with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      -based regimens in patients with pancreatic NET (",
"      <a class=\"graphic graphic_table graphicRef63537 \" href=\"mobipreview.htm?6/42/6829\">",
"       table 4",
"      </a>",
"      ). The most encouraging response rates were reported in a retrospective series of 30 patients who were treated with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"       capecitabine",
"      </a>",
"      (750",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      twice daily on days 21 to 14) plus temozolomide (200",
"      <span class=\"nowrap\">",
"       mg/m",
"       <sup>",
"        2",
"       </sup>",
"      </span>",
"      daily on days 10 to 14); the response rate was 70 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    As has been noted in patients with glioblastoma, there seems to be a correlation between expression of methylguanine DNA methyltransferase (MGMT) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    responsiveness. MGMT is an enzyme that is responsible for DNA repair induced by alkylating agent chemotherapy. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14169?source=see_link&amp;anchor=H21#H21\">",
"     \"Pathogenesis and biology of malignant gliomas\", section on 'Chemotherapy responsiveness'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The dependence of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    responsiveness on deficient MGMT expression may explain the lack of benefit from this drug in some NETs and in carcinoids. In one study, the prevalence of MGMT deficiency was significantly higher in pancreatic NETs than in carcinoid tumors. Of 21 patients treated with temozolomide-based regimens, none of the 16 with MGMT expression (including all 13 carcinoid tumors) responded to treatment. In contrast, four of the five patients whose tumors lacked MGMT expression (all pancreatic NETs) had a radiologic response. Although these data are compelling, routine assay of MGMT expression to select patients for temozolomide therapy is not yet a standard approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190948984\">",
"    <span class=\"h3\">",
"     Oxaliplatin-containing regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preliminary reports suggest antitumor activity for some",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based regimens [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/42-44\">",
"     42-44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A preliminary report of a phase II trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus short-term infusional 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (FOLFOX) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in 11 patients with advanced progressive NETs noted a partial response in three of five patients with advanced pancreatic NET, and stable disease in two others [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in patients with advanced NET was suggested in a preliminary report of another phase II trial, in which 7 of 31 evaluable patients (23 percent) had a partial response; 22 others had stable disease (71 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/43\">",
"     43",
"    </a>",
"    ]. The contribution of bevacizumab to these results is unclear; similar outcomes have been shown with capecitabine plus oxaliplatin alone [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190948991\">",
"    <span class=\"h2\">",
"     Carcinoid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to pancreatic NETs, the benefit of chemotherapy for advanced carcinoid is debated, particularly for gastrointestinal primary tumors. Single-agent therapy with 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    (5-FU),",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"     streptozocin",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"     doxorubicin",
"    </a>",
"    is associated with only modest response rates in patients with metastatic carcinoid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/45\">",
"     45",
"    </a>",
"    ]. Single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    (1000",
"    <span class=\"nowrap\">",
"     mg/m",
"     <sup>",
"      2",
"     </sup>",
"    </span>",
"    twice daily for 14 days, every three weeks) was studied in a small phase II trial of 19 patients with carcinoid (12 arising in the gut, one in ovary, and six unknown) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/46\">",
"     46",
"    </a>",
"    ]. Although there were no radiologic partial or complete responses, 13 (68 percent) achieved stable disease radiographically, four for over 12 months; there were two patients with a &gt;50 percent decrease in the tumor marker chromogranin A (CGA) from baseline. Other chemotherapeutic agents such as the taxanes,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/2/32807?source=see_link\">",
"     topotecan",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?31/1/31769?source=see_link\">",
"     gemcitabine",
"    </a>",
"    are relatively inactive as single agents [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/47-50\">",
"     47-50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190948998\">",
"    <span class=\"h3\">",
"     Streptozocin combinations",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies in advanced carcinoid patients have focused on",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"     streptozocin",
"    </a>",
"    -based regimens (",
"    <a class=\"graphic graphic_table graphicRef52299 \" href=\"mobipreview.htm?31/30/32237\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An early ECOG trial randomly assigned 118 patients to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"       streptozocin",
"      </a>",
"      plus either 5-FU or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/20/9546?source=see_link\">",
"       cyclophosphamide",
"      </a>",
"      [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/51\">",
"       51",
"      </a>",
"      ]. Response rates (objective radiographic tumor regression or decreased urinary 5-HIAA) were similar (33 and 26 percent 5-FU and cyclophosphamide, respectively), as was survival. Toxicity was prominent in both regimens.",
"     </li>",
"     <li>",
"      A subsequent ECOG trial increased the dosing interval between cycles of",
"      <span class=\"nowrap\">",
"       <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"        streptozocin",
"       </a>",
"       /5-FU,",
"      </span>",
"      comparing this regimen to",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"       doxorubicin",
"      </a>",
"      alone [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/52\">",
"       52",
"      </a>",
"      ]. Although this",
"      <span class=\"nowrap\">",
"       streptozocin/5-FU",
"      </span>",
"      regimen was somewhat better tolerated than the one used in the earlier study, the response rate was similar to doxorubicin alone (22 versus 21 percent), as was survival. More recently,",
"      <span class=\"nowrap\">",
"       streptozocin/5-FU",
"      </span>",
"      was compared to",
"      <span class=\"nowrap\">",
"       doxorubicin/5-FU",
"      </span>",
"      in a randomized trial of 249 patients with advanced carcinoid [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/53\">",
"       53",
"      </a>",
"      ]. The radiographic response rate was similar with the two regimens (16 percent each), although there was a slight but statistically significant median survival benefit associated with",
"      <span class=\"nowrap\">",
"       streptozocin/5-FU",
"      </span>",
"      (24 versus 16 months). However, progression-free survival was short (4.5 months) and over one-third of the patients receiving streptozocin developed mild to moderate renal toxicity.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The relatively modest response rates of these regimens, together with the reported toxicity, have led many to question their utility in the routine treatment of patients with advanced carcinoid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/13\">",
"     13",
"    </a>",
"    ]. As such, they are rarely utilized in this setting.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949005\">",
"    <span class=\"h3\">",
"     Dacarbazine and temozolomide",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a SWOG study of 56 patients with metastatic carcinoid receiving single agent",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    , the overall tumor response rate was 16 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/54\">",
"     54",
"    </a>",
"    ]. Toxicity was a concern: 88 percent of patients reported nausea",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    vomiting. In another report of second-line dacarbazine following treatment with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"      streptozocin",
"     </a>",
"     /5-FU",
"    </span>",
"    or",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"mobipreview.htm?35/37/36440?source=see_link\">",
"      doxorubicin",
"     </a>",
"     /5-FU,",
"    </span>",
"    the response rate was only 8 percent [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     Temozolomide",
"    </a>",
"    is an oral analog of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    that is generally better tolerated. However, activity was limited in a retrospective series that included 44 carcinoid tumor patients treated with temozolomide-based regimens; only one (2 percent) had an objective tumor response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/55\">",
"     55",
"    </a>",
"    ]. The majority of these patients had primary gastrointestinal carcinoids.",
"   </p>",
"   <p>",
"    More recent reports suggest that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    may be active in some patients with bronchial carcinoid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/56\">",
"     56",
"    </a>",
"    ]. However, a phase II study of combined temozolomide plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    reported no objective responses among 19 patients with advanced carcinoid, four of whom had bronchial carcinoids [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4153?source=see_link&amp;anchor=H1143201255#H1143201255\">",
"     \"Bronchial carcinoid tumors: Treatment and prognosis\", section on 'Chemotherapy'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949012\">",
"    <span class=\"h3\">",
"     Oxaliplatin-based regimens",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antitumor activity has been suggested in preliminary reports of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    -based combinations, though the total number of treated patients has been small.",
"   </p>",
"   <p>",
"    A preliminary report of a phase II trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    plus short-term infusional 5-",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    (FOLFOX) and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in 11 patients with advanced progressive NETs noted a partial response in one of five patients with advanced carcinoid and stable disease in the other four [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in patients with advanced NET was suggested in a preliminary report of another phase II trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/43\">",
"     43",
"    </a>",
"    ]. Seven of 31 evaluable patients (23 percent) had a partial response (six had pancreatic NET, and one had a liver metastases with an unknown primary site), and 22 others had stable disease (71 percent).",
"   </p>",
"   <p>",
"    While these regimens may have activity in carcinoid, the data are too limited and preliminary to draw any conclusions as to the relative contributions of the fluoropyrimidine,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/11/2233?source=see_link\">",
"     oxaliplatin",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26472645\">",
"    <span class=\"h3\">",
"     Capecitabine plus bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    was suggested in a preliminary report of a multicenter phase II trial [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/57\">",
"     57",
"    </a>",
"    ]. Forty-nine patients with progressive, metastatic digestive tract NET (82 percent originating in small bowel, the remainder in the cecum, rectum, and stomach) received bevacizumab with capecitabine. The median treatment duration was 13.8 months. In a preliminary report, at 24 months, the tumor control rate was 87 percent (partial response in 18 percent, stable disease in 69 percent), and the median progression-free survival was 23.4 months. However, grade 3 or 4 treatment-related toxicity was experienced by 84 percent of patients, mainly digestive; 31 percent developed grade 3 or 4 hypertension. (See",
"    <a class=\"local\" href=\"#H88977934\">",
"     'Bevacizumab'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26471971\">",
"    <span class=\"h3\">",
"     Summary",
"    </span>",
"    &nbsp;&mdash;&nbsp;The role of systemic chemotherapy in patients with metastatic carcinoid is unclear, and year 2012 guidelines from the European Neuroendocrine Tumor Society (ENETS) recommend against its use in these patients [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/13\">",
"     13",
"    </a>",
"    ]. Consensus-based guidelines from the",
"    <a class=\"external\" href=\"file://www.nccn.org/professionals/physician_gls/f_guidelines.asp\">",
"     National Comprehensive Cancer Network (NCCN)",
"    </a>",
"    suggest that anticancer agents such as",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?4/49/4887?source=see_link\">",
"     dacarbazine",
"    </a>",
"    , 5-FU, interferon-alfa (IFNa), and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    can be used in patients with progressive metastases from carcinoid for whom there are no other treatment options. However, objective radiologic responses are rare, and no chemotherapy drug or regimen has demonstrated a PFS or overall survival benefit.",
"   </p>",
"   <p>",
"    We generally prefer that patients with progressive disease despite somatostatin analog therapy be enrolled on trials testing new systemic therapy strategies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949019\">",
"    <span class=\"h2\">",
"     Poorly differentiated tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with poorly differentiated gastroenteropancreatic NETs are thought to be more responsive to cytotoxic chemotherapy than those with the more typical well-differentiated tumors. Platinum-based regimens are active in this setting:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In an early study, a combination of",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      , a regimen commonly used for small cell lung cancer, was associated with an overall tumor response rate of 67 percent in 18 patients with \"anaplastic\" NETs (presumably analogous to poorly differentiated tumors), but had little activity in the more well-differentiated tumor subtypes [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/58\">",
"       58",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=see_link\">",
"       \"First-line chemotherapy for patients with extensive stage small cell lung cancer\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In a subsequent study of 36 patients with advanced NETs, treatment with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?20/51/21305?source=see_link\">",
"       cisplatin",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?29/57/30617?source=see_link\">",
"       etoposide",
"      </a>",
"      was associated with an overall radiologic response rate of 36 percent and a median survival time of 19 months. All patients enrolled in this study had either poorly-differentiated histology or a rapidly progressing clinical course, suggesting that few, if any, had more classic, indolent carcinoid or pancreatic endocrine tumors [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/59\">",
"       59",
"      </a>",
"      ].",
"      <br/>",
"      <br/>",
"      Using this same regimen, a similar response rate (42 percent) and median survival (15 months) was reported in another retrospective series of 41 patients with poorly differentiated NET [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/60\">",
"       60",
"      </a>",
"      ]; in contrast, only one of 11 patients with well-differentiated NET responded.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Second-line therapy has not been well studied. In one report of 25 patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"     temozolomide",
"    </a>",
"    with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    , seven patients had a partial response (33 percent) and nine more had stable disease, with response lasting a median of 18 months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/61\">",
"     61",
"    </a>",
"    ]. In another series of 19 patients treated with short-term infusional",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?32/32/33280?source=see_link\">",
"     fluorouracil",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?23/54/24423?source=see_link\">",
"     leucovorin",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?7/41/7834?source=see_link\">",
"     irinotecan",
"    </a>",
"    (FOLFIRI), there were six objective responders (31 percent), and six others with stable disease; the median progression-free survival was only four months [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/62\">",
"     62",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949026\">",
"    <span class=\"h1\">",
"     MOLECULARLY TARGETED THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of studies have noted elevated expression of several cellular growth factors and their receptors (including vascular endothelial growth factor [VEGF], VEGF receptor [VEGFR], platelet-derived growth factor [PDGF], PDGF receptor [PDGFR], and stem cell factor receptor [KIT]) in carcinoids and pancreatic NETs. Many of these receptors function as tyrosine kinases (TKs). In preclinical models, disruption of these signaling pathways inhibits neuroendocrine cell growth. This has prompted a number of clinical trials evaluating small molecule TK inhibitors (eg,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    ) and monoclonal antibodies (MoAbs) targeting growth factor signaling (such as the anti-VEGF MoAb",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    ) in patients with advanced NETs.",
"   </p>",
"   <p>",
"    The mammalian Target of Rapamycin (mTOR) is a threonine kinase that mediates downstream signaling in a number of pathways that are implicated in neuroendocrine tumor growth, including the VEGF and IGF signaling pathways [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/63\">",
"     63",
"    </a>",
"    ]. In addition, mTOR regulates angiogenesis by controlling the production of hypoxia inducible factor.",
"   </p>",
"   <p>",
"    Studies have demonstrated activity associated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    , several tyrosine kinase (TK) inhibitors that inhibit VEGFR, as well as the mTOR inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    . As has been seen with cytotoxic chemotherapy, these agents appear to be more active in pancreatic NETs than in carcinoid (",
"    <a class=\"graphic graphic_table graphicRef59354 \" href=\"mobipreview.htm?34/19/35133\">",
"     table 6",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949033\">",
"    <span class=\"h2\">",
"     Pancreatic NET",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949040\">",
"    <span class=\"h3\">",
"     Small molecule TK inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949047\">",
"    <span class=\"h4\">",
"     Sunitinib",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    is a multi-targeted TK inhibitor that has shown activity against a range of signaling pathways and growth",
"    <span class=\"nowrap\">",
"     factors/receptors",
"    </span>",
"    including VEGFR 1, 2, and 3 as well as PDGFR alpha and beta, KIT, glial cell-line derived neurotrophic factor, RET, FMS-like tyrosine kinase-3 (FLT3) and colony-stimulating factor receptor (CSF-1R).",
"   </p>",
"   <p>",
"    In an initial phase II trial,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    (50 mg daily for four of every six weeks) was administered to 109 patients with advanced NETs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/64\">",
"     64",
"    </a>",
"    ]. Of 61 patients with pancreatic NETs, 11 (18 percent) had a partial response, and 68 percent had prolonged periods of stable disease; median time to tumor progression (TTP) was 7.7 months.",
"   </p>",
"   <p>",
"    Continuous administration of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    (37.5 mg daily) was compared to placebo in a phase III trial of 171 patients with progressing pancreatic NETs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/65\">",
"     65",
"    </a>",
"    ]. Accrual was stopped prematurely prior to the first preplanned interim efficacy analysis. Median PFS was significantly longer with sunitinib (11.4 versus 5.5 months) (",
"    <a class=\"graphic graphic_table graphicRef68953 \" href=\"mobipreview.htm?32/37/33372\">",
"     table 7",
"    </a>",
"    ). There were eight objective responses with sunitinib (versus none in the placebo group), two of which were complete. Hand-foot skin reaction and hypertension of any grade occurred in 23 and 26 percent of patients receiving sunitinib, respectively, and the most common grade 3 or 4 adverse events in this group were neutropenia (12 percent) and hypertension (10 percent). Despite these side effects, there were no differences in the quality of life index with sunitinib. &nbsp;",
"   </p>",
"   <p>",
"    Largely based upon these data,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     sunitinib",
"    </a>",
"    is approved in the US for the treatment of progressive, well-differentiated pancreatic neuroendocrine tumors in patients with unresectable, locally advanced, or metastatic disease.&nbsp;Side effects may include hypertension, proteinuria, and other forms of renal toxicity, arterial thromboembolism, left ventricular dysfunction, and clinical heart failure, thyroid dysfunction, bleeding, myelosuppression, hand-foot skin reaction, delayed wound healing, hepatotoxicity, and muscle wasting. These side effects and their management are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=see_link&amp;anchor=H9#H9\">",
"     \"Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy\", section on 'Sorafenib and sunitinib'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=see_link\">",
"     \"Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949054\">",
"    <span class=\"h4\">",
"     Sorafenib and pazopanib",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two other orally active TK inhibitors,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    , have demonstrated modest activity in pancreatic NET in the phase II setting. Sorafenib, which targets VEGFR-2 and PDGFR-B, was evaluated in 50 patients with carcinoid, and 43 patients with pancreatic neuroendocrine tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/66\">",
"     66",
"    </a>",
"    ]. In a preliminary analysis, responses were observed in 11 percent of the patients with pancreatic NET.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     Pazopanib",
"    </a>",
"    , which targets VEGFR-1, VEGFR-2, VEGFR-3, PDGFR-alpha and beta, as well as KIT, was evaluated in a prospective study of 51 patients with advanced NET (29 with pancreatic NETs and 22 with carcinoid) on stable doses of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    -LAR [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/67\">",
"     67",
"    </a>",
"    ]. Patients received pazopanib at a dose of 800 mg daily. In a preliminary report, the response rate among patients with pancreatic NETs was 17 percent.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949061\">",
"    <span class=\"h3\">",
"     mTOR inhibitors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949068\">",
"    <span class=\"h4\">",
"     Everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several studies have explored the activity of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    , with and without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef59354 \" href=\"mobipreview.htm?34/19/35133\">",
"     table 6",
"    </a>",
"    ). The activity of everolimus (10 mg daily) in pancreatic NET was initially explored in an international multicenter phase II trial of 160 patients, 45 of whom also received treatment with concurrent octreotide at the discretion of the investigators [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/68\">",
"     68",
"    </a>",
"    ]. In patients who received octreotide plus everolimus, the median PFS was longer (17 versus 9.7 months), but whether octreotide contributed to the higher PFS in this cohort is unclear, since the study was not randomized.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    monotherapy (10 mg daily) was compared to best supportive care alone in the placebo-controlled RADIANT-3 trial of 410 patients with advanced progressing pancreatic NET [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/69\">",
"     69",
"    </a>",
"    ]. Everolimus was associated with a significant prolongation in median PFS (11.0 versus 4.6 months, hazard ratio [HR] for progression 0.35, 95% CI 0.27 to 0.45) (",
"    <a class=\"graphic graphic_table graphicRef68953 \" href=\"mobipreview.htm?32/37/33372\">",
"     table 7",
"    </a>",
"    ). There were confirmed objective partial responses (as defined by RECIST v1.0 (",
"    <a class=\"graphic graphic_table graphicRef74693 \" href=\"mobipreview.htm?41/48/42764\">",
"     table 8",
"    </a>",
"    )) in 5 versus 2 percent of the placebo group. Drug-related adverse events were mostly grade 1 or 2, and included stomatitis (64 versus 17 percent of the placebo group), rash (49 versus 10 percent), diarrhea (34 versus 10 percent), fatigue (31 versus 14 percent), and infections (23 versus 6 percent), predominantly of the upper respiratory tract. The most common grade 3 or 4 drug-related adverse events were stomatitis (7 percent), anemia (6 percent), and hyperglycemia (5 percent).",
"   </p>",
"   <p>",
"    Largely based upon these data,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    is approved in the US for the treatment of progressive NETs of pancreatic origin in patients with unresectable, locally advanced or metastatic disease.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    may be of particular value to improve glycemic control in patients with functioning insulinomas [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/70-72\">",
"     70-72",
"    </a>",
"    ]. In one report, four patients with malignant insulinoma and refractory hypoglycemia normalized their glucose levels during everolimus therapy; two had an objective antitumor response [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/70\">",
"     70",
"    </a>",
"    ]. Clinical improvement in the other two patients who had stable disease as the best response suggests a possible direct effect of the drug on insulin production",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    release.",
"   </p>",
"   <p>",
"    However,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    also causes hyperglycemia. In a later analysis of data from the RADIANT-3 trial described above, the frequency of severe (grade 3 or 4) hyperglycemia was higher in those with preexisting diabetes mellitus or baseline hyperglycemia (15 versus 3 percent in those without diabetes or baseline hyperglycemia) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/73\">",
"     73",
"    </a>",
"    ]. Rates of grade 3 or 4 hyperglycemia were similar in those with glucagonoma versus those without glucagonoma (9.1 versus 7.8 percent). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31640?source=see_link&amp;anchor=H27#H27\">",
"     \"Glucagonoma and the glucagonoma syndrome\", section on 'Chemotherapy and novel treatment approaches'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949075\">",
"    <span class=\"h4\">",
"     Temsirolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;In a phase II study of 37 patients with progressive NET treated with the mTOR inhibitor",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    , the objective overall response rate was 6 percent, but 64 percent of patients had disease control (partial response or stable disease) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/74\">",
"     74",
"    </a>",
"    ]. Higher baseline tumor levels of mTOR predicted for better outcomes.",
"   </p>",
"   <p>",
"    Encouraging early results were noted in a phase II trial of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?14/1/14360?source=see_link\">",
"     temsirolimus",
"    </a>",
"    (25 mg IV weekly) plus the anti-VEGF monoclonal antibody",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every other week) in 35 patients with RECIST criteria progression within seven months of study entry [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/75\">",
"     75",
"    </a>",
"    ]. In a preliminary report presented at the 2012 ASCO GI Cancers Symposium, a confirmed partial response was documented in 11 of the first 25 assessable patients (44 percent) and 20 (80 percent) were progression-free at six months. The most common grade 3 or 4 toxic effects were leucopenia, hypertension and hyperglycemia (12 percent each), and oral mucositis and fatigue (9 percent each).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949082\">",
"    <span class=\"h2\">",
"     Carcinoid tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In contrast to pancreatic NET, the benefit of molecularly targeted therapy for carcinoid tumors is less well established.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949089\">",
"    <span class=\"h3\">",
"     Small molecule TK inhibitors",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"     Sunitinib",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?9/45/9944?source=see_link\">",
"     sorafenib",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?1/2/1064?source=see_link\">",
"     pazopanib",
"    </a>",
"    have been evaluated in advanced carcinoid tumors in phase II trials (",
"    <a class=\"graphic graphic_table graphicRef59354 \" href=\"mobipreview.htm?34/19/35133\">",
"     table 6",
"    </a>",
"    ). Response rates have been low, although all studies report a high rate of disease stabilization and potentially encouraging PFS durations. In the absence of randomized studies, the activity of these TK inhibitors in advanced carcinoid remains uncertain.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949103\">",
"    <span class=\"h3\">",
"     Everolimus",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     Everolimus",
"    </a>",
"    was evaluated in conjunction with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    in a phase II study of 30 patients with advanced carcinoid tumors (",
"    <a class=\"graphic graphic_table graphicRef59354 \" href=\"mobipreview.htm?34/19/35133\">",
"     table 6",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/76\">",
"     76",
"    </a>",
"    ]. Partial responses were observed in 5 of 30 (17 percent) patients.",
"   </p>",
"   <p>",
"    Based upon these results, the RADIANT 2 trial was undertaken in which 429 patients with advanced carcinoid tumors, a history of carcinoid syndrome, and radiologic disease progression in the preceding 12 months were randomly assigned to depot",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    (30 mg IM every 28 days) with or without",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    (10 mg daily) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/77\">",
"     77",
"    </a>",
"    ]. As assessed by central radiographic review, combined therapy was associated with a potentially clinically meaningful prolongation in median progression-free survival (PFS), but it was only of borderline statistical significance (16.4 versus 11.3 months; hazard ratio [HR] for tumor progression 0.77, 95% CI 0.59-1.0) (",
"    <a class=\"graphic graphic_table graphicRef68953 \" href=\"mobipreview.htm?32/37/33372\">",
"     table 7",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Imbalances between study groups were noted in important prognostic variables, including disease site and performance status, all of which favored the control group and could have affected the primary outcome results. A later analysis, presented at the 2012 ASCO GI Cancers Symposium, found a significant PFS benefit for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    after adjusting for randomization imbalances (HR for progression 0.62, 95% CI 0.51-0.87, p = 0.003) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/78\">",
"     78",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The best overall response was a partial response in only 2 percent of both groups; stable disease was the best response in 84 percent of the patients treated with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    and 81 percent of the control group [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/77\">",
"     77",
"    </a>",
"    ]. Patients treated with everolimus had higher proportions of tumor marker responses in CGA and 5-HIAA (46 and 61 percent) compared to the control group (36 and 54 percent), but data on symptoms related to carcinoid syndrome were not systematically collected. There was no significant difference in overall survival between the two groups (HR for death 1.22, 95% CI 0.91-1.62); however, patients who were randomly assigned to the placebo group were permitted to cross over to the active treatment group, potentially obscuring any meaningful survival benefit.",
"   </p>",
"   <p>",
"    Drug-related adverse events were mostly low-grade. The most common drug-related adverse events of any grade were stomatitis (62 versus 14 percent in the",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    and control groups, respectively), rash (37 versus 12 percent), fatigue (31 versus 23 percent), and diarrhea (27 versus 16 percent). The most common grade 3 or 4 adverse events were stomatitis, fatigue, diarrhea, hyperglycemia, thrombocytopenia, and infection. The incidence of drug-related pneumonitis in the everolimus group was 8 percent (versus 0 percent in the control group). (See",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?28/49/29466?source=see_link&amp;anchor=H22#H22\">",
"     \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\", section on 'Everolimus'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    These data demonstrate that",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    has some activity in advanced carcinoids; however, the risk to benefit ratio and optimal use of this agent remain uncertain. Prognostic factors for benefit were studied in a multivariate analysis of the RADIANT-2 trial, with a preliminary report presented at the 2012 ASCO GI Cancers Symposium [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/78\">",
"     78",
"    </a>",
"    ]. Among the factors that were associated with a significantly greater likelihood of benefit from treatment were non-elevated baseline CGA levels (median PFS 27 versus 11 months), ECOG performance status of 0 versus 1 or more (median PFS 17 versus 11 months), absence of liver involvement (median PFS &ldquo;not reached&rdquo; versus 14 months), and absence of bone involvement (median PFS 15 versus 8 months). However, further study is needed before it can be concluded that specific subsets of patients with advanced carcinoid can be identified who derive more or less benefit from the addition of everolimus to",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Further support for a benefit for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    in carcinoid tumors comes from a phase II trial in which 34 patients with radiologically progressing, locally advanced, recurrent, or metastatic but nonfunctioning NETs at a variety of sites, including the intestinal tract, received everolimus 10 mg daily [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/79\">",
"     79",
"    </a>",
"    ]. The best response was a partial response in three patients and stable disease in 28, for an overall disease control rate of 94 percent. The median PFS was 15.3 months, and four-month progression-free survival rate was 78 percent. The major grade 3 or 4 adverse events were thrombocytopenia (15 percent), hyperglycemia, stomatitis, and anemia (6 percent each), &nbsp;",
"   </p>",
"   <p>",
"    For patients with symptomatic advanced disease whose symptoms are not adequately controlled with a somatostatin analog,",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"     everolimus",
"    </a>",
"    is an option for those who are willing to accept treatment-related toxicity in return for the possibility of longer progression-free survival [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/13,80\">",
"     13,80",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H88977934\">",
"    <span class=\"h3\">",
"     Bevacizumab",
"    </span>",
"    &nbsp;&mdash;&nbsp;Activity for",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    was suggested in a phase II trial, in which 44 patients with advanced or metastatic carcinoid tumors on a stable dose of",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"     octreotide",
"    </a>",
"    were randomly assigned to 18 weeks of bevacizumab or pegylated IFNa-2b [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/81\">",
"     81",
"    </a>",
"    ]. At disease progression or at the completion of 18 weeks of therapy (whichever came first), all patients received bevacizumab plus interferon. During the first 18 weeks of therapy, four (18 percent) of the bevacizumab-treated patients experienced radiographic partial responses while 17 (77 percent) had stable disease. Furthermore, after 18 weeks, 95 percent of patients treated with octreotide plus bevacizumab remained progression-free, compared with only 68 percent of those receiving octreotide plus IFNa-2b. Based upon these results, SWOG is leading a large, randomized study of bevacizumab versus interferon in patients with advanced carcinoid tumors [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/82\">",
"     82",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Results with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?2/20/2377?source=see_link\">",
"     bevacizumab",
"    </a>",
"    in combination with",
"    <a class=\"drug drug_general\" href=\"mobipreview.htm?40/0/40967?source=see_link\">",
"     capecitabine",
"    </a>",
"    are discussed above. (See",
"    <a class=\"local\" href=\"#H26472645\">",
"     'Capecitabine plus bevacizumab'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949111\">",
"    <span class=\"h1\">",
"     SYSTEMIC RADIONUCLIDE THERAPY",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949119\">",
"    <span class=\"h2\">",
"     Peptide receptor radioligand therapy",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949126\">",
"    <span class=\"h3\">",
"     Radiolabeled somatostatin analogs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Traditional external beam radiation therapy is beneficial for patients with painful bone metastases but has little utility for the more common visceral metastases. There has been substantial interest, however, in targeted radiotherapy using radiolabeled somatostatin analogs [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/83-93\">",
"     83-93",
"    </a>",
"    ]. The most frequently used radionuclides for targeted radiotherapy include yttrium (",
"    <sup>",
"     90",
"    </sup>",
"    Y) and lutetium (",
"    <sup>",
"     177",
"    </sup>",
"    Lu), which differ from one another in terms of emitted particles, particle energy, and tissue penetration [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/94,95\">",
"     94,95",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The largest series of",
"      <sup>",
"       90",
"      </sup>",
"      Y-DOTA tyr3-",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      (",
"      <sup>",
"       90",
"      </sup>",
"      Y-edotreotide,",
"      <sup>",
"       90",
"      </sup>",
"      Y-DOTA-TOC) included 1109 patients with metastatic neuroendocrine tumor and disease progression within 12 months of study entry, with visible tumor uptake on pretreatment somatostatin receptor scintigraphy [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/96\">",
"       96",
"      </a>",
"      ]. After the initial dose, additional treatment cycles were withheld if there was tumor progression or permanent toxicity; otherwise, patients were offered retreatment; the specific interval was not specified. The median number of courses administered was two, range one to ten.",
"      <br/>",
"      <br/>",
"      Overall, 378 patients (34 percent) had a &ldquo;morphologic&rdquo; response (defined as any measurable decrease in the sum of the longest diameters of all pre-therapeutically detected tumor lesions by CT, MRI or ultrasound), 172 (15 percent) had a biochemical response (defined as any posttreatment decrease in a tumor marker that had demonstrated progression prior to enrollment), and 329 (29.7 percent) improved symptomatically. The median survival from diagnosis was 94.6 months. Longer survival correlated with responses by any of the above criteria. Transient grade 3 or 4 hematologic toxicities developed in 142 (12 percent), and loss of renal function was the main dose limiting toxicity. In all, 103 patients (9 percent) had permanent grade 4 or 5 (fatal, n = 35) renal toxicity. Older age, low baseline glomerular filtration rate, and high kidney update score were associated with severe nephrotoxicity. &nbsp;",
"     </li>",
"     <li>",
"      <sup>",
"       177",
"      </sup>",
"      Lu-DOTA, Tyr",
"      <sup>",
"       3",
"      </sup>",
"      -octreotate has been utilized in the treatment of over 500 patients with neuroendocrine tumors. Efficacy results, reported for 310 patients, suggest an overall tumor response rate of up to 30 percent [",
"      <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/97\">",
"       97",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Long-term side effects of radiopeptide therapy may include loss of renal function, pancytopenia, and myelodysplastic syndrome. At least in the US, the use of radiolabeled somatostatin analogs for the treatment of neuroendocrine tumors remains investigational. Randomized, prospective studies better defining the antitumor activity and long-term toxicity of radiolabeled somatostatin analogs as compared to standard somatostatin analogs are anticipated [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/98\">",
"     98",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949133\">",
"    <span class=\"h3\">",
"     MIBG",
"    </span>",
"    &nbsp;&mdash;&nbsp;Benefit also has been suggested for systemic radionuclide therapy using iodine-131-labeled metaiodobenzylguanidine (",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/99,100\">",
"     99,100",
"    </a>",
"    ] in patients with metastatic carcinoid who have evidence of MIBG uptake, as determined by",
"    <sup>",
"     123",
"    </sup>",
"    I-MIBG scanning. MIBG is a compound resembling norepinephrine that is accumulated by some neuroendocrine tumors. In two separate retrospective series, biochemical (5-HIAA) responses were observed in 37 percent of patients with gastroenteropancreatic tumors treated with",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG, and objective radiographic responses were noted in 15 and 28 percent, respectively [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/100,101\">",
"     100,101",
"    </a>",
"    ]. In one report, symptomatic improvement was reported by 27 of 48 patients (56 percent) [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/101\">",
"     101",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, the benefit of",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG was subsequently called into question in a nonrandomized comparison of outcomes with radiolabeled",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG in 30 patients with carcinoid syndrome or tumor symptoms (fever, pain) attributed to the carcinoid tumor versus unlabeled MIBG in 20 patients with carcinoid syndrome who were not suitable for treatment with the radioactive compound [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/102\">",
"     102",
"    </a>",
"    ]. The rate of symptom response was identical in both groups (60 percent), though symptom response was not accompanied by either a biochemical or radiographic response in any patient.",
"   </p>",
"   <p>",
"    While",
"    <sup>",
"     131",
"    </sup>",
"    I-MIBG has been licensed by regulatory authorities in some countries [",
"    <a class=\"abstract\" href=\"mobipreview.htm?38/46/39658/abstract/98\">",
"     98",
"    </a>",
"    ], in our view, its use for the treatment of carcinoid tumors remains investigational.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949140\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949148\">",
"    <span class=\"h2\">",
"     Carcinoid tumors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1974409\">",
"    <span class=\"h3\">",
"     Initial therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Somatostatin analogs such as",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      are highly effective in controlling the symptoms associated with carcinoid tumors. For patients who are symptomatic from carcinoid syndrome, we recommend initiating treatment with a somatostatin analog (",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H190948928\">",
"       'Octreotide and other somatostatin analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We also suggest initiating therapy with a somatostatin analog for patients who do not have carcinoid syndrome but who have",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      -avid disease&nbsp;(as determined by somatostatin receptor scintigraphy) and&nbsp;a high tumor burden (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=see_link&amp;anchor=H5#H5\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring\", section on 'Somatostatin receptor scintigraphy'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with metastatic disease that is resectable with curative intent in the absence of extrahepatic metastases, diffuse bilobar involvement, or compromised liver function, we suggest resection rather than medical therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=see_link&amp;anchor=H691406#H691406\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Resection'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with asymptomatic advanced unresectable carcinoid tumors and small volume disease, we suggest observation alone rather than early administration of a somatostatin analog (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H190948935\">",
"       'Use in asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949177\">",
"    <span class=\"h3\">",
"     Progressive disease",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For patients with",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?42/7/43128?source=see_link\">",
"       octreotide",
"      </a>",
"      -avid disease&nbsp;and&nbsp;disease progression who are not already on a somatostatin analog, we suggest initiating treatment with a somatostatin analog (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H190948928\">",
"       'Octreotide and other somatostatin analogs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest hepatic arterial embolization, chemoembolization, or radioembolization rather than medical therapy alone as a palliative technique for symptomatic patients with hepatic-predominant unresectable disease (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=see_link&amp;anchor=H691449#H691449\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Hepatic artery embolization'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with carcinoid tumor and progressive disease despite a somatostatin analog, there is no standard approach. We prefer that patients be enrolled on clinical trials testing new strategies, if feasible. For patients who are unable or unwilling to participate in clinical trials,",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      is an option for those who are willing to accept treatment-related toxicity in return for the possibility of longer progression-free survival. (See",
"      <a class=\"local\" href=\"#H190949103\">",
"       'Everolimus'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The benefit of cytotoxic chemotherapy for advanced carcinoid continues to be debated. We prefer that eligible patients be enrolled on trials testing new systemic therapy strategies. (See",
"      <a class=\"local\" href=\"#H190948991\">",
"       'Carcinoid tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      While IFNa may be an option for patients with advanced carcinoid who have worsening symptoms or evidence of disease progression while on treatment with somatostatin analogs, widespread acceptance of this agent for the treatment of advanced carcinoid has been limited by questions as to efficacy, as well as the potential for disabling side effects. (See",
"      <a class=\"local\" href=\"#H190948949\">",
"       'Interferon'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Anecdotal evidence suggests a possible role for",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      in patients with bronchial carcinoid. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4153?source=see_link&amp;anchor=H1143201255#H1143201255\">",
"       \"Bronchial carcinoid tumors: Treatment and prognosis\", section on 'Chemotherapy'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949184\">",
"    <span class=\"h2\">",
"     Pancreatic neuroendocrine tumors",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949192\">",
"    <span class=\"h3\">",
"     Initial therapy",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Patients with symptoms of hormone hypersecretion should be managed with somatostatin analogs and other agents, as appropriate to the specific syndrome. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=see_link&amp;anchor=H25#H25\">",
"       \"Insulinoma\", section on 'Medical therapy to control symptomatic hypoglycemia'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31640?source=see_link&amp;anchor=H22#H22\">",
"       \"Glucagonoma and the glucagonoma syndrome\", section on 'Octreotide and interferon alfa'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16311?source=see_link&amp;anchor=H7#H7\">",
"       \"The VIPoma syndrome\", section on 'Octreotide and lanreotide'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      For patients with metastatic disease that is resectable with curative intent in the absence of extrahepatic metastases, diffuse bilobar involvement, or compromised liver function, we suggest resection rather than medical therapy (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=see_link&amp;anchor=H691406#H691406\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Resection'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949200\">",
"    <span class=\"h3\">",
"     Progressive disease and/or symptomatic from tumor bulk",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      For most patients with progressive advanced pancreatic NET, we suggest treatment with a molecularly targeted agent (",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?6/4/6218?source=see_link\">",
"       everolimus",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?43/10/44200?source=see_link\">",
"       sunitinib",
"      </a>",
"      ) over best supportive care alone (",
"      <a class=\"grade\" href=\"._grade_4?title=Grade 2A\">",
"       Grade 2A",
"      </a>",
"      ). In the absence of comparative trials, the choice of initial agent may be influenced by the expected toxicity profile. (See",
"      <a class=\"local\" href=\"#H190949068\">",
"       'Everolimus'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H190949047\">",
"       'Sunitinib'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients who are highly symptomatic from tumor bulk or who have rapidly enlarging metastases, we suggest chemotherapy rather than molecularly targeted therapy because of the higher objective response rate (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ). There are two acceptable options for therapy, a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?9/30/9702?source=see_link\">",
"       streptozocin",
"      </a>",
"      -based combination or a",
"      <a class=\"drug drug_general\" href=\"mobipreview.htm?10/47/11000?source=see_link\">",
"       temozolomide",
"      </a>",
"      -containing regimen. In the absence of comparative trials, the choice of regimen should be individualized, taking into account the convenience of oral rather than intravenous treatment, performance status, and the anticipated side effect profile of both combinations. (See",
"      <a class=\"local\" href=\"#H190948963\">",
"       'Pancreatic NETs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hepatic arterial embolization is a reasonable alternative approach to cytotoxic chemotherapy or molecularly targeted therapy for symptomatic patients with hepatic predominant disease who are not candidates for surgical resection. (See",
"      <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=see_link&amp;anchor=H691449#H691449\">",
"       \"Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth\", section on 'Hepatic artery embolization'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H190949207\">",
"    <span class=\"h2\">",
"     Poorly differentiated neuroendocrine tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients with poorly differentiated neuroendocrine tumors, we recommend systemic chemotherapy with a platinum-based combination regimen, analogous to that used for small cell lung cancer (",
"    <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"     Grade 1B",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H190949019\">",
"     'Poorly differentiated tumors'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=see_link&amp;anchor=H8#H8\">",
"     \"First-line chemotherapy for patients with extensive stage small cell lung cancer\", section on 'Platinum-based combinations'",
"    </a>",
"    .)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Rindi G, Arnold R, Bosman FT, et al. Nomenclature and classification of neuroendocrine neoplasms of the digestive system. In: WHO Classification of Tumours of the Digestive System, 4th ed, Bosman TF, Carneiro F, Hruban RH, Theise ND (Eds), International Agency for Research on cancer (IARC), Lyon 2010. p.13.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/2\">",
"      Duerr EM, Chung DC. Molecular genetics of neuroendocrine tumors. Best Pract Res Clin Endocrinol Metab 2007; 21:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/3\">",
"      Panzuto F, Nasoni S, Falconi M, et al. Prognostic factors and survival in endocrine tumor patients: comparison between gastrointestinal and pancreatic localization. Endocr Relat Cancer 2005; 12:1083.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/4\">",
"      Klimstra DS, Modlin IR, Coppola D, et al. The pathologic classification of neuroendocrine tumors: a review of nomenclature, grading, and staging systems. Pancreas 2010; 39:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/5\">",
"      Metz DC, Jensen RT. Gastrointestinal neuroendocrine tumors: pancreatic endocrine tumors. Gastroenterology 2008; 135:1469.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/6\">",
"      Reubi JC, Kvols LK, Waser B, et al. Detection of somatostatin receptors in surgical and percutaneous needle biopsy samples of carcinoids and islet cell carcinomas. Cancer Res 1990; 50:5969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/7\">",
"      Leong WL, Pasieka JL. Regression of metastatic carcinoid tumors with octreotide therapy: two case reports and a review of the literature. J Surg Oncol 2002; 79:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/8\">",
"      Imtiaz KE, Monteith P, Khaleeli A. Complete histological regression of metastatic carcinoid tumour after treatment with octreotide. Clin Endocrinol (Oxf) 2000; 53:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/9\">",
"      Ricci S, Antonuzzo A, Galli L, et al. Long-acting depot lanreotide in the treatment of patients with advanced neuroendocrine tumors. Am J Clin Oncol 2000; 23:412.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/10\">",
"      Romeo S, Milione M, Gatti A, et al. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. Horm Res 2006; 65:120.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/11\">",
"      Kraenzlin ME, Ch'ng JL, Wood SM, et al. Long-term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 1985; 88:185.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/12\">",
"      Ramage JK, Ahmed A, Ardill J, et al. Guidelines for the management of gastroenteropancreatic neuroendocrine (including carcinoid) tumours (NETs). Gut 2012; 61:6.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/13\">",
"      Pavel M, Baudin E, Couvelard A, et al. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology 2012; 95:157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/14\">",
"      Rubin J, Ajani J, Schirmer W, et al. Octreotide acetate long-acting formulation versus open-label subcutaneous octreotide acetate in malignant carcinoid syndrome. J Clin Oncol 1999; 17:600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/15\">",
"      Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med 1996; 334:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/16\">",
"      Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients--a clinical research center study. J Clin Endocrinol Metab 1995; 80:2768.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/17\">",
"      Kvols LK, Moertel CG, O'Connell MJ, et al. Treatment of the malignant carcinoid syndrome. Evaluation of a long-acting somatostatin analogue. N Engl J Med 1986; 315:663.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/18\">",
"      Rinke A, M&uuml;ller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol 2009; 27:4656.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/19\">",
"      Aparicio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer 2001; 37:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/20\">",
"      Oberg K, Funa K, Alm G. Effects of leukocyte interferon on clinical symptoms and hormone levels in patients with mid-gut carcinoid tumors and carcinoid syndrome. N Engl J Med 1983; 309:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/21\">",
"      Detjen KM, Welzel M, Farwig K, et al. Molecular mechanism of interferon alfa-mediated growth inhibition in human neuroendocrine tumor cells. Gastroenterology 2000; 118:735.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/22\">",
"      Faiss S, Pape UF, B&ouml;hmig M, et al. Prospective, randomized, multicenter trial on the antiproliferative effect of lanreotide, interferon alfa, and their combination for therapy of metastatic neuroendocrine gastroenteropancreatic tumors--the International Lanreotide and Interferon Alfa Study Group. J Clin Oncol 2003; 21:2689.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/23\">",
"      Granberg D, Eriksson B, Wilander E, et al. Experience in treatment of metastatic pulmonary carcinoid tumors. Ann Oncol 2001; 12:1383.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/24\">",
"      di Bartolomeo M, Bajetta E, Buzzoni R, et al. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. Cancer 1996; 77:402.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/25\">",
"      Pisegna JR, Slimak GG, Doppman JL, et al. An evaluation of human recombinant alpha interferon in patients with metastatic gastrinoma. Gastroenterology 1993; 105:1179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/26\">",
"      Sch&ouml;ber C, Schmoll E, Schmoll HJ, et al. Antitumour effect and symptomatic control with interferon alpha 2b in patients with endocrine active tumours. Eur J Cancer 1992; 28A:1664.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/27\">",
"      Biesma B, Willemse PH, Mulder NH, et al. Recombinant interferon alpha-2b in patients with metastatic apudomas: effect on tumours and tumour markers. Br J Cancer 1992; 66:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/28\">",
"      Eriksson B, Oberg K, Alm G, et al. Treatment of malignant endocrine pancreatic tumours with human leucocyte interferon. Lancet 1986; 2:1307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/29\">",
"      Bajetta E, Zilembo N, Di Bartolomeo M, et al. Treatment of metastatic carcinoids and other neuroendocrine tumors with recombinant interferon-alpha-2a. A study by the Italian Trials in Medical Oncology Group. Cancer 1993; 72:3099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/30\">",
"      Dirix LY, Vermeulen PB, Fierens H, et al. Long-term results of continuous treatment with recombinant interferon-alpha in patients with metastatic carcinoid tumors--an antiangiogenic effect? Anticancer Drugs 1996; 7:175.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/31\">",
"      K&ouml;lby L, Persson G, Franz&eacute;n S, Ahr&eacute;n B. Randomized clinical trial of the effect of interferon alpha on survival in patients with disseminated midgut carcinoid tumours. Br J Surg 2003; 90:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/32\">",
"      Arnold R, Rinke A, Klose KJ, et al. Octreotide versus octreotide plus interferon-alpha in endocrine gastroenteropancreatic tumors: a randomized trial. Clin Gastroenterol Hepatol 2005; 3:761.",
"     </a>",
"    </li>",
"    <li>",
"     Information available online at file://clinicaltrials.gov/ct2/show/NCT00569127?term=carcinoid&amp;intr=bevacizumab&amp;rank=6 (Accessed on February 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/34\">",
"      V&auml;lim&auml;ki M, J&auml;rvinen H, Salmela P, et al. Is the treatment of metastatic carcinoid tumor with interferon not as successful as suggested? Cancer 1991; 67:547.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/35\">",
"      Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992; 326:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/36\">",
"      Kouvaraki MA, Ajani JA, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment of patients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004; 22:4762.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/37\">",
"      Ramanathan RK, Cnaan A, Hahn RG, et al. Phase II trial of dacarbazine (DTIC) in advanced pancreatic islet cell carcinoma. Study of the Eastern Cooperative Oncology Group-E6282. Ann Oncol 2001; 12:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/38\">",
"      Stevens MF, Hickman JA, Langdon SP, et al. Antitumor activity and pharmacokinetics in mice of 8-carbamoyl-3-methyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one (CCRG 81045; M &amp; B 39831), a novel drug with potential as an alternative to dacarbazine. Cancer Res 1987; 47:5846.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/39\">",
"      Kulke MH, Stuart K, Enzinger PC, et al. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors. J Clin Oncol 2006; 24:401.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/40\">",
"      Chan JA, Stuart K, Earle CC, et al. Prospective study of bevacizumab plus temozolomide in patients with advanced neuroendocrine tumors. J Clin Oncol 2012; 30:2963.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/41\">",
"      Strosberg JR, Fine RL, Choi J, et al. First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas. Cancer 2011; 117:268.",
"     </a>",
"    </li>",
"    <li>",
"     Bergsland, EK, Ko, AH, Tempero, M, et al. Phase II trial of FOLFOX plus bevacizumab in advanced, progressive neuroendocrine tumors (abstract 216). Data presented at the 2008 ASCO Gastrointestinal Cancers Symposium, Orlando, FL, January 25-27, 2008, file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=53&amp;abstractID=10380 (Accessed on February 10, 2011).",
"    </li>",
"    <li>",
"     Kunz, PL, Kuo, T, Zahn, JM, et al. A phase II study of capecitabine, oxaliplatin, and bevacizumab for metastatic or unresectable neuroendocrine tumors (abstract 4104). J Clin Oncol 2010; 28:326s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=54381 (Accessed on February 10, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/44\">",
"      Bajetta E, Catena L, Procopio G, et al. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 2007; 59:637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/45\">",
"      Kulke MH, Mayer RJ. Carcinoid tumors. N Engl J Med 1999; 340:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/46\">",
"      Medley L, Morel AN, Farrugia D, et al. Phase II study of single agent capecitabine in the treatment of metastatic non-pancreatic neuroendocrine tumours. Br J Cancer 2011; 104:1067.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/47\">",
"      Ansell SM, Pitot HC, Burch PA, et al. A Phase II study of high-dose paclitaxel in patients with advanced neuroendocrine tumors. Cancer 2001; 91:1543.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/48\">",
"      Kulke MH, Kim H, Stuart K, et al. A phase II study of docetaxel in patients with metastatic carcinoid tumors. Cancer Invest 2004; 22:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/49\">",
"      Kulke MH, Kim H, Clark JW, et al. A Phase II trial of gemcitabine for metastatic neuroendocrine tumors. Cancer 2004; 101:934.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/50\">",
"      Ansell SM, Mahoney MR, Green EM, Rubin J. Topotecan in patients with advanced neuroendocrine tumors: a phase II study with significant hematologic toxicity. Am J Clin Oncol 2004; 27:232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/51\">",
"      Moertel CG, Hanley JA. Combination chemotherapy trials in metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer Clin Trials 1979; 2:327.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/52\">",
"      Engstrom PF, Lavin PT, Moertel CG, et al. Streptozocin plus fluorouracil versus doxorubicin therapy for metastatic carcinoid tumor. J Clin Oncol 1984; 2:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/53\">",
"      Sun W, Lipsitz S, Catalano P, et al. Phase II/III study of doxorubicin with fluorouracil compared with streptozocin with fluorouracil or dacarbazine in the treatment of advanced carcinoid tumors: Eastern Cooperative Oncology Group Study E1281. J Clin Oncol 2005; 23:4897.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/54\">",
"      Bukowski RM, Tangen CM, Peterson RF, et al. Phase II trial of dimethyltriazenoimidazole carboxamide in patients with metastatic carcinoid. A Southwest Oncology Group study. Cancer 1994; 73:1505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/55\">",
"      Kulke MH, Hornick JL, Frauenhoffer C, et al. O6-methylguanine DNA methyltransferase deficiency and response to temozolomide-based therapy in patients with neuroendocrine tumors. Clin Cancer Res 2009; 15:338.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/56\">",
"      Ekeblad S, Sundin A, Janson ET, et al. Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors. Clin Cancer Res 2007; 13:2986.",
"     </a>",
"    </li>",
"    <li>",
"     Mitry E, Walter T, Baudin E,  et al. Efficacy and safety of bevacizumasb combined with capecitabine in pregressive, metastatic well-differentiated digestive endocrine tumros (BETTER study). J Clin Oncol 30, 2012 (suppl); abstr 4071. file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=114&amp;abstractID=94731.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/58\">",
"      Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer 1991; 68:227.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/59\">",
"      Fj&auml;llskog ML, Granberg DP, Welin SL, et al. Treatment with cisplatin and etoposide in patients with neuroendocrine tumors. Cancer 2001; 92:1101.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/60\">",
"      Mitry E, Baudin E, Ducreux M, et al. Treatment of poorly differentiated neuroendocrine tumours with etoposide and cisplatin. Br J Cancer 1999; 81:1351.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/61\">",
"      Welin S, Sorbye H, Sebjornsen S, et al. Clinical effect of temozolomide-based chemotherapy in poorly differentiated endocrine carcinoma after progression on first-line chemotherapy. Cancer 2011; 117:4617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/62\">",
"      Hentic O, Hammel P, Couvelard A, et al. FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3. Endocr Relat Cancer 2012; 19:751.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/63\">",
"      Missiaglia E, Dalai I, Barbi S, et al. Pancreatic endocrine tumors: expression profiling evidences a role for AKT-mTOR pathway. J Clin Oncol 2010; 28:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/64\">",
"      Kulke MH, Lenz HJ, Meropol NJ, et al. Activity of sunitinib in patients with advanced neuroendocrine tumors. J Clin Oncol 2008; 26:3403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/65\">",
"      Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:501.",
"     </a>",
"    </li>",
"    <li>",
"     Hobday, TJ, Rubin, J, Holen, K, et al. MC044h, a phase II trial of sorafenib in patients (pts) with metastatic neuroendocrine tumors (NET): A Phase II Consortium (P2C) study (abstract 4504). J Clin Oncol 2007; 25:199s.Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=47&amp;abstractID=32899 (Accessed on February 11, 2011).",
"    </li>",
"    <li>",
"     Phan, AT,  Yao, JC, Fogelman, DR, et al. A prospective, multi-institutional phase II study of GW786034 (pazopanib) and depot octreotide (sandostatin LAR) in advanced low-grade neuroendocrine carcinoma (LGNEC) (abstract 4001). J Clin Oncol 2010; 28:301s. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=74&amp;abstractID=47809 (Accessed on February 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/68\">",
"      Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010; 28:69.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/69\">",
"      Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/70\">",
"      Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009; 360:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/71\">",
"      Fiebrich HB, Siemerink EJ, Brouwers AH, et al. Everolimus induces rapid plasma glucose normalization in insulinoma patients by effects on tumor as well as normal tissues. Oncologist 2011; 16:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/72\">",
"      Ong GS, Henley DE, Hurley D, et al. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol 2010; 162:1001.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/73\">",
"      van der Veldt AA, Kleijn SA. Advances in pancreatic neuroendocrine tumor treatment. N Engl J Med 2011; 364:1873; author reply 1873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/74\">",
"      Duran I, Kortmansky J, Singh D, et al. A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 2006; 95:1148.",
"     </a>",
"    </li>",
"    <li>",
"     Hobday TJ, Qin R, Reidy DL, et al. Multicenter phase II trial of temsirolimus and bevacizumab in pancreatic neuroendocrine tumor (abstract). J Clin Oncol 2012; 30 (suppl 4): Abstract 260. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=115&amp;abstractID=87929 (Accessed on March 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/76\">",
"      Yao JC, Phan AT, Chang DZ, et al. Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low- to intermediate-grade neuroendocrine tumors: results of a phase II study. J Clin Oncol 2008; 26:4311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/77\">",
"      Pavel ME, Hainsworth JD, Baudin E, et al. Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study. Lancet 2011; 378:2005.",
"     </a>",
"    </li>",
"    <li>",
"     Yao JC, Hainsworth JD, Wolin EM, et al. Multivariate analysis including biomarkers in the phase III RADIANT-2 study of octreotide LAR plus everolimus or placebo among patients with advanced neuroendocrine tumors (abstract). J Clin Oncol 2012; 30 (sauppl 4): abstract 157. Abstract available online at file://www.asco.org/ASCOv2/Meetings/Abstracts?&amp;vmview=abst_detail_view&amp;confID=115&amp;abstractID=88080 (Accessed on March 16, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/79\">",
"      Oh DY, Kim TW, Park YS, et al. Phase 2 study of everolimus monotherapy in patients with nonfunctioning neuroendocrine tumors or pheochromocytomas/paragangliomas. Cancer 2012; 118:6162.",
"     </a>",
"    </li>",
"    <li>",
"     National Comprehensive Cancer Network (NCCN) guidelines available online at file://www.nccn.org/professionals/physician_gls/f_guidelines.asp (Accessed on July 02, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/81\">",
"      Yao JC, Phan A, Hoff PM, et al. Targeting vascular endothelial growth factor in advanced carcinoid tumor: a random assignment phase II study of depot octreotide with bevacizumab and pegylated interferon alpha-2b. J Clin Oncol 2008; 26:1316.",
"     </a>",
"    </li>",
"    <li>",
"     Trial information available online at file://www.clinicaltrials.gov/ct2/show/NCT00569127?term=carcinoid+and+bevacizumab&amp;rank=6 (Accessed on February 11, 2011).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/83\">",
"      McCarthy KE, Woltering EA, Espenan GD, et al. In situ radiotherapy with 111In-pentetreotide: initial observations and future directions. Cancer J Sci Am 1998; 4:94.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/84\">",
"      Buscombe JR, Caplin ME, Hilson AJ. Long-term efficacy of high-activity 111in-pentetreotide therapy in patients with disseminated neuroendocrine tumors. J Nucl Med 2003; 44:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/85\">",
"      Anthony LB, Woltering EA, Espenan GD, et al. Indium-111-pentetreotide prolongs survival in gastroenteropancreatic malignancies. Semin Nucl Med 2002; 32:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/86\">",
"      McStay MK, Maudgil D, Williams M, et al. Large-volume liver metastases from neuroendocrine tumors: hepatic intraarterial 90Y-DOTA-lanreotide as effective palliative therapy. Radiology 2005; 237:718.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/87\">",
"      Waldherr C, Pless M, Maecke HR, et al. Tumor response and clinical benefit in neuroendocrine tumors after 7.4 GBq (90)Y-DOTATOC. J Nucl Med 2002; 43:610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/88\">",
"      Kwekkeboom DJ, Bakker WH, Kam BL, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA(0),Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003; 30:417.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/89\">",
"      Kwekkeboom DJ, de Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. J Clin Oncol 2008; 26:2124.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/90\">",
"      Grozinsky-Glasberg S, Barak D, Fraenkel M, et al. Peptide receptor radioligand therapy is an effective treatment for the long-term stabilization of malignant gastrinomas. Cancer 2011; 117:1377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/91\">",
"      Wang SC, Parekh JR, Zuraek MB, et al. Identification of unknown primary tumors in patients with neuroendocrine liver metastases. Arch Surg 2010; 145:276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/92\">",
"      Villard L, Romer A, Marincek N, et al. Cohort study of somatostatin-based radiopeptide therapy with [(90)Y-DOTA]-TOC versus [(90)Y-DOTA]-TOC plus [(177)Lu-DOTA]-TOC in neuroendocrine cancers. J Clin Oncol 2012; 30:1100.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/93\">",
"      Savelli G, Bertagna F, Franco F, et al. Final results of a phase 2A study for the treatment of metastatic neuroendocrine tumors with a fixed activity of 90Y-DOTA-D-Phe1-Tyr3 octreotide. Cancer 2012; 118:2915.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/94\">",
"      Schillaci O, Corleto VD, Annibale B, et al. Single photon emission computed tomography procedure improves accuracy of somatostatin receptor scintigraphy in gastro-entero pancreatic tumours. Ital J Gastroenterol Hepatol 1999; 31 Suppl 2:S186.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/95\">",
"      Gibril F, Reynolds JC, Doppman JL, et al. Somatostatin receptor scintigraphy: its sensitivity compared with that of other imaging methods in detecting primary and metastatic gastrinomas. A prospective study. Ann Intern Med 1996; 125:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/96\">",
"      Imhof A, Brunner P, Marincek N, et al. Response, survival, and long-term toxicity after therapy with the radiolabeled somatostatin analogue [90Y-DOTA]-TOC in metastasized neuroendocrine cancers. J Clin Oncol 2011; 29:2416.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/97\">",
"      Hillman N, Herranz L, Alvarez C, et al. Efficacy of octreotide in the regression of a metastatic carcinoid tumour despite negative imaging with In-111-pentetreotide (Octreoscan). Exp Clin Endocrinol Diabetes 1998; 106:226.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/98\">",
"      Kennedy A, Coldwell D, Sangro B, et al. Integrating radioembolization into the treatment paradigm for metastatic neuroendocrine tumors in the liver. Am J Clin Oncol 2012; 35:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/99\">",
"      Sywak MS, Pasieka JL, McEwan A, et al. 131I-meta-iodobenzylguanidine in the management of metastatic midgut carcinoid tumors. World J Surg 2004; 28:1157.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/100\">",
"      Safford SD, Coleman RE, Gockerman JP, et al. Iodine-131 metaiodobenzylguanidine treatment for metastatic carcinoid. Results in 98 patients. Cancer 2004; 101:1987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/101\">",
"      Nwosu AC, Jones L, Vora J, et al. Assessment of the efficacy and toxicity of (131)I-metaiodobenzylguanidine therapy for metastatic neuroendocrine tumours. Br J Cancer 2008; 98:1053.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"mobipreview.htm?38/46/39658/abstract/102\">",
"      Taal BG, Hoefnagel CA, Valdes Olmos RA, et al. Palliative effect of metaiodobenzylguanidine in metastatic carcinoid tumors. J Clin Oncol 1996; 14:1829.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 16901 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.4 - C21.36",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Southeast Alabama Med Ctr",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.248-A392849A5D-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39658=[""].join("\n");
var outline_f38_46_39658=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H190949140\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190948900\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1973644\">",
"      CLASSIFICATION, BIOLOGIC BEHAVIOR, AND IMPLICATIONS FOR TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1974073\">",
"      Overview of treatment options",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190948921\">",
"      SOMATOSTATIN ANALOGS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190948928\">",
"      Octreotide and other somatostatin analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190948935\">",
"      - Use in asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190948942\">",
"      Prevention and management of carcinoid crisis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190948949\">",
"      INTERFERON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190948956\">",
"      CYTOTOXIC CHEMOTHERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190948963\">",
"      Pancreatic NETs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190948970\">",
"      - Streptozocin combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190948977\">",
"      - Dacarbazine (DTIC) and temozolomide-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190948984\">",
"      - Oxaliplatin-containing regimens",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190948991\">",
"      Carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190948998\">",
"      - Streptozocin combinations",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190949005\">",
"      - Dacarbazine and temozolomide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190949012\">",
"      - Oxaliplatin-based regimens",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26472645\">",
"      - Capecitabine plus bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26471971\">",
"      - Summary",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190949019\">",
"      Poorly differentiated tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190949026\">",
"      MOLECULARLY TARGETED THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190949033\">",
"      Pancreatic NET",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190949040\">",
"      - Small molecule TK inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H190949047\">",
"      Sunitinib",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H190949054\">",
"      Sorafenib and pazopanib",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190949061\">",
"      - mTOR inhibitors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H190949068\">",
"      Everolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem2\">",
"     <a class=\"outlineLink\" href=\"#H190949075\">",
"      Temsirolimus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190949082\">",
"      Carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190949089\">",
"      - Small molecule TK inhibitors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190949103\">",
"      - Everolimus",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H88977934\">",
"      - Bevacizumab",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190949111\">",
"      SYSTEMIC RADIONUCLIDE THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190949119\">",
"      Peptide receptor radioligand therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190949126\">",
"      - Radiolabeled somatostatin analogs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190949133\">",
"      - MIBG",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H190949140\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190949148\">",
"      Carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1974409\">",
"      - Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190949177\">",
"      - Progressive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190949184\">",
"      Pancreatic neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190949192\">",
"      - Initial therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H190949200\">",
"      - Progressive disease and/or symptomatic from tumor bulk",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H190949207\">",
"      Poorly differentiated neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/16901\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/16901|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?17/14/17644\" title=\"table 1\">",
"      Nomenclature and classification for neuroendocrine tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/9/34973\" title=\"table 2\">",
"      Octreotide IFN met neuroend tum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/59/35771\" title=\"table 3\">",
"      Products of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?6/42/6829\" title=\"table 4\">",
"      Chemo met panc endocrine tum",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?31/30/32237\" title=\"table 5\">",
"      Chemo met carcinoid",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?34/19/35133\" title=\"table 6\">",
"      Nonrandomized trials novel targeted therapies NET",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?32/37/33372\" title=\"table 7\">",
"      Randomized trials of novel agents in advanced NETs",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"mobipreview.htm?41/48/42764\" title=\"table 8\">",
"      RECIST response criteria solid tumors",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?4/3/4153?source=related_link\">",
"      Bronchial carcinoid tumors: Treatment and prognosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/11/12472?source=related_link\">",
"      Carcinoid heart disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?17/57/18330?source=related_link\">",
"      Classification, epidemiology, clinical presentation, localization, and staging of pancreatic neuroendocrine tumors (islet-cell tumors)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?0/60/969?source=related_link\">",
"      Clinical characteristics of carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?8/63/9206?source=related_link\">",
"      Clinical features of the carcinoid syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?34/63/35834?source=related_link\">",
"      Cutaneous complications of molecularly targeted therapy and other biologic agents used for cancer therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?11/8/11400?source=related_link\">",
"      Diagnosis of the carcinoid syndrome and tumor localization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/39/6778?source=related_link\">",
"      First-line chemotherapy for patients with extensive stage small cell lung cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?30/57/31640?source=related_link\">",
"      Glucagonoma and the glucagonoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?12/30/12777?source=related_link\">",
"      Insulinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/30/43496?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Local options to control tumor growth",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/32/6665?source=related_link\">",
"      Metastatic gastroenteropancreatic neuroendocrine tumors: Presentation, prognosis, imaging, and biochemical monitoring",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?40/13/41174?source=related_link\">",
"      Neuroendocrine cancer of unknown primary site",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?13/53/14169?source=related_link\">",
"      Pathogenesis and biology of malignant gliomas",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?6/40/6794?source=related_link\">",
"      Pathology, classification, and grading of neuroendocrine tumors arising in the digestive system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?28/49/29466?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?3/34/3623?source=related_link\">",
"      Somatostatinoma",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?15/59/16311?source=related_link\">",
"      The VIPoma syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?35/43/36538?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?42/54/43882?source=related_link\">",
"      Toxicity of molecularly targeted antiangiogenic agents: Non-cardiovascular effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?38/61/39897?source=related_link\">",
"      Treatment and surveillance of non-metastatic carcinoid tumors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"mobipreview.htm?16/31/16888?source=related_link\">",
"      Treatment of the carcinoid syndrome",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f38_46_39659="VFD localization asso sx";
var content_f38_46_39659=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F63087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F63087&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Localizing retrochiasmal visual field defects",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Defect",
"      </td>",
"      <td class=\"subtitle1\">",
"       Localization",
"      </td>",
"      <td class=\"subtitle1\">",
"       Associated symptoms, signs",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Homonymous sectoranopia",
"      </td>",
"      <td>",
"       Lateral geniculate body",
"      </td>",
"      <td>",
"       Optic atrophy, hemianesthesia, hemiparesis",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Homonymous pie-in-the-sky",
"      </td>",
"      <td>",
"       Anterior temporal lobe",
"      </td>",
"      <td>",
"       Receptive aphasia (dominant hemisphere)",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Homonymous quadrantanopia",
"      </td>",
"      <td>",
"       Posterior optic radiations, visual cortex",
"      </td>",
"      <td>",
"       Hemisensory loss, depending on lateralization: hemineglect Gerstmann's syndrome",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Homonymous paracentral scotomas",
"      </td>",
"      <td>",
"       Posterior primary visual cortex",
"      </td>",
"      <td>",
"       Isolated symptom",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Macular-sparing homonymous hemianopia",
"      </td>",
"      <td>",
"       Primary visual cortex (sparing posterior portion)",
"      </td>",
"      <td>",
"       Isolated if occipital lobe",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Temporal crescent only",
"      </td>",
"      <td>",
"       Far anterior primary visual cortex",
"      </td>",
"      <td>",
"       Often isolated symptom",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Temporal crescent-sparing homonymous hemianopia",
"      </td>",
"      <td>",
"       Primary visual cortex (sparing far anterior portion)",
"      </td>",
"      <td>",
"       Isolated symptom",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       Bilateral homonymous hemianopia",
"      </td>",
"      <td>",
"       Bilateral posterior optic radiations or primary visual cortex",
"      </td>",
"      <td>",
"       Anton's syndrome",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39659=[""].join("\n");
var outline_f38_46_39659=null;
var title_f38_46_39660="Consensus criteria for Cowden syndrome diagnosis";
var content_f38_46_39660=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F64799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F64799&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    International Cowden Consortium consensus criteria for diagnosis of Cowden syndrome",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Pathognomonic criteria",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Major criteria",
"       </td>",
"       <td class=\"subtitle1_single\">",
"        Minor criteria",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        <p>",
"         Mucocutaneous lesions:",
"        </p>",
"        <p>",
"         - Trichilemmomas, facial",
"         <br/>",
"         - Acral keratoses",
"         <br/>",
"         - Papillomatous lesions",
"         <br/>",
"         - Mucosal lesions",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Breast cancer",
"        </p>",
"        <p>",
"         Thyroid cancer, especially follicular thyroid cancer",
"        </p>",
"        <p>",
"         Macrocephaly (occipital frontal circumference &ge;97th percentile)",
"        </p>",
"        <p>",
"         Lhermitte-Duclos disease, defined as presence of a cerebellar dysplastic gangliocytoma",
"        </p>",
"        <p>",
"         Endometrial carcinoma",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         Other thyroid lesions (for example, goiter)",
"        </p>",
"        <p>",
"         Mental retardation (IQ &le;75)",
"        </p>",
"        <p>",
"         Harmartomatous intestinal polyps",
"        </p>",
"        <p>",
"         Fibrocystic disease of the breast",
"        </p>",
"        <p>",
"         Lipomas",
"        </p>",
"        <p>",
"         Fibromas",
"        </p>",
"        <p>",
"         Genitourinary tumours (for example, uterine fibroids, renal cell carcinoma) or genitourinary malformation",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        An operational diagnosis of Cowden syndrome is made if an individual meets any one of the following criteria:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1_start\" colspan=\"3\">",
"        1. Pathognomic mucocutaneous lesions alone if there are:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"3\">",
"        Six or more facial papules, of which three or more must be trichilemmomas, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"3\">",
"        Cutaneous facial papules and oral mucosal papillomatosis, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"3\">",
"        Oral mucosal papillomatosis and acral keratoses, or",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist2\" colspan=\"3\">",
"        Six or more palmoplantar keratoses",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        2. Two major criteria, but one must be either macrocephaly or Lhermitte-Duclos disease",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        3. One major and three minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        4. Four minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\" colspan=\"3\">",
"        In a family in which one individual meets the diagnostic criteria for Cowden syndrome, other relatives are considered to have a diagnosis of Cowden syndrome if they meet any of the following criteria:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        1. A pathognomonic mucocutaneous lesion",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        2. Any one major criterion with or without minor criteria",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"3\">",
"        3. Two minor criteria",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from: Pilarski R, Eng C. Will the real Cowden syndrome please stand up (again)? Expanding mutational and clinical spectra of the PTEN hamartoma tumour syndrome. J Med Genet 2000; 37:828; with permission from BMJ Publishing Group Ltd. Copyright &copy; 2000.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39660=[""].join("\n");
var outline_f38_46_39660=null;
var title_f38_46_39661="Nonpharm Rx subacute LBP";
var content_f38_46_39661=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PC%2F61982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PC%2F61982&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Non-pharmacologic therapies for chronic or subacute low back pain",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Intervention",
"       </td>",
"       <td class=\"subtitle1\">",
"        Net benefit*",
"       </td>",
"       <td class=\"subtitle1\">",
"        Graded recommendation&sect;",
"       </td>",
"       <td class=\"subtitle1\">",
"        Comments",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Acupuncture",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Suggested",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        Efficacy of acupuncture versus sham acupuncture inconsistent.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Exercise therapy",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Suggested",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Functional restoration",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Suggested",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interdisciplinary rehabilitation",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Suggested",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        More intense interdisciplinary rehabilitation more effective than less intense interdisciplinary rehabilitation.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Interferential therapy",
"       </td>",
"       <td>",
"        Unable to estimate",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Low-level laser therapy",
"       </td>",
"       <td>",
"        Unable to estimate",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        Trials evaluated different types and intensity of laser, with inconsistent findings.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lumbar supports",
"       </td>",
"       <td>",
"        Unable to estimate",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2C)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Massage therapy",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Suggested",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        Some trials evaluated minimal or light massage techniques.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Percutaneous electrical nerve stimulation",
"       </td>",
"       <td>",
"        Unable to estimate",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Psychological therapies",
"       </td>",
"       <td>",
"        Moderate (cognitive-behavioral treatment)",
"       </td>",
"       <td>",
"        Suggest cognitive-behavioral treatment",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Short-wave diathermy",
"       </td>",
"       <td>",
"        Not effective",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Spinal manipulation",
"       </td>",
"       <td>",
"        Moderate",
"       </td>",
"       <td>",
"        Suggested",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Traction",
"       </td>",
"       <td>",
"        Not effective (for continuous traction)",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Transcutaneous electrical nerve stimulation (TENS)",
"       </td>",
"       <td>",
"        Unable to estimate",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Ultrasound",
"       </td>",
"       <td>",
"        Unable to estimate",
"       </td>",
"       <td>",
"        Suggest not using",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Yoga",
"       </td>",
"       <td>",
"        Moderate (for Viniyoga)",
"       </td>",
"       <td>",
"        Suggested",
"        <strong>",
"         (2B)",
"        </strong>",
"       </td>",
"       <td>",
"        Insufficient evidence to judge non-Viniyoga techniques.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Based on evidence showing medication is more effective than placebo, and/or evidence showing medication is at least as effective as other medications or interventions thought to be effective, for one or more of the following outcomes: pain, functional status, or work status. Versus placebo, small benefit defined as 5-10 points on a 100-point Visual Analogue Scale (VAS) for pain (or equivalent), 1-2 points on the Roland Morris Disability Questionnaire (RDQ), 10-20 points on the Oswestry Disability Index (ODI), or a standardized mean difference (SMD) of 0.2-0.5. Moderate benefit defined as 10-20 points on a VAS for pain, 2-5 points on the RDQ, 10-20 points on the ODI, or a SMD of 0.5-0.8. Large benefit defined as &gt;20 points on a 100 point VAS for pain; &gt;5 points on the RDQ, &gt;20 points on the ODI, or a SMD of &gt;0.8.",
"     <br>",
"      &sect; Grading:",
"      <br>",
"       <strong>",
"        1A",
"       </strong>",
"       - Strong recommendation. High quality evidence. Strong recommendation, can apply to most patients in most circumstances without reservation.",
"       <br>",
"        <strong>",
"         1B",
"        </strong>",
"        - Strong recommendation. Moderate quality evidence. Strong recommendation, likely to apply to most patients.",
"        <br>",
"         <strong>",
"          1C",
"         </strong>",
"         - Strong recommendation. Low quality evidence. Relatively strong recommendation; might change when higher quality evidence becomes available.",
"         <br>",
"          <strong>",
"           2A",
"          </strong>",
"          - Weak recommendation. High quality evidence. Weak recommendation, best action may differ depending on circumstances or patients or societal values.",
"          <br>",
"           <strong>",
"            2B",
"           </strong>",
"           - Weak recommendation. Moderate quality evidence. Weak recommendation, alternative approaches likely to be better for some patients under some circumstances.",
"           <br>",
"            <strong>",
"             2C",
"            </strong>",
"            - Weak recommendation. Low quality evidence. Very weak recommendation; other alternatives may be equally reasonable.",
"           </br>",
"          </br>",
"         </br>",
"        </br>",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39661=[""].join("\n");
var outline_f38_46_39661=null;
var title_f38_46_39662="PCOS pathogenesis model";
var content_f38_46_39662=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F87315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F87315&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 471px\">",
"   <div class=\"ttl\">",
"    Minimal model for the pathogenesis of polycystic ovary syndrome (PCOS)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 451px; height: 264px; background-image: url(data:image/gif;base64,R0lGODlhwwEIAfcAAP////8tiwAz/wAAAACZZkRERIiIiIig/7u7u8XFxX+Z/5OTk/87k0Rp/+/y/6ioqA8///+dyb/M/+Li4vj4+GZmZj9l/9TU1MzMzJqamp+y//Hx8bvJ/19//4yMjJmZmS9Z/9/l/+np6be3t93d3SIiIiJO/x9M/zMzMxEREW+M///x9/+Pwe7u7pmt/6Ghof9XomaF/8/Z/76+vt3k/9vb2//K4v/V6P/y+LCwsDNc/4jPuP85kq+//09y//9hqI+l//9Jmv97tv9zslVVVT+yjA+fb/9UoP/l8BFB/+7x//9lqv+52M/s4v9Hmf+Wxf/X6e/v76qqqu/59R8fH/+w03d3d5+fn7/l2f+IvVV3/3/MsszW//+jzL+/v8/Pz+749RGgcP9ur/+92/+r0f/H4D8/Py+sgpnWwh+leQ8PD3eS/5/Zxd/y7F+/n7vk1n9/f19fX//j8C8vL/+Bua/fz0S0jyKnenfJrU9PT4/SvG9vb6+vr93x62bCozOthY+Pj6q7/2/FqU+5lczr4N/f36rdzFW7mTAwMCcnJ2iG//9DlwAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAAACH5BAAAAAAALAAAAADDAQgBAAj/AAEIHEiwoMGDCBMqXMiwocOHECNKnEixosWLGDNq3Mixo8ePIEOKHEmypMmTKFOqXMmypcuXMGPKnEmzps2bOHPq3Mmzp8+fQIMKHUq0qNGjSJMqXcq0qdOnUKNKnUq1qtWrWLNq3cq1q9evYMOKHUu2rNmzaNOqXcu2rdu3cOPKnUu37lACePPq3cu3r9+/gAPvtUu48EUCRREbXsy4oeK7jSNLLvhYaOXJmA1fBro5s2esbbCIxtKkYmefpz+rDhoay5bXRWKf8Rs7tpG+RmoX2cLmYGqev1cLp4mlzhY3RW7nLiLodZ3RUya2Lr4Fi++COy4T2DEwu8zgw8On/2xivEgaAmd26yHd8rJ3gtu7gzc5X7x9j1PKE8i9pU7pme5px51A7xEEhh142QEGGHcMiMYdfQDgB153vAEAGmEQEAYaAuGB14YXZkgAHpTdZ+JI+QkyG3N1tJFTgJQNCECBA9nxx4J/+AEAIWFEeAchAOARBpA77PAGARyiQUAfhvQ4ox9gEGDIhXaUeOKVGzWhIgG7WdcTjPDxVVCUQF54B4F+oDFgGCQOhMchA92BRpMWChSljFZiqedEdbhhRBqC1BEdZ9gJKF9BR+p1pkB/PIYkQQjqxeGEBPxh4Q4ZhoEnAPXt6WmfRpyhx380IYGEY4XGeKiBBIBhUJE7tP/JJkF4tHmQjQRl5+pAnXp6YhN+pqGHizjhEIAQNiwEJq8y0iiQHQ7qyOOCYVjox5AzGhmGnYe8sQOUQdrxhh1ANrmrQL36Gt4UbJxhhCCk6iREAAH8kCxCAep1ZLObgdGohjsw6CCEABxCoYVKJtjHG//+0UcfkVaYp7qetuFnEb3JhIQNHHfc8akAjEEvvfZeR1S6FGeGRXJuEEvSxjY88UQWP9TMw8j08lDzzjzfjDPOJcOXWMpYtpvGFoN+BMUYTwjxgxMB6PxDFjJ3DIVEVfwsRhU4TBwUykQvxkYaaWTMEQ4xi3FEAE788EQXNlzNEdRsdwGyQWB/F7Z4WJz/UTZHUHQhBtRTV3FvSFXwkIXcCeUdk+N7x9VEcmZfFLgYPDghRBeMl3S3skNH7tkUfiJ9EQ5jCOEED0JU8flNkL8Uu+hq6WHEIC5PhEMVYgRwxBOd7yTY8MQXb/zstJs1eRpeUjRG70fYnfz0Z21BwBYVQZEFD9G/Tv33XzVxxhnxQlTFD4oHD/76XdmOvUQ4POHEEVWwb/9XUwySRvkNIbG9GIe7nwCz0oQ0DCJpDkHCvITgvQE6cCpsIIAeIhI/1jXwgRh8ip/4t5Au8EAMF8ygCJUyhSKcIXcMscH8AjjCFi5lCmc44ENwgLn6ufCGS2mCEdwAkTGwrms4DOJR/3T4vobQ0AksFKISgaLDyi3Eh1kA4hKn+JMmPmR7Y7AI2mZWM7r5rmZUs4EUqUhGiljRiEc4QggVgjrV1SuMHBtIx5r2A7YJYQxjLKMeFXJGhkBBcRNJne+AF5GYrW1re0zkQdpghAk2JHE2nGEXnOAE6VkECV04guLWqEghwpCHDXkCD9THRlEGbSNQWCAnO+nCIoCSIUJQo/nalsSNKPBYeWQlDt1wBgQmJJa5TAgSnpbFlwmBB13QpRDZYARfIgSYD/HgE4IZEhUegZQ32cAEtpmAbnrzm97EwDYnQAFlbqUJBOCgQaBpxMFhkySijKRMtJmAGTzgAR7wwALu+f+AGYDznwkYAT/zuc8HJECc5TQnVKYgrIaw04+ao6ZJbMC6l0wAAwLVZz8TUANyYkSbFwgoPvc5gwuIQKFLGcQgHHoEiRYkccmECQ7S6FKPUKAG9vRABkaAUJPQMwcZ2GcCJoDSoughDc40yBNa6pDE1bIlDy2mR0SQgBd44AUzqEFCXbKBC8wgAx7IAQY2UNSfMLJ5CUncKgVyzHdClakU7UgNRrCAnWoVJ13NQV1ncNKy6oQ5fgyAWwmiusG+FQdQWytDJkDXDPAVKHPdK1n9WpOjJpUgOOCBPBXy0JsIYRH02mxENpCADDi2r0SJ7AsusFXKumQKRkArQqbmkO3/KVYlNsjC2kaWBYow1gMjqMFSKHCBByxgBJN1LUvcsNKFLLWpo8wJDrLwsyNI5AIvWEACktuUDdA1B0RV7niMgEKD/HGtPjQsTGywW3pB5AKmvUBVKJCAfYZXvCXZzUIQG9OF/FG0ORElvZ5aEPhmQL5Yoa998fuRNvwHC81cCM2MWMmgDDMAT1jIBF5w4K4oOAfcZXBGjFAa/SrkvA35gRCIMobeImQDek1AWCgwAw8koLUitghe8BBhhfygvwpZak2HgoHj4vgrInhABu6bY9PghWzoQUgVnNAQiqoXKBtQMpPJcoEF5ODITX7IXnp5EMQSeCD8bUqRZawWCgB1/8thdohekIqQJ/ygIWIQA1PcvGS3rDnOESkCXkiMkMyeWSA+HPJPRJCBL8NFBC94AJgBfRBBExohXbjzfnkgVaR0GQNzocAIMoBaSickOeoUCBIZkgU9K6XIwq1LfeFsaoIUoQ4KGYN1F0LR2+6ErqWmywU8gOBaG6S8BUHkQn6nlBG8IMQlKUEFMiLtmUxgAcU29kPEUFMkuBopzp60RgpQgIEgYAAIuIgByo0TEWBb22gJ90jIbW50q5vd7X43vMlSZGh7hN4COXe6CzBtA6CgAAMoQQsQPgAUgNreAKiAAc49gIqTgOAAwAAKKl6AFpyb4RWoAMdLMgEPBHvfXf/p8sk/AnAACBwAGDdACgwgECugAAAtIMIHAABxiQNg3QPBOAqskHEUkODcRP94C0iQAimUROVh+5nUp071qlv96ljPuta3zvWu4+wh7o41SRhe8YoPvOD4tjkJCNJzmgNdIELHt8sHMBCIo4DmJamquK/k9b77/e+AD7zgHUKBF7C5JC1/eczxfXGOr73tP8c3xhGw8QFM+9x1TzfM8V6SB+TgIgIIvehHT/rSm/70qE+96lfP+taXPiKCj73sZ0/7rjvEnihJvL0XbxASlIDokH87zKddbylgXiAQLwDnSUIBfVPE9dCPvvSnT/3XQ6T22M++9mPfkBosYO//xrf/4tE+ECLg/e4AmDkAPlACt6egBXCfNgp2znQEHJ/nmlc+Sq7tb4dU//8AGIDVB3vbV4AGeIBUxxAUkAFiZxK6d3aRNxAyV3FEEHAVhwLo1wKVd3HTJnIVR3P3l3zLVxIz8HnPF3ppIXoEODLi8TMMkQAPcB/NR2sNoYJoYYMP4YLhoYMJsQEe0H+qAV8nKAApiILX93U7iIQJMQIjcCUdJhE4aBZR2BA8KBxVaBA+CISrIYRQaIRnMYUMcYWqIYYEMQNNiCVPCBFgiBEcIAA0QAMC4AIgAYdyGBJrqBBk6Bl5CADNp4XCUVxdSIQCAYehFwMW0YY00BIH0ABQyAEF/3GHCbGHQsEAARABO7GHgKgnfRgRUygAB3ARiKiIjMiJjkgQkIgQkigSN7AEI8MCGUGJlqgTe5gD2XYlPMWJXigQnigQDdAAOiAAScAFArEGoZcEctgAnwgALsCIoRiHANCLvxiMB3EAOtAAAmACAECMAqADwqgE1riNwuiMLpAEobcGbSh6NPCNAqAFAnEAJvCNxyh6hqiLuUiFSogSZRAADHADABABAQADVpGHFOAB4BcUA7BzDFFtNFEDL4CLgjgQu/iMOuCIWsCOgZAEiXgAhoiMArGMANCMxziRAFCR05gEyeiOwhgD2LgGOgAASqAFchiHSiAAgaCMjLiIBv/BBTQJAAdgkjyZBLpYihBZj2F4jycBA5U4EEgZATdAL3IAAEygjwCAlPTCALFIiXSAlCuwlFM5MlYpEJQ4BKwYBPyoEnlYAzGIEkQwACPIEQeJEMKHEz+ohvUYkRypjNh4kUL5jMnokSDJlx2JjQaBkwKhA8kIhzTAkokIkS4wk8nYjqNYEBxJmIgJAAKwl5ZJlAuRih+xAvRSBgPBAgGwBAAQBElJBwFABwSxApQImpQ4MluZlAPBmgHgmgEwBAAwBAEQBCuRh/6EEi2QAgcXEm95EHF5Ew9QiwvRicl4ly4gmDEQeiLpnMzohpZ5jH2JjecoAIZImJk5em/4jQ3/kIjO2JPA+IneuYyih56jWJmX+YiaiYdGWRJNGQBlCQCiCZD+SJqmCZpyIJojY4mwqJRJ+Z84I6AB4Ir+yAC9OZ8C8QI0CBJSUAJSMABr93MlwHAISQKVV4FS8H4CYQAlEIEAQAJ0x3M7R3YVSHEWh3EAsJYNt3bn5oHEZxL1RJcPqYvNmZ2S2ZLU+ZHW6YzOKZgF4Z06UJMHQQMmsAbXSRAHIABKQJncyYvsOYhBipmneBCc6RGeWZuhOZoAIAf6GJW8SZu4OaADKhBLaaYAgKYJ2o9SaZYOCgAEqZZEp34/p34yJxAZWqLtl34IiX5vZ6LIh5ACgQED4HTCh3EV/1ACa0dvM5pxAwBqJjEBael/dbmjgcmTMaAE2ciIWsCIXFCNQEqe2LmpgxmZB8COADCqI5mMhnmdHNAAwniRUZoEnqqTjsgBJlClAFCZPmmK8RmJczoSXKmmsjmWbxqVAbACbZqUadqVEcCszuqmChqnKUGGjAackxpxN0eiJkoCiEqpIgoAVlBuiLp2g3qixRl0bid504an6Xp/JWCoJLEBC4CjA0GIUzqkH/mL25iISnqNvViqTeqvqUoQ0VmIPxl6rBqH6Rh6JuCISgCwNLCwOtCrPNme1ukCDEuPOWqPLKgS+biPcAqQAkEGI8OP+WifcuCmsSitLXsDLwutb/+6oA06sgVhqSjBfgJRoerKbuF6bheKeeP6dutaqOtHdu8adNPWruhGr/ZKEh6grzc4rKhYrCOxiq24mpSIsnD6jzBLoJboj2Jrs9fKoHKqswRxAWdoEjBadk1bohY6riE6ogAwdPUaokLLrh9gosSnf4sar3g3rycKAHt7EqT2EFnqFY1bEFvaGGTYTSfRAt0qEBVwc+u6dn3qe3hnAAMAonnaAjnnt4iabgjwpzIHf8MXcY4Kc+UmtSjxABFqEI/LFbc7EJHLGJN7eCRRrgNRoRiwuSXaoQNhuTUKcxUnckrrgSjwpxrYosQHo0Y3dwORuCZBu4yLtV+RuwKxu4v/0bspo72YGrJk4b0AAL6GIb4UQ741SJR36REqeRENYIjzixD3axHoK4aU6Io3Qa0nUZ/3aRHsqy7uyxBgGL82Ub8msb/z2b84AcAmIcAZQYZomTIL4IfCar4KXBMMXBIOzLZg+ab/Sy/OOhRkyLMUU7Xby8G+CIzCGKsuaYxtqAUf642h1wCeSo3W2KuCuY7kqAO5CrA63IYDMbHP2J0/rAVBvMPYiMPgaJnfaJjkaAKLucEr6F4FEZZjyY+mSQYjXAa6CQNIyQBMIBBywIq7Ccb1yQIMAAPMSi9L8JRma7aqKRAASpUrsKCi6YpkYJqjWZZMgJRBYJr+GwGvOQTV/3qbXQwAXcqPfxygz0oHrAgDN4CaAXDGkOug+Eox29rCBuGLFMmO4+ippdyGn6iTIakEFdudweqOujieSqCxOsCko0oDRiwQSMzAsCzFNDDL6LmSLfmSManDSpAE3AgAtWy73GsQ/Hububmb+AnNKguQYwwAKssAK7AC/SnA9UkvYDvNpGm2N1CfYJyfUGnCZksvLECmK1Cy20yJYIyU10qaunmm0KybZUovNxCV2kwQWAkAYwmnaksQeZjB6pKJ5RvKPHrMchiruTySnSoAwoiXGzsQvfyeABADhkiqAxHRu6zEQSkQHM2TwnzFllmKd7kGkTmU5ruZD3yzUgnPuv9piffsyPRCBv6IsqbJlJ85EBGgxlJptotsiT2dzs2KswLBinfc00pNz896xtn8rGmL0/bJx2A8wpaIzhKsu3P6AA2oJ78JypLJo9k4sdYZ0THQANspsRfdjj9ciiXNAQBriCDtiLwc1yQt0hErAOOZ0lQKmcz80vIpwlRN0ALR0wzwzzfdpREAoDjDAhQ8zUHABDhL1M8aAV16xtSq1F3pv/SMzp/dpT9Dm1X9yLE5Mmc8oFxtwpts2AJxo/OWvBxholMLErY9EhBqtQSBsHCoA6wa0bU8k57qpKqq1xs9jwLRhoFw10ls0iOd3NC9r0sK2ID51lh8hIYNwUq9oKn/KRA3Laa16Y+8SRCTDdWX7dpuCsadja1MndiVSN7I6oryvMUyzaCPLBBMwAJISZqs/Y9IfcJeDdsAMAEZYBFlNwBEwLoG4aLj1pZJ4YMOydCo+owa3YbC6LF43ZfdedzRXdI6IIc0kAQcoKs8+Z55/eEirQWw+okafZfe6dJZHAAGwd1xKt72Cd7QLN+0GYt04NM5LtDQjJoMitkDqpvjrM7Y6s75GAQrUJ9lwM1vmp/OygT+fd9WPcCsSN9J2drN+tpafBAITRFsmXEK2eC0fRH65xQXYIJk3dtmPd1AagLAWIcVW4y+Ot0aXdILG5FPCsR4LdLWXdKwbJ7rGN0w/97SIDvjNY7lSw3gOg4DlDjHaKyb4FzO/IzGVFnGYVvUjqzGarzH2IrNgLwEZUkGk37U/QjIb2rj+M3PkE3C/w2QXf29xToCM1ARZZ6nLlcCHxh/lqt5RBtxFVcClId3wblzVlBxKfABoFvsKFqiDFe9BPHsxp63nNfsLHrtPFcBKXCQb7lwHAd/GjfuFJGcE+4QwQqkUxHCYd4Qqh7NuNkTN0CJA7y2776zB07meGcFKWCiILh7HchuFVBu/g5qBmAAHwCiC98CH6qu07bm0Y6BpEsEmicQH2Bvqwu8H8rgL/qtA1AAF/qWBYACpIsC8kd0Gneho/V96c4QpfzRhP+9FO5O4w4x1QNx0zpBlf+oyS0hiQzI7xmXAlawpwJBBBF/eRYa7OlHdMfb7NgOAB968ZtXdx+AqE53EERQgQLR7EyP9AVxfBCHopZLqT47nBZhhoFYhDOftQSeGZKo0BGR4AWHtxHooigPvO1ac8ZuoZh7gQPHeQc57Afh4Pq39cGZbi3g7WWHfBc/+AmecC5XeWneEM23csvZzF1R8y2otTM4EbseoilQfkmP8Snwp01fECaKAlxPECVf9YWK9Qix9QMB9RUKvJmLuuz6+B9guR5PEOeW9RABgxOBvljB+Un49rF9qRAR+nQb8BCIcykgut6O8HiHcJpnABUAf+f/+qL49pYlYPIvSvUZn26r2/W7TgTstpaOb/Ww/wHyR38pQPWWvwC1mxDGfxXIPxypCBAUMtQAUNDgQYQGBxhAiKDEgIUFC1QwOPEgEYglEBQ0UMIgAhQQUZAAgOGhxwEfAJAIOWAkQgMZNxa0MoBkyYcDMBYcMBNASgAtWqZgWAFixIRJD87IodSpQQFRn06lWtXqVaxWowrIGsCr16xhxY4lW3bsV7BTa2SgYJYqhgEYphJ1W9cuVREeNozd2tfvX8CBBQ8mXNjwYcFd0d5l3NixWbQBqj6Y8fhghQJTP6RoYdlz2RcJyCImXdr0adR/FUdm3dr1a9ixZc+mXdv2/+20UzcsmPDZ9+/HCV6UTV3c+PHUq3EvZ97c+fPmVi8saAvc+nWxeUVg5979LnTw4cWPv311xAPv6dUDoLBA7nr48Z2Sp1/fPvirFF5Ult/f8osR/BNQvvsKNPDA17Da7YIBGzRrhBeqc5AqDagKIYQJM9Rww4JEWIBBDkNMCEIJRTzIAa6m6gAIE1t0kbsaPADxRQ1nWGA7B+HwgioJLKDKAgloFHJIxy6QkcgGR7hxwijU2IMqBVSgSgAHkLTySrGMnBFL9ZTE0cE4BpiDKh8qfCoECLh8MUg1w/LwvTaxowDCvSb04qgopoIAw6d68DHOEFHkE1CrPAyQ0N/0i/9QQzOOuuIpGU6gSgUFEN1QAwE6sNQqRUvc9C5DN7ziqAHieAoITaeyoIdPJwQhqkFbdUrJ3mStCwMP4GRSDVKpeKrMKau01b8QtpJyWKem4w/ZsCh4IIMvM9xDTEQSgegLp6icSgJJmZVPha0gENZbhDZ44IVoyX2qhgVG8HTCKwoBYA4vvKACEKV6AAHKVNVV74S+KvUXoQQWmOHdgQEwdwGCWoxiAIP4UEoFFlU1M2HuevBLXIwNMjeDLRMu+OAX+TCDqhNkmDLWjoHrAAIFFFFBhRMEbhmAtR6o1d8LMnggXRP3gGOqSHnc9+brNKgyyoJURpq9gnOok9kJng3/2UUqsH1q5kmPffo6P79GiIKCR5i61ao/RPILX6dKmSoQ2BQbOG7nHrtgnT/tGWSEXdzjSUi7PTNNu61LsXCDyM6A7zg3SCCDF64eMmsVbXYKCB8QB+4EuTUv6IIH2gVayBpy8GCEna9km6o9f7zYc8t8qBh2j2dYfIazWxRByQww6JvIOIZ+SoM/n0JxXNodU6Df5A2qgfcZRnfw+dult7JJeZ+y4HWlNMi8+cckOBp8hKhv94Lc5RMBA9P3sx7LK/KYCs2qgCW/sePvT2p90zMY4YL3/WYC7FvAAnKAPllRYUdb85pTioU8/dUFBKyKoFIGmIMMeIAyGJjA7+qy/4EJJABCHgAQAJHFh7Y5xQGtmwrmKsgYrr3wKRQIYQ4e4IEFPCAHCUjABCYQwP1NoAY8fMANNTgCDvrLDI8a3vemAgLuyZAs+pLiVUB4gQTMoIgL8EAXfVZEMIaRi14sIg9r0MGO2QtlnVOKDAhXRbPkD45lEYEP7XjHCaTva0ucigbGtzXmzXEs2xNkIauCQrhFMSkQcJohxYIqR0YyKVSQ2FPqRqE/SvIq9NOkJgFxMotVhZCdzMoJKEjKQjZJa0655Pw4hsqrqCCQsJRiHgD3lBMoMiEdmCUtneJGX8IRhXkaXiaVskKWBdMpplTmC5u0QBVyripAKF4zT+VEa/+Sz5ZQqiYu2ZjNhDwQnOC7AhWI6UAW9lFw41SK7NhJuy+oYZVO8UEDcanLdwJAA+vM59yiQAUmWvKVU+kBP/t5EGkedG5mMNVUHMBMUeKzn8tTqNjiMKZJYdOSBq0oAATV0ZsBYg7nZGU6QwlShHTAnigl1xXkSZWHSvQg+2QpQtAEwZoOy6XzdEoHNHrPnB7EApYLqqx2WpUeDFSdRTWIBJRKSzvyUKpS9SEQCXVUC0Hgm8dMKFMBMFRUDvA8ZKTMVHl4ntDhkDIm/BRWHQoCoj5FAd0sqlNxCkcRJOCG/uuhHp0igiHmoIA5wIBfrRQHylWlA3RFZyO9+tW4ylD/BLY7n2GzsgH2kbCwXIpCHkZqFSCc4K5K4eVjD4KmZOqPAhd4QbsaZpnSeSAHrx3SF+YQB5L2iZFXsatpD1LaF5JtAZG7DgUwsDjJicil+LKKG09ZFRDMzrce1WoF8ZY67OwtuRnqbGKrgiaZIkQBxvTtXPU3Achh1zvT+ZmI7JWH3BoPrlhB01Z9m0vwUUCwuoIPBWbgAdFoKApxUEMlreIAEPRSeyudLgB6SzsR+Myy6UHvAzy4HkCoAbdYQbCCLyfaBifFBz+123QC7CD9LklAXpgDvbLS4azUN8RJWaF9nzYd2k6oYFYFjhfMANCwwDgrFmDwjAFQ0NHebDo8/47PkuHjYzXAIb5UiZSHP5zkGfvAyhhzsom63J0r/FjKYnFjeBPiRhsbeYXPRVpechyix124MYWAAxXmENCwaAACZk7IfI2s29QmTCAndlEOmvKbKMSvVNAUiwp2GxYVkPfPCFEBYxOmxSG15813SXQeBrDEKV8FwSDAslOSGuhJGwTBkfXXBvRCpJ455gtwmMMA8gCI7JUlqUXOKptTnRTn3mwEhyLSA7Z7lSh4AQ5mUAMV4sCHUL/Y0b4+MAh4/euDnLpjrp5wiGIdli/wAQ55oIKY9hAvxnDLAqV+ymKxbZVIs7tVGCA2WRAAsbBUwCN2gZZSkl0vOMAhDj8eAP8VzACHKzD6Lg5wtHTDElp5vxsAI8bYCzbtlA+0BAUqAcC9y+Jxs8xgWQYJ06fNYAahAcILPH2Mnn0Q8Xw9WuIwTXDCPCBng0hhAFYoiFGk0HF8jwXkZanBcPojvq6Opcwz3+Se/TUBo1ulBBSpCAqAjpEBUB0DLeE5ADYDEZ535CdHiclM7n0TqlDAA/LpkdPjeAKHM51obvdWDdBjFRIM4OcG+cAAWnBvhsDlAy1IAUUwkILB693rmRH70DHT88xcZQHd/kzbFQBzFdZc7ljRmGOHxcOr3NsnQCfB0IlQASmkwCAVqEALkMIRjwz97K4fPVXy5h3iwQzz2iPx5vv/KPPPE3oqed97Qfr+96BjJiakoogBUjAAujQ+6ABAQQXEjpXbXycECjgBFBnTAVL7Ps/AlxW9sTL1gxTA6qa3ghSsrpSYtED6B9lMCRiClReo1zIO8F6m0iwW8Ns98SsIPfO8T6karNC5rvM5oHsPjSC89zAAA0CAApCL1JM/j4ALnyA8zsiKtfMN/vMBASgTAaSKABzAsSjAYfGQrMg4keC4e8sJjjMJkUAAEigAmQCA6zMKoAAAi1CQBeija7Ok8RpBpbGMlzFAFLwKFbSVyWsQuOAvqriAQwsnRxMAVgM2Dag0AbA2avs+8lvCrGjCVkGiBnm8rCCshOgBEdyK/9EKAQnQAAXwAQsQgBMYKgkowbBIQjE0C0zhMytZiyvhtoPgPr+Aq+WxAEWsQwGAAAvwAQXQgDzkDvBTwj7MiqQCRCTJAP1zkQSowoKQgDbcCkQEAgk4xf+zjhO8RLdwoy3DEuFAkvbQvxB4GTccEAewgPBjxboIARB4uU/pHSIxNOMJLQGIu/VAsHXjxYXzARBANSxhF8qbniekih4YQuyoMmZ0DEdLRSSZgahrkQVZE5jZxpYrR0TRj3oLEXV8ET3TRHPEChkAgWUklHYUEf0ARRHhw3jcv5fxRiEJFQ7plBbxxV3sR8/QM2zMtBewMA0RAQDBOf/YNYQEjhDQRf9LtBJn6TcHURYXmbaKvA4FwEJESQAAG5AUu7gJMUhoDEnHmMe4IRSIzL/+mI4ckMj+AAJ0dEnu0EkV0EMOwZtptAyoG4iCtICk40nsCAEfoLs28S/Z6sTPAJ0FED4O8UmgVMq6UDeAfBHHGa4LwEmycBzkEsv4uMik1Mr0UAAI6ICWzDTQka2wdAzMegHZUskMGcmfVMv+cIAOwMKs3BDMuqH9qAGzLJcLGIEMOqDDjA91y0i+TI+L1D1LoYAa0CIP8JkE4CA0SgoQCiEtKqAH6CEhmUx4jMzrsLzAFBHAEqEi6iLYjM0cKqs8IhKGA0zU1BDVnDQHYEu3zM0QaTv/FXhLlupNR+xK4JSPWvQ/0zJOIElOGtk+CPC+oHJO5IROB/EjCBhOlKpFCPCB68TODJGBl9me1RQkUcwU4hTPFuG/OuyAL6QlBwitmjlP9lzJ0GrL+JQkCfhLH9jP+1QTGaAZ/SSlEKCZmlnPABXQSPvOIxSkEAACEGjL8FzQNolQEbS2Cv0aGRivArXQm7nGV8FD8LnGE/hQEBWbENCADgAYPLRPQunQOoQryEzRpwkBEe3CFdnQOJGAOYSAE+iAB7XR+5EAVHmVBFMACVBQK5GBLZxRIWVSIoUdI+VCAbCADlDSGm3PKq3D71RSGJ1SxIFDIKg0gLnDLJXELWW7jB5IRAi40iydRDEFJxkw0jlEyqigR0hUAFM8xTAlmlMEgihRxDwlMiWV0jltJgc4RTlMRF3sC3pcRENVAEqtVEu9VEtdrEUEmKi4QyylVD9N1JlDxVNsU0w91VPtU1QUVVZtVVd9VViNVVmdVVqtVVu9VVzNVV3dVV7tVV/9VWANVmEdVmItVmNFyIAAADs=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    A minimal model for the pathogenesis of PCOS. Ovarian hyperandrogenism is nearly universal and causes the cardinal clinical features of the syndrome. About half of patients have insulin-resistant hyperinsulinism, which aggravates ovarian hyperandrogenism and contributes to adiposity. Androgen excess may also cause LH excess, which aggravates ovarian hyperandrogenism in the presence of hyperinsulinism. Obesity increases insulin-resistance, and the resultant increased hyperinsulinism further aggravates hyperandrogenism.",
"    <br/>",
"    The cause of the ovarian hyperandrogenism and insulin resistance is usually intrinsic, and may have common genetic or environmental determinants. This model does not exclude the possibility that the unknown intrinsic ovarian defects that underpin the ovarian steroidogenic dysfunction also involve granulosa cell folliculogenesis as well, and it does not depict other associated defects, such as the adrenal hyperandrogenism that parallels the ovarian hyperandrogenism.",
"    <br/>",
"    Excess adipose tissue can produce excess androgen as well as estrogen. However, in the absence of an intrinsic ovarian defect, the hyperandrogenemia of simple obesity is mild and polycystic ovaries unusual. In contrast to PCOS, the anovulation of simple obesity is the consequence of suppression, rather than augmentation, of LH pulsatility.",
"    <div class=\"footnotes\">",
"     PCOS: polycystic ovary syndrome; LH: luteinizing hormone.",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Robert Rosenfield.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39662=[""].join("\n");
var outline_f38_46_39662=null;
var title_f38_46_39663="Patient information: Chorionic villus sampling (The Basics)";
var content_f38_46_39663=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"topicTitle\">",
"   Patient information: Chorionic villus sampling (The Basics)",
"  </div>",
"  <a href=\"./authors-and-editors/patient-information\">",
"   Written by the doctors and editors at UpToDate",
"  </a>",
"  <br/>",
"  <br/>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 17, 2010.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H469586769\">",
"    <span class=\"h1\">",
"     What is chorionic villus sampling?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chorionic villus sampling, also called CVS, is a test that takes out a tiny piece of the placenta. The placenta is the organ inside a pregnant woman&rsquo;s uterus that brings her fetus nutrients and oxygen, and carries away waste. The fetus and its placenta share many of the same genes.",
"   </p>",
"   <p>",
"    CVS can show if there is something wrong with the fetus&rsquo; genes or chromosomes. Chromosomes are structures within cells that contain thousands of genes. This test is done between 10 and 13 weeks of pregnancy. Results come back in a few days.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469586776\">",
"    <span class=\"h1\">",
"     Why is CVS done?",
"    </span>",
"    &nbsp;&mdash;&nbsp;CVS is done to check if your fetus has a specific genetic problem, such as Down syndrome, Tay Sachs, cystic fibrosis, or another disease. You might have this test if you have a family history of one of these conditions, or if another test suggests there might be something wrong with your fetus. Keep in mind, though, that doctors cannot use CVS to check for every possible genetic problem. If your CVS results come back normal, that does not necessarily mean the fetus has no genetic problems. It just means it does not have the condition the doctors tested for.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469586783\">",
"    <span class=\"h1\">",
"     How is CVS done?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Here are the main steps:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The doctor will do an ultrasound. That is an imaging test that uses sound waves to create a picture of your uterus, fetus, and placenta.",
"     </li>",
"     <li>",
"      While looking at the ultrasound picture, the doctor will put either a needle into your belly or a tiny tube into your vagina (",
"      <a class=\"graphic graphic_figure graphicRef65622 \" href=\"mobipreview.htm?38/13/39123\">",
"       figure 1",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Next, the doctor will guide the needle or tube into your placenta. Then, he or she will take a very tiny sample of tissue.",
"     </li>",
"     <li>",
"      The tissue will be sent to a lab for tests.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469586790\">",
"    <span class=\"h1\">",
"     Does CVS have any risks?",
"    </span>",
"    &nbsp;&mdash;&nbsp;Yes. Problems are rare, but they can happen. Risks include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Miscarriage",
"     </li>",
"     <li>",
"      Leaking of blood from the fetus into your own bloodstream. This can cause problems for later pregnancies.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469586797\">",
"    <span class=\"h1\">",
"     Should I be worried about symptoms after the procedure?",
"    </span>",
"    &nbsp;&mdash;&nbsp;That depends on what symptoms you have and how bad they are. After CVS, it is normal to bleed a little from your vagina.",
"   </p>",
"   <p>",
"    Call your doctor if:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      You have vaginal bleeding that is like what you have during your period",
"     </li>",
"     <li>",
"      You are leaking fluid from your vagina",
"     </li>",
"     <li>",
"      You have cramps that are getting worse",
"     </li>",
"     <li>",
"      You have a fever higher than 100.4&deg;F (38&ordm;C)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469586804\">",
"    <span class=\"h1\">",
"     Is there an alternative to CVS?",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is another test, called amniocentesis, which can also test for genetic problems in the fetus. But amniocentesis is done later in pregnancy, usually around week 15 to 17.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469586811\">",
"    <span class=\"h1\">",
"     Is it better to do CVS or amniocentesis?",
"    </span>",
"    &nbsp;&mdash;&nbsp;That depends on your individual situation. You might not need either one. If you do decide to have testing, you might choose CVS over amniocentesis because:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      You want results as soon as possible in the pregnancy",
"     </li>",
"     <li>",
"      You want results more quickly after the test",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    You might choose amniocentesis over CVS because:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There is slightly less risk of miscarriage with amniocentesis",
"     </li>",
"     <li>",
"      You are already in the second trimester, meaning you have been pregnant for more than 3 months",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469586818\">",
"    <span class=\"h1\">",
"     What if the test shows that something is wrong with my fetus?",
"    </span>",
"    &nbsp;&mdash;&nbsp;You should talk to a genetic counselor before and after the test. He or she can help you understand your feelings and decide what to do.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H469586825\">",
"    <span class=\"h1\">",
"     More on this topic",
"    </span>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/57/42897?source=see_link\">",
"     Patient information: Amniocentesis (The Basics)",
"    </a>",
"   </p>",
"   <p>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/7/2161?source=see_link\">",
"     Patient information: Chorionic villus sampling (Beyond the Basics)",
"    </a>",
"    <br/>",
"    <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/28/14785?source=see_link\">",
"     Patient information: Amniocentesis (Beyond the Basics)",
"    </a>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 15612 Version 1.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"footerNav\">",
"   <ul>",
"    <li>",
"     <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Wolters Kluwer Health",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Facts &amp; Comparisons&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"      Medi-Span&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Order Sets",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"      ProVation&reg; Medical",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Pharmacy OneSource&reg;",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"      Medicom",
"     </a>",
"    </li>",
"    <li>",
"     <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"      Lexicomp",
"     </a>",
"    </li>",
"    <li class=\"last\">",
"     <a href=\"/home/privacy-policy\">",
"      Privacy Policy",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <div id=\"footerLogo\">",
"   <a href=\"./toc\">",
"    Wolters Kluwer Health | UpToDate",
"   </a>",
"  </div>",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"sfInfo\">",
"    <a href=\"/home/terms-use\">",
"     Terms of Use",
"    </a>",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     UpToDate Marketing Professional",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-41.222.196.37-7F2101851E-14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f38_46_39663=[""].join("\n");
var outline_f38_46_39663=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469586769\">",
"      What is chorionic villus sampling?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469586776\">",
"      Why is CVS done?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469586783\">",
"      How is CVS done?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469586790\">",
"      Does CVS have any risks?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469586797\">",
"      Should I be worried about symptoms after the procedure?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469586804\">",
"      Is there an alternative to CVS?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469586811\">",
"      Is it better to do CVS or amniocentesis?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469586818\">",
"      What if the test shows that something is wrong with my fetus?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H469586825\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   GRAPHICS",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     FIGURES",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"mobipreview.htm?38/13/39123\" title=\"figure 1\">",
"      CVS PI",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?14/28/14785?source=related_link\">",
"      Patient information: Amniocentesis (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"mobipreview.htm?41/57/42897?source=related_link\">",
"      Patient information: Amniocentesis (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"mobipreview.htm?2/7/2161?source=related_link\">",
"      Patient information: Chorionic villus sampling (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
